-DOCSTART-	O

Title	O
:	O
Galantamine	B-I
in	O
the	O
treatment	O
of	O
cognitive	O
decline	O
in	O
patients	B-P
with	I-P
vascular	I-P
dementia	I-P
or	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
with	I-P
cerebrovascular	I-P
disease	I-P
.	O

METHODS	O
:	O
A	O
post	O
hoc	O
sub	O
-	O
analysis	O
of	O
a	O
6	O
-	O
month	O
,	O
multicentre	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
and	O
a	O
subsequent	O
6	O
-	O
month	O
,	O
open	O
-	O
label	O
extension	O
.	O

Patients	B-P
diagnosed	I-P
with	I-P
probable	I-P
vascular	I-P
dementia	I-P
or	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
with	I-P
cerebrovascular	I-P
disease	I-P
were	O
treated	O
with	O
galantamine	B-I
(	I-I
Reminyl	I-I
)	I-I
24	O
mg	O
/	O
day	O
for	O
12	O
months	O
(	O
6	O
months	O
double	O
-	O
blind	O
and	O
6	O
months	O
open	O
-	O
label	O
)	O
or	O
placebo	B-C
for	O
6	O
months	O
(	O
double	O
-	O
blind	O
)	O
followed	O
by	O
galantamine	B-I
24	O
mg	O
/	O
day	O
for	O
6	O
months	O
(	O
open	O
-	O
label	O
)	O
.	O

Changes	O
in	O
scores	O
on	O
the	B-O
11	I-O
-	I-O
item	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
/	I-O
11	I-O
)	I-O
were	O
assessed	O
at	O
months	O
6	O
,	O
7	O
.	O
5	O
and	O
12	O
.	O

Mean	O
changes	O
from	O
baseline	O
were	O
analysed	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
study	O
on	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
from	O
the	O
viewpoint	O
of	O
Xin	O
and	O
Shen	O
]	O
.	O

METHODS	O
:	O
Sixty	B-P
patients	I-P
with	I-P
AD	I-P
were	O
divided	O
into	O
3	O
groups	O
according	O
to	O
their	O
MMSE	O
and	O
ADL	O
scores	O
before	O
treatment	O
,	O
using	O
randomized	O
block	O
design	O
.	O

They	O
were	O
treated	O
separately	O
with	O
TXR	B-I
,	O
BSR	B-I
and	O
Donepezil	B-I
(	I-I
Dp	I-I
)	I-I
for	O
12	O
weeks	O
.	O

The	O
changes	O
of	O
MMSE	B-O
score	I-O
,	O
ADL	B-O
score	I-O
,	O
neuro	B-O
-	I-O
psychology	I-O
amount	I-O
table	I-O
score	I-O
,	O
including	O
FOM	B-O
,	O
RVR	B-O
,	O
DS	B-O
and	O
BD	B-O
,	O
as	O
well	O
as	O
the	B-O
overall	I-O
operational	I-O
evaluation	I-O
before	O
and	O
after	O
treatment	O
were	O
analyzed	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
the	O
effects	O
of	O
donepezil	B-I
on	O
neuronal	O
markers	O
and	O
hippocampal	O
volumes	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
pilot	O
study	O
,	O
67	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
received	O
24	O
weeks	O
of	O
treatment	O
with	O
donepezil	B-I
(	O
5	O
mg	O
/	O
day	O
for	O
the	O
first	O
28	O
days	O
and	O
10	O
mg	O
/	O
day	O
thereafter	O
)	O
or	O
placebo	B-C
.	O

Patients	O
were	O
reevaluated	O
at	O
6	O
-	O
week	O
intervals	O
to	O
measure	O
change	O
from	O
baseline	O
in	O
several	O
outcome	O
measures	O
,	O
including	O
right	B-O
,	O
left	B-O
,	O
and	O
total	B-O
hippocampal	I-O
volumes	I-O
,	O
measured	O
with	O
magnetic	B-O
resonance	I-O
imaging	I-O
;	O
brain	B-O
concentrations	I-O
of	I-O
N	I-O
-	I-O
acetylaspartate	I-O
,	O
measured	O
with	O
proton	B-O
magnetic	I-O
resonance	I-O
spectroscopy	I-O
;	O
and	O
cognition	B-O
,	O
assessed	O
with	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
cognitive	I-O
subscale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Metal	O
-	O
protein	O
attenuation	O
with	O
iodochlorhydroxyquin	B-I
(	I-I
clioquinol	I-I
)	I-I
targeting	O
Abeta	O
amyloid	O
deposition	O
and	O
toxicity	O
in	O
Alzheimer	O
disease	O
:	O
a	O
pilot	O
phase	O
2	O
clinical	O
trial	O
.	O

METHODS	O
:	O
A	O
pilot	O
phase	O
2	O
clinical	O
trial	O
in	O
patients	B-P
with	I-P
moderately	I-P
severe	I-P
Alzheimer	I-P
disease	I-P
.	O

-DOCSTART-	O

Title	O
:	O
The	O
efficacy	O
of	O
donepezil	B-I
in	O
the	O
treatment	O
of	O
neuropsychiatric	O
symptoms	O
in	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
with	I-P
marked	I-P
neuropsychiatric	I-P
symptoms	I-P
at	I-P
baseline	I-P
(	I-P
Neuropsychiatric	I-P
Inventory	I-P
[	I-P
NPI	I-P
]	I-P
>	I-P
11	I-P
points	I-P
)	I-P
were	O
treated	O
openly	O
with	O
donepezil	O
5	O
mg	O
daily	O
for	O
6	O
weeks	O
followed	O
by	O
10	O
mg	O
daily	O
for	O
a	O
further	O
6	O
weeks	O
.	O

Patients	O
were	O
then	O
randomized	O
(	O
60	O
:	O
40	O
)	O
to	O
either	O
placebo	B-C
or	O
10	B-I
mg	I-I
donepezil	I-I
daily	O
.	O

All	O
patients	O
were	O
assessed	O
at	O
6	O
weeks	O
and	O
provided	O
there	O
was	O
no	O
marked	O
cognitive	O
deterioration	O
their	O
blinded	O
treatment	O
was	O
continued	O
for	O
a	O
further	O
6	O
weeks	O
.	O

NPI	B-O
and	O
carer	B-O
distress	I-O
were	O
assessed	O
at	O
6	O
weekly	O
intervals	O
throughout	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
open	O
-	O
label	O
,	O
comparative	O
study	O
of	O
rivastigmine	B-I
,	O
donepezil	B-I
and	O
galantamine	B-I
in	O
a	O
real	O
-	O
world	O
setting	O
.	O

METHODS	O
:	O
Outcome	O
measures	O
included	O
the	B-O
MiniMental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
the	B-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
)	I-O
,	O
Instrumental	B-O
Activity	I-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
IADL	I-O
)	I-O
and	O
ADL	B-O
scales	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
donepezil	B-I
in	O
early	O
-	O
stage	O
Alzheimer	O
disease	O
:	O
a	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
24	O
-	O
week	O
,	O
placebo	O
-	O
controlled	O
study	O
that	O
enrolled	O
patients	B-P
with	I-P
early	I-P
-	I-P
stage	I-P
Alzheimer	I-P
disease	I-P
.	O

Patients	O
were	O
randomized	O
in	O
an	O
approximately	O
2	O
:	O
1	O
ratio	O
to	O
donepezil	B-I
,	O
5	O
mg	O
/	O
d	O
,	O
for	O
the	O
first	O
6	O
weeks	O
,	O
with	O
a	O
forced	O
escalation	O
to	O
10	O
mg	O
/	O
d	O
thereafter	O
(	O
n	O
=	O
96	O
)	O
,	O
or	O
placebo	B-C
(	O
n	O
=	O
57	O
)	O
.	O

The	O
primary	O
efficacy	O
measure	O
was	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
.	O

Secondary	O
efficacy	O
measures	O
included	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
the	B-O
Computerized	I-O
Memory	I-O
Battery	I-O
Test	I-O
,	O
the	B-O
Clinical	I-O
Dementia	I-O
Rating	I-O
Scale	I-O
-	I-O
Sum	I-O
of	I-O
the	I-O
Boxes	I-O
,	O
the	B-O
Patient	I-O
Global	I-O
Assessment	I-O
Scale	I-O
,	O
and	O
the	B-O
Apathy	I-O
Scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Vitamin	B-I
E	I-I
and	O
donepezil	B-I
for	O
the	O
treatment	O
of	O
mild	O
cognitive	O
impairment	O
.	O

METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
study	O
,	O
we	O
evaluated	O
subjects	B-P
with	I-P
the	I-P
amnestic	I-P
subtype	I-P
of	I-P
mild	I-P
cognitive	I-P
impairment	I-P
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
receive	O
2000	B-I
IU	I-I
of	I-I
vitamin	I-I
E	I-I
daily	O
,	O
10	B-I
mg	I-I
of	I-I
donepezil	I-I
daily	O
,	O
or	O
placebo	B-C
for	O
three	O
years	O
.	O

The	O
primary	O
outcome	O
was	O
clinically	B-O
possible	I-O
or	O
probable	B-O
Alzheimer	I-O
'	I-O
s	I-O
disease	I-O
;	O
secondary	O
outcomes	O
were	O
cognition	B-O
and	O
function	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
effects	O
of	O
Abeta	B-I
immunization	I-I
(	I-I
AN1792	I-I
)	I-I
in	O
patients	B-P
with	I-P
AD	I-P
in	O
an	O
interrupted	O
trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
multicenter	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
trial	O
of	O
IM	B-I
AN1792	I-I
225	O
microg	O
plus	O
the	B-I
adjuvant	I-I
QS	I-I
-	I-I
21	I-I
50	O
microg	O
(	O
300	O
patients	O
)	O
and	O
saline	B-C
(	O
72	O
patients	O
)	O
included	O
patients	B-P
aged	I-P
50	I-P
to	I-P
85	I-P
years	I-P
with	I-P
probable	I-P
AD	I-P
,	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
15	I-P
to	I-P
26	I-P
.	O

Injections	O
were	O
planned	O
for	O
months	O
0	O
,	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
.	O

Safety	O
and	O
tolerability	O
were	O
evaluated	O
,	O
and	O
pilot	B-O
efficacy	I-O
(	O
AD	B-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
[	I-O
ADAS	I-O
-	I-O
Cog	I-O
]	I-O
,	O
MRI	B-O
,	O
neuropsychological	B-O
test	I-O
battery	I-O
[	I-O
NTB	I-O
]	I-O
,	O
CSF	B-O
tau	I-O
,	O
and	O
Abeta42	B-O
)	O
was	O
assessed	O
in	O
anti	O
-	O
AN1792	O
antibody	O
responder	O
patients	O
(	O
immunoglobulin	O
G	O
titer	O
>	O
or	O
=	O
1	O
:	O
2	O
,	O
200	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
cohort	O
study	O
of	O
effectiveness	O
of	O
acetylcholinesterase	B-I
inhibitors	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
From	O
September	O
2000	O
to	O
December	O
2001	O
,	O
a	B-P
total	I-P
of	I-P
5	I-P
,	I-P
462	I-P
patients	I-P
diagnosed	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
were	O
enrolled	O
at	O
the	O
time	O
of	O
their	O
first	O
prescription	O
of	O
the	O
study	O
drugs	O
and	O
followed	O
up	O
for	O
an	O
average	O
of	O
10	O
.	O
5	O
months	O
.	O

Responders	O
were	O
defined	O
as	O
patients	O
with	O
a	B-O
mini	I-O
-	I-O
mental	I-O
state	I-O
examination	I-O
(	I-O
MMSE	I-O
)	I-O
score	I-O
improvement	O
of	O
2	O
or	O
more	O
points	O
from	O
baseline	O
after	O
9	O
months	O
of	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
timed	B-I
bright	I-I
light	I-I
treatment	I-I
for	O
rest	O
-	O
activity	O
disruption	O
in	O
institutionalized	B-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
The	O
purpose	O
of	O
this	O
randomized	O
clinical	O
trial	O
was	O
to	O
test	O
the	O
effectiveness	O
of	O
timed	B-I
bright	I-I
light	I-I
therapy	I-I
in	O
reducing	O
rest	O
-	O
activity	O
(	O
circadian	O
)	O
disruption	O
in	O
institutionalized	B-P
patients	I-P
with	I-P
AD	I-P
.	O

The	O
experimental	O
groups	O
received	O
either	O
morning	B-I
(	I-I
9	I-I
.	I-I
30	I-I
-	I-I
10	I-I
.	I-I

30	I-I
am	I-I
)	I-I
or	O
afternoon	B-I
(	I-I
3	I-I
.	I-I
30	I-I
-	I-I
4	I-I
.	I-I

30	I-I
pm	I-I
)	I-I
bright	I-I
light	I-I
exposure	I-I
(	O
>	O
or	O
=	O
2500	O
lux	O
in	O
gaze	O
direction	O
)	O
Monday	O
through	O
Friday	O
for	O
10	O
weeks	O
.	O

The	O
control	O
group	O
received	O
usual	B-C
indoor	I-C
light	I-C
(	O
150	O
-	O
200	O
lux	O
)	O
.	O

Nighttime	B-O
sleep	I-O
,	O
daytime	B-O
wake	I-O
,	O
and	O
rest	B-O
-	I-O
activity	I-O
parameters	I-O
were	O
determined	O
by	O
actigraphy	B-O
.	O

Repeated	O
measures	O
analysis	O
of	O
variance	O
was	O
employed	O
to	O
test	O
the	O
primary	O
study	O
hypotheses	O
.	O

-DOCSTART-	O

Title	O
:	O
Brief	B-I
psychotherapy	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Individuals	O
were	O
randomised	O
to	O
receive	O
six	O
sessions	O
of	O
psychodynamic	B-I
interpersonal	I-I
therapy	I-I
or	O
treatment	B-C
as	I-C
usual	I-C
;	O
cognitive	B-O
function	I-O
,	O
activities	B-O
of	I-O
daily	I-O
living	I-O
,	O
a	B-O
global	I-O
measure	I-O
of	I-O
change	I-O
,	O
and	O
carer	B-O
stress	I-O
and	O
coping	B-O
were	O
assessed	O
prior	O
to	O
and	O
after	O
the	O
intervention	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
crossover	O
trial	O
of	O
high	B-I
-	I-I
carbohydrate	I-I
foods	I-I
in	O
nursing	B-P
home	I-P
residents	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
associations	O
among	O
intervention	O
response	O
,	O
body	O
mass	O
index	O
,	O
and	O
behavioral	O
and	O
cognitive	O
function	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
four	I-P
nursing	I-P
home	I-P
residents	I-P
with	I-P
probable	I-P
AD	I-P
who	I-P
ate	I-P
independently	I-P
participated	O
in	O
a	O
randomized	O
,	O
crossover	O
,	O
nonblinded	O
study	O
of	O
two	O
nutrition	O
interventions	O
.	O

The	O
intervention	O
described	O
here	O
included	O
replacing	O
12	O
nonconsecutive	O
"	O
traditional	O
"	O
dinners	O
with	O
meals	B-I
high	I-I
in	I-I
carbohydrate	I-I
but	O
comparable	O
to	O
traditional	B-C
dinners	I-C
in	O
protein	O
.	O

Measures	O
included	O
weighed	B-O
food	I-O
intake	I-O
,	O
body	B-O
weight	I-O
,	O
cognitive	B-O
function	I-O
(	O
as	O
assessed	O
using	O
the	B-O
Severe	I-O
Impairment	I-O
Battery	I-O
and	O
Global	B-O
Deterioration	I-O
Scale	I-O
)	O
,	O
behavioral	B-O
disturbances	I-O
(	O
as	O
assessed	O
using	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
-	I-O
Nursing	I-O
Home	I-O
Version	I-O
)	O
,	O
and	O
behavioral	B-O
function	I-O
(	O
as	O
assessed	O
using	O
the	B-O
London	I-O
Psychogeriatric	I-O
Rating	I-O
Scale	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
observation	O
and	O
mechanism	O
study	O
on	O
treatment	O
of	O
senile	O
dementia	O
with	O
Naohuandan	B-I
.	O

METHODS	O
:	O
Clinical	O
study	O
:	O
Fifty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
SD	I-P
,	I-P
whose	I-P
diagnosis	I-P
conforms	I-P
to	I-P
the	I-P
Diagnostic	I-P
Standard	I-P
of	I-P
DSM	I-P
-	I-P
IV	I-P
issued	I-P
by	I-P
American	I-P
Association	I-P
of	I-P
Psychiatry	I-P
,	O
were	O
enrolled	O
and	O
randomly	O
assigned	O
into	O
two	O
groups	O
.	O

The	O
30	O
patients	O
in	O
the	O
treated	O
group	O
were	O
treated	O
with	O
NHD	B-I
,	O
4	O
capsules	O
each	O
time	O
,	O
3	O
times	O
daily	O
.	O

The	O
28	O
patients	O
in	O
the	O
control	O
group	O
were	O
treated	O
with	O
Piracetam	B-C
,	O
1	O
.	O
6	O
g	O
each	O
time	O
,	O
3	O
times	O
daily	O
.	O

The	O
therapeutic	O
course	O
for	O
both	O
groups	O
was	O
3	O
months	O
.	O

The	O
therapeutic	O
efficacy	O
was	O
estimated	O
and	O
compared	O
by	O
comprehensive	B-O
scores	I-O
of	I-O
memory	I-O
and	O
cognition	B-O
,	O
scores	B-O
of	I-O
Mini	I-O
-	I-O
mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
and	O
Activities	B-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
ADL	I-O
)	I-O
.	O

Experimental	O
study	O
:	O
Rats	O
were	O
divided	O
into	O
the	O
control	O
group	O
,	O
the	O
model	O
group	O
and	O
the	B-I
high	I-I
-	I-I
dosage	I-I
and	O
low	B-I
-	I-I
dosage	I-I
NHD	I-I
treated	O
groups	O
.	O

The	O
protective	O
effect	O
of	O
NHD	B-I
on	O
the	O
per	O
-	O
oxidative	O
damage	O
of	O
hippocampal	O
neurons	O
in	O
beta	O
-	O
amyloid	O
protein	O
induced	O
SD	O
model	O
was	O
observed	O
and	O
the	O
related	O
criteria	O
were	O
determined	O
.	O

-DOCSTART-	O

Title	O
:	O
Risperidone	B-I
in	O
the	O
treatment	O
of	O
psychosis	O
of	O
Alzheimer	O
disease	O
:	O
results	O
from	O
a	O
prospective	O
clinical	O
trial	O
.	O

METHODS	O
:	O
The	O
authors	O
conducted	O
a	O
randomized	O
,	O
eight	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
involving	O
nursing	B-P
home	I-P
residents	I-P
diagnosed	I-P
with	I-P
AD	I-P
and	I-P
psychosis	I-P
.	O

Four	B-P
hundred	I-P
seventy	I-P
-	I-P
three	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
placebo	B-C
(	O
N	O
=	O
238	O
)	O
or	O
1	B-I
.	I-I
0	I-I
to	I-I
1	I-I
.	I-I
5	I-I
mg	I-I
risperidone	I-I
per	O
day	O
(	O
N	O
=	O
235	O
)	O
.	O

Coprimary	O
efficacy	O
end	O
points	O
were	O
:	O
changes	O
in	O
scores	O
on	O
the	B-O
Behavioral	I-O
pathology	I-O
in	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
(	I-O
BEHAVE	I-O
-	I-O
AD	I-O
)	I-O
Psychosis	I-O
subscale	I-O
and	O
Clinical	B-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGI	I-O
-	I-O
C	I-O
)	I-O
.	O

Protocol	O
-	O
specified	O
subgroup	O
analyses	O
were	O
performed	O
by	O
demographics	O
and	O
dementia	O
severity	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Correlation	O
analysis	O
on	O
changes	O
between	O
cognitive	O
ability	O
and	O
brain	O
fMRI	O
after	O
acupoint	B-I
thread	I-I
embedding	I-I
in	O
Alzheimer	B-P
'	I-P
s	I-P
disease	I-P
patients	I-P
]	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
six	I-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
were	O
assigned	O
to	O
the	O
tested	O
group	O
and	O
the	O
control	O
group	O
in	O
pairing	O
,	O
13	O
in	O
each	O
group	O
.	O

ATE	B-I
was	O
performed	O
in	O
patients	O
of	O
the	O
tested	O
group	O
at	O
Shenmen	O
(	O
HT7	O
)	O
,	O
Fenglong	O
(	O
ST40	O
)	O
,	O
Taixi	O
(	O
KI3	O
)	O
and	O
Zusanli	O
(	O
ST36	O
)	O
acupoints	O
,	O
once	O
every	O
month	O
for	O
6	O
times	O
in	O
total	O
;	O
but	O
for	O
patients	O
of	O
the	O
control	O
group	O
only	O
sham	O
operation	O
was	O
done	O
at	O
the	O
same	O
acupoints	O
.	O

The	O
correlation	O
between	O
cognitive	B-O
ability	I-O
and	O
fMRI	B-O
were	O
assessed	O
by	O
comparing	O
the	B-O
scores	I-O
of	I-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
and	O
Alzhemer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
section	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
,	O
monitored	O
at	O
two	O
time	O
points	O
,	O
namely	O
,	O
in	O
one	O
week	O
before	O
starting	O
treatment	O
and	O
1	O
week	O
after	O
terminating	O
6	O
-	O
month	O
treatment	O
.	O

Furthermore	O
,	O
fMRI	B-O
was	O
detected	O
to	O
obtain	O
the	O
data	O
of	O
the	B-O
cerebral	I-O
blood	I-O
oxygen	I-O
content	I-O
before	O
treatment	O
and	O
6	O
months	O
after	O
completing	O
the	O
6	O
-	O
month	O
therapeutic	O
course	O
.	O

Correlation	O
analysis	O
was	O
conducted	O
on	O
the	O
obtained	O
data	O
using	O
software	O
SPM	O
.	O

-DOCSTART-	O

Title	O
:	O
Melatonin	B-I
fails	O
to	O
improve	O
sleep	O
or	O
agitation	O
in	O
double	O
-	O
blind	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
of	O
institutionalized	B-P
patients	I-P
with	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

Nursing	O
homes	O
in	O
San	O
Diego	O
,	O
CA	O
,	O
metropolitan	O
area	O
.	O

Subjects	O
were	O
patients	B-P
with	I-P
probable	I-P
Alzheimer	I-P
disease	I-P
.	O

Melatonin	B-I
(	O
8	O
.	O
5	O
mg	O
immediate	O
release	O
and	O
1	O
.	O
5	O
mg	O
sustained	O
release	O
)	O
(	O
N	O
=	O
24	O
)	O
or	O
placebo	B-C
(	O
N	O
=	O
17	O
)	O
administered	O
at	O
10	O
:	O
00	O
P	O
.	O
M	O
.	O
for	O
10	O
consecutive	O
nights	O
.	O

The	O
protocol	O
consisted	O
of	O
baseline	O
(	O
3	O
days	O
)	O
,	O
treatment	O
(	O
10	O
days	O
)	O
,	O
and	O
posttreatment	O
(	O
5	O
days	O
)	O
phases	O
.	O

Sleep	B-O
was	O
measured	O
continuously	O
using	O
actigraphy	B-O
.	O

Agitation	B-O
was	O
rated	O
using	O
both	O
the	B-O
Agitated	I-O
Behavior	I-O
Rating	I-O
Scale	I-O
and	O
the	B-O
Cohen	I-O
-	I-O
Mansfield	I-O
Agitation	I-O
Inventory	I-O
.	O

Treatment	O
effects	O
were	O
examined	O
both	O
across	O
the	O
24	O
-	O
hr	O
day	O
and	O
separately	O
by	O
nursing	O
shift	O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
treatment	I-I
of	O
patients	B-P
with	I-P
MCI	I-P
:	O
a	O
48	O
-	O
week	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
multicenter	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
subjects	B-P
with	I-P
MCI	I-P
entered	O
a	O
3	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
followed	O
by	O
48	B-I
weeks	I-I
of	I-I
double	I-I
-	I-I
blind	I-I
donepezil	I-I
(	O
5	O
mg	O
/	O
day	O
for	O
6	O
weeks	O
,	O
then	O
10	O
mg	O
/	O
day	O
for	O
42	O
weeks	O
)	O
or	O
placebo	B-C
treatment	I-C
.	O

Primary	O
efficacy	O
variables	O
included	O
change	O
from	O
baseline	O
in	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
Clinical	B-O
Dementia	I-O
Rating	I-O
Scale	I-O
-	I-O
sum	I-O
of	I-O
boxes	I-O
(	I-O
CDR	I-O
-	I-O
SB	I-O
)	I-O
after	O
48	O
weeks	O
of	O
treatment	O
(	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
)	O
.	O

Secondary	O
efficacy	O
measures	O
evaluated	O
cognition	B-O
,	O
behavior	B-O
,	O
and	O
function	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Different	B-I
cholinesterase	I-I
inhibitor	I-I
effects	O
on	O
CSF	O
cholinesterases	O
in	O
Alzheimer	B-P
patients	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
cranial	B-I
electrical	I-I
stimulation	I-I
on	O
sleep	O
disturbances	O
,	O
depressive	O
symptoms	O
,	O
and	O
caregiving	O
appraisal	O
in	O
spousal	B-P
caregivers	I-P
of	I-P
persons	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
eight	I-P
participants	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
active	B-I
CES	I-I
or	O
sham	B-C
CES	I-C
for	O
4	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
delays	O
progression	O
to	O
AD	O
in	O
MCI	B-P
subjects	I-P
with	I-P
depressive	I-P
symptoms	I-P
.	O

METHODS	O
:	O
The	O
study	O
sample	O
was	O
composed	O
of	O
756	B-P
participants	I-P
with	I-P
aMCI	I-P
from	I-P
the	I-P
3	I-P
-	I-P
year	I-P
,	I-P
double	I-P
-	I-P
blind	I-P
,	I-P
placebo	I-P
-	I-P
controlled	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
Cooperative	I-P
Study	I-P
drug	I-P
trial	I-P
of	I-P
donepezil	I-P
and	I-P
vitamin	I-P
E	I-P
.	O

Beck	B-O
Depression	I-O
Inventory	I-O
(	I-O
BDI	I-O
)	I-O
was	O
used	O
to	O
assess	O
depressive	B-O
symptoms	I-O
at	O
baseline	O
and	O
participants	O
were	O
followed	O
either	O
to	O
the	O
end	O
of	O
study	O
or	O
to	O
the	O
primary	O
endpoint	O
of	O
progression	O
to	O
probable	O
or	O
possible	O
AD	O
.	O

-DOCSTART-	O

Title	O
:	O
Lithium	B-I
trial	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
10	O
-	O
week	O
study	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
71	I-P
patients	I-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
>	I-P
or	I-P
=	I-P
21	I-P
and	I-P
<	I-P
or	I-P
=	I-P
26	I-P
)	I-P
were	O
successfully	O
randomly	O
assigned	O
to	O
placebo	B-C
(	O
N	O
=	O
38	O
)	O
or	O
lithium	B-I
treatment	I-I
(	O
N	O
=	O
33	O
)	O
at	O
6	O
academic	O
expert	O
memory	O
clinics	O
.	O

The	O
10	O
-	O
week	O
treatment	O
included	O
a	O
6	O
-	O
week	O
titration	O
phase	O
to	O
reach	O
the	O
target	O
serum	O
level	O
of	O
lithium	B-I
(	O
0	O
.	O
5	O
-	O
0	O
.	O

8	O
mmol	O
/	O
L	O
)	O
.	O

The	O
primary	O
outcome	O
measures	O
were	O
cerebrospinal	B-O
fluid	I-O
(	I-O
CSF	I-O
)	I-O
levels	I-O
of	I-O
phosphorylated	I-O
tau	I-O
(	I-O
p	I-O
-	I-O
tau	I-O
)	I-O
and	O
GSK	B-O
-	I-O
3	I-O
activity	I-O
in	I-O
lymphocytes	I-O
.	O

Secondary	O
outcome	O
measures	O
were	O
CSF	B-O
concentration	I-O
of	I-O
total	I-O
tau	I-O
and	O
beta	B-O
-	I-O
amyloid	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
(	I-O
Abeta	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
)	I-O
,	O
plasma	B-O
levels	I-O
of	I-O
Abeta	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
,	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
-	I-O
Cognitive	I-O
summary	I-O
scores	I-O
,	O
MMSE	B-O
,	O
and	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
.	O

Patients	O
were	O
enrolled	O
in	O
the	O
study	O
from	O
November	O
2004	O
to	O
July	O
2005	O
.	O

-DOCSTART-	O

Title	O
:	O
Atomoxetine	B-I
augmentation	O
of	O
cholinesterase	B-I
inhibitor	I-I
therapy	I-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
disease	I-P
:	O
6	O
-	O
month	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
trial	O
study	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
(	O
PLA	O
)	O
-	O
controlled	O
,	O
parallel	O
-	O
groups	O
study	O
,	O
starting	O
with	O
a	O
5	O
-	O
33	O
-	O
day	O
screening	O
and	O
evaluation	O
period	O
,	O
followed	O
by	O
a	O
6	O
-	O
month	O
treatment	O
period	O
.	O

Eight	O
independent	O
or	O
academic	O
outpatient	O
clinics	O
in	O
the	O
United	O
States	O
.	O

Male	B-P
or	I-P
female	I-P
patients	I-P
,	I-P
aged	I-P
55	I-P
years	I-P
and	I-P
older	I-P
,	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
(	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
between	I-P
10	I-P
and	I-P
26	I-P
)	I-P
at	I-P
baseline	I-P
.	O

ATX	B-I
(	O
25	O
-	O
80	O
mg	O
/	O
day	O
)	O
or	O
PLA	B-I
for	O
up	O
to	O
6	O
months	O
,	O
added	O
to	O
ongoing	B-I
cholinesterase	I-I
-	I-I
inhibitor	I-I
therapy	I-I
.	O

Alzheimer	B-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Portion	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
,	O
primary	O
measure	O
)	O
,	O
Clinician	B-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
score	I-O
at	O
end	O
point	O
,	O
Neuropsychiatric	B-O
Inventory	I-O
,	O
and	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
Inventory	I-O
-	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Inventory	I-O
total	I-O
score	I-O
,	O
safety	B-O
measures	I-O
(	O
secondary	O
measures	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effectiveness	O
of	O
donepezil	B-I
in	O
reducing	O
clinical	O
worsening	O
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Data	O
from	O
906	B-P
patients	I-P
(	I-P
388	I-P
receiving	I-P
placebo	I-P
;	I-P
518	I-P
receiving	I-P
donepezil	I-P
)	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
[	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
score	I-P
10	I-P
-	I-P
27	I-P
]	I-P
were	O
pooled	O
from	O
3	O
randomized	O
,	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
studies	O
.	O

Clinical	O
worsening	O
was	O
defined	O
as	O
decline	O
in	O
(	O
1	O
)	O
cognition	B-O
(	O
MMSE	B-O
)	O
,	O
(	O
2	O
)	O
cognition	B-O
and	O
global	B-O
ratings	I-O
(	O
Clinician	B-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
plus	I-O
Caregiver	I-O
Input	I-O
/	O
Gottfries	B-O
-	I-O
Brne	I-O
-	I-O
Steen	I-O
scale	I-O
)	O
or	O
(	O
3	O
)	O
cognition	B-O
,	O
global	B-O
ratings	I-O
and	O
function	B-O
(	O
various	B-O
functional	I-O
measures	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
25	O
-	O
week	O
,	O
open	O
-	O
label	O
trial	O
investigating	O
rivastigmine	B-I
transdermal	I-I
patches	I-I
with	O
concomitant	B-I
memantine	I-I
in	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
post	O
hoc	O
analysis	O
.	O

METHODS	O
:	O
Post	O
hoc	O
analysis	O
of	O
a	O
25	O
-	O
week	O
,	O
randomized	O
,	O
prospective	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
.	O

Patients	O
receiving	O
donepezil	O
were	O
switched	O
to	O
rivastigmine	O
patches	O
(	O
4	O
.	O
6	O
mg	O
/	O
24	O
h	O
)	O
immediately	O
or	O
following	O
a	O
7	O
-	O
day	O
withdrawal	O
for	O
4	O
weeks	O
(	O
core	O
phase	O
)	O
,	O
before	O
titrating	O
up	O
to	O
9	O
.	O
5	O
mg	O
/	O
24	O
h	O
for	O
a	O
further	O
20	O
-	O
week	O
extension	O
phase	O
.	O

Prior	O
memantine	O
therapy	O
was	O
continued	O
throughout	O
.	O

Tolerability	B-O
(	O
adverse	B-O
events	I-O
[	I-O
AEs	I-O
]	I-O
,	O
serious	B-O
AEs	I-O
[	I-O
SAEs	I-O
]	I-O
and	O
discontinuations	B-O
)	O
and	O
efficacy	B-O
(	O
cognition	B-O
,	O
global	B-O
functioning	I-O
and	O
activities	B-O
of	I-O
daily	I-O
living	I-O
[	I-O
ADLs	I-O
]	I-O
)	O
were	O
assessed	O
for	O
the	O
rivastigmine	B-I
transdermal	I-I
patch	I-I
,	O
with	O
or	O
without	O
concomitant	B-I
memantine	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
tarenflurbil	B-I
on	O
cognitive	O
decline	O
and	O
activities	O
of	O
daily	O
living	O
in	O
patients	B-P
with	I-P
mild	I-P
Alzheimer	I-P
disease	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
enrolling	O
patients	B-P
with	I-P
mild	I-P
AD	I-P
was	O
conducted	O
at	O
133	O
trial	O
sites	O
in	O
the	O
United	O
States	O
between	O
February	O
21	O
,	O
2005	O
,	O
and	O
April	O
30	O
,	O
2008	O
.	O

Concomitant	O
treatment	O
with	O
cholinesterase	O
inhibitors	O
or	O
memantine	O
was	O
permitted	O
.	O

Tarenflurbil	B-I
,	O
800	O
mg	O
,	O
or	O
placebo	B-C
,	O
administered	O
twice	O
a	O
day	O
.	O

Co	O
-	O
primary	O
efficacy	O
end	O
points	O
were	O
the	O
change	O
from	O
baseline	O
to	O
month	O
18	O
in	O
total	O
score	O
on	O
the	B-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
,	I-O
80	I-O
-	I-O
point	I-O
version	I-O
)	I-O
and	O
Alzheimer	B-O
Disease	I-O
Cooperative	I-O
Studies	I-O
-	I-O
activities	I-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADCS	I-O
-	I-O
ADL	I-O
)	I-O
scale	I-O
.	O

Additional	O
prespecified	O
slope	O
analyses	O
explored	O
the	O
possibility	O
of	O
disease	O
modification	O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
,	O
controlled	O
phase	O
II	O
study	O
of	O
a	B-I
5	I-I
-	I-I
HT6	I-I
receptor	I-I
antagonist	I-I
,	O
SB	B-I
-	I-I
742457	I-I
,	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Participating	B-P
subjects	I-P
had	I-P
a	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
score	I-P
of	I-P
12	I-P
to	I-P
26	I-P
after	I-P
a	I-P
4	I-P
-	I-P
week	I-P
,	I-P
single	I-P
-	I-P
blind	I-P
,	I-P
placebo	I-P
run	I-P
-	I-P
in	I-P
phase	I-P
,	O
and	O
were	O
randomized	O
(	O
2:1:1	O
:	O
2	O
)	O
to	O
receive	O
placebo	B-C
,	O
SB	B-I
-	I-I
742457	I-I
5	O
mg	O
,	O
15	O
mg	O
,	O
or	O
35	O
mg	O
once	O
daily	O
for	O
24	O
weeks	O
.	O

Coprimary	O
efficacy	O
endpoints	O
were	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
with	I-O
caregiver	I-O
input	I-O
(	I-O
CIBIC	I-O
+	I-O
)	I-O
score	I-O
and	O
change	O
from	O
baseline	O
in	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
score	I-O
at	O
Week	O
24	O
,	O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
.	O

A	O
model	O
-	O
based	O
design	O
provided	O
90	O
%	O
power	O
to	O
detect	O
a	O
linear	O
trend	O
in	O
treatment	O
response	O
across	O
increasing	O
doses	O
and	O
>	O
or	O
=90	O
%	O
power	O
to	O
compare	O
SB	B-I
-	I-I
742457	I-I
35	O
mg	O
with	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
aerobic	B-I
exercise	I-I
on	O
mild	O
cognitive	O
impairment	O
:	O
a	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Six	O
-	O
month	O
,	O
randomized	O
,	O
controlled	O
,	O
clinical	O
trial	O
.	O

Veterans	O
Affairs	O
Puget	O
Sound	O
Health	O
Care	O
System	O
clinical	O
research	O
unit	O
.	O

Thirty	B-P
-	I-P
three	I-P
adults	I-P
(	I-P
17	I-P
women	I-P
)	I-P
with	I-P
amnestic	I-P
mild	I-P
cognitive	I-P
impairment	I-P
ranging	I-P
in	I-P
age	I-P
from	I-P
55	I-P
to	I-P
85	I-P
years	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
70	I-P
years	I-P
)	I-P
.	O

Intervention	O
Participants	O
were	O
randomized	O
either	O
to	O
a	B-I
high	I-I
-	I-I
intensity	I-I
aerobic	I-I
exercise	I-I
or	O
stretching	B-C
control	I-C
group	O
.	O

The	B-I
aerobic	I-I
group	O
exercised	O
under	O
the	O
supervision	O
of	O
a	O
fitness	O
trainer	O
at	O
75	O
%	O
to	O
85	O
%	O
of	O
heart	O
rate	O
reserve	O
for	O
45	O
to	O
60	O
min	O
/	O
d	O
,	O
4	O
d	O
/	O
wk	O
for	O
6	O
months	O
.	O

The	O
control	O
group	O
carried	O
out	O
supervised	B-C
stretching	I-C
activities	I-C
according	O
to	O
the	O
same	O
schedule	O
but	O
maintained	O
their	O
heart	O
rate	O
at	O
or	O
below	O
50	O
%	O
of	O
their	O
heart	O
rate	O
reserve	O
.	O

Before	O
and	O
after	O
the	O
study	O
,	O
glucometabolic	B-O
and	O
treadmill	B-O
tests	I-O
were	O
performed	O
and	O
fat	B-O
distribution	I-O
was	O
assessed	O
using	O
dual	B-O
-	I-O
energy	I-O
x	I-O
-	I-O
ray	I-O
absorptiometry	I-O
.	O

At	O
baseline	O
,	O
month	O
3	O
,	O
and	O
month	O
6	O
,	O
blood	O
was	O
collected	O
for	O
assay	B-O
and	O
cognitive	B-O
tests	I-O
were	O
administered	O
.	O

Performance	O
measures	O
on	O
Symbol	B-O
-	I-O
Digit	I-O
Modalities	I-O
,	O
Verbal	B-O
Fluency	I-O
,	O
Stroop	B-O
,	O
Trails	B-O
B	I-O
,	O
Task	B-O
Switching	I-O
,	O
Story	B-O
Recall	I-O
,	O
and	O
List	B-O
Learning	I-O
.	O

Fasting	B-O
plasma	I-O
levels	I-O
of	I-O
insulin	I-O
,	O
cortisol	B-O
,	O
brain	B-O
-	I-O
derived	I-O
neurotrophic	I-O
factor	I-O
,	O
insulinlike	B-O
growth	I-O
factor	I-O
-	I-O
I	I-O
,	O
and	O
beta	B-O
-	I-O
amyloids	I-O
40	I-O
and	O
42	B-O
.	O

-DOCSTART-	O

Title	O
:	O
11	O
C	O
-	O
PiB	O
PET	O
assessment	O
of	O
change	O
in	O
fibrillar	O
amyloid	O
-	O
beta	O
load	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
treated	O
with	O
bapineuzumab	B-I
:	O
a	O
phase	O
2	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
ascending	O
-	O
dose	O
study	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
intravenous	B-I
bapineuzumab	I-I
or	O
placebo	B-C
in	O
a	O
ratio	O
of	O
seven	O
to	O
three	O
in	O
three	O
ascending	O
dose	O
groups	O
(	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
or	O
2	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Each	O
dose	O
group	O
was	O
enrolled	O
after	O
safety	O
review	O
of	O
the	O
previous	O
group	O
.	O

Randomisation	O
was	O
by	O
interactive	O
voice	O
response	O
system	O
;	O
masking	O
was	O
achieved	O
with	O
numbered	O
kit	O
allocation	O
.	O

Patients	O
,	O
investigators	O
,	O
study	O
site	O
personnel	O
,	O
sponsor	O
staff	O
,	O
and	O
carers	O
were	O
masked	O
to	O
treatment	O
.	O

Patients	O
received	O
up	O
to	O
six	O
infusions	O
,	O
13	O
weeks	O
apart	O
,	O
and	O
had	O
(	O
11	O
)	O
C	O
-	O
PiB	O
PET	O
scans	O
at	O
baseline	O
and	O
at	O
weeks	O
20	O
,	O
45	O
,	O
and	O
78	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
difference	O
between	O
the	B-I
pooled	I-I
bapineuzumab	I-I
group	O
and	O
the	B-C
pooled	I-C
placebo	I-C
group	O
in	O
mean	O
change	O
from	O
screening	O
to	O
week	O
78	O
in	O
(	B-O
11	I-O
)	I-O
C	I-O
-	I-O
PiB	I-O
cortical	I-O
to	I-O
cerebellar	I-O
retention	I-O
ratio	I-O
averaged	I-O
across	I-O
six	I-O
cortical	I-O
regions	I-O
of	I-O
interest	I-O
.	O

Analysis	O
was	O
by	O
modified	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
with	O
EudraCT	O
,	O
number	O
2004-004120-12	O
;	O
ISRCTN17517446	O
.	O

-DOCSTART-	O

Title	O
:	O
Spine	B-I
Surgery	I-I
under	O
general	B-I
anesthesia	I-I
may	O
not	O
increase	O
the	O
risk	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
We	O
searched	O
the	O
Clinical	O
Data	O
Repository	O
of	O
the	O
University	O
of	O
Virginia	O
for	O
patients	B-P
receiving	I-P
spine	I-P
surgery	I-P
from	I-P
January	I-P
1	I-P
,	I-P
1992	I-P
to	I-P
March	I-P
1	I-P
,	I-P
2004	I-P
.	O

Patients	B-P
with	I-P
newly	I-P
-	I-P
diagnosed	I-P
AD	I-P
after	I-P
the	I-P
surgery	I-P
but	I-P
before	I-P
March	I-P
1	I-P
,	I-P
2009	I-P
(	I-P
a	I-P
minimal	I-P
5	I-P
-	I-P
year	I-P
follow	I-P
-	I-P
up	I-P
time	I-P
after	I-P
the	I-P
surgery	I-P
)	I-P
were	O
identified	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
modafinil	B-I
for	O
the	O
treatment	O
of	O
apathy	O
in	O
individuals	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
23	B-P
participants	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
probable	I-P
AD	I-P
according	I-P
to	I-P
National	I-P
Institute	I-P
of	I-P
Neurologic	I-P
and	I-P
Communicative	I-P
Disorder	I-P
and	I-P
Stroke	I-P
-	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
and	I-P
Related	I-P
Disorders	I-P
criteria	I-P
were	O
randomized	O
into	O
the	O
experimental	O
(	O
modafinil	B-I
200	O
mg	O
daily	O
)	O
or	O
control	O
(	O
placebo	B-C
)	O
groups	O
.	O

All	O
participants	O
were	O
also	O
receiving	O
stable	O
doses	O
of	O
a	O
cholinesterase	O
inhibitor	O
medication	O
.	O

Participants	O
completed	O
assessments	O
at	O
baseline	O
and	O
after	O
8	O
weeks	O
of	O
treatment	O
.	O

Outcome	O
measures	O
included	O
family	O
report	O
measures	O
of	O
apathy	B-O
,	O
ADL	B-O
performance	I-O
,	O
and	O
caregiver	B-O
burden	I-O
,	O
as	O
well	O
as	O
direct	O
assessment	O
of	O
ADL	B-O
performance	I-O
.	O

The	O
study	O
was	O
conducted	O
at	O
a	O
private	O
psychiatric	O
hospital	O
in	O
Rhode	O
Island	O
from	O
September	O
2005	O
until	O
September	O
2007	O
.	O

-DOCSTART-	O

Title	O
:	O
Heat	B-I
-	I-I
processed	I-I
ginseng	I-I
enhances	O
the	O
cognitive	O
function	O
in	O
patients	B-P
with	I-P
moderately	I-P
severe	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
with	I-P
AD	I-P
were	O
randomized	O
into	O
one	O
of	O
three	O
different	O
dose	O
groups	O
or	O
the	O
control	O
group	O
as	O
follows	O
:	O
1	O
.	O
5	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
,	O
3	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
4	O
.	O
5	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
groups	O
,	O
or	O
control	O
(	O
n	O
=	O
10	O
)	O
.	O

The	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
and	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
for	O
24	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Chinese	B-I
herbal	I-I
medicine	I-I
for	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
based	I-P
on	I-P
syndrome	I-P
differentiation	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
]	O
.	O

METHODS	O
:	O
Adopting	O
the	O
internationally	O
recognized	O
criteria	O
developed	O
by	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Diseases	O
and	O
Stroke	O
/	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
,	O
the	O
clinical	O
trial	O
was	O
conducted	O
on	O
131	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
from	I-P
5	I-P
communities	I-P
and	I-P
7	I-P
social	I-P
welfare	I-P
institutions	I-P
.	O

Participants	O
were	O
accepted	O
after	O
informed	O
consent	O
was	O
received	O
,	O
and	O
laboratory	O
tests	O
and	O
a	O
head	O
imaging	O
study	O
were	O
conducted	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
Chinese	B-I
medicine	I-I
group	O
(	O
CMG	O
)	O
(	O
66	O
cases	O
)	O
or	O
Western	B-I
medicine	I-I
group	O
(	O
WMG	O
)	O
(	O
65	O
cases	O
)	O
.	O

Patients	O
in	O
the	O
CMG	O
were	O
treated	O
monthly	O
with	O
Chinese	B-I
medicine	I-I
according	O
to	O
syndrome	O
differentiation	O
.	O

Patients	O
in	O
the	O
WMG	O
were	O
treated	O
with	O
donepezil	B-I
at	O
a	O
dose	O
of	O
5	O
mg	O
once	O
daily	O
.	O

The	O
therapeutic	O
course	O
lasted	O
48	O
weeks	O
.	O

The	B-O
scores	I-O
of	I-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Fuld	B-O
Object	I-O
-	I-O
Memory	I-O
Evaluation	I-O
(	I-O
FOM	I-O
)	I-O
,	O
Block	B-O
Design	I-O
(	I-O
BD	I-O
)	I-O
and	O
Digit	B-O
Span	I-O
(	I-O
DS	I-O
)	I-O
were	O
used	O
to	O
evaluate	O
the	B-O
cognitive	I-O
function	I-O
;	O
resting	B-O
-	I-O
state	I-O
fMRI	I-O
was	O
used	O
for	O
observing	O
brain	B-O
function	I-O
.	O

The	B-O
questionnaires	I-O
and	O
fMRI	B-O
were	O
performed	O
before	O
and	O
after	O
treatments	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
psychosocial	O
intervention	O
in	O
patients	B-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
the	O
multicentre	O
,	O
rater	O
blinded	O
,	O
randomised	O
Danish	O
Alzheimer	O
Intervention	O
Study	O
(	O
DAISY	O
)	O
.	O

METHODS	O
:	O
Multicentre	O
,	O
randomised	O
,	O
controlled	O
,	O
rater	O
blinded	O
trial	O
.	O

Primary	O
care	O
and	O
memory	O
clinics	O
in	O
five	O
Danish	O
districts	O
.	O

330	B-P
outpatients	I-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
and	I-P
their	I-P
330	I-P
primary	I-P
care	I-P
givers	I-P
.	O

Participating	O
dyads	O
(	O
patient	O
and	O
primary	O
care	O
giver	O
)	O
were	O
randomised	O
to	O
control	B-C
support	I-C
during	O
follow	O
-	O
up	O
or	O
to	O
control	B-C
support	I-C
plus	O
DAISY	B-I
intervention	I-I
(	O
multifaceted	B-I
and	I-I
semi	I-I
-	I-I
tailored	I-I
counselling	I-I
,	O
education	B-I
,	O
and	O
support	B-I
)	O
.	O

Primary	O
outcomes	O
at	O
12	O
months	O
for	O
patients	O
were	O
change	O
from	O
baseline	O
in	O
mini	B-O
mental	I-O
state	I-O
examination	I-O
(	I-O
MMSE	I-O
)	I-O
score	I-O
,	O
Cornell	B-O
depression	I-O
scale	I-O
score	I-O
,	O
and	O
proxy	B-O
rated	I-O
European	I-O
quality	I-O
of	I-O
life	I-O
visual	I-O
analogue	I-O
scale	I-O
(	I-O
EQ	I-O
-	I-O
VAS	I-O
)	I-O
score	I-O
.	O

For	O
care	O
givers	O
,	O
outcomes	O
were	O
change	O
from	O
baseline	O
in	O
geriatric	B-O
depression	I-O
scale	I-O
(	I-O
GDS	I-O
30	I-O
items	I-O
)	I-O
score	I-O
and	O
EQ	B-O
-	I-O
VAS	I-O
score	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Psychosocial	B-I
care	I-I
assistants	I-I
caring	I-I
for	O
residents	B-P
with	I-P
dementia	I-P
according	I-P
to	I-P
section	I-P
87	I-P
b	I-P
SGB	I-P
XI	I-P
.	O

Emotional	O
and	O
cognitive	O
effects	O
]	O
.	O

METHODS	O
:	O
Using	O
a	O
longitudinal	O
control	O
group	O
design	O
the	O
effects	O
of	O
additional	B-I
low	I-I
threshold	I-I
psychosocial	I-I
assistance	I-I
were	O
recorded	O
and	O
analysed	O
for	O
ten	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
ASCOMALVA	O
trial	O
:	O
association	O
between	O
the	B-I
cholinesterase	I-I
inhibitor	I-I
donepezil	I-I
and	O
the	B-I
cholinergic	I-I
precursor	I-I
choline	I-I
alphoscerate	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
with	O
cerebrovascular	O
injury	O
:	O
interim	O
results	O
.	O

METHODS	O
:	O
ASCOMALVA	O
is	O
a	O
double	O
-	O
blind	O
multicentre	O
trial	O
that	O
has	O
completed	O
the	O
first	O
12	O
months	O
of	O
observation	O
of	O
91	B-P
patients	I-P
of	I-P
the	I-P
210	I-P
planned	I-P
.	O

Patients	O
were	O
aged	O
between	O
56	O
and	O
91	O
years	O
(	O
mean	O
75	O
	O
10	O
years	O
)	O
and	O
were	O
included	O
in	O
the	O
protocol	O
with	O
a	O
MMSE	O
score	O
between	O
15	O
and	O
24	O
.	O

Patients	B-P
with	I-P
AD	I-P
diagnosed	I-P
according	I-P
to	I-P
the	I-P
DSM	I-P
IV	I-P
criteria	I-P
suffer	I-P
from	I-P
ischemic	I-P
brain	I-P
damage	I-P
documented	I-P
by	I-P
neuroimaging	I-P
(	I-P
MRI	I-P
and	I-P
CT	I-P
scan	I-P
)	I-P
,	I-P
with	I-P
a	I-P
score?2	I-P
in	I-P
at	I-P
least	I-P
one	I-P
subfield	I-P
of	I-P
the	I-P
New	I-P
Rating	I-P
Scale	I-P
for	I-P
Age	I-P
-	I-P
Related	I-P
White	I-P
Matter	I-P
Changes	I-P
(	I-P
ARWMC	I-P
)	I-P
.	O

Patients	O
were	O
randomly	O
allotted	O
to	O
an	O
active	O
treatment	O
group	O
(	O
donepezil	B-I
+	O
choline	B-I
alphoscerate	I-I
)	O
or	O
to	O
a	O
reference	O
treatment	O
group	O
(	O
donepezil	B-C
+	O
placebo	B-C
)	O
and	O
were	O
examined	O
after	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	O
outcomes	O
after	O
sertaline	B-I
treatment	I-I
in	O
patients	B-P
with	I-P
depression	I-P
of	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
.	O

Outpatient	O
memory	O
clinics	O
at	O
five	O
academic	O
medical	O
centers	O
in	O
the	O
United	O
States	O
.	O

A	B-P
total	I-P
of	I-P
131	I-P
patients	I-P
with	I-P
dAD	I-P
(	I-P
60	I-P
men	I-P
)	I-P
and	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
scores	I-P
of	I-P
10	I-P
-	I-P
26	I-P
.	O

Sertraline	B-I
(	O
n	O
=	O
67	O
)	O
,	O
target	O
dose	O
of	O
100	O
mg	O
daily	O
or	O
matching	B-C
placebo	I-C
(	O
n	O
=	O
64	O
)	O
.	O

Caregivers	O
received	O
standardized	O
psychosocial	O
intervention	O
throughout	O
the	O
trial	O
.	O

Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
cognitive	B-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
,	O
letter	B-O
fluency	I-O
,	O
backward	B-O
digit	I-O
span	I-O
,	O
Symbol	B-O
Digit	I-O
Modalities	I-O
Test	I-O
,	O
and	O
Finger	B-O
Tapping	I-O
Test	I-O
,	O
administered	O
at	O
baseline	O
,	O
and	O
8	O
,	O
16	O
,	O
and	O
24	O
weeks	O
following	O
baseline	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
apolipoprotein	I-I
E	I-I
?4	I-I
allele	I-I
on	O
functional	O
MRI	O
during	O
n	O
-	O
back	O
working	O
memory	O
tasks	O
in	O
healthy	B-P
middle	I-P
-	I-P
aged	I-P
adults	I-P
.	O

METHODS	O
:	O
From	O
110	B-P
participants	I-P
,	I-P
81	I-P
individuals	I-P
without	I-P
objective	I-P
or	I-P
subjective	I-P
cognitive	I-P
impairment	I-P
underwent	O
APOE	O
genotyping	O
.	O

Nine	B-P
APOE4	I-P
carriers	I-P
and	I-P
9	I-P
age	I-P
-	I-P
and	I-P
sex	I-P
-	I-P
matched	I-P
non	I-P
-	I-P
APOE4	I-P
controls	I-P
were	O
recruited	O
for	O
fMRI	O
examinations	O
during	O
WM	O
tasks	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
pharmacology	O
of	O
ponezumab	B-I
(	I-I
PF	I-I
-	I-I
04360365	I-I
)	I-I
after	O
a	O
single	O
10	O
-	O
minute	O
intravenous	O
infusion	O
in	O
subjects	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Subjects	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
received	O
ponezumab	B-I
1	O
mg	O
/	O
kg	O
(	O
n	O
=	O
3	O
)	O
,	O
3	O
mg	O
/	O
kg	O
(	O
n	O
=	O
3	O
)	O
,	O
5	O
mg	O
/	O
kg	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
10	O
mg	O
/	O
kg	O
(	O
n	O
=	O
5	O
)	O
.	O

They	O
were	O
followed	O
up	O
as	O
outpatients	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
immunoglobulin	I-I
for	O
treatment	O
of	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
phase	O
2	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
dose	O
-	O
finding	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
multicentre	O
,	O
placebo	O
-	O
controlled	O
phase	O
2	O
trial	O
at	O
seven	O
sites	O
in	O
the	O
USA	O
and	O
five	O
in	O
Germany	O
.	O

Participants	B-P
with	I-P
probable	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
aged	I-P
50	I-P
-	I-P
85	I-P
years	I-P
were	O
randomly	O
assigned	O
(	O
by	O
a	O
computer	O
-	O
generated	O
randomisation	O
sequence	O
,	O
with	O
block	O
sizes	O
of	O
eight	O
)	O
to	O
infusions	O
every	O
4	O
weeks	O
(	O
02	B-I
,	O
05	B-I
,	O
or	O
08	B-I
g	I-I
intravenous	I-I
immunoglobulin	I-I
per	O
kg	O
bodyweight	O
,	O
or	O
placebo	B-C
)	O
or	O
infusions	O
every	O
2	O
weeks	O
(	O
01	B-I
,	O
025	B-I
,	O
or	O
04	B-I
g	I-I
/	I-I
kg	I-I
,	O
or	O
placebo	B-C
)	O
.	O

Patients	O
,	O
caregivers	O
,	O
investigators	O
assessing	O
outcomes	O
,	O
and	O
staff	O
at	O
imaging	O
facilities	O
and	O
the	O
clinical	O
research	O
organisation	O
were	O
masked	O
to	O
treatment	O
allocation	O
,	O
but	O
dispensing	O
pharmacists	O
,	O
the	O
statistician	O
,	O
and	O
the	O
person	O
responsible	O
for	O
final	O
PET	O
analyses	O
were	O
not	O
.	O

Treatment	O
was	O
masked	O
with	O
opaque	O
pouches	O
and	O
infusion	O
lines	O
.	O

The	O
primary	O
endpoint	O
was	O
median	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
plasma	B-O
amyloid	I-O
?	I-O
(	I-O
A?	I-O
)	I-O
(	I-O
1	I-O
-	I-O
40	I-O
)	I-O
between	O
the	O
last	O
infusion	O
and	O
the	O
final	O
visit	O
(	O
2	O
weeks	O
or	O
4	O
weeks	O
depending	O
on	O
infusion	O
interval	O
)	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
trial	O
is	O
registered	O
at	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT00812565	O
)	O
and	O
controlled	O
-	O
trials	O
.	O
com	O
(	O
ISRCTN64846759	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
SolCos	B-I
model	I-I
-	I-I
based	I-I
individual	I-I
reminiscence	I-I
on	O
older	B-P
adults	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
dementia	I-P
due	I-P
to	I-P
Alzheimer	I-P
disease	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
82	B-P
older	I-P
adults	I-P
with	I-P
probable	I-P
AD	I-P
were	O
recruited	O
from	O
psychiatric	O
day	O
care	O
,	O
inpatient	O
,	O
and	O
long	O
term	O
care	O
facilities	O
.	O

Of	O
the	O
study	O
group	O
,	O
41	O
participants	O
were	O
randomly	O
selected	O
for	O
individual	B-I
reminiscence	I-I
sessions	I-I
during	O
4	O
weeks	O
performed	O
by	O
1	O
facilitator	O
.	O

A	O
control	O
group	O
of	O
41	O
older	O
adults	O
were	O
randomly	O
involved	O
and	O
had	O
no	B-C
planned	I-C
reminiscence	I-C
treatment	I-C
of	O
any	O
kind	O
in	O
the	O
study	O
period	O
.	O

All	O
study	O
participants	O
were	O
tested	O
pre	O
-	O
and	O
postintervention	O
period	O
with	O
validated	O
assessment	O
scales	O
to	O
evaluate	O
cognition	B-O
and	O
behavior	B-O
.	O

Analyses	O
were	O
based	O
on	O
delta	O
scores	O
,	O
the	O
differences	O
between	O
assessment	O
scales	O
pre	O
-	O
and	O
postintervention	O
scores	O
,	O
compared	O
between	O
the	O
intervention	O
and	O
the	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Phase	O
I	O
study	O
on	O
the	O
pharmacokinetics	O
and	O
tolerance	O
of	O
ZT	B-I
-	I-I
1	I-I
,	O
a	B-I
prodrug	I-I
of	I-I
huperzine	I-I
A	I-I
,	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
single	O
-	O
and	O
multiple	O
-	O
dose	O
study	O
.	O

For	O
the	O
single	O
-	O
dose	O
study	O
,	O
9	B-P
subjects	I-P
were	O
randomly	O
divided	O
into	O
3	O
groups	O
receiving	O
ZT	B-I
-	I-I
1	I-I
(	O
0	O
.	O
5	O
,	O
0	O
.	O
75	O
or	O
1	O
mg	O
,	O
po	O
)	O
according	O
to	O
a	O
Three	O
-	O
way	O
Latin	O
Square	O
Design	O
.	O

For	O
the	O
multiple	O
-	O
dose	O
study	O
,	O
9	B-P
subjects	I-P
receiving	O
ZT	B-I
-	I-I
1	I-I
(	O
0	O
.	O
75	O
mg	O
/	O
d	O
,	O
po	O
)	O
for	O
8	O
consecutive	O
days	O
.	O

In	O
the	O
tolerance	O
study	O
,	O
40	B-P
subjects	I-P
were	O
randomly	O
divided	O
into	O
5	O
groups	O
receiving	O
a	B-I
single	I-I
dose	I-I
of	I-I
ZT	I-I
-	I-I
1	I-I
(	O
0	O
.	O
5	O
,	O
0	O
.	O
75	O
,	O
1	O
,	O
1	O
.	O
25	O
or	O
1	O
.	O
5	O
mg	O
,	O
po	O
)	O
.	O

Plasma	B-O
and	O
urine	B-O
concentrations	I-O
of	I-O
ZT	I-O
-	I-O
1	I-O
and	O
Hup	B-O
A	I-O
were	O
determined	O
using	O
LC	B-O
-	I-O
MS	I-O
/	I-O
MS	I-O
.	O

Pharmacokinetic	B-O
parameters	I-O
,	O
including	O
Cmax	B-O
,	O
AUC0	B-O
-	I-O
72	I-O
h	I-O
and	O
AUC0	B-O
-	I-O
?	I-O
were	O
calculated	O
.	O

Tolerance	B-O
assessments	I-O
were	O
conducted	O
throughout	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
rivastigmine	B-I
in	O
comparison	O
to	O
ginkgo	B-C
for	O
treating	O
Alzheimer	O
'	O
s	O
dementia	O
.	O

METHODS	O
:	O
Total	B-P
56	I-P
patients	I-P
aged	I-P
50	I-P
-	I-P
75	I-P
years	I-P
,	I-P
suffering	I-P
from	I-P
dementia	I-P
,	O
were	O
allocated	O
into	O
one	O
of	O
the	O
two	O
treatments	O
:	O
group	O
1	O
)	O
Ginkgo	B-C
biloba	I-C
(	O
120	O
mg	O
daily	O
dose	O
)	O
;	O
group	O
2	O
)	O
rivastigmine	B-I
(	O
4	O
.	O
5	O
mg	O
daily	O
dose	O
)	O
in	O
a	O
24	O
-	O
week	O
randomized	O
double	O
blind	O
study	O
.	O

The	B-O
degree	I-O
of	I-O
severity	I-O
of	I-O
dementia	I-O
was	O
assessed	O
by	O
the	B-O
Seven	I-O
Minute	I-O
test	I-O
and	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
methylphenidate	B-I
for	O
apathy	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Six	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
trial	O
enrolling	O
Alzheimer	B-P
'	I-P
s	I-P
disease	I-P
participants	I-P
(	I-P
NINCDS	I-P
-	I-P
ADRDA	I-P
criteria	I-P
)	I-P
with	I-P
apathy	I-P
assigned	O
to	O
methylphenidate	B-I
20	O
mg	O
daily	O
or	O
placebo	B-C
,	O
conducted	O
from	O
June	O
2010	O
to	O
December	O
2011	O
.	O

Primary	O
outcomes	O
were	O
change	O
in	O
Apathy	B-O
Evaluation	I-O
Scale	I-O
(	I-O
AES	I-O
)	I-O
score	I-O
and	O
modified	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
ADCS	I-O
-	I-O
CGI	I-O
-	I-O
C	I-O
)	I-O
.	O

Secondary	O
outcomes	O
included	O
change	O
in	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
apathy	I-O
score	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
score	I-O
,	O
and	O
safety	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
non	I-I
-	I-I
focal	I-I
plasticity	I-I
protocol	I-I
on	O
apathy	O
in	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
sham	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
were	O
randomized	O
to	O
receive	O
either	O
active	B-I
or	O
sham	B-C
-	I-C
tDCS	I-C
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLPFC	O
)	O
.	O

Patients	O
received	O
six	O
sessions	O
of	O
intervention	O
during	O
2	O
weeks	O
and	O
were	O
evaluated	O
at	O
baseline	O
,	O
at	O
week	O
1	O
and	O
2	O
,	O
and	O
after	O
1	O
week	O
without	O
intervention	O
.	O

Clinical	O
raters	O
,	O
patients	O
,	O
and	O
caregivers	O
were	O
blinded	O
.	O

The	O
primary	O
outcome	O
was	O
apathy	B-O
.	O

Global	B-O
cognition	I-O
and	O
neuropsychiatric	B-O
symptoms	I-O
were	O
examined	O
as	O
secondary	O
outcomes	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
Souvenaid	B-I
on	O
plasma	O
micronutrient	O
levels	O
and	O
fatty	O
acid	O
profiles	O
in	O
mild	O
and	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Subjects	B-P
with	I-P
mild	I-P
(	I-P
RCT1	I-P
,	I-P
RCT2	I-P
)	I-P
or	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
(	I-P
RCT3	I-P
)	I-P
received	O
active	O
or	O
control	O
product	O
once	O
daily	O
for	O
12	O
-	O
24	O
weeks	O
or	O
active	O
product	O
during	O
the	O
24	O
-	O
week	O
OLE	O
following	O
RCT2	O
(	O
n	O
=	O
212	O
-	O
527	O
)	O
.	O

Measurements	O
included	O
plasma	B-O
levels	I-O
of	I-O
B	I-O
vitamins	I-O
,	O
choline	B-O
,	O
vitamin	B-O
E	I-O
,	O
selenium	B-O
,	O
uridine	B-O
and	O
homocysteine	B-O
and	O
proportions	B-O
of	I-O
DHA	I-O
,	O
EPA	B-O
and	O
total	B-O
n	I-O
-	I-O
3	I-O
long	I-O
-	I-O
chain	I-O
polyunsaturated	I-O
fatty	I-O
acids	I-O
in	I-O
plasma	I-O
and	O
erythrocytes	B-O
.	O

Between	O
-	O
group	O
comparisons	O
were	O
made	O
using	O
t	O
tests	O
or	O
non	O
-	O
parametric	O
alternatives	O
.	O

-DOCSTART-	O

Title	O
:	O
Citalopram	B-I
for	O
the	O
Treatment	O
of	O
Agitation	O
in	O
Alzheimer	O
Dementia	O
:	O
Genetic	O
Influences	O
.	O

METHODS	O
:	O
We	O
utilized	O
data	O
from	O
the	B-I
Citalopram	I-I
for	O
Agitation	O
in	O
Alzheimer	O
'	O
s	O
Disease	O
(	O
CitAD	O
)	O
database	O
.	O

CitAD	O
was	O
a	O
9	O
-	O
week	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
clinical	O
trial	O
showing	O
significant	O
improvement	O
in	O
agitation	O
and	O
caregiver	O
distress	O
in	O
patients	O
treated	O
with	O
citalopram	B-I
.	O

Proportional	O
odds	O
logistic	O
regression	O
and	O
mixed	O
effects	O
models	O
were	O
used	O
to	O
examine	O
the	O
above	O
-	O
mentioned	O
outcome	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
Acetylcholine	I-I
Release	I-I
Agent	I-I
ST101	I-I
with	O
Donepezil	B-I
in	O
Alzheimer	O
'	O
s	O
Disease	O
:	O
A	O
Randomized	O
Phase	O
2	O
Study	O
.	O

METHODS	O
:	O
A	O
phase	O
2	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
enrolled	O
210	B-P
AD	I-P
patients	I-P
(	I-P
MMSE	I-P
10	I-P
-	I-P
20	I-P
)	I-P
on	O
10	B-I
mg	I-I
donepezil	I-I
QD	I-I
.	O

Patients	O
received	O
ST101	B-I
(	O
10	O
,	O
60	O
,	O
or	O
120	O
mg	O
QD	O
)	O
or	O
placebo	B-C
for	O
12	O
weeks	O
.	O

The	O
primary	O
endpoint	O
was	O
change	O
in	O
cognitive	B-O
function	I-O
measured	O
by	O
ADAS	B-O
-	I-O
cog	I-O
in	O
the	O
modified	O
Intent	O
To	O
Treat	O
(	O
MITT	O
)	O
population	O
and	O
the	O
Per	O
Protocol	O
(	O
PP	O
)	O
population	O
.	O

-DOCSTART-	O

Title	O
:	O
Nutritional	B-I
Guidance	I-I
Improves	O
Nutrient	O
Intake	O
and	O
Quality	O
of	O
Life	O
,	O
and	O
May	O
Prevent	O
Falls	O
in	O
Aged	B-P
Persons	I-P
with	I-P
Alzheimer	I-P
Disease	I-P
Living	I-P
with	I-P
a	I-P
Spouse	I-P
(	O
NuAD	O
Trial	O
)	O
.	O

METHODS	O
:	O
Randomised	O
controlled	O
trial	O
.	O

Persons	B-P
with	I-P
AD	I-P
living	I-P
with	I-P
a	I-P
spouse	I-P
.	O

Tailored	B-I
nutritional	I-I
guidance	I-I
with	O
home	O
visits	O
during	O
one	O
year	O
.	O

The	O
control	O
group	O
received	O
a	B-C
written	I-C
guide	I-C
about	O
nutrition	O
in	O
older	B-P
adults	I-P
and	I-P
all	I-P
community	I-P
-	I-P
provided	I-P
normal	I-P
care	I-P
.	O

The	O
primary	O
outcome	O
measure	O
was	O
weight	B-O
change	I-O
,	O
and	O
secondary	O
outcomes	O
included	O
changes	O
in	O
protein	B-O
and	O
micronutrient	B-O
intakes	I-O
from	I-O
three	I-O
-	I-O
day	I-O
food	I-O
records	I-O
,	O
HRQoL	B-O
(	I-O
15	I-O
D	I-O
)	I-O
and	O
rate	B-O
of	I-O
falls	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Changes	O
in	O
Brain	O
Volume	O
with	O
Bapineuzumab	B-I
in	O
Mild	O
to	O
Moderate	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
Bapineuzumab	B-I
dosages	O
included	O
0	O
.	O
5	O
mg	O
/	O
kg	O
in	O
carriers	O
and	O
0	O
.	O
5	O
or	O
1	O
.	O
0	O
mg	O
/	O
kg	O
in	O
noncarriers	O
,	O
every	O
13	O
weeks	O
for	O
78	O
weeks	O
.	O

Volumetric	O
outcomes	O
included	O
annualized	B-O
brain	I-O
,	O
ventricular	B-O
,	O
and	O
mean	B-O
hippocampal	I-O
boundary	I-O
shift	I-O
integrals	I-O
(	O
BBSI	B-O
;	O
VBSI	B-O
;	O
HBSI	B-O
)	O
up	O
to	O
Week	O
71	O
.	O

Treatment	O
differences	O
were	O
estimated	O
using	O
mixed	O
models	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Transcranial	B-I
direct	I-I
current	I-I
stimulation	I-I
as	O
a	O
memory	O
enhancer	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
in	O
which	O
tDCS	B-I
was	O
applied	O
in	O
six	O
30	O
-	O
minute	O
sessions	O
for	O
10	O
days	O
.	O

tDCS	B-I
was	O
delivered	O
to	O
the	O
left	O
temporal	O
cortex	O
with	O
2	O
-	O
mA	O
intensity	O
.	O

A	B-P
total	I-P
of	I-P
25	I-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

All	O
of	O
the	O
patients	O
were	O
diagnosed	O
according	O
to	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
and	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
criteria	O
.	O

Twelve	O
patients	O
received	O
active	B-I
stimulation	I-I
,	O
and	O
thirteen	O
patients	O
received	O
placebo	B-C
stimulation	I-C
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
change	O
in	O
two	B-O
parallel	I-O
versions	I-O
of	I-O
the	I-O
California	I-O
Verbal	I-O
Learning	I-O
Test	I-O
-	I-O
Second	I-O
Edition	I-O
,	O
a	B-O
standardized	I-O
neuropsychological	I-O
memory	I-O
test	I-O
normalized	I-O
by	I-O
age	I-O
and	I-O
gender	I-O
.	O

The	O
secondary	O
outcome	O
measures	O
were	O
the	B-O
Mini	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
clock	B-O
-	I-O
drawing	I-O
test	I-O
,	O
and	O
Trail	B-O
Making	I-O
Test	I-O
A	I-O
and	O
B	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
tolerability	O
of	O
BAN2401	B-I
-	O
-	O
a	O
clinical	O
study	O
in	O
Alzheimer	O
'	O
s	O
disease	O
with	O
a	B-I
protofibril	I-I
selective	I-I
A?	I-I
antibody	I-I
.	O

METHODS	O
:	O
Here	O
we	O
describe	O
the	O
first	O
clinical	O
study	O
with	O
BAN2401	B-I
.	O

Safety	B-O
and	O
tolerability	B-O
were	O
investigated	O
in	O
mild	O
to	O
moderate	O
AD	O
.	O

A	O
study	O
design	O
was	O
used	O
with	O
staggered	O
parallel	O
single	O
and	O
multiple	O
ascending	O
doses	O
,	O
from	O
0	O
.	O
1	O
mg	O
/	O
kg	O
as	O
a	O
single	O
dose	O
to	O
10	O
mg	O
/	O
kg	O
biweekly	O
for	O
four	O
months	O
.	O

The	B-O
presence	I-O
of	I-O
amyloid	I-O
related	I-O
imaging	I-O
abnormalities	I-O
(	O
ARIA	B-O
,	O
E	B-O
for	I-O
edema	I-O
,	O
H	B-O
for	I-O
hemorrhage	I-O
)	O
was	O
assessed	O
with	O
magnetic	B-O
resonance	I-O
imaging	I-O
(	I-O
MRI	I-O
)	I-O
.	O

Cerebrospinal	B-O
fluid	I-O
(	I-O
CSF	I-O
)	I-O
and	O
plasma	B-O
samples	I-O
were	O
analyzed	O
to	O
investigate	O
pharmacokinetics	B-O
(	I-O
PK	I-O
)	I-O
and	O
effects	B-O
on	I-O
biomarkers	I-O
.	O

-DOCSTART-	O

Title	O
:	O
R	B-I
-	I-I
and	O
S	B-I
-	I-I
citalopram	I-I
concentrations	O
have	O
differential	O
effects	O
on	O
neuropsychiatric	O
scores	O
in	O
elders	B-P
with	I-P
dementia	I-P
and	I-P
agitation	I-P
.	O

METHODS	O
:	O
Citalopram	B-I
enantiomer	O
exposures	O
(	O
AUC	O
(	O
0	O
,	O
24	O
h	O
)	O
)	O
derived	O
from	O
an	O
established	O
population	O
pharmacokinetic	O
analysis	O
were	O
utilized	O
to	O
explore	O
the	O
relationship	O
between	O
(	B-I
R	I-I
)	I-I
-	I-I
and	O
(	B-I
S	I-I
)	I-I
-	I-I
citalopram	I-I
area	O
under	O
the	O
curve	O
(	O
AUC	O
(	O
0	O
,	O
24	O
)	O
)	O
and	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Neurobehavioural	B-O
Rating	I-O
Scale	I-O
-	I-O
Agitation	I-O
Subscale	I-O
(	I-O
NBRS	I-O
-	I-O
A	I-O
)	I-O
,	O
modified	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
mADCS	I-O
-	I-O
CGIC	I-O
)	I-O
and	O
Neuropsychiatric	B-O
Inventory	I-O
Agitation	I-O
subscale	I-O
(	I-O
NPIA	I-O
)	I-O
scores	I-O
.	O

Time	O
dependent	O
changes	O
in	O
these	O
scores	O
(	O
disease	O
progression	O
)	O
were	O
accounted	O
for	O
prior	O
to	O
exploring	O
the	O
exposure	O
effect	O
relationship	O
for	O
each	O
enantiomer	O
.	O

These	O
relationships	O
were	O
evaluated	O
using	O
a	O
non	O
-	O
linear	O
-	O
mixed	O
effects	O
modelling	O
approach	O
as	O
implemented	O
in	O
nonmem	O
v7	O
.	O
3	O
.	O

-DOCSTART-	O

Title	O
:	O
Alzheimer	O
'	O
s	O
Disease	O
Severity	O
is	O
Not	O
Significantly	O
Associated	O
with	O
Short	B-I
Sleep	I-I
:	O
Survey	O
by	O
Actigraphy	O
on	O
208	B-P
Mild	I-P
and	I-P
Moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
Patients	I-P
.	O

METHODS	O
:	O
During	O
an	O
observational	O
first	O
step	O
of	O
a	O
clinical	O
trial	O
,	O
sleep	O
was	O
assessed	O
in	O
institutionalized	B-P
patients	I-P
with	I-P
mild	I-P
or	I-P
moderate	I-P
AD	I-P
using	O
actigraphy	B-O
(	O
MW8	B-O
,	O
Camtech	O
,	O
Cambridge	O
,	O
UK	O
)	O
for	O
14	O
consecutive	O
24	O
-	O
hour	O
periods	O
.	O

Sleep	O
parameters	O
analyzed	O
were	O
:	O
TST	B-O
,	O
time	B-O
in	I-O
bed	I-O
(	I-O
TIB	I-O
)	I-O
,	O
wake	B-O
after	I-O
sleep	I-O
onset	I-O
(	I-O
WASO	I-O
)	I-O
,	O
sleep	B-O
efficiency	I-O
(	I-O
SE	I-O
)	I-O
defined	O
by	O
the	B-O
ratio	I-O
TST	I-O
/	I-O
TIB	I-O
,	O
in	O
percentage	O
)	O
,	O
the	B-O
number	I-O
and	I-O
length	I-O
of	I-O
awakenings	I-O
,	O
the	B-O
night	I-O
fragmentation	I-O
index	I-O
,	O
the	B-O
interdaily	I-O
stability	I-O
,	O
and	O
intradaily	B-O
variability	I-O
indexes	I-O
.	O

Statistical	O
association	O
analyses	O
were	O
tested	O
between	O
these	O
values	O
and	O
AD	O
apathy	O
and	O
severity	O
scores	O
.	O

-DOCSTART-	O

Title	O
:	O
Cost	O
-	O
effectiveness	O
of	O
donepezil	B-I
and	O
memantine	B-I
in	O
moderate	O
to	O
severe	O
Alzheimer	O
'	O
s	O
disease	O
(	O
the	O
DOMINO	O
-	O
AD	O
trial	O
)	O
.	O

METHODS	O
:	O
Cost	O
-	O
effectiveness	O
analysis	O
was	O
based	O
on	O
a	O
52	O
-	O
week	O
,	O
multicentre	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
factorial	O
clinical	O
trial	O
.	O

A	B-P
total	I-P
of	I-P
295	I-P
community	I-P
-	I-P
dwelling	I-P
patients	I-P
with	I-P
moderate	I-P
/	I-P
severe	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
,	O
already	O
treated	O
with	O
donepezil	B-I
,	O
were	O
randomised	O
to	O
:	O
(	O
i	O
)	O
continue	O
donepezil	B-I
;	O
(	O
ii	O
)	O
discontinue	O
donepezil	B-I
;	O
(	O
iii	O
)	O
discontinue	O
donepezil	B-I
and	O
start	O
memantine	B-I
;	O
or	O
(	O
iv	O
)	O
continue	O
donepezil	B-I
and	O
start	O
memantine	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Poor	O
Safety	O
and	O
Tolerability	O
Hamper	O
Reaching	O
a	O
Potentially	O
Therapeutic	O
Dose	O
in	O
the	O
Use	O
of	O
Thalidomide	B-I
for	O
Alzheimer	O
'	O
s	O
Disease	O
:	O
Results	O
from	O
a	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
24	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
study	O
with	O
escalating	O
dose	O
regimen	O
of	O
thalidomide	B-I
with	O
a	O
target	O
dose	O
of	O
400	O
mg	O
daily	O
in	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
.	O

The	O
primary	O
outcome	O
measures	O
were	O
tolerability	B-O
and	O
cognitive	B-O
performance	I-O
assessed	O
by	O
a	O
battery	O
of	O
tests	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
Term	O
Extensions	O
of	O
Randomized	O
Vaccination	O
Trials	O
of	O
ACC	B-I
-	I-I
001	I-I
and	O
QS	B-I
-	I-I
21	I-I
in	O
Mild	O
to	O
Moderate	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
Phase	O
2	O
a	O
extension	O
studies	O
of	O
randomized	O
parent	O
trials	O
were	O
conducted	O
in	O
the	O
United	O
States	O
,	O
European	O
Union	O
,	O
and	O
Japan	O
.	O

Four	O
immunizations	O
of	O
ACC	B-I
-	I-I
001	I-I
were	O
administered	O
at	O
the	O
same	O
3	O
dose	O
levels	O
(	O
3	O
,	O
10	O
,	O
and	O
30	O
?g	O
)	O
to	O
subjects	B-P
randomized	I-P
in	I-P
the	I-P
parent	I-P
studies	I-P
;	O
ACC	B-I
-	I-I
001	I-I
was	O
administered	O
with	O
QS	B-I
-	I-I
21	I-I
adjuvant	O
.	O

Safety	B-O
,	O
tolerability	B-O
,	O
and	O
immunogenicity	B-O
were	O
assessed	O
during	O
active	O
treatment	O
and	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Hearing	B-I
Aids	I-I
on	O
the	O
Cognitive	O
Status	O
of	O
Patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
and	I-P
Hearing	I-P
Loss	I-P
:	O
A	O
Multicenter	O
Controlled	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
A	O
multicenter	O
double	O
-	O
blind	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
was	O
conducted	O
in	O
patients	B-P
aged	I-P
more	I-P
than	I-P
65	I-P
years	I-P
.	O

A	O
group	O
was	O
equipped	O
with	O
active	B-I
HA	I-I
for	O
6	O
months	O
(	O
active	O
group	O
)	O
and	O
a	O
second	O
group	O
had	O
placebo	B-C
HA	I-C
for	O
6	O
months	O
(	O
placebo	O
group	O
)	O
followed	O
by	O
a	O
secondary	O
activation	O
phase	O
for	O
a	O
further	O
6	O
months	O
(	O
semi	O
crossover	O
procedure	O
)	O
.	O

Both	O
groups	O
were	O
retested	O
after	O
a	O
12	O
-	O
month	O
period	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
change	O
from	O
baseline	O
of	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
Cog	I-O
)	I-O
after	O
a	O
6	O
-	O
month	O
period	O
in	O
both	O
groups	O
and	O
after	O
6	O
months	O
of	O
secondary	O
HA	O
activation	O
in	O
the	O
placebo	O
group	O
.	O

A	O
smaller	O
cognitive	O
decline	O
should	O
be	O
obtained	O
with	O
HA	B-I
use	O
;	O
an	O
increase	O
in	O
ADAS	B-O
Cog	I-O
score	I-O
of	O
less	O
than	O
6	O
points	O
was	O
defined	O
a	O
success	O
.	O

-DOCSTART-	O

Title	O
:	O
Home	B-I
-	I-I
Based	I-I
Exercise	I-I
Program	I-I
Improves	O
Balance	O
and	O
Fear	O
of	O
Falling	O
in	O
Community	B-P
-	I-P
Dwelling	I-P
Older	I-P
Adults	I-P
with	I-P
Mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Pilot	O
Study	O
.	O

METHODS	O
:	O
A	O
prospective	O
randomized	O
controlled	O
parallel	O
-	O
group	O
trial	O
(	O
Wii	B-I
-	I-I
Fit	I-I
versus	O
walking	B-I
)	O
was	O
conducted	O
in	O
thirty	B-P
community	I-P
-	I-P
dwelling	I-P
older	I-P
adults	I-P
(	I-P
736	I-P
.	I-P
2	I-P
years	I-P
)	I-P
with	I-P
mild	I-P
AD	I-P
.	O

Home	B-I
-	I-I
based	I-I
exercises	I-I
were	O
performed	O
under	O
caregiver	O
supervision	O
for	O
8	O
weeks	O
.	O

Primary	O
(	O
Berg	B-O
Balance	I-O
Scale	I-O
,	I-O
BBS	I-O
)	O
and	O
secondary	O
outcomes	O
(	O
fear	B-O
of	I-O
falls	I-O
and	O
quality	B-O
of	I-O
life	I-O
)	O
were	O
measured	O
at	O
baseline	O
,	O
8	O
weeks	O
(	O
end	O
of	O
intervention	O
)	O
,	O
and	O
16	O
weeks	O
(	O
8	O
-	O
weeks	O
post	O
-	O
intervention	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
Safety	O
of	O
Citalopram	B-I
Compared	O
to	O
Atypical	B-C
Antipsychotics	I-C
on	O
Agitation	O
in	O
Nursing	B-P
Home	I-P
Residents	I-P
With	I-P
Alzheimer	I-P
Dementia	I-P
.	O

METHODS	O
:	O
Longitudinal	O
,	O
6	O
-	O
month	O
study	O
.	O

Nursing	O
home	O
(	O
NH	O
)	O
.	O

75	B-P
NH	I-P
residents	I-P
with	I-P
AD	I-P
and	I-P
agitation	I-P
,	O
randomized	O
to	O
citalopram	B-I
(	O
n	O
=	O
25	O
)	O
,	O
quetiapine	B-I
(	O
n	O
=	O
25	O
)	O
,	O
or	O
olanzapine	B-I
(	O
n	O
=	O
25	O
)	O
.	O

Changes	O
in	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
agitation	I-O
subscale	I-O
score	I-O
and	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
mADCS	I-O
-	I-O
CGIC	I-O
)	I-O
were	O
used	O
to	O
assess	O
treatment	O
efficacy	O
.	O

Participants	O
were	O
surveilled	O
for	O
adverse	B-O
health	I-O
outcomes	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Introduction	O
of	O
a	B-I
Management	I-I
Toolkit	I-I
for	O
Lewy	O
Body	O
Dementia	O
:	O
A	O
Pilot	O
Cluster	O
-	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
We	O
randomized	O
23	O
memory	O
/	O
dementia	O
,	O
movement	O
disorder	O
,	O
or	O
nonspecialist	O
secondary	O
care	O
services	O
to	O
the	B-I
management	I-I
toolkit	I-I
or	O
usual	B-C
care	I-C
.	O

People	B-P
with	I-P
dementia	I-P
with	I-P
Lewy	I-P
bodies	I-P
or	I-P
Parkinson	I-P
'	I-P
s	I-P
disease	I-P
dementia	I-P
underwent	I-P
assessments	I-P
of	I-P
cognition	I-P
,	I-P
motor	I-P
and	I-P
neuropsychiatric	I-P
symptoms	I-P
,	I-P
and	I-P
global	I-P
outcome	I-P
at	I-P
baseline	I-P
and	I-P
3	I-P
and	I-P
6	I-P
months	I-P
.	O

Healthcare	B-O
,	O
personal	B-O
and	O
social	B-O
care	I-O
costs	I-O
,	O
and	O
carer	B-O
-	I-O
related	I-O
outcomes	I-O
of	I-O
carer	I-O
stress	I-O
,	O
depression	B-O
,	O
and	O
anxiety	B-O
were	O
also	O
examined	O
.	O

-DOCSTART-	O

Title	O
:	O
One	O
call	O
makes	O
a	O
difference	O
:	O
An	O
evaluation	O
of	O
the	B-I
Alzheimer	I-I
'	I-I
s	I-I
Association	I-I
National	I-I
Helpline	I-I
on	O
dementia	B-P
caregiver	I-P
outcomes	O
.	O

METHODS	O
:	O
Four	B-P
hundred	I-P
and	I-P
forty	I-P
-	I-P
five	I-P
non	I-P
-	I-P
crisis	I-P
callers	I-P
were	O
randomly	O
assigned	O
to	O
the	B-C
traditional	I-C
Helpline	I-C
"	I-C
Care	I-C
Consultation	I-C
"	I-C
or	O
a	B-I
"	I-I
Care	I-I
Consultation	I-I
Plus	I-I
"	I-I
condition	I-I
that	O
included	O
one	O
additional	O
booster	O
call	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
long	B-I
-	I-I
term	I-I
omega	I-I
-	I-I
3	I-I
supplementation	I-I
and	O
a	B-I
lifestyle	I-I
multidomain	I-I
intervention	I-I
on	O
intrinsic	O
capacity	O
among	O
community	B-P
-	I-P
dwelling	I-P
older	I-P
adults	I-P
:	O
Secondary	O
analysis	O
of	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
MAPT	O
study	O
)	O
.	O

METHODS	O
:	O
Secondary	O
analysis	O
from	O
the	O
factorial	O
-	O
design	O
3	O
-	O
year	O
Multidomain	O
Alzheimer	O
Preventive	O
Trial	O
(	O
MAPT	O
)	O
with	O
1445	B-P
subjects	I-P
(	I-P
64	I-P
.	I-P
2	I-P
%	I-P
female	I-P
,	I-P
mean	I-P
age	I-P
75	I-P
.	I-P
3	I-P
years	I-P
,	I-P
SD	I-P
=	I-P
4	I-P
.	I-P
4	I-P
)	I-P
randomized	O
to	O
one	O
group	O
of	O
MI	B-I
plus	O
?	B-I
-	I-I
3	I-I
(	O
800	B-I
mg	I-I
docosahexaenoic	I-I
acid	I-I
and	O
225	B-I
mg	I-I
eicosapentaenoic	I-I
acid	I-I
/	O
day	O
)	O
;	O
MI	B-I
plus	O
placebo	B-C
;	O
?	B-I
-	I-I
3	I-I
supplementation	I-I
alone	O
;	O
or	O
placebo	B-C
alone	I-C
.	O

Data	O
collection	O
was	O
held	O
between	O
2008	O
and	O
2014	O
.	O

IC	B-O
domains	I-O
were	O
examined	O
with	O
the	B-O
Geriatric	I-O
Depression	I-O
Scale	I-O
(	O
psychological	B-O
)	O
;	O
Short	B-O
Physical	I-O
Performance	I-O
Battery	I-O
(	O
mobility	B-O
)	O
;	O
Z	B-O
-	I-O
score	I-O
combining	I-O
four	I-O
tests	I-O
(	O
cognitive	B-O
function	I-O
)	O
;	O
and	O
handgrip	B-O
strength	I-O
(	O
vitality	B-O
)	O
.	O

All	O
domains	O
were	O
combined	O
into	O
a	O
composite	O
IC	O
Z	O
-	O
score	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Cognition	O
and	O
Flow	O
Study	O
:	O
A	O
Feasibility	O
Randomized	O
Controlled	O
Trial	O
of	O
the	O
Effects	O
of	O
Cognitive	B-I
Training	I-I
on	O
Cerebral	O
Blood	O
Flow	O
.	O

METHODS	O
:	O
Twenty	B-P
HG	I-P
,	I-P
24	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
,	I-P
and	I-P
12	I-P
with	I-P
MCI	I-P
were	O
randomized	O
to	O
12	O
weeks	O
of	O
multi	B-I
-	I-I
domain	I-I
CT	I-I
or	O
control	O
.	O

Outcomes	O
included	O
:	O
cognition	B-O
(	O
Addenbrooke	B-O
'	I-O
s	I-O
Cognitive	I-O
Examination	I-O
III	I-O
)	O
,	O
mood	B-O
,	O
quality	B-O
of	I-O
life	I-O
(	I-O
QoL	I-O
)	I-O
,	O
physical	B-O
,	O
and	O
neurovascular	B-O
function	I-O
(	O
transcranial	B-O
Doppler	I-O
ultrasonography	I-O
measured	I-O
task	I-O
activation	I-O
of	I-O
CBFv	I-O
responses	I-O
)	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
difference	O
(	O
MD	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
,	O
pharmacokinetics	O
and	O
exploratory	O
pro	O
-	O
cognitive	O
effects	O
of	O
HTL0018318	B-I
,	O
a	B-I
selective	I-I
M	I-I
1	I-I
receptor	I-I
agonist	I-I
,	O
in	O
healthy	B-P
younger	I-P
adult	I-P
and	I-P
elderly	I-P
subjects	I-P
:	O
a	O
multiple	O
ascending	O
dose	O
study	O
.	O

METHODS	O
:	O
This	O
randomised	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
was	O
performed	O
,	O
investigating	O
oral	B-I
doses	I-I
of	I-I
15	I-I
-	I-I
35	I-I
mg	I-I
/	I-I
day	I-I
HTL0018318	I-I
or	O
placebo	B-C
in	O
7	B-P
cohorts	I-P
of	I-P
healthy	I-P
younger	I-P
adult	I-P
(	I-P
n	I-P
=	I-P
36	I-P
;	I-P
3	I-P
cohorts	I-P
)	I-P
and	I-P
elderly	I-P
(	I-P
n	I-P
=	I-P
50	I-P
;	I-P
4	I-P
cohorts	I-P
)	I-P
subjects	I-P
.	O

Safety	B-O
,	O
tolerability	B-O
and	O
pharmacokinetic	B-O
measurements	I-O
were	O
performed	O
.	O

Pharmacodynamics	O
were	O
assessed	O
using	O
a	B-O
battery	I-O
of	I-O
neurocognitive	I-O
tasks	I-O
and	O
electrophysiological	B-O
biomarkers	I-O
of	I-O
synaptic	I-O
and	O
cognitive	B-O
functions	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Interventional	O
Study	O
to	O
Evaluate	O
the	O
Clinical	O
Effects	O
and	O
Safety	O
of	O
the	B-I
Nutraceutical	I-I
Compound	I-I
BrainUp	I-I
-	I-I
10	I-I
in	O
a	B-P
Cohort	I-P
of	I-P
Patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Multicenter	O
,	O
Randomized	O
,	O
Double	O
-	O
Blind	O
,	O
and	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
The	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
II	O
clinical	O
study	O
in	O
mild	B-P
to	I-P
moderate	I-P
AD	I-P
patients	I-P
treated	O
with	O
BrainUp	B-I
-	I-I
10	I-I
daily	O
,	O
while	O
controls	O
received	O
a	B-C
placebo	I-C
.	O

Primary	O
endpoint	O
was	O
Apathy	B-O
(	O
AES	B-O
scale	I-O
)	O
,	O
while	O
secondary	O
endpoints	O
included	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
(	O
TMT	B-O
A	I-O
and	O
TMT	B-O
B	I-O
)	O
,	O
and	O
Neuropsychiatry	B-O
Index	I-O
(	I-O
NPI	I-O
)	I-O
.	O

AD	O
blood	O
biomarkers	O
were	O
analyzed	O
.	O

Laboratory	O
tests	O
were	O
applied	O
to	O
all	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Learning	B-I
to	I-I
play	I-I
golf	I-I
for	O
elderly	B-P
people	I-P
with	I-P
subjective	I-P
memory	I-P
complaints	I-P
:	O
feasibility	O
of	O
a	O
single	O
-	O
blinded	O
randomized	O
pilot	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
22	O
-	O
week	O
single	O
-	O
blinded	O
randomized	O
controlled	O
trial	O
,	O
elderly	B-P
people	I-P
with	I-P
SMC	I-P
were	O
allocated	O
to	O
the	B-I
golf	I-I
(	O
n	O
=	O
25	O
,	O
180	O
min	O
training	O
/	O
week	O
)	O
or	O
control	O
group	O
(	O
n	O
=	O
21	O
)	O
.	O

Primary	O
outcomes	O
were	O
feasibility	B-O
(	O
golf	B-O
exam	I-O
,	O
adherence	B-O
,	O
adverse	B-O
events	I-O
)	O
and	O
general	B-O
cognitive	I-O
function	I-O
(	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
)	O
.	O

Secondary	O
outcomes	O
include	O
specific	B-O
cognitive	I-O
functions	I-O
(	O
Response	B-O
Inhibition	I-O
,	O
Corsi	B-O
Block	I-O
Tapping	I-O
Test	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
)	O
,	O
KP	B-O
metabolites	I-O
and	O
physical	B-O
performance	I-O
(	O
6	B-O
-	I-O
Minute	I-O
-	I-O
Walk	I-O
-	I-O
Test	I-O
)	O
.	O

Baseline	O
-	O
adjusted	O
Analysis	O
-	O
of	O
-	O
Covariance	O
was	O
conducted	O
for	O
each	O
outcome	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
Folic	B-I
Acid	I-I
and	O
Vitamin	B-I
B12	I-I
Supplementation	I-I
on	O
Cognitive	O
Impairment	O
and	O
Inflammation	O
in	O
Patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Randomized	O
,	O
Single	O
-	O
Blinded	O
,	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Patients	B-P
(	I-P
n=120	I-P
)	I-P
diagnosed	I-P
clinically	I-P
as	I-P
probable	I-P
AD	I-P
and	I-P
in	I-P
stable	I-P
condition	I-P
from	I-P
Tianjin	I-P
Key	I-P
Laboratory	I-P
of	I-P
Cerebrovascular	I-P
and	I-P
Neurodegenerative	I-P
Diseases	I-P
.	O

Individuals	O
were	O
randomly	O
divided	O
into	O
the	O
intervention	O
group	O
(	O
n=60	O
,	O
folic	B-I
acid	I-I
1	O
.	O
2	O
mg	O
/	O
d	O
+	O
vitamin	B-I
B12	I-I
50	O
?g	O
/	O
d	O
)	O
and	O
the	B-C
placebo	I-C
group	O
(	O
n=60	O
)	O
.	O

Cognitive	B-O
performance	I-O
,	O
blood	B-O
folate	I-O
,	O
vitamin	B-O
B12	I-O
,	O
one	B-O
carbon	I-O
cycle	I-O
metabolite	I-O
,	O
and	O
inflammatory	B-O
cytokine	I-O
levels	I-O
were	O
measured	O
at	O
baseline	O
and	O
after	O
6	O
months	O
.	O

The	O
data	O
were	O
analyzed	O
using	O
linear	O
mixed	O
models	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
tablet	B-I
huperzine	I-I
-	I-I
A	I-I
on	O
memory	O
,	O
cognition	O
,	O
and	O
behavior	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Using	O
multicenter	O
,	O
prospective	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
,	O
placebo	O
controlled	O
and	O
randomized	O
method	O
,	O
50	B-P
patients	I-P
were	O
administered	O
orally	O
0	B-I
.	I-I
2	I-I
mg	I-I
(	I-I
4	I-I
tablets	I-I
)	I-I
Hup	I-I
and	O
53	O
patients	O
were	O
given	O
po	B-C
4	I-C
tablets	I-C
of	I-C
placebo	I-C
bid	O
for	O
8	O
wk	O
.	O

All	O
patients	O
were	O
evaluated	O
with	O
Wechsler	B-O
memory	I-O
scale	I-O
,	O
Hasegawa	B-O
dementia	I-O
scale	I-O
,	O
mini	B-O
-	I-O
mental	I-O
state	I-O
examination	I-O
scale	I-O
,	O
activity	B-O
of	I-O
daily	I-O
living	I-O
scale	I-O
,	O
treatment	B-O
emergency	I-O
symptom	I-O
scale	I-O
,	O
and	O
measured	O
with	O
BP	B-O
,	O
HR	B-O
,	O
ECG	B-O
,	O
EEG	B-O
,	O
ALT	B-O
,	O
AKP	B-O
,	O
BUN	B-O
,	O
Cr	B-O
,	O
Hb	B-O
,	O
WBC	B-O
,	O
and	O
urine	B-O
routine	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Relationship	O
between	O
pharmacodynamic	O
activity	O
and	O
cognitive	O
effects	O
of	O
eptastigmine	B-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

Eptastigmine	O
Study	O
Group	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
unbalanced	O
parallel	O
-	O
group	O
study	O
.	O

One	B-P
-	I-P
hundred	I-P
and	I-P
three	I-P
patients	I-P
(	O
83	O
in	O
the	B-I
eptastigmine	I-I
group	O
and	O
20	O
in	O
the	B-C
placebo	I-C
group	O
)	O
were	O
recruited	O
by	O
10	O
centers	O
.	O

Patients	O
received	O
20	B-I
mg	I-I
eptastigmine	I-I
or	O
placebo	B-C
for	O
4	O
weeks	O
with	O
twice	O
-	O
a	O
-	O
day	O
or	O
three	O
-	O
times	O
-	O
a	O
-	O
day	O
regimens	O
,	O
depending	O
on	O
body	O
weight	O
(	O
<	O
or	O
=	O
65	O
kg	O
or	O
>	O
65	O
kg	O
,	O
respectively	O
)	O
.	O

Patient	O
performance	O
on	O
the	B-O
Logical	I-O
Memory	I-O
Test	I-O
,	O
Semantic	B-O
Word	I-O
Fluency	I-O
Test	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
,	O
Index	B-O
of	I-O
Independence	I-O
in	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
,	O
Instrumental	B-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Scales	I-O
(	I-O
IADL	I-O
)	I-O
,	O
and	O
the	B-O
Physician	I-O
and	I-O
Caregiver	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGIC	I-O
)	I-O
was	O
assessed	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
family	I-I
intervention	I-I
to	O
delay	O
nursing	O
home	O
placement	O
of	O
patients	B-P
with	I-P
Alzheimer	I-P
disease	I-P
.	O

A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
intervention	O
study	O
.	O

Outpatient	O
research	O
clinic	O
in	O
the	O
New	O
York	O
City	O
metropolitan	O
area	O
.	O

Referred	B-P
,	I-P
volunteer	I-P
sample	I-P
of	I-P
206	I-P
spouse	I-P
-	I-P
caregivers	I-P
of	I-P
AD	I-P
patients	I-P
who	I-P
enrolled	I-P
in	I-P
the	I-P
study	I-P
during	I-P
a	I-P
3	I-P
1	I-P
/	I-P
2	I-P
-	I-P
year	I-P
period	I-P
.	O

All	O
patients	O
were	O
living	O
at	O
home	O
at	O
baseline	O
and	O
had	O
at	O
least	O
1	O
relative	O
living	O
in	O
the	O
area	O
.	O

Caregivers	O
in	O
the	O
treatment	O
group	O
were	O
provided	O
with	O
6	B-I
sessions	I-I
of	I-I
individual	I-I
and	I-I
family	I-I
counseling	I-I
within	O
4	O
months	O
of	O
enrollment	O
in	O
the	O
study	O
and	O
were	O
required	O
to	O
join	O
support	O
groups	O
.	O

In	O
addition	O
,	O
counselors	O
were	O
available	O
for	O
further	O
counseling	O
at	O
any	O
time	O
.	O

Time	B-O
from	I-O
enrollment	I-O
of	I-O
caregivers	I-O
in	I-O
the	I-O
study	I-O
to	I-O
placement	I-O
of	I-O
the	I-O
AD	I-O
patients	I-O
in	I-O
a	I-O
nursing	I-O
home	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
multicenter	O
double	O
-	O
blind	O
study	O
of	O
controlled	B-I
-	I-I
release	I-I
physostigmine	I-I
for	O
the	O
treatment	O
of	O
symptoms	O
secondary	O
to	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Physostigmine	O
Study	O
Group	O
.	O

METHODS	O
:	O
During	O
dose	O
titration	O
,	O
subjects	O
received	O
18	B-I
,	O
24	B-I
,	O
or	O
30	B-I
mg	I-I
of	I-I
physostigmine	I-I
or	O
placebo	B-C
daily	O
.	O

After	O
a	O
2	O
-	O
week	O
washout	O
period	O
,	O
366	B-P
subjects	I-P
with	I-P
putative	I-P
improvement	I-P
were	O
randomized	O
to	O
receive	O
either	O
placebo	B-C
or	O
their	B-I
best	I-I
dose	I-I
of	I-I
physostigmine	I-I
in	O
a	O
6	O
-	O
week	O
double	O
-	O
blind	O
trial	O
.	O

Nonresponding	O
patients	O
(	O
439	O
)	O
were	O
randomized	O
to	O
receive	O
in	O
a	O
separate	O
double	O
-	O
blind	O
trial	O
either	O
placebo	B-C
or	O
their	B-I
highest	I-I
tolerated	I-I
dose	I-I
of	I-I
physostigmine	I-I
.	O

The	O
primary	O
efficacy	O
measures	O
included	O
the	B-O
cognitive	I-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
and	O
a	B-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGIC	I-O
)	I-O
.	O

Secondary	O
measures	O
included	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
and	O
two	B-O
activities	I-O
-	I-O
of	I-O
-	I-O
daily	I-O
-	I-O
living	I-O
scales	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
tacrine	B-I
on	O
language	O
,	O
praxis	O
,	O
and	O
noncognitive	O
behavioral	O
problems	O
in	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
An	O
exploratory	O
analysis	O
using	O
last	O
observation	O
carried	O
forward	O
.	O

The	O
study	O
population	O
included	O
a	B-C
placebo	I-C
group	O
(	O
n	O
=	O
181	O
)	O
and	O
all	O
patients	O
randomized	O
to	O
treatment	O
within	O
160	B-I
mg	I-I
/	I-I
d	I-I
of	I-I
tacrine	I-I
hydrochloride	I-I
(	O
n	O
=	O
234	O
)	O
,	O
regardless	O
of	O
highest	O
dose	O
achieved	O
or	O
duration	O
of	O
tacrine	B-I
therapy	I-I
.	O

Male	B-P
and	I-P
female	I-P
subjects	I-P
,	I-P
at	I-P
least	I-P
50	I-P
years	I-P
of	I-P
age	I-P
,	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
detectable	I-P
baseline	I-P
deficits	I-P
in	I-P
discrete	I-P
cognitive	I-P
and	I-P
noncognitive	I-P
parameters	I-P
.	O

Change	O
from	O
baseline	O
to	O
last	O
observation	O
carried	O
forward	O
in	O
discrete	B-O
subscale	I-O
scores	I-O
of	I-O
the	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
:	O
cognitive	B-O
(	O
memory	B-O
,	O
language	B-O
,	O
praxis	B-O
)	O
and	O
noncognitive	B-O
(	O
mood	B-O
,	O
behavior	B-O
)	O
.	O

Improvement	O
was	O
defined	O
as	O
a	O
decrease	O
of	O
at	O
least	O
1	O
point	O
from	O
baseline	O
;	O
stabilization	O
was	O
defined	O
as	O
no	O
change	O
or	O
a	O
decrease	O
from	O
baseline	O
.	O

-DOCSTART-	O

Title	O
:	O
Metrifonate	B-I
benefits	O
cognitive	O
,	O
behavioral	O
,	O
and	O
global	O
function	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
A	O
prospective	O
,	O
36	O
-	O
week	O
,	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
parallel	O
group	O
study	O
of	O
metrifonate	B-I
in	O
probable	B-P
AD	I-P
patients	I-P
,	O
including	O
a	O
2	O
-	O
week	O
screening	O
period	O
,	O
a	O
26	O
-	O
week	O
double	O
-	O
blind	O
treatment	O
period	O
,	O
and	O
a	O
follow	O
-	O
up	O
visit	O
at	O
8	O
weeks	O
post	O
-	O
treatment	O
.	O

A	O
total	O
of	O
24	O
ambulatory	O
clinics	O
in	O
the	O
United	O
States	O
in	O
a	O
variety	O
of	O
settings	O
,	O
including	O
contract	O
research	O
organizations	O
,	O
public	O
health	O
facilities	O
,	O
and	O
universities	O
.	O

Patients	O
met	O
diagnostic	O
criteria	O
for	O
probable	O
AD	O
as	O
defined	O
by	O
the	O
work	O
group	O
of	O
the	O
National	O
Institute	O
for	O
Neurological	O
and	O
Communicative	O
Diseases	O
and	O
Stroke	O
and	O
the	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
.	O

Patients	O
had	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
scores	O
of	O
10	O
to	O
26	O
and	O
Ischemic	O
Scores	O
(	O
Rosen	O
Modification	O
)	O
of	O
<	O
4	O
.	O

A	B-P
total	I-P
of	I-P
408	I-P
patients	I-P
were	O
enrolled	O
.	O

Percentages	O
of	O
patients	O
completing	O
double	O
-	O
blind	O
treatment	O
were	O
88	O
%	O
and	O
79	O
%	O
in	O
the	B-C
placebo	I-C
and	O
metrifonate	B-I
groups	O
,	O
respectively	O
.	O

Rates	O
of	O
discontinuation	O
due	O
to	O
adverse	O
events	O
were	O
4	O
%	O
in	O
the	B-C
placebo	I-C
group	O
and	O
12	O
%	O
in	O
the	B-I
metrifonate	I-I
group	O
.	O

Placebo	B-C
or	O
metrifonate	B-I
was	O
administered	O
once	O
daily	O
.	O

Metrifonate	B-I
-	O
treated	O
patients	O
received	O
a	O
loading	O
dose	O
of	O
100	O
to	O
180	O
mg	O
based	O
on	O
weight	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
)	O
for	O
2	O
weeks	O
,	O
followed	O
by	O
a	O
maintenance	O
dose	O
of	O
30	O
to	O
60	O
mg	O
based	O
on	O
weight	O
(	O
0	O
.	O
65	O
mg	O
/	O
kg	O
)	O
for	O
24	O
weeks	O
.	O

Primary	O
efficacy	O
variables	O
were	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
with	I-O
Caregiver	I-O
Input	I-O
(	I-O
CIBIC	I-O
-	I-O
plus	I-O
)	I-O
.	O

Secondary	O
efficacy	O
variables	O
included	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
,	O
the	B-O
Disability	I-O
Assessment	I-O
in	I-O
Dementia	I-O
,	O
the	B-O
Global	I-O
Deterioration	I-O
Scale	I-O
(	I-O
GDS	I-O
)	I-O
,	O
the	B-O
ADAS	I-O
-	I-O
Noncognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Noncog	I-O
)	I-O
,	O
the	B-O
MMSE	I-O
,	O
and	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Severity	I-O
with	I-O
Caregiver	I-O
Input	I-O
(	I-O
CIBIS	I-O
-	I-O
plus	I-O
)	I-O
.	O

Outcome	O
measures	O
reflected	O
changes	O
from	O
baseline	O
at	O
week	O
26	O
for	O
all	O
variables	O
.	O

Safety	O
was	O
assessed	O
with	O
incidences	B-O
of	I-O
premature	I-O
termination	I-O
,	O
treatment	B-O
-	I-O
emergent	I-O
events	I-O
and	O
mortality	B-O
,	O
and	O
routine	B-O
safety	I-O
evaluations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Caffeine	O
based	O
measures	O
of	O
CYP1A2	O
activity	O
correlate	O
with	O
oral	O
clearance	O
of	O
tacrine	B-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
The	B-O
pharmokinetics	I-O
of	O
a	B-I
single	I-I
40	I-I
mg	I-I
oral	I-I
dose	I-I
of	I-I
tacrine	I-I
were	O
measured	O
in	O
19	B-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

Each	O
patient	O
also	O
received	O
2	O
mg	O
kg	O
(	O
-	O
1	O
)	O
[	O
13	O
C	O
-	O
3	O
-	O
methyl	O
]	O
caffeine	O
orally	O
and	O
had	O
breath	O
and	O
urine	O
samples	O
collected	O
.	O

-DOCSTART-	O

Title	O
:	O
Heparan	B-I
sulfate	I-I
in	O
the	O
treatment	O
of	O
intermittent	O
claudication	O
:	O
results	O
of	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
doubleblind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
,	O
performed	O
in	O
24	O
Italian	O
centers	O
.	O

Two	B-P
hundred	I-P
seventeen	I-P
patients	I-P
with	I-P
intermittent	I-P
claudication	I-P
(	I-P
stages	I-P
IIa	I-P
and	I-P
IIb	I-P
of	I-P
Fontaine	I-P
'	I-P
s	I-P
PAD	I-P
classification	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
heparan	B-I
sulfate	I-I
(	O
40	O
mg	O
orally	O
twice	O
a	O
day	O
)	O
or	O
placebo	B-C
for	O
6	O
months	O
.	O

The	O
primary	O
end	O
-	O
point	O
was	O
an	B-O
increase	I-O
in	I-O
pain	I-O
-	I-O
free	I-O
walking	I-O
distance	I-O
[	O
initial	B-O
claudication	I-O
distance	I-O
(	I-O
ICD	I-O
)	I-O
]	O
during	O
the	O
24	O
weeks	O
of	O
treatment	O
.	O

The	B-O
pain	I-O
-	I-O
free	I-O
and	O
the	B-O
absolute	I-O
walking	I-O
distance	I-O
(	I-O
ACD	I-O
)	I-O
were	O
monitored	O
by	O
standardized	B-O
treadmill	I-O
test	I-O
at	O
baseline	O
and	O
at	O
4	O
,	O
12	O
and	O
24	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
valociclovir	B-I
hydrochloride	I-I
on	O
patients	B-P
with	I-P
herpes	I-P
zoster	I-P
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Marimastat	B-I
as	O
maintenance	O
therapy	O
for	O
patients	B-P
with	I-P
advanced	I-P
gastric	I-P
cancer	I-P
:	O
a	O
randomised	O
trial	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
and	I-P
sixty	I-P
-	I-P
nine	I-P
patients	I-P
with	I-P
histological	I-P
proof	I-P
of	I-P
adenocarcinoma	I-P
,	O
who	O
had	O
received	O
no	O
more	O
than	O
a	O
single	O
regimen	O
of	O
5	O
-	O
fluorouracil	O
-	O
based	O
chemotherapy	O
,	O
were	O
randomised	O
to	O
receive	O
either	O
marimastat	B-I
(	O
10	O
mg	O
b	O
.	O
d	O
.	O
)	O
or	O
placebo	B-C
.	O

Patients	O
were	O
treated	O
for	O
as	O
long	O
as	O
was	O
tolerable	O
.	O

The	O
primary	O
endpoint	O
was	O
overall	B-O
survival	I-O
with	O
secondary	O
endpoints	O
of	O
time	B-O
to	I-O
disease	I-O
progression	I-O
and	O
quality	B-O
of	I-O
life	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Overexpression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
cellular	O
receptor	O
KDR	O
(	O
VEGFR	O
-	O
2	O
)	O
in	O
the	O
bone	O
marrow	O
of	O
patients	B-P
with	I-P
acute	I-P
myeloid	I-P
leukemia	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Pain	B-I
and	I-I
fatigue	I-I
management	I-I
:	O
results	O
of	O
a	O
nursing	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Chemotherapy	O
clinics	O
of	O
two	O
comprehensive	O
and	O
two	O
community	O
cancer	O
centers	O
.	O

Interviews	O
were	O
conducted	O
at	O
baseline	O
and	O
10	O
and	O
20	O
weeks	O
.	O

An	B-I
18	I-I
-	I-I
week	I-I
,	I-I
10	I-I
-	I-I
contact	I-I
nursing	I-I
intervention	I-I
utilizing	O
problem	B-I
-	I-I
solving	I-I
approaches	I-I
to	I-I
symptom	I-I
management	I-I
and	O
improving	B-I
physical	I-I
functioning	I-I
and	O
emotional	B-I
health	I-I
was	O
implemented	O
.	O

The	O
sample	O
consisted	O
of	O
53	O
patients	O
in	O
the	O
experimental	O
arm	O
and	O
60	O
in	O
the	O
control	O
arm	O
who	O
reported	O
pain	B-O
and	O
fatigue	B-O
at	O
baseline	O
.	O

Pain	B-O
and	O
fatigue	B-O
,	O
numbers	B-O
of	I-O
other	I-O
symptoms	I-O
,	O
and	O
physical	B-O
role	I-O
impact	I-O
and	O
social	B-O
-	I-O
functioning	I-O
subscales	I-O
from	O
the	B-O
Medical	I-O
Outcomes	I-O
Study	I-O
36	I-O
Short	I-O
Form	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
of	O
secretin	B-I
:	O
effects	O
on	O
aberrant	O
behavior	O
in	O
children	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
examined	O
the	O
effect	O
of	O
a	B-I
single	I-I
dose	I-I
of	I-I
synthetic	I-I
human	I-I
secretin	I-I
on	O
aberrant	B-O
behavior	I-O
.	O

Parent	O
and	O
teacher	O
data	O
from	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
for	O
eight	B-P
male	I-P
children	I-P
were	O
analyzed	O
for	O
reliable	O
change	O
in	O
a	O
clinical	O
replication	O
series	O
.	O

-DOCSTART-	O

Title	O
:	O
Monitoring	O
tumour	O
cells	O
in	O
the	O
peripheral	O
blood	O
of	O
small	B-P
cell	I-P
lung	I-P
cancer	I-P
patients	I-P
.	O

METHODS	O
:	O
Fresh	B-I
venous	I-I
blood	I-I
was	O
taken	O
throughout	O
treatment	O
and	O
follow	O
-	O
up	O
.	O

Aliquots	O
were	O
stained	O
with	O
a	B-I
"	I-I
tumour	I-I
-	I-I
specific	I-I
"	I-I
antibody	I-I
against	I-I
epithelial	I-I
tissue	I-I
(	I-I
Ber	I-I
EP4	I-I
)	I-I
,	O
verified	O
as	O
a	O
good	O
marker	O
of	O
SCLC	O
cells	O
by	O
immunohistochemistry	O
.	O

Matched	O
samples	O
labelled	O
with	O
Ber	O
EP4	O
were	O
separated	O
magnetically	O
by	O
adding	O
a	O
secondary	O
bead	O
-	O
antibody	O
conjugate	O
for	O
confirmation	O
of	O
tumour	B-O
cell	I-O
identity	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Oral	B-I
desensitization	I-I
in	O
papular	O
urticaria	O
in	O
children	O
.	O

METHODS	O
:	O
In	O
this	O
double	O
blind	O
placebo	O
controlled	O
study	O
,	O
an	B-I
oral	I-I
vaccine	I-I
prepared	O
from	O
insect	O
saliva	O
was	O
compared	O
with	O
placebo	B-C
(	I-C
stable	I-C
vaccine	I-C
solvent	I-C
)	I-C
.	O

Vaccine	B-I
and	O
placebo	B-C
effectiveness	B-O
were	O
tested	O
by	O
counting	O
active	B-O
PU	I-O
lesions	I-O
,	O
serum	B-O
eosinophils	I-O
,	O
and	O
IgE	B-O
,	O
before	O
and	O
after	O
4	O
months	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Combined	O
therapy	O
in	O
the	O
treatment	O
of	O
primary	O
mediastinal	O
B	O
-	O
cell	O
lymphoma	O
:	O
conventional	B-C
versus	O
escalated	B-I
chemotherapy	I-I
.	O

METHODS	O
:	O
From	O
1989	O
to	O
1997	O
,	O
68	B-P
patients	I-P
diagnosed	I-P
with	I-P
previously	I-P
untreated	I-P
PMBCL	I-P
,	I-P
aged	I-P
18	I-P
-	I-P
65	I-P
years	I-P
and	I-P
negative	I-P
for	I-P
immunodeficiency	I-P
virus	I-P
test	I-P
,	O
were	O
considered	O
candidates	O
to	O
receive	O
either	O
conventional	B-C
chemotherapy	I-C
with	I-C
CEOP	I-C
-	I-C
Bleo	I-C
(	O
cyclophosphamide	B-C
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
vincristine	B-C
1	O
.	O
4	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
prednisone	B-C
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
epirubicin	B-C
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
and	O
bleomycin	B-C
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
or	O
mega	B-I
CEOP	I-I
-	I-I
Bleo	I-I
(	O
cyclophosphamide	B-I
1000	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
epirubicin	B-I
120	O
mg	O
/	O
m	O
(	O
2	O
)	O
,	O
vincristine	B-I
,	O
prednisone	B-I
,	O
and	O
bleomycin	B-I
at	O
the	O
same	O
doses	O
)	O
every	O
21	O
days	O

for	O
six	O
cycles	O
,	O
followed	O
by	O
radiotherapy	B-I
to	I-I
the	I-I
mediastinum	I-I
with	O
the	B-I
mantle	I-I
technique	I-I
(	O
35	O
-	O
45	O
Gy	O
,	O
mean	O
38	O
Gy	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Home	B-I
sleep	I-I
studies	I-I
in	O
the	O
assessment	O
of	O
sleep	O
apnea	O
/	O
hypopnea	O
syndrome	O
.	O

METHODS	O
:	O
Prospective	O
case	O
study	O
.	O

The	O
sleep	O
-	O
disorders	O
unit	O
of	O
a	O
tertiary	O
referral	O
university	O
hospital	O
.	O

Fifty	B-P
-	I-P
five	I-P
patients	I-P
suspected	I-P
of	I-P
having	I-P
SAHS	I-P
and	I-P
living	I-P
within	I-P
30	I-P
km	I-P
of	I-P
our	I-P
laboratory	I-P
.	O

Patients	O
were	O
studied	O
first	O
in	O
their	O
homes	O
with	O
the	B-I
limited	I-I
sleep	I-I
-	I-I
recording	I-I
device	I-I
.	O

Polysomnography	B-I
was	O
performed	O
within	O
30	O
days	O
of	O
the	O
first	O
study	O
.	O

Both	O
studies	O
were	O
read	O
by	O
independent	O
investigators	O
blinded	O
to	O
the	O
results	O
of	O
the	O
other	O
study	O
.	O

Diagnoses	B-O
and	O
therapeutic	B-O
decisions	I-O
regarding	O
the	B-O
use	I-O
of	I-O
continuous	I-O
positive	I-O
airway	I-O
pressure	I-O
obtained	O
from	O
the	O
home	O
and	O
laboratory	O
studies	O
were	O
compared	O
.	O

Agreement	O
between	O
the	O
home	O
and	O
laboratory	O
study	O
recordings	O
was	O
also	O
assessed	O
using	O
receiver	B-O
operating	I-O
characteristic	I-O
(	I-O
ROC	I-O
)	I-O
curves	I-O
and	O
Bland	B-O
-	I-O
Altman	I-O
analysis	I-O
.	O

One	O
half	O
of	O
the	O
home	O
studies	O
were	O
randomly	O
assigned	O
to	O
be	O
performed	O
with	O
a	B-I
sleep	I-I
technician	I-I
'	I-I
s	I-I
set	I-I
up	I-I
of	I-I
the	I-I
equipment	I-I
in	I-I
the	I-I
patient	I-I
'	I-I
s	I-I
home	I-I
(	O
group	O
1	O
)	O
,	O
and	O
the	O
other	O
half	O
with	O
the	B-I
patient	I-I
'	I-I
s	I-I
own	I-I
setup	I-I
of	I-I
the	I-I
sleep	I-I
-	I-I
recording	I-I
device	I-I
(	O
group	O
2	O
)	O
,	O
after	O
an	O
instruction	O
period	O
in	O
the	O
hospital	O
.	O

An	O
economic	O
analysis	O
was	O
performed	O
,	O
considering	O
the	O
cost	O
of	O
repeating	O
studies	O
in	O
cases	O
with	O
faulty	O
or	O
inconclusive	O
home	O
studies	O
(	O
these	O
patients	O
should	O
undergo	O
polysomnography	O
as	O
a	O
second	O
step	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Transurethral	O
prostate	O
resection	O
and	O
bleeding	O
:	O
a	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
of	O
role	O
of	O
finasteride	B-I
for	O
decreasing	O
operative	O
blood	O
loss	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
70	I-P
patients	I-P
scheduled	I-P
to	I-P
undergo	I-P
elective	I-P
transurethral	I-P
prostate	I-P
resection	I-P
were	O
randomized	O
to	O
receive	O
5	B-I
mg	I-I
.	I-I

finasteride	I-I
daily	O
or	O
placebo	B-C
for	O
2	O
weeks	O
before	O
surgery	O
.	O

Serum	B-O
hemoglobin	I-O
was	O
measured	O
before	O
and	O
after	O
surgery	O
,	O
and	O
the	O
following	O
day	O
.	O

The	B-O
volume	I-O
of	I-O
irrigation	I-O
fluid	I-O
used	O
and	O
its	B-O
hemoglobin	I-O
concentration	I-O
as	O
well	O
as	B-O
resected	I-O
prostate	I-O
weight	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
vehicle	O
-	O
controlled	O
study	O
to	O
assess	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
for	O
the	O
treatment	O
of	O
multiple	O
actinic	O
keratoses	O
.	O

METHODS	O
:	O
Patients	O
in	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
vehicle	O
-	O
controlled	O
study	O
applied	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
or	O
vehicle	B-C
to	O
AK	O
lesions	O
3	O
times	O
per	O
week	O
for	O
a	O
maximum	O
of	O
12	O
weeks	O
or	O
until	O
lesions	O
had	O
resolved	O
.	O

In	O
the	O
event	O
of	O
an	O
adverse	O
reaction	O
,	O
application	O
of	O
imiquimod	B-I
was	O
reduced	O
to	O
1	O
or	O
2	O
times	O
per	O
week	O
.	O

Rest	O
periods	O
were	O
also	O
allowed	O
if	O
necessary	O
.	O

A	O
specialized	O
outpatient	O
dermatology	O
clinic	O
within	O
a	O
state	O
-	O
funded	O
hospital	O
in	O
Germany	O
.	O

The	O
study	O
population	O
was	O
aged	O
45	O
to	O
85	O
years	O
.	O

Of	O
52	O
patients	O
screened	O
,	O
36	B-P
men	I-P
and	I-P
women	I-P
with	I-P
AK	I-P
confirmed	I-P
by	I-P
histological	I-P
diagnosis	I-P
were	I-P
enrolled	I-P
.	O

Patients	O
were	O
excluded	O
from	O
the	O
study	O
if	O
they	O
did	O
not	O
have	O
a	O
histological	O
diagnosis	O
for	O
AK	O
,	O
if	O
they	O
were	O
older	O
than	O
85	O
years	O
,	O
or	O
if	O
they	O
did	O
not	O
comply	O
with	O
the	O
protocol	O
.	O

All	O
patients	O
had	O
responded	O
to	O
a	O
notice	O
asking	O
for	O
volunteers	O
.	O

The	B-O
number	I-O
and	O
appearance	B-O
of	I-O
lesions	I-O
were	O
evaluated	O
before	O
,	O
during	O
,	O
and	O
after	O
treatment	O
.	O

All	O
adverse	O
effects	O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Pharmacokinetics	O
of	O
azithromycin	B-I
in	O
lung	O
tissue	O
,	O
bronchial	O
washing	O
,	O
and	O
plasma	O
in	O
patients	B-P
given	I-P
multiple	I-P
oral	I-P
doses	I-P
of	I-P
500	I-P
and	I-P
1000	I-P
mg	I-P
daily	I-P
.	O

METHODS	O
:	O
Samples	O
were	O
taken	O
during	O
surgery	O
for	O
lung	O
resection	O
at	O
various	O
time	O
points	O
up	O
to	O
204	O
h	O
after	O
the	O
last	O
drug	O
dose	O
,	O
and	O
azithromycin	B-O
levels	I-O
were	O
analyzed	O
by	O
HPLC	B-O
method	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Treatment	O
effects	O
of	O
eptifibatide	B-I
in	O
planned	O
coronary	O
stent	O
implantation	O
in	O
patients	B-P
with	I-P
chronic	I-P
kidney	I-P
disease	I-P
(	O
ESPRIT	O
Trial	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
S	B-I
-	I-I
phase	I-I
kinase	I-I
-	I-I
associated	I-I
protein	I-I
2	I-I
expression	I-I
in	O
laryngeal	O
squamous	O
cell	O
carcinomas	O
and	O
its	O
prognostic	O
implications	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
a	B-O
potential	I-O
distribution	I-O
of	I-O
Skp2	I-O
in	I-O
LSCC	I-O
and	O
its	O
clinical	B-O
implications	I-O
was	O
investigated	O
by	O
an	O
immunohistochemical	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Sustained	O
ventricular	O
arrhythmias	O
and	O
mortality	O
among	O
patients	B-P
with	I-P
acute	I-P
myocardial	I-P
infarction	I-P
:	O
results	O
from	O
the	O
GUSTO	O
-	O
III	O
trial	O
.	O

METHODS	O
:	O
We	O
identified	O
independent	B-O
predictors	I-O
of	I-O
inhospital	I-O
ventricular	I-O
fibrillation	I-O
(	I-O
VF	I-O
)	I-O
and	O
ventricular	B-O
tachycardia	I-O
(	I-O
VT	I-O
)	I-O
and	O
compared	O
30	O
-	O
day	O
and	O
1	O
-	O
year	O
mortality	B-O
rates	I-O
of	O
patients	O
who	O
did	O
(	O
n	O
=	O
1121	O
)	O
and	O
did	O
not	O
(	O
n	O
=	O
13	O
,	O
921	O
)	O
have	O
these	O
arrhythmias	O
during	O
the	O
index	O
hospitalization	O
.	O

-DOCSTART-	O

Title	O
:	O
Dose	O
-	O
response	O
characteristics	O
during	O
long	B-I
-	I-I
term	I-I
inhalation	I-I
of	I-I
nitric	I-I
oxide	I-I
in	O
patients	B-P
with	I-P
severe	I-P
acute	I-P
respiratory	I-P
distress	I-P
syndrome	I-P
:	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
for	O
conventional	B-C
therapy	I-C
(	O
control	O
)	O
or	O
continuous	B-I
treatment	I-I
with	I-I
10	I-I
parts	I-I
per	I-I
million	I-I
(	I-I
ppm	I-I
)	I-I
inhaled	I-I
NO	I-I
until	O
weaning	O
was	O
initiated	O
.	O

We	O
measured	O
DR	B-O
curves	I-O
of	I-O
PaO2	I-O
/	O
FIO2	B-O
versus	O
the	B-O
inhaled	I-O
NO	I-O
dose	I-O
at	O
regular	O
intervals	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
exposure	O
prevention	O
rating	O
method	O
for	O
intervention	O
needs	O
assessment	O
and	O
effectiveness	O
evaluation	O
.	O

METHODS	O
:	O
We	O
developed	O
a	B-I
checklist	I-I
containing	O
six	O
unique	O
sets	O
of	O
yes	O
/	O
no	O
variables	O
organized	O
in	O
a	O
2	O
x	O
3	O
matrix	O
of	O
exposure	O
potential	O
versus	O
protection	O
(	O
two	O
columns	O
)	O
at	O
the	O
levels	O
of	O
materials	O
,	O
processes	O
,	O
and	O
human	O
interface	O
(	O
three	O
rows	O
)	O
.	O

The	O
three	O
levels	O
correspond	O
to	O
a	O
simplified	O
hierarchy	O
of	O
controls	O
.	O

Each	O
of	O
the	O
six	O
sets	O
of	O
indicator	O
variables	O
was	O
reduced	O
to	O
a	O
high	O
/	O
moderate	O
/	O
low	O
rating	O
.	O

Ratings	O
from	O
the	O
matrix	O
were	O
then	O
combined	O
to	O
generate	O
a	O
single	O
overall	O
exposure	O
prevention	O
rating	O
for	O
each	O
area	O
.	O

Reflecting	O
the	O
hierarchy	O
of	O
controls	O
,	O
material	O
factors	O
were	O
weighted	O
highest	O
,	O
followed	O
by	O
process	O
,	O
and	O
then	O
human	O
interface	O
.	O

The	B-I
checklist	I-I
was	O
filled	O
out	O
by	O
an	O
industrial	O
hygienist	O
while	O
conducting	O
a	O
walk	O
-	O
through	O
inspection	O
(	O
N	O
=	O
131	O
manufacturing	O
processes	O
/	O
areas	O
in	O
17	O
large	O
work	O
sites	O
)	O
.	O

One	B-O
area	I-O
or	O
process	B-O
per	I-O
manufacturing	I-O
department	I-O
was	O
assessed	O
and	O
rated	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
trial	O
of	O
the	O
canalith	B-I
repositioning	I-I
procedure	I-I
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
controlled	O
trial	O
in	O
the	O
setting	O
of	O
a	O
neurotological	O
clinic	O
in	O
Thailand	O
.	O

Fifty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
posterior	I-P
benign	I-P
paroxysmal	I-P
positional	I-P
vertigo	I-P
were	O
randomly	O
assigned	O
to	O
treatment	O
and	O
control	O
groups	O
using	O
a	O
block	O
of	O
four	O
.	O

The	O
treatment	O
group	O
was	O
treated	O
with	O
the	B-I
modified	I-I
CRP	I-I
technique	I-I
until	O
the	O
nystagmus	O
disappeared	O
.	O

A	O
mastoid	O
oscillator	O
was	O
not	O
used	O
,	O
nor	O
were	O
any	O
instructions	O
given	O
for	O
patients	O
after	O
the	O
maneuver	O
.	O

Both	O
groups	O
recorded	O
the	B-O
daily	I-O
grading	I-O
of	I-O
symptoms	I-O
and	O
the	B-O
amount	I-O
of	I-O
anti	I-O
-	I-O
vertiginous	I-O
drugs	I-O
(	I-O
cinnarizine	I-O
)	I-O
taken	O
.	O

Objective	O
and	O
subjective	O
assessments	O
were	O
made	O
weekly	O
until	O
the	O
nystagmus	O
disappeared	O
or	O
until	O
4	O
weeks	O
had	O
passed	O
since	O
treatment	O
began	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
prospective	O
randomized	O
trial	O
of	O
two	B-I
different	I-I
endoscopic	I-I
resection	I-I
techniques	I-I
for	O
early	O
stage	O
cancer	O
of	O
the	O
esophagus	O
.	O

METHODS	O
:	O
In	O
a	O
prospective	O
randomized	O
study	O
,	O
100	O
consecutive	O
endoscopic	O
resections	O
were	O
performed	O
in	O
72	B-P
patients	I-P
with	I-P
early	I-P
stage	I-P
esophageal	I-P
cancer	I-P
.	O

Fifty	O
endoscopic	O
resections	O
were	O
performed	O
with	O
a	B-I
"	I-I
suck	I-I
-	I-I
and	I-I
-	I-I
ligate	I-I
"	I-I
device	I-I
without	I-I
prior	I-I
submucosa	I-I
injection	I-I
and	O
50	O
with	O
the	B-I
cap	I-I
technique	I-I
with	I-I
prior	I-I
submucosa	I-I
injection	I-I
of	I-I
a	I-I
dilute	I-I
saline	I-I
solution	I-I
of	I-I
epinephrine	I-I
.	O

The	O
main	O
assessment	O
criteria	O
were	O
maximum	B-O
diameter	I-O
of	I-O
the	I-O
resection	I-O
specimen	I-O
and	O
of	O
the	B-O
resection	I-O
area	I-O
,	O
and	O
the	B-O
complication	I-O
rate	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Children	B-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
.	O

I	O
:	O
comparison	O
of	O
placebo	B-C
and	O
single	B-I
dose	I-I
of	I-I
human	I-I
synthetic	I-I
secretin	I-I
.	O

METHODS	O
:	O
Randomised	O
,	O
crossover	O
,	O
double	O
blind	O
,	O
and	O
placebo	O
controlled	O
trial	O
of	O
a	B-I
single	I-I
intravenous	I-I
dose	I-I
of	I-I
human	I-I
synthetic	I-I
secretin	I-I
(	I-I
HSS	I-I
)	I-I
2	O
CU	O
/	O
kg	O
.	O

The	B-P
62	I-P
subjects	I-P
(	I-P
3	I-P
-	I-P
8	I-P
years	I-P
)	I-P
were	O
assigned	O
to	O
group	O
1	O
(	O
saline	B-C
placebo	I-C
/	O
HSS	B-I
)	O
or	O
group	O
2	O
(	O
HSS	B-I
/	O
saline	B-C
placebo	I-C
)	O
.	O

Diagnosis	O
was	O
confirmed	O
by	O
ADI	B-O
-	I-O
R	I-O
(	I-O
Autism	I-O
Diagnostic	I-O
Interview	I-O
-	I-O
Revised	I-O
)	I-O
algorithm	I-O
.	O

Severity	B-O
of	I-O
symptoms	I-O
was	O
rated	O
using	O
the	B-O
CARS	I-O
(	I-O
Childhood	I-O
Autism	I-O
Rating	I-O
Scale	I-O
)	I-O
.	O

Outcome	O
measures	O
included	O
Communication	B-O
and	I-O
Symbolic	I-O
Behavior	I-O
Scale	I-O
(	I-O
CSBS	I-O
)	I-O
,	O
Ritvo	B-O
Real	I-O
-	I-O
life	I-O
Rating	I-O
Scale	I-O
,	O
weekly	B-O
Global	I-O
Rating	I-O
Scale	I-O
(	I-O
GBRS	I-O
)	O
by	O
parents	O
and	O
teachers	O
,	O
and	O
daily	B-O
log	I-O
of	I-O
gastrointestinal	I-O
symptoms	I-O
.	O

The	B-O
communication	I-O
subscale	I-O
of	I-O
the	I-O
CSBS	I-O
,	O
specifying	O
communication	B-O
function	I-O
,	O
reciprocity	B-O
,	O
and	O
social	B-O
-	I-O
affective	I-O
signalling	O
was	O
videotaped	O
and	O
scored	O
by	O
a	O
blinded	O
,	O
trained	O
observer	O
.	O

-DOCSTART-	O

Title	O
:	O
Cone	O
biopsy	O
:	O
has	O
endocervical	B-I
sampling	I-I
a	O
role	O
?	O
.	O

METHODS	O
:	O
A	O
randomized	O
study	O
of	O
two	O
methods	O
of	O
endocervical	O
sampling	O
.	O

Colposcopy	O
clinic	O
at	O
Aberdeen	O
Royal	O
Infirmary	O
.	O

100	B-P
women	I-P
with	I-P
abnormal	I-P
cervical	I-P
smears	I-P
selected	I-P
for	I-P
cone	I-P
biopsy	I-P
according	I-P
to	I-P
current	I-P
colposcopy	I-P
criteria	I-P
.	O

53	O
women	O
were	O
randomized	O
to	O
have	O
endocervical	B-I
sampling	I-I
with	I-I
the	I-I
Kevorkian	I-I
curette	I-I
and	O
47	O
to	O
have	O
sampling	O
with	O
the	B-I
Medscand	I-I
endocervical	I-I
brush	I-I
.	O

Cytology	B-O
and	O
histology	B-O
results	I-O
from	O
endocervical	O
sampling	O
compared	O
with	O
cone	B-O
biopsy	I-O
histology	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Perioperative	B-I
immunotherapy	I-I
with	O
recombinant	B-I
interleukin	I-I
2	I-I
in	O
patients	B-P
undergoing	I-P
surgery	I-P
for	I-P
colorectal	I-P
cancer	I-P
.	O

METHODS	O
:	O
Patients	O
were	O
randomly	O
allocated	O
to	O
control	O
(	O
n	O
=	O
13	O
)	O
or	O
treatment	O
groups	O
(	O
n	O
=	O
12	O
)	O
.	O

Immunological	B-O
studies	I-O
of	O
both	O
lymphocyte	B-O
function	I-O
and	O
subset	B-O
number	I-O
were	O
performed	O
preoperatively	O
and	O
on	O
Days	O
1	O
,	O
4	O
,	O
7	O
,	O
and	O
10	O
.	O

-DOCSTART-	O

Title	O
:	O
Micronized	B-I
flavonoids	I-I
in	O
pain	O
control	O
after	O
hemorrhoidectomy	O
:	O
a	O
prospective	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
The	B-P
subjects	I-P
were	I-P
112	I-P
consecutive	I-P
patients	I-P
randomly	O
assigned	O
either	O
to	O
receive	O
MFF	B-I
(	O
group	O
1	O
)	O
for	O
1	O
week	O
or	O
not	B-C
to	I-C
receive	I-C
MFF	I-C
,	O
as	O
a	O
control	O
(	O
group	O
2	O
)	O
,	O
after	O
hemorrhoidectomy	O
,	O
The	B-O
severity	I-O
of	I-O
pain	I-O
and	O
the	B-O
number	I-O
of	I-O
intramuscular	I-O
analgesic	I-O
injections	I-O
required	O
were	O
recorded	O
for	O
the	O
first	O
3	O
days	O
,	O
then	O
1	O
week	O
after	O
hemorrhoidectomy	O
.	O

The	B-O
number	I-O
of	I-O
days	I-O
that	I-O
intramuscular	I-O
analgesic	I-O
injections	I-O
were	O
required	O
,	O
hospital	B-O
stay	I-O
,	O
and	O
patient	B-O
satisfaction	I-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Parent	O
-	O
defined	O
target	O
symptoms	O
respond	O
to	O
risperidone	B-I
in	O
RUPP	O
autism	O
study	O
:	O
customer	O
approach	O
to	O
clinical	O
trials	O
.	O

METHODS	O
:	O
In	O
the	O
Research	O
Units	O
on	O
Pediatric	O
Psychopharmacology	O
(	O
RUPP	O
)	O
Autism	O
Network	O
8	O
-	O
week	O
double	O
-	O
blind	O
trial	O
of	O
risperidone	B-I
versus	O
placebo	B-C
,	O
the	B-O
chief	I-O
concerns	I-O
of	I-O
parents	I-O
were	O
collected	O
at	O
0	O
,	O
4	O
,	O
and	O
8	O
weeks	O
(	O
endpoint	O
)	O
,	O
in	O
addition	O
to	O
standardized	O
primary	O
measures	O
.	O

Blinded	B-O
clinical	I-O
judges	I-O
rated	O
change	O
from	O
baseline	O
to	O
4	O
and	O
8	O
weeks	O
on	O
a	O
9	O
-	O
point	O
scale	O
(	O
1	O
=	O
normalized	O
,	O
5	O
=	O
unchanged	O
,	O
9	O
=	O
disastrous	O
)	O
;	O
94	O
participants	O
had	O
usable	O
data	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
carbohydrate	I-I
-	I-I
protein	I-I
supplement	I-I
on	O
endurance	O
performance	O
during	O
exercise	O
of	O
varying	O
intensity	O
.	O

METHODS	O
:	O
Nine	B-P
trained	I-P
cyclists	I-P
exercised	I-P
on	I-P
3	I-P
separate	I-P
occasions	I-P
at	I-P
intensities	I-P
that	I-P
varied	I-P
between	I-P
45	I-P
%	I-P
and	I-P
75	I-P
%	I-P
VO2max	I-P
for	I-P
3	I-P
h	I-P
and	I-P
then	I-P
at	I-P
85	I-P
%	I-P
VO2max	I-P
until	I-P
fatigued	I-P
.	O

Supplements	B-I
(	O
200	O
ml	O
)	O
were	O
provided	O
every	O
20	O
min	O
and	O
consisted	O
of	O
placebo	B-C
,	O
a	B-I
7	I-I
.	I-I
75	I-I
%	I-I
carbohydrate	I-I
solution	I-I
,	O
and	O
a	B-I
7	I-I
.	I-I
75	I-I
%	I-I
carbohydrate	I-I
/	O
1	B-I
.	I-I
94	I-I
%	I-I
protein	I-I
solution	I-I
.	O

Treatments	O
were	O
administered	O
using	O
a	O
double	O
-	O
blind	O
randomized	O
design	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
efficacy	O
of	O
sublingual	O
immunotherapy	O
for	O
respiratory	O
allergy	O
is	O
not	O
affected	O
by	O
different	B-I
dosage	I-I
regimens	I-I
in	O
the	O
induction	O
phase	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Combined	B-I
preoperative	I-I
xeloda	I-I
and	O
radiotherapy	B-I
for	O
lower	O
rectal	O
cancer	O
]	O
.	O

METHODS	O
:	O
Sixty	B-P
lower	I-P
rectal	I-P
cancer	I-P
patients	I-P
were	O
divided	O
randomly	O
into	O
two	O
groups	O
.	O

30	O
patients	O
(	O
Group	O
A	O
)	O
were	O
treated	O
with	O
operation	B-C
alone	I-C
and	O
30	O
patients	O
(	O
Group	O
B	O
)	O
were	O
treated	O
with	O
xeloda	B-I
and	O
radiotherapy	B-I
before	O
operation	O
.	O

-DOCSTART-	O

Title	O
:	O
Outcomes	O
in	O
patients	B-P
with	I-P
diabetes	I-P
mellitus	I-P
undergoing	I-P
percutaneous	I-P
coronary	I-P
intervention	I-P
in	O
the	O
current	O
era	O
:	O
a	O
report	O
from	O
the	O
Prevention	O
of	O
REStenosis	O
with	O
Tranilast	B-I
and	O
its	O
Outcomes	O
(	O
PRESTO	O
)	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
long	O
-	O
term	O
effect	O
of	O
oxandrolone	B-I
on	O
hepatic	O
acute	O
phase	O
proteins	O
in	O
severely	B-P
burned	I-P
children	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
five	I-P
children	I-P
with	I-P
>	I-P
or	I-P
=40	I-P
%	I-P
total	I-P
body	I-P
surface	I-P
area	I-P
burns	I-P
were	O
randomized	O
to	O
receive	O
either	O
placebo	B-C
or	O
oxandrolone	B-I
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
by	O
mouth	O
twice	O
daily	O
)	O
from	O
postoperative	O
day	O
5	O
to	O
1	O
year	O
postburn	O
.	O

Levels	B-O
of	I-O
constitutive	I-O
proteins	I-O
and	O
acute	B-O
phase	I-O
proteins	I-O
were	O
measured	O
at	O
admission	O
;	O
at	O
discharge	O
;	O
and	O
at	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
after	O
burn	O
.	O

Total	B-O
albumin	I-O
supplementation	I-O
and	O
hepatic	B-O
transaminases	I-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Clonidine	B-I
treatment	I-I
of	O
hyperactive	B-P
and	I-P
impulsive	I-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
.	O

METHODS	O
:	O
Eight	B-P
male	I-P
children	I-P
(	I-P
8	I-P
.	I-P
1	I-P
+	I-P
/	I-P
-	I-P
2	I-P
.	I-P
8	I-P
years	I-P
)	I-P
with	I-P
autistic	I-P
disorder	I-P
,	I-P
diagnosed	I-P
by	I-P
DSM	I-P
-	I-P
III	I-P
-	I-P
R	I-P
criteria	I-P
,	O
completed	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
crossover	O
trial	O
of	O
clonidine	B-I
.	O

Subjects	O
were	O
included	O
in	O
the	O
study	O
if	O
they	O
had	O
inattention	O
,	O
impulsivity	O
,	O
and	O
hyperactivity	O
that	O
was	O
excessive	O
for	O
their	O
developmental	O
level	O
.	O

Subjects	O
had	O
not	O
tolerated	O
or	O
responded	O
to	O
other	O
psychopharmacologic	O
treatments	O
(	O
neuroleptics	O
,	O
methylphenidate	O
,	O
or	O
desipramine	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Oscillatory	B-I
potentials	I-I
,	O
retinopathy	B-I
,	O
and	O
long	B-I
-	I-I
term	I-I
glucose	I-I
control	I-I
in	O
insulin	O
-	O
dependent	O
diabetes	O
.	O

METHODS	O
:	O
Individual	B-O
(	O
OP	B-O
-	I-O
1	I-O
,	O
OP	B-O
-	I-O
2	I-O
,	O
OP	B-O
-	I-O
3	I-O
)	O
and	O
summed	B-O
(	I-O
OP	I-O
-	I-O
sum	I-O
)	I-O
amplitudes	I-O
of	I-O
oscillatory	I-O
potentials	I-O
(	I-O
OPs	I-O
)	I-O
of	I-O
electroretinography	I-O
were	O
recorded	O
at	O
study	O
start	O
and	O
7	O
-	O
years	O
later	O
in	O
45	B-P
patients	I-P
(	O
the	O
Oslo	O
study	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	O
combination	O
of	O
evening	B-I
primrose	I-I
oil	I-I
(	I-I
gamma	I-I
linolenic	I-I
acid	I-I
)	I-I
and	O
fish	B-I
oil	I-I
(	O
eicosapentaenoic	B-I
+	O
docahexaenoic	B-I
acid	I-I
)	O
versus	O
magnesium	B-I
,	O
and	O
versus	O
placebo	B-C
in	O
preventing	O
pre	O
-	O
eclampsia	O
.	O

METHODS	O
:	O
All	O
were	O
given	O
as	O
nutritional	B-I
supplements	I-I
for	O
six	O
months	O
to	O
a	B-P
group	I-P
of	I-P
primiparous	I-P
and	I-P
multiparous	I-P
pregnant	I-P
women	I-P
.	O

Some	O
of	O
these	O
women	O
had	O
personal	O
or	O
family	O
histories	O
of	O
hypertension	O
(	O
21	O
%	O
)	O
.	O

Only	O
those	O
patients	O
who	O
received	O
prenatal	O
care	O
at	O
the	O
Central	O
Maternity	O
Hospital	O
for	O
Luanda	O
were	O
included	O
in	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Injection	O
pain	O
and	O
postinjection	O
pain	O
of	O
the	B-I
palatal	I-I
-	I-I
anterior	I-I
superior	I-I
alveolar	I-I
injection	I-I
,	O
administered	O
with	O
the	O
Wand	O
Plus	O
system	O
,	O
comparing	O
2	B-I
%	I-I
lidocaine	I-I
with	O
1	B-I
:	I-I
100	I-I
,	I-I
000	I-I
epinephrine	I-I
to	O
3	B-I
%	I-I
mepivacaine	I-I
.	O

METHODS	O
:	O
Using	O
a	O
crossover	O
design	O
,	O
40	B-P
subjects	I-P
randomly	O
received	O
,	O
in	O
a	O
double	O
-	O
blind	O
manner	O
,	O
P	B-I
-	I-I
ASA	I-I
injections	I-I
of	I-I
1	I-I
.	I-I
4	I-I
mL	I-I
of	I-I
2	I-I
%	I-I
lidocaine	I-I
with	O
1	B-I
:	I-I
100	I-I
,	I-I
000	I-I
epinephrine	I-I
and	O
1	B-I
.	I-I
4	I-I
mL	I-I
of	I-I
3	I-I
%	I-I
mepivacaine	I-I
,	O
at	O
2	O
separate	O
appointments	O
.	O

The	B-I
P	I-I
-	I-I
ASA	I-I
injection	I-I
was	O
administered	O
,	O
utilizing	O
the	O
Wand	O
Plus	O
system	O
,	O
6	O
to	O
10	O
mm	O
into	O
the	O
incisive	O
canal	O
located	O
lingual	O
to	O
the	O
central	O
incisors	O
.	O

The	B-O
pain	I-O
of	I-O
needle	I-O
insertion	I-O
,	O
needle	B-O
placement	I-O
,	O
solution	B-O
deposition	I-O
and	O
postinjection	B-O
pain	I-O
were	O
recorded	O
on	O
a	B-O
Heft	I-O
-	I-O
Parker	I-O
visual	I-O
analog	I-O
scale	I-O
for	O
the	B-I
2	I-I
P	I-I
-	I-I
ASA	I-I
injections	I-I
.	O

Eighty	O
injections	O
were	O
randomly	O
administered	O
in	O
the	O
study	O
,	O
40	O
using	O
topical	B-C
anesthetic	I-C
gel	I-C
and	O
40	O
using	O
a	B-C
placebo	I-C
gel	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Rapid	O
-	O
sequence	O
intubation	O
of	O
head	B-P
trauma	I-P
patients	I-P
:	O
prevention	O
of	O
fasciculations	O
with	O
pancuronium	B-I
versus	O
minidose	B-I
succinylcholine	I-I
.	O

METHODS	O
:	O
A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

An	O
inner	O
-	O
city	O
county	O
trauma	O
center	O
with	O
70	O
,	O
000	O
patient	O
visits	O
per	O
year	O
.	O

Sequential	B-P
adult	I-P
head	I-P
trauma	I-P
patients	I-P
requiring	I-P
rapid	I-P
-	I-P
sequence	I-P
intubation	I-P
who	I-P
had	I-P
no	I-P
contraindications	I-P
to	I-P
succinylcholine	I-P
or	I-P
pancuronium	I-P
.	O

Each	O
head	O
trauma	O
patient	O
requiring	O
rapid	O
-	O
sequence	O
intubation	O
who	O
met	O
the	O
inclusion	O
criteria	O
received	O
standard	O
rapid	O
-	O
sequence	O
intubation	O
maneuvers	O
and	O
lidocaine	O
(	O
1	O
mg	O
/	O
kg	O
)	O
IV	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
either	O
minidose	B-I
succinylcholine	I-I
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
)	O
or	O
pancuronium	B-I
(	O
0	O
.	O
03	O
mg	O
/	O
kg	O
)	O
IV	O
one	O
minute	O
prior	O
to	O
the	O
full	O
paralytic	O
dose	O
of	O
succinylcholine	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
)	O
IV	O
.	O

Fasciculations	B-O
were	O
recorded	O
using	O
a	B-O
graded	I-O
visual	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Metoprolol	B-I
CR	I-I
/	O
XL	B-I
improves	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
.	O

METHODS	O
:	O
In	O
an	O
echocardiographic	O
substudy	O
to	O
the	B-I
Metoprolol	I-I
CR	I-I
/	O
XL	B-I
Randomized	O
Intervention	O
Trial	O
in	O
Heart	O
Failure	O
(	O
MERIT	O
-	O
HF	O
)	O
,	O
66	B-P
patients	I-P
were	O
examined	O
three	O
times	O
during	O
a	O
12	O
-	O
month	O
period	O
blinded	O
to	O
treatment	O
group	O
,	O
assessing	O
left	B-O
ventricular	I-O
dimensions	I-O
and	O
ejection	B-O
fraction	I-O
,	O
and	O
Doppler	B-O
mitral	I-O
inflow	I-O
parameters	I-O
,	O
all	O
measured	O
in	O
a	O
core	O
laboratory	O
.	O

-DOCSTART-	O

Title	O
:	O
Bitewing	O
film	O
quality	O
:	O
a	O
clinical	O
comparison	O
of	O
the	B-I
loop	I-I
vs	O
.	O
holder	B-I
techniques	I-I
.	O

METHODS	O
:	O
Four	O
bitewing	O
films	O
were	O
taken	O
from	O
the	B-P
right	I-P
and	I-P
left	I-P
premolar	I-P
and	I-P
molar	I-P
regions	I-P
of	I-P
45	I-P
dental	I-P
students	I-P
using	O
both	O
the	B-I
bitewing	I-I
holder	I-I
and	O
paper	B-I
loop	I-I
techniques	I-I
.	O

A	B-P
total	I-P
of	I-P
360	I-P
films	I-P
were	O
taken	O
and	O
assessed	O
by	O
an	O
experienced	O
practitioner	O
not	O
apprised	O
of	O
the	B-I
bitewing	I-I
technique	I-I
used	O
.	O

Of	O
interest	O
were	O
:	O
(	O
1	O
)	O
the	B-O
number	I-O
of	I-O
overlaps	I-O
and	O
the	B-O
percentage	I-O
of	I-O
teeth	I-O
showing	I-O
the	I-O
alveolar	I-O
crest	I-O
;	O
(	O
2	O
)	O
proper	B-O
film	I-O
positioning	I-O
;	O
and	O
(	O
3	O
)	O
the	B-O
percentage	I-O
of	I-O
cone	I-O
cutting	I-O
.	O

A	O
Poisson	O
regression	O
using	O
generalized	O
estimating	O
equations	O
(	O
GEEs	O
)	O
was	O
used	O
to	O
estimate	O
the	O
difference	O
in	O
overlap	O
between	O
the	O
two	O
techniques	O
.	O

For	O
proper	O
positioning	O
and	O
cone	O
cutting	O
,	O
logistic	O
regressions	O
using	O
GEEs	O
were	O
used	O
.	O

-DOCSTART-	O

Title	O
:	O
Mouth	B-I
closing	I-I
device	I-I
(	I-I
chinstrap	I-I
)	I-I
reduces	O
mouth	O
leak	O
during	O
nasal	O
CPAP	O
.	O

METHODS	O
:	O
Fifteen	B-P
patients	I-P
with	I-P
mouth	I-P
leak	I-P
complaining	I-P
of	I-P
mouth	I-P
dryness	I-P
and	I-P
nasal	I-P
obstruction	I-P
underwent	O
two	O
consecutive	O
overnight	O
polysomnographies	O
,	O
one	O
with	O
a	B-I
chinstrap	I-I
,	O
in	O
random	O
order	O
.	O

Cephalometry	B-O
with	B-I
and	O
without	B-C
a	I-C
chinstrap	I-C
was	O
randomly	O
performed	O
on	O
six	O
patients	O
.	O

-DOCSTART-	O

Title	O
:	O
Clarithromycin	B-I
reduces	O
the	O
severity	O
of	O
bronchial	O
hyperresponsiveness	O
in	O
patients	B-P
with	I-P
asthma	I-P
.	O

METHODS	O
:	O
Adult	B-P
asthma	I-P
patients	I-P
undergoing	I-P
treatment	I-P
with	I-P
budesonide	I-P
400	I-P
microg	I-P
b	I-P
.	I-P
i	I-P
.	I-P
d	I-P
.	I-P
and	I-P
salbutamol	I-P
200	I-P
microg	I-P
p	I-P
.	I-P
r	I-P
.	I-P
n	I-P
.	I-P
less	I-P
than	I-P
twice	I-P
weekly	I-P
were	O
studied	O
.	O

Arm	O
A	O
(	O
16	O
males	O
/	O
six	O
females	O
,	O
aged	O
48	O
+	O
/	O
-	O
16	O
yrs	O
)	O
received	O
clarithromycin	B-I
250	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
for	O
8	O
weeks	O
,	O
arm	O
B	O
(	O
eight	O
males	O
/	O
12	O
females	O
,	O
aged	O
42	O
+	O
/	O
-	O
12	O
yrs	O
)	O
clarithromycin	B-I
250	O
mg	O
t	O
.	O
id	O
.	O
and	O
arm	O
C	O
(	O
six	O
males	O
/	O
15	O
females	O
,	O
aged	O
41	O
+	O
/	O
-	O
16	O
yrs	O
)	O
placebo	B-C
dextrose	I-C
tablets	O
.	O

Bronchial	B-O
hyperresponsiveness	I-O
was	O
quantified	O
by	O
measurement	O
of	O
the	O
provocative	O
dose	O
of	O
methacholine	O
causing	O
a	O
20	O
%	O
fall	O
in	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
PD20	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Chronic	B-I
fatigue	I-I
syndrome	I-I
versus	O
neuroendocrineimmune	B-I
dysfunction	I-I
syndrome	I-I
:	O
differential	O
attributions	O
.	O

METHODS	O
:	O
Nurses	O
and	O
physician	O
assistants	O
(	O
PAs	O
)	O
were	O
presented	O
a	O
case	O
study	O
of	O
a	O
patient	O
with	O
symptoms	O
of	O
CFS	B-I
.	O

They	O
were	O
told	O
that	O
the	O
patient	O
had	O
either	O
"	O
chronic	B-I
fatigue	I-I
syndrome	I-I
,	O
"	O
"	O
chronic	B-I
neuroendocrineimmune	I-I
dysfunction	I-I
syndrome	I-I
,	O
"	O
or	O
"	O
chronic	B-I
neuroendocrineimmune	I-I
dysfunction	I-I
syndrome	I-I
,	O
which	O
had	O
formerly	O
been	O
called	O
chronic	O
fatigue	O
syndrome	O
.	O

-DOCSTART-	O

Title	O
:	O
Needle	B-I
versus	O
loop	B-I
diathermy	I-I
excision	I-I
of	I-I
the	I-I
transformation	I-I
zone	I-I
for	O
the	O
treatment	O
of	O
cervical	O
intraepithelial	O
neoplasia	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
prospective	O
randomised	O
controlled	O
trial	O
.	O

A	O
gynaecological	O
oncology	O
centre	O
and	O
a	O
teaching	O
hospital	O
in	O
West	O
London	O
.	O

Four	B-P
hundred	I-P
and	I-P
four	I-P
women	I-P
due	I-P
to	I-P
receive	I-P
treatment	I-P
for	I-P
suspected	I-P
CIN	I-P
.	O

Women	O
were	O
randomised	O
to	O
receive	O
either	O
LLETZ	B-I
or	O
NETZ	B-I
.	O

The	O
study	O
was	O
designed	O
to	O
demostrate	O
a	O
difference	O
in	O
the	B-O
proportion	I-O
of	I-O
women	I-O
with	I-O
clear	I-O
histological	I-O
margins	I-O
of	O
82	O
%	O
for	O
LLETZ	B-I
compared	O
to	O
94	O
%	O
for	O
NETZ	B-I
with	O
90	O
%	O
power	O
at	O
a	O
5	O
%	O
significance	O
level	O
,	O
allowing	O
for	O
absence	O
of	O
CIN	O
in	O
the	O
treatment	O
specimen	O
in	O
15	O
%	O
.	O

-DOCSTART-	O

Title	O
:	O
Public	O
and	O
private	O
heart	O
rate	O
feedback	O
in	O
social	O
phobia	O
:	O
a	O
manipulation	O
of	O
anxiety	O
visibility	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
32	I-P
social	I-P
phobics	I-P
and	I-P
32	I-P
controls	I-P
were	O
asked	O
twice	O
to	O
sit	B-I
in	I-I
a	I-I
chair	I-I
and	O
appear	B-I
relaxed	I-I
while	O
being	O
evaluated	O
.	O

Half	O
of	O
the	O
participants	O
heard	O
their	B-O
heart	I-O
sounds	I-O
first	O
via	O
headphones	O
and	O
then	O
via	O
loudspeakers	O
which	O
were	O
also	O
audible	O
to	O
observers	O
.	O

The	O
presentation	O
order	O
of	O
the	O
heart	O
sound	O
was	O
reversed	O
for	O
the	O
other	O
half	O
of	O
the	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Peripheral	O
arterial	O
disease	O
:	O
therapeutic	O
confidence	O
of	O
CT	B-I
versus	O
digital	B-I
subtraction	I-I
angiography	I-I
and	O
effects	O
on	O
additional	O
imaging	O
recommendations	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
controlled	O
trial	O
,	O
73	O
patients	O
were	O
assigned	O
to	O
CT	B-I
angiography	I-I
,	O
and	O
72	O
were	O
assigned	O
to	O
DSA	B-I
.	O

Physician	B-O
confidence	I-O
in	O
the	O
treatment	O
decision	O
was	O
measured	O
as	O
a	O
continuous	O
outcome	O
on	O
a	B-O
scale	I-O
of	I-O
0	I-O
-	I-O
10	I-O
(	I-O
uncertain	I-O
to	I-O
certain	I-O
)	I-O
and	O
as	O
a	B-O
dichotomous	I-O
outcome	I-O
(	I-O
further	I-O
imaging	I-O
recommended	I-O
,	I-O
yes	I-O
or	I-O
no	I-O
)	I-O
.	O

Mean	B-O
confidence	I-O
scores	I-O
and	O
additional	B-O
imaging	I-O
recommendations	I-O
were	O
compared	O
between	O
CT	B-I
and	O
DSA	B-I
groups	O
in	O
an	O
intention	O
-	O
to	O
-	O
diagnose	O
-	O
and	O
-	O
treat	O
analysis	O
.	O

To	O
detect	O
trends	O
in	O
confidence	O
,	O
confidence	O
scores	O
were	O
plotted	O
over	O
time	O
,	O
and	O
multiple	O
linear	O
regression	O
analysis	O
was	O
performed	O
.	O

To	O
detect	O
trends	O
in	O
additional	O
imaging	O
recommendations	O
,	O
logistic	O
regression	O
analysis	O
was	O
used	O
.	O

Data	O
from	O
eligible	O
nonrandomized	O
patients	O
were	O
analyzed	O
separately	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
ibuprofen	B-I
on	O
cyclooxygenase	O
and	O
nitric	O
oxide	O
synthase	O
of	O
gastric	O
mucosa	O
:	O
correlation	O
with	O
endoscopic	O
lesions	O
and	O
adverse	O
reactions	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
Helicobacter	I-P
pylori	I-P
-	I-P
negative	I-P
subjects	I-P
were	O
randomized	O
to	O
treatment	O
with	O
ibuprofen	B-I
or	O
ibuprofen	B-I
-	I-I
arginate	I-I
(	O
each	O
600	O
mg	O
/	O
6	O
hr	O
during	O
3	O
days	O
)	O
.	O

Endoscopies	B-O
were	O
performed	O
1	O
week	O
before	O
and	O
after	O
treatment	O
.	O

Biopsies	B-O
were	O
taken	O
from	O
the	B-O
gastric	I-O
antrum	I-O
and	O
corpus	B-O
for	O
determination	B-O
of	I-O
prostaglandin	I-O
E2	I-O
(	I-O
PGE2	I-O
)	I-O
by	O
ELISA	B-O
and	O
cyclooxygenase	B-O
(	B-O
COX	I-O
-	I-O
1	I-O
and	O
COX	B-O
-	I-O
2	I-O
)	I-O
and	O
nitric	B-O
oxide	I-O
synthase	I-O
(	B-O
eNOS	I-O
and	O
iNOS	B-O
)	I-O
by	O
western	B-O
blot	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Risperidone	B-I
in	O
the	O
treatment	O
of	O
disruptive	O
behavioral	O
symptoms	O
in	O
children	B-P
with	I-P
autistic	I-P
and	I-P
other	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
.	O

METHODS	O
:	O
In	O
this	O
8	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
risperidone	B-I
/	O
placebo	B-C
solution	I-C
(	O
0	O
.	O
01	O
-	O
0	O
.	O

06	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
administered	O
to	O
79	B-P
children	I-P
who	I-P
were	I-P
aged	I-P
5	I-P
to	I-P
12	I-P
years	I-P
and	I-P
had	I-P
PDD	I-P
.	O

Behavioral	B-O
symptoms	I-O
were	O
assessed	O
using	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
(	I-O
ABC	I-O
)	I-O
,	O
Nisonger	B-O
Child	I-O
Behavior	I-O
Rating	I-O
Form	I-O
,	O
and	O
Clinical	B-O
Global	I-O
Impression	I-O
-	I-O
Change	I-O
.	O

Safety	B-O
assessments	O
included	O
vital	B-O
signs	I-O
,	O
electrocardiogram	B-O
,	O
extrapyramidal	B-O
symptoms	I-O
,	O
adverse	B-O
events	I-O
,	O
and	O
laboratory	B-O
tests	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
antioxidants	B-I
,	O
zinc	B-I
,	O
and	O
copper	B-I
on	O
cognition	O
in	O
the	B-P
elderly	I-P
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Participants	B-P
in	I-P
the	I-P
Age	I-P
-	I-P
Related	I-P
Eye	I-P
Disease	I-P
Study	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
daily	B-I
antioxidants	I-I
(	O
vitamin	B-I
C	I-I
,	O
500	O
mg	O
;	O
vitamin	B-I
E	I-I
,	O
400	O
IU	O
;	O
beta	B-I
carotene	I-I
,	O
15	O
mg	O
)	O
,	O
zinc	B-I
and	O
copper	B-I
(	O
zinc	B-I
,	O
80	O
mg	O
;	O
cupric	B-I
oxide	I-I
,	O
2	O
mg	O
)	O
,	O
antioxidants	B-I
plus	O
zinc	B-I
and	O
copper	B-I
,	O
or	O
placebo	B-C
.	O

A	B-O
cognitive	I-O
battery	I-O
was	O
administered	O
to	O
2	B-P
,	I-P
166	I-P
elderly	I-P
persons	I-P
after	I-P
a	I-P
median	I-P
of	I-P
6	I-P
.	I-P
9	I-P
years	I-P
of	I-P
treatment	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Syncope	O
Evaluation	O
in	O
the	O
Emergency	O
Department	O
Study	O
(	O
SEEDS	O
)	O
:	O
a	O
multidisciplinary	O
approach	O
to	O
syncope	B-I
management	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Dual	O
-	O
task	O
-	O
related	O
gait	O
changes	O
in	O
transitionally	B-P
frail	I-P
older	I-P
adults	I-P
:	O
the	O
type	O
of	O
the	O
walking	O
-	O
associated	O
cognitive	O
task	O
matters	O
.	O

METHODS	O
:	O
Gait	O
was	O
tested	O
in	O
30	B-P
transitionally	I-P
frail	I-P
older	I-P
adults	I-P
(	I-P
mean	I-P
age	I-P
82	I-P
.	I-P
6	I-P
+	I-P
/	I-P
-	I-P
7	I-P
.	I-P
1	I-P
years	I-P
,	I-P
90	I-P
%	I-P
female	I-P
)	I-P
while	O
either	O
walking	B-I
alone	I-I
,	O
performing	B-I
a	I-I
simple	I-I
arithmetic	I-I
task	I-I
,	O
or	O
performing	B-I
a	I-I
task	I-I
of	I-I
verbal	I-I
fluency	I-I
.	O

Walking	B-O
time	I-O
in	I-O
seconds	I-O
,	O
number	B-O
of	I-O
steps	I-O
,	O
frequency	B-O
of	I-O
lateral	I-O
line	I-O
stepping	I-O
-	I-O
over	I-O
,	O
and	O
stops	B-O
were	O
recorded	O
.	O

Health	B-O
status	I-O
was	O
assessed	O
using	O
standard	B-O
instruments	I-O
of	I-O
geriatric	I-O
assessment	I-O
.	O

The	O
classification	O
of	O
Speechley	B-O
and	I-O
Tinetti	I-O
was	O
used	O
to	O
define	O
the	B-O
participants	I-O
'	I-O
degree	I-O
of	I-O
frailty	I-O
.	O

-DOCSTART-	O

Title	O
:	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
and	O
reflectance	B-I
-	I-I
mode	I-I
confocal	I-I
microscopy	I-I
as	O
adjunct	O
modalities	O
to	O
Mohs	O
micrographic	O
surgery	O
for	O
treatment	O
of	O
basal	O
cell	O
carcinoma	O
.	O

METHODS	O
:	O
Subjects	O
applied	O
study	B-I
cream	I-I
to	I-I
one	I-I
biopsy	I-I
-	I-I
confirmed	I-I
basal	I-I
cell	I-I
carcinoma	I-I
tumor	I-I
5	O
x	O
/	O
week	O
for	O
2	O
,	O
4	O
,	O
or	O
6	O
weeks	O
in	O
this	O
vehicle	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

Confocal	B-I
microscopy	I-I
was	O
used	O
for	O
the	O
6	O
-	O
week	O
treatment	O
group	O
to	O
examine	O
the	B-O
target	I-O
tumor	I-O
area	I-O
at	O
each	O
interval	O
visit	O
and	O
immediately	O
before	O
Mohs	O
micrographic	O
surgery	O
.	O

After	O
the	O
Mohs	O
micrographic	O
surgery	O
excision	O
,	O
the	B-O
tissue	I-O
was	O
evaluated	O
histologically	B-O
,	O
and	O
the	B-O
excision	I-O
area	I-O
was	O
measured	O
.	O

Confocal	B-O
microscopy	I-O
readings	I-O
were	O
correlated	O
to	O
the	B-O
histologic	I-O
diagnosis	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Group	B-I
-	I-I
based	I-I
HIV	I-I
risk	I-I
reduction	I-I
intervention	I-I
for	O
adolescent	B-P
girls	I-P
:	O
evidence	O
of	O
feasibility	O
and	O
efficacy	O
.	O

METHODS	O
:	O
The	B-O
feasibility	I-O
of	O
the	O
intervention	O
was	O
demonstrated	O
by	O
successfully	O
implementing	O
it	O
with	O
33	O
sexually	O
-	O
active	O
,	O
single	O
girls	O
.	O

Preliminary	O
evidence	O
of	O
the	B-O
efficacy	I-O
of	O
the	O
intervention	O
was	O
obtained	O
using	O
a	O
randomized	O
trial	O
with	O
62	B-P
sexually	I-P
-	I-P
active	I-P
,	I-P
single	I-P
girls	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Heart	O
rate	O
variability	O
and	O
QT	O
dispersion	O
in	O
patients	B-P
with	I-P
subclinical	I-P
hypothyroidism	I-P
.	O

The	O
effect	O
of	O
subclinical	O
hypothyroidism	O
(	O
SH	O
)	O
on	O
cardiovascular	O
autonomic	O
function	O
and	O
ventricular	O
repolarization	O
has	O
not	O
been	O
yet	O
elucidated	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
dispersion	O
of	O
QT	O
interval	O
,	O
i	O
.	O
e	O
.	O
an	O
index	O
of	O
inhomogeneity	O
of	O
repolarization	O
,	O
and	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
,	O
i	O
.	O
e	O
.	O
a	O
measure	O
of	O
cardiac	O
autonomic	O
modulation	O
,	O
in	O
SH	O
patients	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
42	B-P
patients	I-P
(	I-P
29	I-P
women	I-P
and	I-P
13	I-P
men	I-P
;	I-P
mean	I-P
age	I-P
53	I-P
.	I-P
2	I-P
+	I-P
/	I-P
-	I-P
14	I-P
.	I-P

2	I-P
years	I-P
;	I-P
body	I-P
surface	I-P
area	I-P
1	I-P
.	I-P
76	I-P
+	I-P
/	I-P
-	I-P
0	I-P
.	I-P

14	I-P
m2	I-P
)	I-P
with	I-P
SH	I-P
,	I-P
as	I-P
judged	I-P
by	I-P
elevated	I-P
serum	I-P
TSH	I-P
levels	I-P
(	I-P
>	I-P
3	I-P
.	I-P
6	I-P
mIU	I-P
/	I-P
l	I-P
;	I-P
range	I-P
,	I-P
3	I-P
.	I-P
8	I-P
-	I-P
12	I-P
.	I-P

0	I-P
)	I-P
and	I-P
normal	I-P
free	I-P
thyroid	I-P
hormones	I-P
(	I-P
FT4	I-P
and	I-P
FT3	I-P
)	I-P
and	I-P
30	I-P
euthyroid	I-P
volunteer	I-P
.	O

Subjects	O
with	O
cardiac	O
,	O
metabolic	O
,	O
neurological	O
disease	O
or	O
any	O
other	O
systemic	O
disease	O
that	O
could	O
affect	O
autonomic	O
activity	O
were	O
excluded	O
from	O
the	O
study	O
.	O

Patients	O
with	O
SH	O
and	O
control	O
subjects	O
underwent	O
a	O
full	O
history	O
,	O
physical	O
examination	O
,	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
and	O
24	O
-	O
h	O
ambulatory	O
ECG	O
monitoring	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
treatment	O
with	O
L	O
-	B-I
thyroxine	I-I
on	O
QT	B-O
dispersion	I-O
and	O
HRV	B-O
,	O
15	O
patients	O
with	O
SH	O
were	O
randomly	O
assigned	O
to	O
receive	O
therapy	O
with	O
L	B-I
-	I-I
thyroxine	I-I
.	O

All	O
the	O
subjects	O
were	O
evaluated	O
at	O
enrolment	O
and	O
after	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Virtual	B-I
reality	I-I
exposure	I-I
therapy	I-I
and	O
standard	B-C
(	I-C
in	I-C
vivo	I-C
)	I-C
exposure	I-C
therapy	I-C
in	O
the	O
treatment	O
of	O
fear	O
of	O
flying	O
.	O

METHODS	O
:	O
Eighty	B-P
-	I-P
three	I-P
participants	I-P
with	I-P
FOF	I-P
were	O
randomly	O
assigned	O
to	O
VRE	B-I
,	O
SE	B-C
,	O
or	O
WL	O
.	O

Seventy	O
-	O
five	O
participants	O
,	O
25	O
per	O
group	O
,	O
completed	O
the	O
study	O
.	O

Twenty	O
-	O
three	O
WL	O
participants	O
completed	O
randomly	O
assigned	O
treatment	O
following	O
the	O
waiting	O
period	O
.	O

Treatment	O
consisted	O
of	O
4	B-I
sessions	I-I
of	I-I
anxiety	I-I
management	I-I
training	I-I
followed	O
either	O
by	O
exposure	B-I
to	I-I
a	I-I
virtual	I-I
airplane	I-I
(	I-I
VRE	I-I
)	I-I
or	O
an	B-C
actual	I-C
airplane	I-C
at	I-C
the	I-C
airport	I-C
(	I-C
SE	I-C
)	I-C
conducted	O
over	O
6	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Nordic	B-I
walking	I-I
and	O
chronic	O
low	O
back	O
pain	O
:	O
design	O
of	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
fifty	I-P
patients	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
for	I-P
at	I-P
least	I-P
eight	I-P
weeks	I-P
and	I-P
referred	I-P
to	I-P
a	I-P
specialized	I-P
secondary	I-P
sector	I-P
outpatient	I-P
back	I-P
pain	I-P
clinic	I-P
are	O
included	O
in	O
the	O
study	O
.	O

After	O
completion	O
of	O
the	O
standard	O
back	O
centre	O
treatment	O
patients	O
are	O
randomized	O
into	O
one	O
of	O
three	O
groups	O
:	O
A	O
)	O
Nordic	B-I
Walking	I-I
twice	O
a	O
week	O
for	O
eight	O
weeks	O
under	O
supervision	O
of	O
a	O
specially	O
trained	O
instructor	O
;	O
B	O
)	O
Unsupervised	B-I
Nordic	I-I
Walking	I-I
for	O
eight	O
weeks	O
after	O
one	O
training	O
session	O
with	O
an	O
instructor	O
;	O
C	O
)	O
A	B-I
one	I-I
hour	I-I
motivational	I-I
talk	I-I
including	O
advice	O
to	O
stay	O
active	O
.	O

Outcome	O
measures	O
are	O
pain	B-O
,	O
function	B-O
,	O
overall	B-O
health	I-O
,	O
cardiovascular	B-O
ability	I-O
and	O
activity	B-O
level	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Endocrine	O
response	O
to	O
cataract	B-I
surgery	I-I
under	I-I
total	I-I
intravenous	I-I
anaesthesia	I-I
,	O
local	B-I
anaesthesia	I-I
under	I-I
sedation	I-I
or	O
local	B-I
anaesthesia	I-I
alone	I-I
:	O
a	O
comparative	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Evolution	O
of	O
neuropathy	O
and	O
myopathy	O
during	O
intensive	B-I
vincristine	I-I
/	O
corticosteroid	B-I
chemotherapy	I-I
for	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
vincristine	B-I
was	O
administered	O
by	O
bolus	O
injection	O
followed	O
by	O
a	O
3	O
-	O
day	O
continuous	O
intravenous	O
(	O
IV	O
)	O
infusion	O
(	O
total	O
dose	O
of	O
2	O
.	O
0	O
mg	O
/	O
m2	O
every	O
other	O
week	O
)	O
;	O
the	O
maximum	O
dose	O
of	O
vincristine	B-I
was	O
not	O
arbitrarily	O
limited	O
.	O

Cronassial	B-I
,	O
a	O
mixture	O
of	O
four	O
naturally	O
occurring	O
gangliosides	O
,	O
was	O
administered	O
in	O
a	O
randomized	O
double	O
-	O
blind	O
test	O
to	O
evaluate	O
whether	O
this	O
agent	O
could	O
prevent	O
vincristine	B-O
-	I-O
induced	I-O
neuropathy	I-O
.	O

High	B-I
doses	I-I
of	I-I
dexamethasone	I-I
(	O
50	O
mg	O
/	O
d	O
for	O
3	O
days	O
weekly	O
or	O
every	O
other	O
week	O
)	O
were	O
also	O
prescribed	O
.	O

Patients	O
were	O
monitored	O
every	O
4	O
weeks	O
with	O
comprehensive	B-O
physical	I-O
and	O
neurologic	B-O
examinations	I-O
and	O
electrophysiologic	B-O
studies	I-O
of	I-O
peripheral	I-O
nerve	I-O
function	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Polydioxanone	B-I
sternal	I-I
sutures	I-I
for	O
prevention	O
of	O
sternal	O
dehiscence	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
sixty	I-P
-	I-P
six	I-P
patients	I-P
undergoing	I-P
elective	I-P
cardiac	I-P
surgery	I-P
with	I-P
full	I-P
median	I-P
sternotomy	I-P
and	I-P
having	I-P
body	I-P
surface	I-P
area	I-P
(	I-P
BSA	I-P
)	I-P
less	I-P
than	I-P
1	I-P
.	I-P
5	I-P
m	I-P
(	I-P
2	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
PDS	B-I
(	O
n	O
=	O
181	O
)	O
or	O
stainless	B-C
steel	I-C
(	I-C
SS	I-C
,	I-C
n	I-C
=	I-C
185	I-C
)	I-C
sternal	I-C
approximation	I-C
.	O

The	O
study	O
was	O
focused	O
on	O
aseptic	O
sternal	O
complications	O
,	O
namely	O
bone	B-O
dehiscence	I-O
and	O
superficial	B-O
wound	I-O
instability	I-O
.	O

-DOCSTART-	O

Title	O
:	O
B	B-I
-	I-I
vitamins	I-I
reduce	O
plasma	O
levels	O
of	O
beta	O
amyloid	O
.	O

METHODS	O
:	O
We	O
randomized	O
299	B-P
older	I-P
men	I-P
to	O
treatment	O
with	O
2mg	B-I
of	I-I
folate	I-I
,	O
plus	O
25mg	B-I
of	I-I
B6	I-I
and	O
400	B-I
microg	I-I
of	I-I
B12	I-I
,	O
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ultrasound	B-I
-	I-I
guided	I-I
laser	I-I
photocoagulation	I-I
for	O
treatment	O
of	O
benign	O
thyroid	O
nodules	O
.	O

METHODS	O
:	O
Twenty	B-P
six	I-P
subjects	I-P
were	O
randomized	O
to	O
the	O
intervention	O
(	O
no	O
.	O

13	O
,	O
age	O
68	O
+	O
/	O
-	O
3	O
yr	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
or	O
observation	B-C
(	O
no	O
.	O

13	O
,	O
age	O
71	O
+	O
/	O
-	O
2	O
yr	O
)	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
of	O
chewing	B-I
versus	O
caffeine	B-I
on	O
alertness	O
,	O
cognitive	O
performance	O
and	O
cardiac	O
autonomic	O
activity	O
during	O
sleep	O
deprivation	O
.	O

METHODS	O
:	O
Fourteen	B-P
adults	I-P
participated	O
in	O
a	O
randomized	O
,	O
counterbalanced	O
protocol	O
employing	O
a	B-I
chewing	I-I
,	O
placebo	B-C
and	O
caffeine	B-I
condition	I-I
.	O

Participants	O
completed	O
tasks	O
assessing	O
psychomotor	B-O
vigilance	I-O
,	O
tracking	B-O
,	O
grammatical	B-O
reasoning	I-O
,	O
alertness	B-O
and	O
sleepiness	B-O
each	I-O
hour	I-O
across	I-O
the	I-O
night	I-O
.	O

All	O
participants	O
received	O
either	O
placebo	B-C
or	O
caffeine	B-I
(	O
200	O
mg	O
)	O
,	O
while	O
the	B-I
chewing	I-I
condition	I-I
also	O
chewed	O
on	O
a	O
tasteless	O
and	O
odorless	O
substance	O
for	O
15	O
min	O
each	O
hour	O
.	O

Heart	B-O
rate	I-O
(	I-O
HR	I-O
)	I-O
,	O
root	B-O
mean	I-O
square	I-O
of	I-O
the	I-O
successive	I-O
differences	I-O
in	I-O
R	I-O
-	I-O
R	I-O
intervals	I-O
on	I-O
the	I-O
ECG	I-O
(	I-O
RMSSD	I-O
)	I-O
,	O
and	O
preejection	B-O
period	I-O
(	I-O
PEP	I-O
)	I-O
were	O
simultaneously	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
disease	B-I
severity	I-I
on	O
outcome	O
of	O
antiviral	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
:	O
Lessons	O
from	O
the	O
HALT	O
-	O
C	O
trial	O
.	O

METHODS	O
:	O
All	O
patients	O
had	O
failed	O
prior	O
treatment	O
with	O
IFN	O
or	O
peginterferon	O
+	O
/	O
-	O
RBV	O
and	O
had	O
Ishak	O
fibrosis	O
scores	O
>	O
or	O
=	O
3	O
.	O

Four	B-P
groups	I-P
of	I-P
patients	I-P
with	I-P
increasingly	I-P
severe	I-P
liver	I-P
disease	I-P
were	O
compared	O
:	O
(	O
A	O
)	O
bridging	B-I
fibrosis	I-I
(	I-I
Ishak	I-I
3	I-I
and	I-I
4	I-I
)	I-I
with	I-I
platelet	I-I
counts	I-I
>	I-I
125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
559	O
)	O
;	O
(	O
B	O
)	O
bridging	B-I
fibrosis	I-I
with	I-I
platelet	I-I
counts	I-I
<	I-I
or	I-I
=125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
96	O
)	O
;	O
(	O
C	O
)	O
cirrhosis	B-I
(	I-I
Ishak	I-I
5	I-I
and	I-I
6	I-I
)	I-I
with	I-I
platelet	I-I
counts	I-I
>	I-I
125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
198	O
)	O
;	O
and	O
(	O
D	O
)	O
cirrhosis	B-I
with	I-I
platelet	I-I
counts	I-I
<	I-I
or	I-I
=125	I-I
,	I-I
000	I-I
/	I-I
mm3	I-I
(	O
n	O
=	O
193	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	B-I
-	I-I
behavioural	I-I
stress	I-I
management	I-I
with	O
HIV	B-P
-	I-P
positive	I-P
homosexual	I-P
men	I-P
:	O
mechanisms	O
of	O
sustained	O
reductions	O
in	O
depressive	O
symptoms	O
.	O

METHODS	O
:	O
Men	O
were	O
randomized	O
to	O
either	O
a	B-I
10	I-I
-	I-I
week	I-I
,	I-I
group	I-I
-	I-I
based	I-I
CBSM	I-I
intervention	O
(	O
n	O
=	O
83	O
)	O
or	O
a	B-I
psychoeducational	I-I
seminar	I-I
group	O
(	O
n	O
=	O
46	O
)	O
.	O

All	O
participants	O
completed	O
a	B-O
battery	I-O
of	I-O
psychosocial	I-O
questionnaires	I-O
administered	O
by	O
a	O
research	O
assistant	O
at	O
baseline	O
,	O
immediately	O
following	O
the	B-I
10	I-I
-	I-I
week	I-I
CBSM	I-I
intervention	O
period	O
,	O
and	O
at	O
a	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Dietary	O
status	O
and	O
impact	O
of	O
risperidone	B-I
on	O
nutritional	O
balance	O
in	O
children	B-P
with	I-P
autism	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
Using	O
a	B-O
quantitative	I-O
Food	I-O
Frequency	I-O
Questionnaire	I-O
(	I-O
FFQ	I-O
)	I-O
,	O
we	O
prospectively	O
examined	O
the	B-O
nutritional	I-O
intake	I-O
of	O
20	B-P
children	I-P
with	I-P
autism	I-P
participating	O
in	O
a	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
of	O
risperidone	B-I
for	O
disruptive	O
behaviours	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
additional	O
value	O
of	O
a	B-I
night	I-I
splint	I-I
to	I-I
eccentric	I-I
exercises	I-I
in	O
chronic	O
midportion	O
Achilles	O
tendinopathy	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
single	O
-	O
blind	O
,	O
prospective	O
,	O
single	O
centre	O
,	O
randomised	O
controlled	O
trial	O
set	O
in	O
the	O
Sports	O
Medical	O
Department	O
,	O
The	O
Hague	O
Medical	O
Centre	O
,	O
The	O
Netherlands	O
.	O

Inclusion	O
criteria	O
were	O
:	O
age	O
18	O
-	O
70	O
years	O
,	O
active	O
participation	O
in	O
sports	O
,	O
and	O
tendon	O
pain	O
localised	O
at	O
2	O
-	O
7	O
cm	O
from	O
distal	O
insertion	O
.	O

Exclusion	O
criteria	O
were	O
:	O
insertional	O
disorders	O
,	O
partial	O
or	O
complete	O
ruptures	O
,	O
or	O
systemic	O
illness	O
.	O

70	B-P
tendons	I-P
were	O
included	O
and	O
randomised	O
into	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
eccentric	B-I
exercises	I-I
with	I-I
a	I-I
night	I-I
splint	I-I
(	O
night	B-I
splint	I-I
group	O
,	O
n	O
=	O
36	O
)	O
or	O
eccentric	B-I
exercises	I-I
only	I-I
(	O
eccentric	B-I
group	O
,	O
n	O
=	O
34	O
)	O
.	O

Both	O
groups	O
completed	O
a	B-I
12	I-I
-	I-I
week	I-I
heavy	I-I
-	I-I
load	I-I
eccentric	I-I
training	I-I
programme	I-I
.	O

One	O
group	O
received	O
a	O
night	O
splint	O
in	O
addition	O
to	O
eccentric	O
exercises	O
.	O

At	O
baseline	O
and	O
follow	O
-	O
up	O
at	O
12	O
weeks	O
,	O
patient	B-O
satisfaction	I-O
,	O
Victorian	B-O
Institute	I-O
of	I-O
Sport	I-O
Assessment	I-O
-	I-O
Achilles	I-O
questionnaire	I-O
(	I-O
VISA	I-O
-	I-O
A	I-O
)	I-O
score	I-O
and	O
reported	B-O
compliance	I-O
were	O
recorded	O
by	O
a	O
single	O
-	O
blind	O
trained	O
researcher	O
who	O
was	O
blinded	O
to	O
the	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Developmental	B-I
disabilities	I-I
modification	I-I
of	I-I
the	I-I
Children	I-I
'	I-I
s	I-I
Global	I-I
Assessment	I-I
Scale	I-I
.	O

METHODS	O
:	O
Developmental	B-I
disabilities	I-I
-	I-I
relevant	I-I
descriptors	I-I
were	O
developed	O
for	O
the	B-O
DD	I-O
-	I-O
CGAS	I-O
,	O
and	O
administration	O
procedures	O
were	O
established	O
to	O
enhance	O
rater	O
consistency	O
.	O

Ratings	B-O
of	I-O
clinical	I-O
case	I-O
vignettes	I-O
were	O
used	O
to	O
assess	O
inter	B-O
-	I-O
rater	I-O
reliability	I-O
and	O
temporal	B-O
stability	I-O
.	O

Validity	B-O
was	O
assessed	O
by	O
correlating	O
the	B-O
DD	I-O
-	I-O
CGAS	I-O
with	O
measures	B-O
of	I-O
functioning	I-O
and	O
symptoms	B-O
in	O
83	B-P
youngsters	I-P
with	I-P
PDD	I-P
.	O

Sensitivity	O
to	O
change	O
was	O
assessed	O
by	O
comparing	O
change	O
from	O
baseline	O
to	O
post	O
-	O
treatment	O
with	O
change	O
on	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
-	I-O
Irritability	I-O
and	O
Clinical	B-O
Global	I-O
Impressions	I-O
-	I-O
Improvement	I-O
subscale	I-O
scores	I-O
in	O
a	O
subset	O
of	O
14	O
children	O
.	O

-DOCSTART-	O

Title	O
:	O
Desmopressin	B-I
in	O
the	O
treatment	O
of	O
nocturia	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
Adults	B-P
aged	I-P
>	I-P
or	I-P
=18	I-P
yr	I-P
with	I-P
nocturia	I-P
(	I-P
>	I-P
or	I-P
=2	I-P
voids	I-P
/	I-P
night	I-P
)	I-P
received	O
desmopressin	B-I
tablets	I-I
(	O
0	O
.	O
1	O
,	O
0	O
.	O
2	O
,	O
or	O
0	O
.	O
4	O
mg	O
)	O
during	O
a	O
3	O
-	O
wk	O
dose	O
-	O
titration	O
period	O
.	O

Patients	O
should	O
show	O
sufficient	O
response	O
during	O
the	O
dose	O
-	O
titration	O
period	O
(	O
>	O
or	O
=20	O
%	O
reduction	O
in	O
nocturnal	O
diuresis	O
)	O
and	O
a	O
return	O
of	O
nocturnal	O
diuresis	O
to	O
>	O
or	O
=80	O
%	O
of	O
baseline	O
levels	O
during	O
washout	O
.	O

Eligible	O
patients	O
then	O
entered	O
a	O
3	O
-	O
wk	O
double	O
-	O
blind	O
treatment	O
period	O
and	O
received	O
either	O
desmopressin	B-I
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
alpha	B-I
dihydroergocryptine	I-I
in	O
patients	B-P
with	I-P
fibrocystic	I-P
breast	I-P
disease	I-P
]	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
diagnosis	I-P
of	I-P
fibrocystic	I-P
breast	I-P
disease	I-P
were	O
included	O
in	O
a	O
prospective	O
longitudinal	O
blind	O
double	O
,	O
controlled	O
with	O
placebo	O
study	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
:	O
of	O
treatment	O
group	O
A	O
:	O
Alpha	B-I
dihidroergocriptine	I-I
tablets	I-I
of	O
10	O
mg	O
,	O
group	O
B	O
:	O
Placebo	B-C
,	O
during	O
6	O
months	O
.	O

After	O
to	O
basal	O
evaluation	O
,	O
the	O
patients	O
were	O
revised	O
in	O
a	O
monthly	O
way	O
evaluating	O
the	O
following	O
symptoms	B-O
and	I-O
signs	I-O
:	O
mastalgia	B-O
,	O
mammary	B-O
tension	I-O
,	O
presence	B-O
of	I-O
nodules	I-O
,	O
nipple	B-O
secretion	I-O
,	O
and	O
the	B-O
presence	I-O
of	I-O
adverse	I-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Immediately	O
restored	O
,	O
single	B-I
-	I-I
tapered	I-I
implants	I-I
in	O
the	O
anterior	O
maxilla	O
:	O
prosthodontic	O
and	O
aesthetic	O
outcomes	O
after	O
1	O
year	O
.	O

METHODS	O
:	O
Participants	B-P
(	I-P
mean	I-P
age	I-P
:	I-P
43	I-P
.	I-P
25	I-P
years	I-P
;	I-P
range	I-P
:	I-P
23	I-P
-	I-P
71	I-P
years	I-P
)	I-P
satisfying	I-P
specified	I-P
inclusion	I-P
criteria	I-P
were	O
randomly	O
allocated	O
to	O
conventional	B-C
two	I-C
-	I-C
stage	I-C
restoration	I-C
(	O
control	O
group	O
;	O
n=14	O
)	O
and	O
immediate	B-I
restoration	I-I
groups	O
(	O
test	O
group	O
;	O
n	O
=14	O
)	O
in	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
.	O

Tapered	B-I
,	I-I
roughened	I-I
-	I-I
surface	I-I
Southern	I-I
implants	I-I
were	O
placed	O
using	O
a	O
standardized	O
technique	O
,	O
and	O
implant	B-O
level	I-O
bone	I-O
impressions	I-O
were	O
made	O
.	O

Provisional	O
screw	O
-	O
retained	O
crowns	O
,	O
out	O
of	O
occlusion	O
,	O
were	O
placed	O
at	O
second	O
-	O
stage	O
surgery	O
after	O
26	O
weeks	O
for	O
the	B-C
conventional	I-C
restoration	I-C
group	O
,	O
and	O
within	O
4	O
hours	O
of	O
implant	O
placement	O
for	O
the	B-I
immediate	I-I
restoration	I-I
group	O
.	O

Both	O
groups	O
had	O
definitive	O
screw	O
-	O
retained	O
metal	O
-	O
ceramic	O
crowns	O
placed	O
in	O
occlusion	O
8	O
weeks	O
later	O
.	O

Peri	B-O
-	I-O
implant	I-O
mucosal	I-O
response	I-O
and	O
papilla	B-O
index	I-O
were	O
recorded	O
4	O
weeks	O
after	O
definitive	O
crown	O
placement	O
to	O
allow	O
for	O
mucosal	O
maturation	O
and	O
at	O
1	O
year	O
.	O

Prosthodontic	B-O
and	O
aesthetic	B-O
outcomes	I-O
were	O
assessed	O
using	O
established	O
criteria	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	O
efficacy	O
of	O
mebendazole	B-I
against	O
hookworm	O
in	O
Vietnam	B-P
:	O
two	O
randomized	O
controlled	O
trials	O
.	O

METHODS	O
:	O
We	O
tested	O
the	O
efficacy	O
of	O
single	B-I
dose	I-I
mebendazole	I-I
500	O
mg	O
in	O
the	O
therapy	O
of	O
hookworm	O
infection	O
in	O
a	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
among	O
271	B-P
Vietnamese	I-P
schoolchildren	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
evaluation	O
of	O
imidapril	B-I
in	O
congestive	O
heart	O
failure	O
in	O
dogs	B-P
:	O
results	O
of	O
the	O
EFFIC	O
study	O
.	O

METHODS	O
:	O
This	O
good	O
,	O
clinical	O
practice	O
compliant	O
,	O
multicentre	O
study	O
(	O
EFFIC	O
study	O
)	O
enrolled	O
142	B-P
client	I-P
-	I-P
owned	I-P
dogs	I-P
and	O
was	O
conducted	O
in	O
20	O
locations	O
in	O
France	O
,	O
Belgium	O
and	O
Germany	O
.	O

Dogs	O
of	O
various	O
breed	O
,	O
age	O
and	O
weight	O
were	O
included	O
in	O
the	O
study	O
.	O

These	O
dogs	O
were	O
randomised	O
into	O
two	O
groups	O
that	O
were	O
treated	O
for	O
84	O
days	O
with	O
either	O
the	O
test	O
product	O
,	O
imidapril	B-I
,	O
or	O
the	O
positive	O
control	O
,	O
benazepril	B-C
,	O
and	O
followed	O
up	O
in	O
parallel	O
over	O
this	O
period	O
.	O

Both	O
treatments	O
were	O
administered	O
at	O
a	O
dose	O
of	O
0	O
.	O
25	O
mg	O
/	O
kg	O
once	O
a	O
day	O
with	O
the	O
possibility	O
of	O
doubling	O
this	O
dose	O
to	O
0	O
.	O
5	O
mg	O
/	O
kg	O
if	O
considered	O
necessary	O
from	O
a	O
clinical	O
point	O
of	O
view	O
.	O

In	O
addition	O
,	O
concomitant	O
treatment	O
was	O
given	O
to	O
dogs	O
presenting	O
with	O
pulmonary	O
oedema	O
and	O
/	O
or	O
ascites	O
,	O
supraventricular	O
tachyarrhythmia	O
and	O
/	O
or	O
dilated	O
cardiomyopathy	O
.	O

The	O
evolution	O
of	O
the	B-O
New	I-O
York	I-O
Heart	I-O
Association	I-O
stage	I-O
and	O
the	B-O
"	I-O
functional	I-O
signs	I-O
"	I-O
score	I-O
were	O
evaluated	O
as	O
primary	O
efficacy	O
criteria	O
.	O

-DOCSTART-	O

Title	O
:	O
Fine	B-I
needle	I-I
aspiration	I-I
coupled	O
with	O
real	B-I
-	I-I
time	I-I
PCR	I-I
:	O
a	O
painless	O
methodology	O
to	O
study	O
adaptive	O
functional	O
changes	O
in	O
skeletal	O
muscle	O
.	O

-DOCSTART-	O

Title	O
:	O
Injury	O
and	O
illness	O
costs	O
in	O
the	B-I
Certified	I-I
Safe	I-I
Farm	I-I
study	O
.	O

METHODS	O
:	O
Farms	B-P
(	I-P
316	I-P
)	I-P
located	I-P
in	I-P
a	I-P
9	I-P
-	I-P
county	I-P
area	I-P
of	I-P
northwestern	I-P
Iowa	I-P
were	O
recruited	O
and	O
randomized	O
into	O
intervention	O
and	O
control	O
cohorts	O
.	O

Intervention	O
farms	O
received	O
occupational	B-I
health	I-I
screenings	I-I
,	O
health	B-I
and	I-I
wellness	I-I
screening	I-I
,	O
education	B-I
,	O
on	B-I
-	I-I
farm	I-I
safety	I-I
reviews	I-I
,	O
and	O
performance	B-I
incentives	I-I
.	O

For	O
both	O
cohorts	O
,	O
quarterly	O
calls	O
over	O
3	O
years	O
were	O
used	O
to	O
collect	B-O
self	I-O
-	I-O
reported	I-O
occupational	I-O
injury	I-O
and	O
illness	B-O
information	I-O
,	O
including	O
costs	B-O
to	I-O
the	I-O
farmers	I-O
and	O
their	B-O
insurers	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effects	O
of	O
hetero	B-I
-	I-I
thermal	I-I
water	I-I
administration	O
on	O
leg	O
vein	O
hemodynamics	O
,	O
skin	O
microcirculation	O
and	O
O2	O
tension	O
in	O
chronic	O
venous	O
insufficiency	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
exploratory	O
,	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
of	O
practice	B-I
nurse	I-I
training	I-I
in	O
the	O
use	O
of	O
asthma	O
action	O
plans	O
.	O

METHODS	O
:	O
A	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
with	O
an	O
intervention	O
(	O
an	B-I
interactive	I-I
seminar	I-I
)	O
delivered	O
at	O
practice	O
level	O
(	O
n=13	O
practices	O
;	O
6=intervention	O
,	O
7=control	O
)	O
.	O

The	O
impact	O
of	O
the	O
intervention	O
was	O
assessed	O
against	O
patient	O
outcomes	O
:	O
routinely	B-O
available	I-O
asthma	I-O
outcome	I-O
measures	I-O
(	O
beta2	B-O
-	I-O
agonist	I-O
prescription	I-O
rate	I-O
and	O
number	B-O
of	I-O
oral	I-O
steroid	I-O
courses	I-O
)	O
for	O
asthma	O
patients	O
identified	O
as	O
being	O
poorly	O
-	O
controlled	O
from	O
practice	O
records	O
;	O
and	O
questionnaire	B-O
data	I-O
-	O
Mini	B-O
Asthma	I-O
Quality	I-O
of	I-O
Life	I-O
Questionnaire	I-O
(	I-O
AQLQ	I-O
)	I-O
and	O
the	B-O
Asthma	I-O
Control	I-O
Questionnaire	I-O
(	I-O
ACQ	I-O
)	I-O
-	O
from	O
a	O
subset	O
of	O
consenting	O
patients	O
.	O

Data	O
was	O
collected	O
at	O
baseline	O
and	O
at	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

ANALYSISs	O
:	O
Routine	O
data	O
was	O
analysed	O
for	O
629	O
patients	O
.	O

236	O
(	O
37	O
%	O
)	O
of	O
these	O
patients	O
consented	O
to	O
provide	O
questionnaire	O
data	O
at	O
baseline	O
,	O
with	O
75	O
%	O
returning	O
questionnaires	O
at	O
follow	O
-	O
up	O
.	O

After	O
adjustment	O
for	O
baseline	O
and	O
practice	O
,	O
there	O
was	O
a	O
significant	O
difference	O
at	O
followup	O
between	O
intervention	O
and	O
control	O
practices	O
on	O
the	O
Mini	O
AQLQ	O
only	O
(	O
p=0	O
.	O
03	O
)	O
.	O

Estimates	O
for	O
subsequent	O
sample	O
sizes	O
to	O
inform	O
future	O
trials	O
of	O
asthma	O
training	O
were	O
identified	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
vacuum	B-I
-	I-I
compression	I-I
therapy	I-I
on	O
healing	O
of	O
diabetic	B-P
foot	I-P
ulcers	I-P
:	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Eighteen	B-P
diabetic	I-P
patients	I-P
with	I-P
foot	I-P
ulcers	I-P
were	O
recruited	O
through	O
simple	O
nonprobability	O
sampling	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
an	O
experimental	O
or	O
a	O
control	O
group	O
.	O

Before	O
and	O
after	O
intervention	O
,	O
the	B-O
foot	I-O
ulcer	I-O
surface	I-O
area	I-O
was	O
estimated	O
stereologically	O
,	O
based	O
on	B-O
Cavalieri	I-O
'	I-O
s	I-O
principle	I-O
.	O

The	O
experimental	O
group	O
was	O
treated	O
with	O
VCT	B-I
in	O
addition	O
to	O
conventional	B-C
therapy	I-C
for	O
10	O
sessions	O
.	O

The	O
control	O
group	O
received	O
only	B-C
conventional	I-C
therapy	I-C
,	O
including	O
debridement	B-C
,	O
blood	B-C
glucose	I-C
control	I-C
agents	I-C
,	O
systemic	B-C
antibiotics	I-C
,	O
wound	B-C
cleaning	I-C
with	I-C
normal	I-C
saline	I-C
,	O
offloading	B-C
(	I-C
pressure	I-C
relief	I-C
)	I-C
,	O
and	O
daily	B-C
wound	I-C
dressings	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
intravenous	B-I
acetaminophen	I-I
and	O
lidocaine	B-I
on	O
propofol	O
injection	O
pain	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
fifty	I-P
ASA	I-P
I	I-P
-	I-P
II	I-P
patients	I-P
undergoing	I-P
general	I-P
anaesthesia	I-P
were	O
randomly	O
allocated	O
into	O
three	O
groups	O
.	O

A	O
20	O
-	O
gauge	O
catheter	O
was	O
inserted	O
into	O
a	O
superficial	O
radial	O
vein	O
of	O
the	O
left	O
hand	O
,	O
and	O
after	O
the	O
occlusion	O
of	O
venous	O
drainage	O
,	O
Groups	O
I	O
,	O
II	O
,	O
and	O
III	O
were	O
pretreated	O
with	O
40	B-I
mg	I-I
of	I-I
lidocaine	I-I
in	I-I
saline	I-I
,	O
50	B-I
mg	I-I
of	I-I
i	I-I
.	I-I
v	I-I
.	I-I
acetaminophen	I-I
,	O
and	O
5	B-C
ml	I-C
of	I-C
saline	I-C
,	O
respectively	O
.	O

The	O
occlusion	O
was	O
released	O
after	O
2	O
min	O
and	O
one	O
-	O
fourth	O
of	O
the	O
total	O
propofol	O
dose	O
was	O
injected	O
into	O
the	O
vein	O
over	O
a	O
period	O
of	O
5	O
s	O
.	O

During	O
the	O
injection	O
of	O
both	O
pretreatment	O
solution	O
and	O
propofol	O
,	O
patients	B-O
'	I-O
pain	I-O
was	O
assessed	O
and	O
recorded	O
as	O
0	O
-	O
3	O
,	O
corresponding	O
to	O
no	B-O
,	O
mild	B-O
,	O
moderate	B-O
or	O
severe	B-O
pain	I-O
,	O
respectively	O
.	O

Chi2	O
and	O
Kruskal	O
-	O
Wallis	O
tests	O
were	O
used	O
for	O
the	O
statistical	O
analysis	O
.	O

For	O
all	O
analyses	O
,	O
differences	O
were	O
considered	O
to	O
be	O
significant	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
prospective	O
randomized	O
treatment	O
study	O
comparing	O
three	O
treatment	O
options	O
for	O
chalazia	O
:	O
triamcinolone	B-I
acetonide	I-I
injections	I-I
,	O
incision	B-I
and	O
curettage	B-I
and	O
treatment	O
with	O
hot	B-I
compresses	I-I
.	O

METHODS	O
:	O
This	O
was	O
a	O
single	O
centre	O
randomized	O
treatment	O
study	O
.	O

Patients	B-P
with	I-P
a	I-P
chalazion	I-P
underwent	O
either	O
of	O
the	O
three	O
treatment	O
options	O
.	O

Chalazion	B-O
resolution	I-O
,	O
pain	B-O
,	O
satisfaction	B-O
and	O
inconvenience	B-O
experienced	I-O
because	I-O
of	I-O
treatments	I-O
were	O
the	O
outcomes	O
assessed	O
via	O
a	O
telephone	O
interview	O
at	O
3	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Minimally	B-I
invasive	I-I
treatment	I-I
combined	O
with	O
cytokine	B-I
-	I-I
induced	I-I
killer	I-I
cells	I-I
therapy	I-I
lower	O
the	O
short	O
-	O
term	O
recurrence	O
rates	O
of	O
hepatocellular	O
carcinomas	O
.	O

METHODS	O
:	O
Therefore	O
,	O
85	B-P
HCC	I-P
patients	I-P
after	I-P
transcatheter	I-P
arterial	I-P
chemoembolization	I-P
and	I-P
radiofrequency	I-P
ablation	I-P
therapy	I-P
were	O
randomized	O
to	O
immunotherapy	B-I
group	O
and	O
no	B-I
adjuvant	I-I
therapy	I-I
group	O
.	O

Autologous	O
cytokine	O
-	O
induced	O
killer	O
(	O
CIK	O
)	O
cells	O
were	O
transfused	O
via	O
hepatic	O
artery	O
to	O
the	O
patients	O
.	O

The	B-O
alteration	I-O
of	I-O
levels	I-O
of	I-O
lymphocyte	I-O
subsets	I-O
in	O
peripheral	B-O
blood	I-O
of	O
patients	O
was	O
examined	O
by	O
flow	B-O
cytometry	I-O
.	O

All	O
patients	O
were	O
screened	O
by	O
computed	B-O
tomography	I-O
every	O
2	O
months	O
to	O
observe	O
the	B-O
tumor	I-O
recurrent	I-O
conditions	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
coenzyme	B-I
Q10	I-I
on	O
microcirculatory	O
endothelial	O
function	O
of	O
subjects	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Reduced	O
albuminuria	O
with	O
sarpogrelate	B-I
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
levels	O
in	O
type	O
2	O
diabetes	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
who	I-P
had	I-P
diabetes	I-P
with	I-P
nephropathy	I-P
and	I-P
arteriosclerosis	I-P
obliterans	I-P
and	I-P
had	I-P
already	I-P
been	I-P
treated	I-P
with	I-P
angiotensin	I-P
II	I-P
receptor	I-P
blocker	I-P
(	I-P
n	I-P
=	I-P
40	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
sarpogrelate	B-I
(	O
300	O
mg	O
/	O
d	O
;	O
n	O
=	O
20	O
)	O
or	O
aspirin	B-I
group	O
(	O
100	O
mg	O
/	O
d	O
;	O
n	O
=	O
20	O
)	O
.	O

Plasma	B-O
monocyte	I-O
chemoattractant	I-O
protein	I-O
-	I-O
1	I-O
and	O
urinary	B-O
albumin	I-O
-	I-O
to	I-O
-	I-O
creatinine	I-O
ratio	I-O
and	O
monocyte	B-O
chemoattractant	I-O
protein	I-O
-	I-O
1	I-O
were	O
measured	O
at	O
baseline	O
and	O
16	O
wk	O
after	O
administration	O
.	O

-DOCSTART-	O

Title	O
:	O
The	B-I
dipeptidyl	I-I
peptidase	I-I
-	I-I
4	I-I
inhibitor	I-I
PHX1149	I-I
improves	O
blood	O
glucose	O
control	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

METHODS	O
:	O
This	O
is	O
a	O
multicentre	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
4	O
-	O
week	O
study	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
with	I-P
suboptimal	I-P
metabolic	I-P
control	I-P
.	O

Patients	B-P
with	I-P
a	I-P
baseline	I-P
haemoglobin	I-P
A	I-P
(	I-P
1c	I-P
)	I-P
(	I-P
HbA	I-P
(	I-P
1c	I-P
)	I-P
)	I-P
of	I-P
7	I-P
.	I-P
3	I-P
to	I-P
11	I-P
.	I-P
0	I-P
%	I-P
were	O
randomized	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
once	O
-	O
daily	O
oral	O
therapy	O
with	O
either	O
PHX1149	B-I
(	O
100	O
,	O
200	O
or	O
400	O
mg	O
)	O
or	O
placebo	B-C
;	O
patients	O
were	O
on	O
a	O
constant	O
background	O
therapy	O
of	O
either	O
metformin	O
alone	O
or	O
metformin	O
plus	O
a	O
glitazone	O
.	O

-DOCSTART-	O

Title	O
:	O
Testosterone	B-I
and	O
gonadotropins	B-I
but	O
not	O
estrogen	B-I
associated	O
with	O
spatial	O
ability	O
in	O
women	B-P
suffering	I-P
from	I-P
schizophrenia	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
For	O
this	O
purpose	O
,	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
three	O
-	O
time	O
cross	O
-	O
over	O
study	O
using	O
17beta	B-I
-	I-I
estradiol	I-I
combined	O
with	O
norethisterone	B-I
acetate	I-I
for	O
replacement	O
therapy	O
and	O
as	O
an	O
adjunct	O
to	O
a	O
naturalistic	O
maintenance	O
antipsychotic	O
treatment	O
was	O
carried	O
out	O
over	O
a	O
period	O
of	O
8	O
months	O
.	O

Nineteen	B-P
women	I-P
(	I-P
mean	I-P
age=38	I-P
.	I-P
0	I-P
years	I-P
,	I-P
SD=9	I-P
.	I-P
9	I-P
years	I-P
)	I-P
with	I-P
schizophrenia	I-P
hospitalized	I-P
for	I-P
the	I-P
first	I-P
time	I-P
or	I-P
repeatedly	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	O

Sex	B-O
hormones	I-O
-	O
17beta	B-O
-	I-O
estradiol	I-O
,	I-O
luteinizing	B-O
hormone	I-O
(	I-O
LH	I-O
)	I-O
,	O
follicle	B-O
-	I-O
stimulating	I-O
hormone	I-O
(	I-O
FSH	I-O
)	I-O
,	O
prolactin	B-O
,	O
testosterone	B-O
,	O
and	O
dehydroepiandrosterone	B-O
sulfate	I-O
-	O
were	O
measured	O
and	O
the	O
patients	O
completed	O
a	B-O
neuropsychological	I-O
test	I-O
in	O
the	O
last	O
two	O
active	O
drug	O
and	O
/	O
or	O
placebo	B-C
phases	O
.	O

Three	O
different	O
spatial	O
ability	O
tasks	O
-	O
spatial	B-O
orientation	I-O
,	O
spatial	B-O
visualization	I-O
,	O
and	O
flexibility	B-O
of	I-O
closure	I-O
-	O
were	O
measured	O
by	O
a	B-O
paper	I-O
-	I-O
and	I-O
-	I-O
pencil	I-O
test	I-O
.	O

-DOCSTART-	O

Title	O
:	O
New	B-I
introducer	I-I
PEG	I-I
gastropexy	I-I
does	O
not	O
require	O
prophylactic	B-I
antibiotics	I-I
:	O
multicenter	O
prospective	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
Prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Multicenter	O
;	O
a	O
university	O
tertiary	O
-	O
care	O
hospital	O
and	O
a	O
private	O
practice	O
endoscopy	O
clinic	O
.	O

A	O
total	O
of	O
633	O
patients	O
undergoing	O
PEG	O
were	O
assessed	O
for	O
inclusion	O
.	O

Ninety	B-P
-	I-P
seven	I-P
patients	I-P
who	I-P
had	I-P
malignant	I-P
stenotic	I-P
oropharyngeal	I-P
stricture	I-P
were	O
randomized	O
:	O
group	O
I	O
(	O
49	O
patients	O
)	O
received	O
prophylactic	B-I
ceftriaxone	I-I
,	O
and	O
group	O
II	O
(	O
48	O
patients	O
)	O
received	O
a	B-C
placebo	I-C
.	O

Both	O
groups	O
were	O
similar	O
in	O
patient	O
characteristics	O
.	O

Introducer	B-I
PEG	I-I
was	O
performed	O
by	O
using	O
the	B-I
Freka	I-I
Pexact	I-I
-	I-I
15	I-I
CH	I-I
/	I-I
FR	I-I
,	O
with	O
the	O
gastric	O
wall	O
nonsurgically	O
sutured	O
to	O
the	O
anterior	O
abdominal	O
wall	O
by	O
use	O
of	O
an	O
endoscope	O
.	O

The	B-O
peristomal	I-O
area	I-O
was	O
assessed	O
daily	O
for	O
7	O
days	O
by	O
using	O
2	B-O
different	I-O
types	I-O
of	I-O
infection	I-O
scores	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
simplified	I-I
4	I-I
-	I-I
site	I-I
economical	I-I
intradermal	I-I
post	I-I
-	I-I
exposure	I-I
rabies	I-I
vaccine	I-I
regimen	I-I
:	O
a	O
randomised	O
controlled	O
comparison	O
with	O
standard	O
methods	O
.	O

METHODS	O
:	O
Two	B-P
hundred	I-P
and	I-P
fifty	I-P
-	I-P
four	I-P
volunteers	I-P
were	O
randomly	O
allocated	O
to	O
a	O
single	O
blind	O
controlled	O
trial	O
.	O

Each	O
received	O
purified	O
vero	O
cell	O
rabies	O
vaccine	O
by	O
one	O
of	O
four	B-I
PEP	I-I
regimens	I-I
:	O
the	B-I
currently	I-I
accepted	I-I
2	I-I
-	I-I
site	I-I
ID	I-I
;	O
the	B-I
8	I-I
-	I-I
site	I-I
regimen	I-I
using	O
0	O
.	O
05	O
ml	O
per	O
ID	O
site	O
;	O
a	B-I
new	I-I
4	I-I
-	I-I
site	I-I
ID	I-I
regimen	I-I
(	O
on	O
day	O
0	O
,	O
approximately	O
0	O
.	O
1	O
ml	O
at	O
4	O
ID	O
sites	O
,	O
using	O
the	O
whole	O
0	O
.	O
5	O
ml	O
ampoule	O
of	O
vaccine	O
;	O
on	O
day	O
7	O
,	O
0	O
.	O
1	O
ml	O
ID	O
at	O
2	O
sites	O
and	O
at	O
one	O
site	O
on	O
days	O
28	O
and	O
90	O
)	O
;	O
or	O
the	B-C
standard	I-C
5	I-C
-	I-C
dose	I-C
intramuscular	I-C
regimen	I-C
.	O

All	O
ID	O
regimens	O
required	O
the	O
same	O
total	O
amount	O
of	O
vaccine	O
,	O
60	O
%	O
less	O
than	O
the	O
intramuscular	O
method	O
.	O

Neutralising	B-O
antibody	I-O
responses	I-O
were	O
measured	O
five	O
times	O
over	O
a	O
year	O
in	O
229	O
people	O
,	O
for	O
whom	O
complete	O
data	O
were	O
available	O
.	O

-DOCSTART-	O

Title	O
:	O
Predictive	O
validity	O
of	O
a	B-I
medication	I-I
adherence	I-I
measure	I-I
in	O
an	O
outpatient	O
setting	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
esomeprazole	B-I
triple	I-I
therapy	I-I
on	O
eradication	O
rates	O
of	O
Helicobacter	O
pylori	O
,	O
gastric	O
ulcer	O
healing	O
and	O
prevention	O
of	O
relapse	O
in	O
gastric	B-P
ulcer	I-P
patients	I-P
.	O

METHODS	O
:	O
In	O
this	O
double	O
-	O
blind	O
study	O
,	O
401	B-P
H	I-P
.	I-P
pylori	I-P
-	I-P
positive	I-P
patients	I-P
with	I-P
more	I-P
than	I-P
or	I-P
equal	I-P
to	I-P
two	I-P
GUs	I-P
were	O
randomized	O
to	O
:	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
twice	O
daily	O
(	O
bid	O
)	O
and	O
amoxicillin	B-I
(	O
1000	O
mg	O
)	O
bid	O
and	O
clarithromycin	B-I
(	O
500	O
mg	O
)	O
bid	O
(	O
EAC	B-I
)	O
for	O
1	O
week	O
,	O
followed	O
by	O
placebo	B-C
for	O
3	O
weeks	O
(	O
EAC	B-I
and	O
placebo	B-C
)	O
;	O
EAC	B-I
for	O
1	O
week	O
,	O
followed	O
by	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
once	O
daily	O
(	O
E20	B-I
)	O
for	O
3	O
weeks	O
(	O
EAC	B-I
and	O
E20	B-I
)	O
;	O
or	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
bid	O
and	O
placebo	B-C
antimicrobials	I-C
for	O
1	O
week	O
,	O
followed	O
by	O
E20	B-I
for	O
3	O
weeks	O
(	O
E20	B-I
bid	O
and	O
E20	B-I
)	O
.	O

Patients	O
with	O
unhealed	O
GUs	O
at	O
4	O
weeks	O
received	O
E20	B-I
for	O
an	O
additional	O
4	O
weeks	O
.	O

Healed	O
patients	O
were	O
followed	O
up	O
for	O
12	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Penetration	O
and	O
accumulation	O
of	O
moxifloxacin	B-I
in	O
uterine	O
tissue	O
.	O

METHODS	O
:	O
In	O
a	O
prospective	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
we	O
determined	O
the	O
concentration	B-O
of	I-O
moxifloxacin	I-O
in	I-O
plasma	I-O
and	O
uterine	B-O
tissue	I-O
after	O
a	B-I
single	I-I
,	I-I
400	I-I
-	I-I
mg	I-I
intravenous	I-I
dose	I-I
of	I-I
moxifloxacin	I-I
.	O

Study	O
participants	O
were	O
randomized	O
for	O
time	O
of	O
tissue	O
sampling	O
,	O
which	O
was	O
performed	O
1	O
,	O
2	O
,	O
4	O
,	O
7	O
,	O
or	O
24	O
hours	O
following	O
the	B-I
moxifloxacin	I-I
infusion	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Heart	O
rate	O
variability	O
characteristics	O
in	O
sedentary	B-P
postmenopausal	I-P
women	I-P
following	O
six	B-I
months	I-I
of	I-I
exercise	I-I
training	I-I
:	O
the	O
DREW	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Use	O
of	O
topical	B-I
selamectin	I-I
for	O
the	O
treatment	O
of	O
Syphacia	O
muris	O
infection	O
in	O
laboratory	B-P
rats	I-P
.	O

METHODS	O
:	O
Fourty	B-P
-	I-P
eight	I-P
S	I-P
.	I-P
muris	I-P
-	I-P
positive	I-P
rats	I-P
were	O
divided	O
into	O
six	O
treated	O
and	O
two	O
control	O
groups	O
.	O

Selamectin	B-I
(	O
6	O
mg	O
/	O
kg	O
)	O
was	O
applied	O
topically	O
to	O
the	O
skin	O
in	O
a	O
single	O
spot	O
at	O
the	O
base	O
of	O
the	O
neck	O
in	O
the	O
treatment	O
group	O
.	O

The	O
rats	O
of	O
treated	O
and	O
control	O
groups	O
were	O
necropsied	B-O
on	O
the	O
24th	O
day	O
after	O
the	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
between	O
the	O
effect	O
of	O
oxytocin	B-I
only	I-I
and	O
oxytocin	B-I
plus	O
propranolol	B-I
on	O
the	O
labor	O
(	O
a	O
double	O
blind	O
randomized	O
trial	O
)	O
.	O

METHODS	O
:	O
A	O
double	O
blind	O
randomized	O
controlled	O
trial	O
was	O
performed	O
on	O
150	B-P
nulliparas	I-P
with	I-P
a	I-P
gestational	I-P
age	I-P
of	I-P
39	I-P
-	I-P
41	I-P
weeks	I-P
of	I-P
pregnancy	I-P
and	I-P
a	I-P
Bishop	I-P
score	I-P
of	I-P
<	I-P
or	I-P
=5	I-P
.	O

In	O
the	O
first	O
group	O
(	O
oxytocin	O
group	O
=	O
75	O
)	O
,	O
oxytocin	B-I
alone	I-I
was	O
used	O
for	O
induction	O
of	O
labor	O
.	O

In	O
the	O
second	O
group	O
(	O
propranolol	B-I
group	O
=	O
75	O
cases	O
)	O
,	O
before	O
the	O
beginning	O
of	O
oxytocin	B-I
,	O
2	B-I
mg	I-I
propranolol	I-I
was	O
slowly	O
injected	O
intravenously	O
then	O
the	B-I
oxytocin	I-I
was	O
initiated	O
.	O

-DOCSTART-	O

Title	O
:	O
Central	O
neuronal	O
mechanisms	O
of	O
gastric	B-I
electrical	I-I
stimulation	I-I
in	O
diabetic	O
gastroparesis	O
.	O

METHODS	O
:	O
A	B-I
gastric	I-I
electrical	I-I
stimulator	I-I
was	O
implanted	O
in	O
seven	B-P
diabetic	I-P
patients	I-P
with	I-P
medically	I-P
refractory	I-P
gastroparesis	I-P
.	O

A	O
double	O
-	O
blinded	O
protocol	O
was	O
used	O
to	O
investigate	O
the	O
patients	O
at	O
baseline	O
and	O
one	O
month	O
after	O
recovery	O
with	O
the	B-I
stimulator	I-I
turned	O
on	O
and	O
off	O
(	O
1	O
-	O
month	O
periods	O
)	O
.	O

The	O
following	O
assessments	O
were	O
carried	O
out	O
:	O
mechanical	B-O
,	O
thermal	B-O
and	O
electrical	B-O
stimulations	I-O
with	I-O
sensory	I-O
recordings	I-O
in	I-O
the	I-O
esophagus	I-O
and	I-O
duodenum	I-O
,	O
and	O
standardized	B-O
,	O
self	B-O
-	I-O
administered	I-O
,	O
daily	B-O
symptom	I-O
questionnaires	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Combination	B-I
chemotherapy	I-I
and	O
ALVAC	B-I
-	I-I
CEA	I-I
/	I-I
B7	I-I
.	I-I
1	I-I
vaccine	I-I
in	O
patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
metastatic	I-P
colorectal	I-P
cancer	I-P
were	O
treated	O
with	O
fluorouracil	B-I
,	O
leucovorin	B-I
,	O
and	O
irinotecan	B-I
and	O
were	O
also	O
given	O
ALVAC	B-I
-	I-I
CEA	I-I
/	I-I
B7	I-I
.	I-I
1	I-I
vaccine	I-I
with	I-I
or	O
without	B-I
tetanus	I-I
toxoid	I-I
adjuvant	I-I
.	O

Eligible	O
patients	O
were	O
randomized	O
to	O
ALVAC	B-I
followed	O
by	O
chemotherapy	B-I
and	O
booster	B-I
vaccination	I-I
(	O
group	O
1	O
)	O
,	O
ALVAC	B-I
and	O
tetanus	B-I
toxoid	I-I
followed	O
by	O
chemotherapy	B-I
(	O
group	O
2	O
)	O
,	O
or	O
chemotherapy	B-I
alone	I-I
followed	O
by	O
ALVAC	B-I
in	O
patients	O
without	O
disease	O
progression	O
(	O
group	O
3	O
)	O
.	O

Humoral	B-O
immune	I-O
responses	I-O
were	O
measured	O
by	O
standard	B-O
ELISA	I-O
assay	I-O
,	O
and	O
carcinoembryonic	B-O
antigen	I-O
(	I-O
CEA	I-O
)	I-O
-	I-O
specific	I-O
T	I-O
-	I-O
cell	I-O
responses	I-O
were	O
measured	O
by	O
IFN	B-O
-	I-O
gamma	I-O
enzyme	I-O
-	I-O
linked	I-O
immunospot	I-O
assay	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Beneficial	O
effects	O
of	O
a	B-I
diabetes	I-I
specific	I-I
formula	I-I
on	O
insulin	O
sensitivity	O
and	O
free	O
fatty	O
acid	O
in	O
patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

METHODS	O
:	O
In	B-P
total	I-P
of	I-P
71	I-P
type	I-P
2	I-P
diabetics	I-P
completed	O
the	O
study	O
.	O

Enteral	B-I
formulas	I-I
were	O
given	O
orally	O
as	O
the	O
sole	O
source	O
of	O
nutrition	O
to	O
the	O
subjects	O
for	O
6	O
days	O
.	O

Venous	O
blood	O
samples	O
(	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
hours	O
)	O
were	O
collected	O
at	O
day	O
-	O
7	O
after	O
a	O
75	O
g	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
,	O
day	O
1	O
after	O
a	O
standard	O
test	O
meal	O
(	O
1673	O
.	O
6	O
kJ	O
)	O
and	O
after	O
6	O
days	O
of	O
either	O
the	B-I
test	I-I
diabetes	I-I
specific	I-I
formula	I-I
or	O
a	B-C
standard	I-C
formula	I-C
.	O

Plasma	B-O
glucose	I-O
,	O
serum	B-O
insulin	I-O
,	O
C	B-O
peptide	I-O
and	O
lipids	B-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Social	B-I
stories	I-I
:	O
mechanisms	O
of	O
effectiveness	O
in	O
increasing	O
game	O
play	O
skills	O
in	O
children	B-P
diagnosed	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
using	I-P
a	I-P
pretest	I-P
posttest	I-P
repeated	I-P
measures	I-P
randomized	I-P
control	I-P
group	I-P
design	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
45	I-P
children	I-P
diagnosed	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
(	I-P
ASD	I-P
)	I-P
ages	I-P
7	I-P
-	I-P
14	I-P
were	O
randomly	O
assigned	O
to	O
standard	B-I
,	O
directive	B-I
,	O
or	O
control	B-C
story	I-C
conditions	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Behavior	O
in	O
children	B-P
with	I-P
Down	I-P
syndrome	I-P
.	O

METHODS	O
:	O
Eight	B-P
children	I-P
with	I-P
Down	I-P
syndrome	I-P
who	I-P
displayed	I-P
autistic	I-P
features	I-P
were	O
compared	O
with	O
eight	O
Down	O
syndrome	O
children	O
without	O
autistic	O
features	O
.	O

These	O
children	O
were	O
randomly	O
selected	O
and	O
were	O
matched	O
for	O
age	O
and	O
level	O
of	O
retardation	O
.	O

Standardized	B-O
Psychological	I-O
tests	I-O
were	O
administered	O
to	O
tap	O
the	B-O
behavioral	I-O
differences	I-O
.	O

Mann	O
-	O
Whitney	O
U	O
test	O
was	O
used	O
for	O
significance	O
of	O
difference	O
between	O
both	O
the	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
latanoprost	B-I
when	I-I
stored	I-I
at	I-I
room	I-I
temperature	I-I
.	O

METHODS	O
:	O
Latanoprost	B-I
0	I-I
.	I-I
005	I-I
%	I-I
(	I-I
Xalatan	I-I
)	I-I
was	O
stored	O
at	O
4	O
degrees	O
C	O
or	O
30	O
degrees	O
C	O
for	O
4	O
weeks	O
in	O
the	O
dark	O
.	O

The	O
subjects	O
enrolled	O
to	O
the	O
study	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
latanoprost	B-I
stored	I-I
at	I-I
4	I-I
degrees	I-I
C	I-I
or	O
that	B-I
stored	I-I
at	I-I
30	I-I
degrees	I-I
C	I-I
.	O

The	O
eye	O
drop	O
was	O
applied	O
to	O
the	O
right	O
eye	O
of	O
each	O
subject	O
for	O
3	O
days	O
.	O

The	O
left	O
eye	O
served	O
as	O
a	O
control	O
without	B-C
administration	I-C
.	O

Slit	B-O
-	I-O
lamp	I-O
biomicroscopy	I-O
and	O
circadian	B-O
intra	I-O
ocular	I-O
pressure	I-O
(	I-O
IOP	I-O
)	I-O
curve	I-O
was	O
performed	O
at	O
Day	O
3	O
,	O
every	O
3	O
hours	O
from	O
6	O
pm	O
.	O

This	O
procedure	O
was	O
repeated	O
7	O
days	O
after	O
changing	O
the	O
drug	O
from	O
4	O
degrees	O
C	O
to	O
30	O
degrees	O
C	O
or	O
vice	O
versa	O
,	O
and	O
application	O
to	O
the	O
left	O
eye	O
for	O
3	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
The	O
CARESS	O
-	O
in	O
-	O
AMI	O
trial	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Monitoring	B-I
of	I-I
the	I-I
central	I-I
pulse	I-I
pressure	I-I
is	O
useful	O
for	O
detecting	O
cardiac	O
overload	O
during	O
antiadrenergic	O
treatment	O
:	O
the	O
Japan	O
Morning	O
Surge	O
1	O
study	O
.	O

METHODS	O
:	O
We	O
studied	O
434	B-P
treated	I-P
hypertensive	I-P
patients	I-P
whose	I-P
home	I-P
systolic	I-P
blood	I-P
pressure	I-P
was	I-P
135	I-P
mmHg	I-P
or	I-P
higher	I-P
.	I-P

They	O
were	O
followed	O
for	O
6	O
months	O
after	O
allocation	O
to	O
either	O
a	O
control	O
group	O
or	O
an	O
added	O
treatment	O
group	O
(	O
doxazosin	O
1	O
-	O
4	O
mg	O
and	O
atenolol	O
when	O
needed	O
)	O
.	O

We	O
measured	O
the	B-O
brachial	I-O
and	O
central	B-O
(	I-O
carotid	I-O
)	I-O
blood	I-O
pressure	I-O
simultaneously	O
using	O
a	B-O
validated	I-O
device	I-O
,	O
and	O
the	B-O
B	I-O
-	I-O
type	I-O
natriuretic	I-O
peptide	I-O
at	O
baseline	O
and	O
at	O
the	O
sixth	O
month	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
immunogenicity	O
of	O
a	B-I
cluster	I-I
specific	I-I
immunotherapy	I-I
in	O
children	B-P
with	I-P
bronchial	I-P
asthma	I-P
and	I-P
mite	I-P
allergy	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
34	I-P
children	I-P
(	I-P
6	I-P
-	I-P
18	I-P
years	I-P
)	I-P
with	I-P
allergic	I-P
asthma	I-P
were	O
assigned	O
to	O
cluster	B-I
(	O
n	O
=	O
22	O
)	O
or	O
classic	B-C
SIT	I-C
(	O
n	O
=	O
12	O
)	O
.	O

To	O
achieve	O
a	O
maintenance	O
dose	O
of	O
allergen	O
extract	O
,	O
cluster	B-I
patients	O
received	O
14	O
injections	O
of	O
house	O
dust	O
mite	O
allergen	O
within	O
6	O
weeks	O
,	O
whereas	O
the	O
classic	B-C
SIT	I-C
group	O
received	O
14	O
injections	O
within	O
14	O
weeks	O
.	O

Safety	B-O
was	O
monitored	O
by	O
recording	O
adverse	B-O
events	I-O
.	O

Immunogenicity	B-O
was	O
measured	O
by	O
specific	B-O
IgG	I-O
(	I-O
Mite	I-O
)	I-O
and	O
IgG4	B-O
(	I-O
Mite	I-O
)	O
,	O
by	O
antibody	B-O
-	I-O
blocking	I-O
properties	I-O
on	I-O
basophil	I-O
activation	I-O
,	O
and	O
by	O
the	B-O
T	I-O
cell	I-O
subset	I-O
transcription	I-O
factors	I-O
Foxp3	I-O
,	O
T	B-O
-	I-O
bet	I-O
,	O
and	O
GATA	B-O
-	I-O
3	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Two	O
-	O
year	O
prospective	O
clinical	O
comparison	O
of	O
immediate	B-I
replacement	I-I
vs	O
.	O
immediate	B-C
restoration	I-C
of	I-C
single	I-C
tooth	I-C
in	O
the	O
esthetic	O
zone	O
.	O

METHODS	O
:	O
Sixteen	B-P
patients	I-P
(	I-P
10	I-P
women	I-P
and	I-P
6	I-P
men	I-P
)	I-P
with	I-P
a	I-P
mean	I-P
age	I-P
of	I-P
35	I-P
years	I-P
(	I-P
ranging	I-P
from	I-P
21	I-P
to	I-P
49	I-P
years	I-P
old	I-P
)	I-P
were	O
treated	O
from	O
2004	O
to	O
2005	O
for	O
single	B-I
-	I-I
tooth	I-I
replacement	I-I
in	O
the	O
upper	O
arch	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
in	O
the	O
test	O
group	O
patients	O
received	O
implants	B-I
placed	I-I
and	I-I
restored	I-I
(	I-I
non	I-I
-	I-I
occlusal	I-I
loading	I-I
)	I-I
at	I-I
the	I-I
time	I-I
of	I-I
tooth	I-I
extraction	I-I
;	O
in	O
the	O
control	O
group	O
implants	B-C
were	I-C
placed	I-C
8	I-C
weeks	I-C
after	I-C
tooth	I-C
extraction	I-C
and	I-C
immediately	I-C
restored	I-C
.	O

All	O
the	O
patients	O
received	O
tapered	B-I
effect	I-I
(	I-I
TE	I-I
)	I-I
implants	I-I
from	I-I
the	I-I
Straumann	I-I
Dental	I-I
Implant	I-I
System	I-I
.	O

The	O
following	O
parameters	O
were	O
evaluated	O
at	O
the	O
moment	O
of	O
provisional	O
restoration	O
(	O
within	O
48	O
h	O
after	O
implant	O
placement	O
)	O
and	O
at	O
the	O
2	O
years	O
follow	O
-	O
up	O
visit	O
:	O
marginal	B-O
bone	I-O
resorption	I-O
,	O
papilla	B-O
index	I-O
,	O
position	B-O
of	I-O
the	I-O
mucosal	I-O
margin	I-O
.	O

The	B-O
implant	I-O
stability	I-O
quotient	I-O
was	O
measured	O
at	O
the	B-O
moment	I-O
of	I-O
implant	I-O
placement	I-O
and	O
at	O
the	B-O
moment	I-O
of	I-O
the	I-O
delivery	I-O
of	I-O
the	I-O
definitive	I-O
restoration	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Maintenance	O
of	O
response	O
following	O
stabilization	O
of	O
mixed	O
index	O
episodes	O
with	O
olanzapine	B-I
monotherapy	I-I
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
bipolar	O
1	O
disorder	O
.	O

METHODS	O
:	O
Post	O
-	O
hoc	O
analyses	O
were	O
conducted	O
on	O
data	O
from	O
patients	B-P
presenting	I-P
with	I-P
a	I-P
mixed	I-P
index	I-P
episode	I-P
who	O
were	O
enrolled	O
in	O
a	O
larger	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Patients	O
who	O
met	O
remission	O
criteria	O
at	O
2	O
consecutive	O
weekly	O
visits	O
during	O
6	O
to	O
12	O
weeks	O
of	O
open	O
-	O
label	O
olanzapine	O
treatment	O
were	O
randomly	O
assigned	O
to	O
olanzapine	B-I
or	O
placebo	B-C
treatment	O
for	O
48	O
weeks	O
.	O

The	B-O
incidence	I-O
of	I-O
and	O
time	B-O
to	I-O
symptomatic	I-O
relapse	I-O
were	O
calculated	O
for	O
any	B-O
mood	I-O
episode	I-O
,	O
and	O
for	O
depressive	B-O
,	O
manic	B-O
,	O
hypo	B-O
-	I-O
manic	I-O
,	O
and	O
mixed	B-O
mood	I-O
episodes	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	B-I
maximal	I-I
double	I-I
step	I-I
length	I-I
test	I-I
can	O
evaluate	O
more	O
adequately	O
the	O
decrease	O
of	O
physical	O
function	O
with	O
age	O
,	O
than	O
the	B-I
maximal	I-I
single	I-I
step	I-I
length	I-I
test	I-I
.	O

METHODS	O
:	O
Fifty	B-P
-	I-P
seven	I-P
elderly	I-P
females	I-P
who	I-P
live	I-P
independently	I-P
(	I-P
age	I-P
74	I-P
.	I-P
85	I-P
.	I-P

6	I-P
years	I-P
)	I-P
were	O
recruited	O
.	O

MSL	B-I
and	O
MDSL	B-I
were	O
conducted	O
twice	O
after	O
completing	O
an	B-O
ADL	I-O
questionnaire	I-O
.	O

-DOCSTART-	O

Title	O
:	O
West	O
vs	O
.	O

West	O
like	O
East	O
vs	O
.	O

West	O
?	O
A	O
comparison	O
between	O
Italian	B-P
and	I-P
US	I-P
American	I-P
context	O
sensitivity	O
and	O
Fear	O
of	O
Isolation	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
pilot	O
study	O
of	O
the	B-I
Tele	I-I
-	I-I
Airway	I-I
Management	I-I
System	I-I
in	O
a	O
hospital	O
emergency	O
department	O
.	O

METHODS	O
:	O
In	O
a	O
pilot	O
study	O
we	O
examined	O
the	O
usefulness	O
of	O
the	B-I
TAMS	I-I
for	I-I
intubations	I-I
of	O
actual	B-P
patients	I-P
in	I-P
a	I-P
hospital	I-P
emergency	I-P
department	I-P
.	O

Twenty	B-P
-	I-P
five	I-P
patients	I-P
were	O
allocated	O
randomly	O
either	O
to	O
a	B-I
TAMS	I-I
group	O
or	O
to	O
an	B-I
on	I-I
-	I-I
scene	I-I
directed	I-I
(	I-I
OSD	I-I
)	I-I
group	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effects	O
of	O
parecoxib	B-I
on	O
morphine	O
dosage	O
in	O
postoperative	B-P
patient	I-P
-	I-P
controlled	I-P
analgesia	I-P
following	I-P
thoracoscope	I-P
-	I-P
assisted	I-P
thoracotomy	I-P
]	O
.	O

METHODS	O
:	O
A	B-P
consecutive	I-P
series	I-P
of	I-P
100	I-P
patients	I-P
undergoing	I-P
thoracoscope	I-P
-	I-P
assisted	I-P
thoracotomy	I-P
were	O
randomized	O
into	O
5	O
groups	O
and	O
received	O
PCA	O
with	O
morphine	O
doses	O
at	O
0	O
,	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
mg	O
given	O
in	O
200	O
ml	O
saline	O
(	O
groups	O
P	O
(	O
1	O
)	O
,	O
P	O
(	O
2	O
)	O
,	O
P	O
(	O
3	O
)	O
,	O
P	O
(	O
4	O
)	O
,	O
and	O
P	O
(	O
5	O
)	O
,	O
respectively	O
)	O
.	O

Parecoxib	B-I
(	O
40	O
mg	O
)	O
was	O
given	O
in	O
all	O
the	O
patients	O
immediately	O
before	O
the	O
operation	O
,	O
and	O
the	O
mixture	O
(	O
4	O
-	O
5	O
ml	O
)	O
of	O
lidocaine	O
and	O
ropivacaine	O
was	O
administered	O
into	O
the	O
3	O
intercostal	O
spaces	O
upper	O
and	O
lower	O
to	O
the	O
incision	O
before	O
chest	O
closure	O
.	O

PCA	O
was	O
administered	O
for	O
each	O
patient	O
.	O

The	B-O
visual	I-O
analogue	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
at	O
rest	O
and	O
coughing	O
and	O
the	B-O
respiratory	I-O
functional	I-O
parameters	I-O
were	O
recorded	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
24	O
,	O
36	O
,	O
and	O
48	O
h	O
after	O
the	O
start	O
of	O
PCA	O
,	O
and	O
the	O
actual	O
and	O
effective	O
button	O
-	O
pressing	O
times	O
(	O
D	O
(	O
1	O
)	O
/	O
D	O
(	O
2	O
)	O
)	O
in	O
PCA	O
were	O
also	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Presentation	O
of	O
a	O
randomized	O
multicenter	O
study	O
protocol	O
.	O

"	O
Evaluation	O
of	O
adjuvant	B-I
interferon	I-I
effectiveness	O
after	O
radical	O
nephrectomy	O
in	O
kidney	O
carcinoma	O
with	O
high	O
risk	O
of	O
relapse	O
"	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Fecal	O
butyrate	O
levels	O
vary	O
widely	O
among	O
individuals	O
but	O
are	O
usually	O
increased	O
by	O
a	B-I
diet	I-I
high	I-I
in	I-I
resistant	I-I
starch	I-I
.	O

METHODS	O
:	O
To	O
examine	O
variation	O
in	O
fecal	B-O
variables	I-O
,	O
especially	O
butyrate	B-O
,	O
among	O
individuals	O
and	O
the	O
response	O
to	O
these	O
fibers	O
,	O
a	O
randomized	O
cross	O
-	O
over	O
study	O
was	O
conducted	O
that	O
compared	O
the	O
effects	O
of	O
foods	B-I
supplying	I-I
25	I-I
g	I-I
of	I-I
NSP	I-I
or	O
25	B-I
g	I-I
of	I-I
NSP	I-I
plus	O
22	B-I
g	I-I
of	I-I
RS	I-I
/	I-I
d	I-I
over	O
4	O
wk	O
in	O
46	B-P
healthy	I-P
adults	I-P
(	I-P
16	I-P
males	I-P
,	I-P
30	I-P
females	I-P
;	I-P
age	I-P
31	I-P
-	I-P
66	I-P
y	I-P
)	I-P
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
pain	B-I
-	I-I
free	I-I
treadmill	I-I
training	I-I
on	O
fibrinogen	O
,	O
haematocrit	O
,	O
and	O
lipid	O
profile	O
in	O
patients	B-P
with	I-P
claudication	I-P
.	O

METHODS	O
:	O
Randomized	O
control	O
trial	O
.	O

Sixty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
peripheral	I-P
obstructive	I-P
arterial	I-P
disease	I-P
and	I-P
intermittent	I-P
claudication	I-P
(	I-P
Fontaine	I-P
stage	I-P
II	I-P
)	I-P
were	O
randomly	O
assigned	O
into	O
the	B-I
treadmill	I-I
training	I-I
(	O
repetitive	O
intervals	O
to	O
onset	O
of	O
claudication	O
pain	O
,	O
three	O
times	O
a	O
week	O
)	O
or	O
a	O
control	O
group	O
(	O
no	B-C
change	I-C
in	I-C
physical	I-C
activity	I-C
)	O
over	O
3	O
months	O
.	O

Both	O
groups	O
performed	O
treadmill	O
test	O
to	O
assess	O
pain	B-O
-	I-O
free	I-O
walking	I-O
time	I-O
(	I-O
PFWT	I-O
)	I-O
and	O
maximal	B-O
walking	I-O
time	I-O
(	I-O
MWT	I-O
)	I-O
and	O
had	O
blood	B-O
analyses	I-O
[	O
for	O
haematocrit	B-O
,	O
fibrinogen	B-O
,	O
triglycerides	B-O
,	O
and	O
cholesterol	B-O
:	O
total	B-O
,	I-O
high	I-O
-	I-O
density	I-O
lipoprotein	I-O
(	I-O
HDL	I-O
)	I-O
and	O
low	B-O
-	I-O
density	I-O
lipoprotein	I-O
(	I-O
LDL	I-O
)	I-O
]	O
done	O
at	O
baseline	O
and	O
after	O
6	O
and	O
12	O
weeks	O
of	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Improving	O
emotion	O
regulation	O
with	O
CBT	B-I
in	O
young	B-P
children	I-P
with	I-P
high	I-P
functioning	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
Eleven	B-P
5	I-P
-	I-P
7	I-P
year	I-P
-	I-P
old	I-P
children	I-P
participated	O
in	O
a	B-I
CBT	I-I
-	O
group	O
while	O
parents	O
participated	O
in	O
psychoeducation	O
.	O

Children	O
were	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
delayed	B-C
-	I-C
treatment	I-C
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
intravenous	B-I
immunoglobulin	I-I
therapy	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
fatigue	I-P
syndrome	I-P
.	O

METHODS	O
:	O
Forty	B-P
-	I-P
nine	I-P
patients	I-P
(	I-P
40	I-P
with	I-P
abnormal	I-P
cell	I-P
-	I-P
mediated	I-P
immunity	I-P
)	I-P
participated	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
to	O
determine	O
the	O
effectiveness	O
of	O
high	O
-	O
dose	O
intravenously	O
administered	O
immunoglobulin	B-I
G	I-I
.	O

The	O
patients	O
received	O
three	O
intravenous	O
infusions	O
of	O
a	B-C
placebo	I-C
solution	O
or	O
immunoglobulin	B-I
at	O
a	O
dose	O
of	O
2	O
g	O
/	O
kg	O
/	O
month	O
.	O

Assessment	O
of	O
the	B-O
severity	I-O
of	I-O
symptoms	I-O
and	O
associated	B-O
disability	I-O
,	O
both	O
before	O
and	O
after	O
treatment	O
,	O
was	O
completed	O
at	O
detailed	B-O
interviews	I-O
by	O
a	O
physician	O
and	O
psychiatrist	O
,	O
who	O
were	O
unaware	O
of	O
the	O
treatment	O
status	O
.	O

In	O
addition	O
,	O
any	O
change	O
in	O
physical	B-O
symptoms	I-O
and	O
functional	B-O
capacity	I-O
was	O
recorded	O
using	O
visual	B-O
analogue	I-O
scales	I-O
,	O
while	O
changes	O
in	O
psychologic	B-O
morbidity	I-O
were	O
assessed	O
using	O
patient	B-O
-	I-O
rated	I-O
indices	I-O
of	I-O
depression	I-O
.	O

Cell	B-O
-	I-O
mediated	I-O
immunity	I-O
was	O
evaluated	O
by	O
T	O
-	B-O
cell	I-O
subset	I-O
analysis	I-O
,	O
delayed	B-O
-	I-O
type	I-O
hypersensitivity	I-O
skin	I-O
testing	I-O
,	O
and	O
lymphocyte	B-O
transformation	I-O
with	I-O
phytohemagglutinin	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Theory	O
-	O
driven	O
intervention	O
improves	O
calcium	O
intake	O
,	O
osteoporosis	O
knowledge	O
,	O
and	O
self	O
-	O
efficacy	O
in	O
community	B-O
-	I-O
dwelling	I-O
older	I-O
Black	I-O
adults	I-O
.	O

METHODS	O
:	O
Randomized	O
repeated	O
measures	O
experimental	O
design	O
.	O

Churches	O
and	O
community	O
-	O
based	O
organizations	O
.	O

Men	B-P
and	I-P
women	I-P
(	I-P
n	I-P
=	I-P
110	I-P
)	I-P
50	I-P
years	I-P
old	I-P
and	I-P
older	I-P
from	I-P
3	I-P
south	I-P
Florida	I-P
counties	I-P
.	O

Participants	O
randomly	O
assigned	O
to	O
either	O
of	O
2	O
groups	O
:	O
Group	O
1	O
(	O
experimental	O
group	O
)	O
or	O
Group	O
2	O
(	O
wait	B-C
-	I-C
list	I-C
control	O
group	O
)	O
.	O

Group	O
1	O
participated	O
in	O
6	B-I
weekly	I-I
education	I-I
program	I-I
sessions	I-I
immediately	O
following	O
baseline	O
assessment	O
,	O
and	O
Group	O
2	O
started	O
the	O
program	O
following	O
Group	O
1	O
'	O
s	O
program	O
completion	O
.	O

A	O
tested	O
curriculum	O
was	O
adapted	O
to	O
meet	O
the	O
needs	O
of	O
the	O
target	O
population	O
.	O

Dietary	B-O
calcium	I-O
intake	I-O
,	O
osteoporosis	B-O
knowledge	I-O
,	O
health	B-O
beliefs	I-O
,	O
and	O
self	B-O
-	I-O
efficacy	I-O
.	O

Descriptive	O
and	O
summary	O
statistics	O
,	O
repeated	O
measures	O
analysis	O
of	O
variance	O
,	O
and	O
regression	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Pulsed	B-I
azithromycin	I-I
treatment	I-I
is	O
as	O
effective	O
and	O
safe	O
as	O
2	B-I
-	I-I
week	I-I
-	I-I
longer	I-I
daily	I-I
doxycycline	I-I
treatment	I-I
of	O
acne	O
vulgaris	O
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
noninferiority	O
study	O
.	O

METHODS	O
:	O
The	O
evaluation	O
of	O
clinical	B-O
efficacy	I-O
was	O
based	O
on	O
the	O
change	O
in	O
the	B-O
number	I-O
of	I-O
facial	I-O
inflammatory	I-O
lesions	I-O
from	O
baseline	O
to	O
the	O
end	O
of	O
treatment	O
,	O
and	O
noninferiority	B-O
was	O
defined	O
by	O
the	O
upper	O
95	O
%	O
confidence	O
limit	O
of	O
the	O
difference	O
between	O
two	O
treatments	O
being	O
less	O
than	O
9	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
intensive	B-I
insulin	I-I
therapy	I-I
on	O
the	O
somatotropic	O
axis	O
of	O
critically	B-P
ill	I-P
children	I-P
.	O

METHODS	O
:	O
This	O
was	O
a	O
preplanned	O
subanalysis	O
of	O
a	O
randomized	O
controlled	O
trial	O
on	O
IIT	O
.	O

We	O
studied	O
369	O
patients	O
who	O
stayed	O
in	O
PICU	O
for	O
at	O
least	O
3	O
d	O
(	O
study	O
1	O
)	O
and	O
126	O
patients	O
in	O
a	O
nested	O
case	O
-	O
control	O
study	O
(	O
study	O
2	O
)	O
.	O

Circulating	O
insulin	B-O
,	O
C	B-O
-	I-O
peptide	I-O
,	O
GH	B-O
,	O
IGF	B-O
-	I-O
I	I-O
,	O
bioavailable	B-O
IGF	I-O
-	I-O
I	I-O
,	O
IGF	B-O
-	I-O
binding	I-O
protein	I-O
(	I-O
IGFBP	I-O
)	I-O
-	I-O
1	I-O
,	O
IGFBP	B-O
-	I-O
3	I-O
,	O
and	O
acid	B-O
-	I-O
labile	I-O
subunit	I-O
were	O
analyzed	O
upon	O
admission	O
and	O
d	O
3	O
.	O

In	O
the	O
nested	O
case	O
-	O
control	O
study	O
,	O
the	B-O
somatotropic	I-O
axis	I-O
,	O
cortisol	B-O
,	O
and	O
glucagon	B-O
were	O
analyzed	O
before	O
and	O
after	O
hypoglycemia	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	B-I
-	I-I
dose	I-I
clonidine	I-I
administration	I-I
in	O
the	O
treatment	O
of	O
mild	O
or	O
moderate	O
essential	O
hypertension	O
:	O
results	O
from	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
(	O
Clobass	O
)	O
.	O

The	O
Clobass	O
Study	O
Group	O
.	O

METHODS	O
:	O
Eligible	O
subjects	O
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
clonidine	B-I
(	O
75	O
micrograms	O
twice	O
daily	O
)	O
or	O
a	B-C
placebo	I-C
.	O

After	O
4	O
weeks	O
,	O
'	O
responders	O
'	O
to	O
treatment	O
(	O
diastolic	B-O
blood	I-O
pressure	I-O
reduced	O
to	O
less	O
than	O
or	O
equal	O
to	O
90	O
mmHg	O
or	O
by	O
greater	O
than	O
or	O
equal	O
to	O
10	O
mmHg	O
)	O
were	O
kept	O
on	O
monotherapy	O
and	O
checked	O
at	O
4	O
-	O
weekly	O
intervals	O
for	O
another	O
3	O
months	O
.	O

Non	O
-	O
responders	O
were	O
given	O
15	O
mg	O
chlorthalidone	O
and	O
were	O
also	O
checked	O
for	O
a	O
further	O
3	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Single	B-I
-	I-I
agent	I-I
irinotecan	I-I
or	O
FOLFIRI	B-I
as	O
second	O
-	O
line	O
chemotherapy	O
for	O
advanced	O
colorectal	O
cancer	O
;	O
results	O
of	O
a	O
randomised	O
phase	O
II	O
study	O
(	O
DaVINCI	O
)	O
and	O
meta	O
-	O
analysis	O
[	O
corrected	O
]	O
.	O

METHODS	O
:	O
In	O
DaVINCI	O
,	O
a	O
randomised	O
phase	O
II	O
trial	O
,	O
patients	B-P
with	I-P
advanced	I-P
colorectal	I-P
cancer	I-P
were	O
randomly	O
allocated	O
to	O
:	O
Combination	B-I
therapy	I-I
(	I-I
FOLFIRI	I-I
)	I-I
,	O
irinotecan	B-I
(	O
180	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
over	O
90	O
min	O
,	O
day	O
1	O
)	O
,	O
5	B-I
-	I-I
fluorouracil	I-I
(	O
400mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
bolus	O
and	O
2400	O
mg	O
/	O
m	O
(	O
2	O
)	O
by	O
46	O
-	O
hour	O
infusion	O
from	O
day	O
1	O
)	O
and	O
folinic	B-I
acid	I-I
(	O
20mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
bolus	O
,	O
day	O
1	O
)	O
,	O
2	O
-	O
weekly	O
;	O
or	O
Single	B-I
-	I-I
agent	I-I
,	I-I
irinotecan	I-I
(	O
350	O
mg	O
/	O
m	O
(	O
2	O
)	O
IV	O
over	O
90	O
min	O
)	O
,	O
3	O
-	O
weekly	O
.	O

Toxicity	B-O
was	O
evaluated	O
every	O
treatment	O
cycle	O
;	O
QOL	B-O
and	O
response	B-O
6	O
-	O
weekly	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

The	O
trial	O
,	O
amended	O
from	O
a	O
larger	O
factorial	O
design	O
,	O
was	O
terminated	O
early	O
due	O
to	O
slow	O
recruitment	O
.	O

Results	O
were	O
also	O
combined	O
with	O
other	O
second	O
-	O
line	O
irinotecan	O
trials	O
.	O

-DOCSTART-	O

Title	O
:	O
Alternating	B-I
chemotherapy	I-I
in	O
small	O
cell	O
lung	O
cancer	O
.	O

METHODS	O
:	O
Recently	O
,	O
most	O
trials	O
were	O
designed	O
as	O
2	O
-	O
arm	O
approaches	O
with	O
a	O
comparison	O
of	O
continuous	O
standard	O
therapy	O
based	O
on	O
the	O
CAV	O
-	O
or	O
CMC	O
-	O
protocol	O
with	O
an	O
alternating	O
schedule	O
often	O
consisting	O
of	O
the	O
CAV	O
-	O
or	O
CMC	O
-	O
derived	O
combinations	O
and	O
a	O
second	O
regimen	O
including	O
cisplatinum	O
and	O
/	O
or	O
etoposide	O
.	O

METHODS	O
:	O
To	O
ameliorate	O
this	O
weakness	O
,	O
3	O
studies	O
were	O
designed	O
as	O
3	O
-	O
arms	O
approaches	O
using	O
both	O
alternating	O
protocols	O
as	O
continuous	O
control	O
arms	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
pilot	O
randomized	O
controlled	O
trial	O
of	O
DIR	B-I
/	I-I
Floortime	I-I
parent	I-I
training	I-I
intervention	I-I
for	O
pre	B-P
-	I-P
school	I-P
children	I-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
.	O

METHODS	O
:	O
Measures	O
of	O
functional	B-O
emotional	I-O
development	I-O
and	O
symptom	B-O
severity	I-O
were	O
taken	O
.	O

-DOCSTART-	O

Title	O
:	O
Validity	O
and	O
reliability	O
assessment	O
of	O
the	B-I
Siriraj	I-I
Asthma	I-I
Control	I-I
Questionnaire	I-I
.	O

METHODS	O
:	O
The	O
data	O
of	O
the	B-I
questionnaire	I-I
responses	O
and	O
spirometric	B-I
results	I-I
from	O
20	B-P
randomized	I-P
asthmatic	I-P
patients	I-P
in	I-P
the	I-P
clinic	I-P
including	I-P
the	I-P
record	I-P
of	I-P
3	I-P
visits	I-P
for	I-P
each	I-P
subject	I-P
.	O

The	B-O
validation	I-O
was	O
performed	O
by	O
Kruskal	O
-	O
Wallis	O
test	O
comparing	O
the	B-O
scores	I-O
with	I-O
the	I-O
level	I-O
of	I-O
asthma	I-O
control	O
determined	O
by	O
physicians	O
according	O
to	O
GINA	O
guideline	O
.	O

Internal	B-O
consistency	I-O
reliability	I-O
was	O
analyzed	O
by	O
Cronbach	O
'	O
s	O
alpha	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
shearing	O
on	O
water	O
turnover	O
and	O
thermobiological	O
variables	O
in	O
German	B-P
Blackhead	I-P
mutton	I-P
sheep	I-P
.	O

METHODS	O
:	O
Fourteen	B-P
nonlactating	I-P
German	I-P
Blackhead	I-P
mutton	I-P
ewes	I-P
were	O
randomly	O
allocated	O
into	O
2	O
groups	O
:	O
a	O
control	O
group	O
(	O
n	O
=	O
7	O
)	O
that	O
was	O
already	B-C
shorn	I-C
,	O
and	O
a	O
treatment	O
group	O
(	O
n	O
=	O
7	O
)	O
that	O
was	O
left	B-I
unshorn	I-I
(	O
wool	O
length	O
:	O
10	O
.	O
6	O
	O
1	O
.	O
2	O
cm	O
)	O
.	O

Individual	B-O
feed	I-O
and	O
water	B-O
intakes	I-O
were	O
recorded	O
throughout	O
the	O
experiment	O
(	O
d	O
1	O
to	O
71	O
)	O
.	O

Two	O
weeks	O
after	O
measurements	O
commenced	O
(	O
d	O
15	O
)	O
,	O
treatment	O
sheep	O
were	O
shorn	O
.	O

Water	B-O
intake	I-O
was	O
estimated	O
twice	O
for	O
2	O
consecutive	O
weeks	O
by	O
using	O
deuterium	B-O
dilution	I-O
techniques	I-O
(	O
d	O
1	O
to	O
15	O
and	O
d	O
57	O
to	O
71	O
)	O
.	O

Ambient	B-O
temperature	I-O
(	O
T	O
(	O
a	O
)	O
)	O
,	O
relative	B-O
humidity	I-O
,	O
and	O
respiratory	B-O
rate	I-O
were	O
measured	O
daily	O
,	O
whereas	O
BW	B-O
,	O
rectal	B-O
and	O
animal	B-O
surface	I-O
temperatures	I-O
(	O
using	O
infrared	B-O
thermography	I-O
)	O
,	O
and	O
wool	B-O
length	I-O
were	O
measured	O
weekly	O
.	O

-DOCSTART-	O

Title	O
:	O
Using	O
the	B-I
transporters	I-I
DVD	I-I
as	O
a	O
learning	O
tool	O
for	O
children	B-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorders	I-P
(	I-P
ASD	I-P
)	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
gravity	O
on	O
robot	B-I
-	I-I
assisted	I-I
motor	I-I
training	I-I
after	O
chronic	O
stroke	O
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
trial	O
,	O
single	O
-	O
blinded	O
,	O
with	O
12	O
-	O
week	O
follow	O
-	O
up	O
.	O

Research	O
setting	O
in	O
a	O
large	O
medical	O
center	O
.	O

Adults	B-P
(	I-P
N=62	I-P
)	I-P
with	I-P
chronic	I-P
,	I-P
stroke	I-P
-	I-P
related	I-P
arm	I-P
weakness	I-P
stratified	I-P
by	I-P
impairment	I-P
severity	I-P
using	I-P
baseline	I-P
UE	I-P
motor	I-P
assessments	I-P
.	O

Sixty	B-I
minutes	I-I
,	I-I
3	I-I
times	I-I
a	I-I
week	I-I
for	I-I
6	I-I
weeks	I-I
of	I-I
robot	I-I
-	I-I
assisted	I-I
planar	I-I
reaching	I-I
(	I-I
gravity	I-I
compensated	I-I
)	I-I
,	O
combined	O
planar	B-I
with	I-I
vertical	I-I
robot	I-I
-	I-I
assisted	I-I
reaching	I-I
,	O
or	O
intensive	B-C
conventional	I-C
arm	I-C
exercise	I-C
program	I-C
.	O

UE	B-O
Fugl	I-O
-	I-O
Meyer	I-O
Assessment	I-O
(	I-O
FMA	I-O
)	I-O
mean	O
change	O
from	O
baseline	O
to	O
final	O
training	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
ozone	B-I
application	I-I
on	O
the	O
resin	O
-	O
dentin	O
microtensile	O
bond	O
strength	O
.	O

METHODS	O
:	O
Forty	B-P
human	I-P
third	I-P
molars	I-P
were	O
divided	O
into	O
four	O
groups	O
:	O
Group	O
1	O
,	O
not	B-C
treated	I-C
with	I-C
ozone	I-C
;	O
Group	O
2	O
,	O
ozone	B-I
application	I-I
followed	O
by	O
acid	B-I
etching	I-I
;	O
Group	O
3	O
,	O
acid	B-I
etching	I-I
followed	O
by	O
ozone	B-I
application	I-I
;	O
and	O
Group	O
4	O
,	O
ozone	B-I
and	I-I
application	I-I
of	I-I
sodium	I-I
ascorbate	I-I
.	O

Bonded	B-O
beams	I-O
(	O
1	O
.	O
0	O
mm	O
(	O
2	O
)	O
)	O
were	O
tested	O
under	O
tension	B-O
(	O
0	O
.	O
5	O
mm	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	B-O
?TBS	I-O
values	I-O
were	O
analyzed	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
and	O
the	B-O
Tukey	I-O
test	I-O
(	O
p=0	O
.	O
05	O
)	O
.	O

All	O
beams	O
that	O
fractured	O
were	O
analyzed	O
under	O
stereomicroscopy	B-O
(	O
40	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Symptomatic	O
and	O
functional	O
improvement	O
in	O
employed	B-P
depressed	I-P
patients	I-P
:	O
a	O
double	O
-	O
blind	O
clinical	O
trial	O
of	O
desvenlafaxine	B-I
versus	O
placebo	B-C
.	O

METHODS	O
:	O
Gainfully	B-P
employed	I-P
(	I-P
?20	I-P
h	I-P
/	I-P
wk	I-P
)	I-P
male	I-P
and	I-P
female	I-P
outpatients	I-P
with	I-P
MDD	I-P
were	O
randomly	O
assigned	O
(	O
2	O
:	O
1	O
ratio	O
)	O
to	O
12	O
weeks	O
of	O
double	O
-	O
blind	O
treatment	O
with	O
desvenlafaxine	B-I
50	O
mg	O
/	O
d	O
or	O
placebo	B-C
.	O

Analysis	O
of	O
covariance	O
was	O
used	O
to	O
compare	O
differences	O
in	O
week	O
12	O
adjusted	O
mean	O
changes	O
from	O
baseline	O
on	O
the	B-O
17	I-O
-	I-O
item	I-O
Hamilton	I-O
Depression	I-O
Rating	I-O
Scale	I-O
(	I-O
HAM	I-O
-	I-O
D??	I-O
)	I-O
(	O
primary	O
outcome	O
)	O
and	O
Sheehan	B-O
Disability	I-O
Scale	I-O
(	I-O
SDS	I-O
)	I-O
(	O
key	O
secondary	O
outcome	O
)	O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
.	O

A	O
predefined	O
,	O
modified	B-O
ITT	I-O
population	I-O
(	O
ie	O
,	O
those	O
in	O
the	O
ITT	O
population	O
with	O
baseline	O
HAM	O
-	O
D??	O
?20	O
)	O
was	O
also	O
analyzed	O
.	O

Tolerability	B-O
was	O
assessed	O
by	O
recording	O
adverse	O
events	O
and	O
change	O
on	O
the	B-O
Arizona	I-O
Sexual	I-O
Experience	I-O
Scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Sublingually	O
administered	O
captopril	B-I
versus	O
nifedipine	B-I
in	O
hypertension	O
emergencies	O
]	O
.	O

METHODS	O
:	O
During	O
hypertensive	O
crises	O
(	O
systolic	O
blood	O
pressure	O
exceeding	O
200	O
mmHg	O
and	O
diastolic	O
blood	O
pressure	O
exceeding	O
115	O
mmHg	O
)	O
forty	B-P
hypertensive	I-P
patients	I-P
received	O
either	O
25	B-I
mg	I-I
of	I-I
SLC	I-I
or	O
10	B-I
mg	I-I
of	I-I
SLN	I-I
in	O
a	O
randomized	O
single	O
blind	O
fashion	O
.	O

Blood	B-O
pressure	I-O
and	O
heart	B-O
rate	I-O
were	O
then	O
controlled	O
after	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
120	O
min	O
.	O

and	O
,	O
in	O
18	O
cases	O
,	O
up	O
to	O
the	O
8th	O
hour	O
from	O
the	O
administration	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
an	B-I
induction	I-I
period	I-I
of	I-I
pegylated	I-I
interferon	I-I
-	I-I
?2a	I-I
and	O
ribavirin	B-I
on	O
early	O
virological	O
response	O
in	O
HIV	B-P
-	I-P
HCV	I-P
-	I-P
coinfected	I-P
patients	I-P
:	O
results	O
from	O
the	O
CORAL	O
-	O
2	O
study	O
.	O

METHODS	O
:	O
HIV	B-P
and	I-P
HCV	I-P
genotype	I-P
1	I-P
-	I-P
and	I-P
4	I-P
-	I-P
coinfected	I-P
subjects	I-P
were	O
randomized	O
to	O
receive	O
pegylated	B-I
interferon	I-I
-	I-I
?2a	I-I
270	O
?g	O
/	O
week	O
plus	O
ribavirin	B-I
1	O
,	O
600	O
mg	O
daily	O
and	O
epoetin	B-I
-	I-I
?	I-I
for	O
4	O
weeks	O
,	O
followed	O
by	O
pegylated	B-I
interferon	I-I
-	I-I
?2a	I-I
at	O
standard	O
dosages	O
plus	O
weight	B-I
-	I-I
based	I-I
ribavirin	I-I
(	I-I
WBR	I-I
)	I-I
dosage	O
for	O
8	O
weeks	O
(	O
induction	O
arm	O
[	O
IA	O
]	O
)	O
,	O
or	O
pegylated	B-I
interferon	I-I
-	I-I
?2a	I-I
plus	O
WBR	B-I
for	O
12	O
weeks	O
(	O
standard	O
therapy	O
arm	O
[	O
SA	O
]	O
)	O
.	O

HCV	B-O
RNA	I-O
was	O
determined	O
at	O
weeks	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
8	O
and	O
12	O
.	O

Ribavirin	B-O
plasma	I-O
trough	I-O
concentrations	I-O
were	O
determined	O
at	O
weeks	O
4	O
(	O
RBV	O
-	O
C	O
(	O
4	O
)	O
)	O
and	O
12	O
(	O
RBV	O
-	O
C	O
(	O
12	O
)	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Social	B-I
skills	I-I
training	I-I
for	O
young	B-P
adults	I-P
with	I-P
high	I-P
-	I-P
functioning	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
randomized	O
controlled	O
pilot	O
study	O
.	O

METHODS	O
:	O
Using	O
a	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
design	O
,	O
the	O
current	O
study	O
tested	O
the	O
effectiveness	O
of	O
an	B-I
evidence	I-I
-	I-I
based	I-I
,	I-I
caregiver	I-I
-	I-I
assisted	I-I
social	I-I
skills	I-I
intervention	I-I
known	O
as	O
PEERS	B-I
for	O
Young	B-P
Adults	I-P
with	I-P
high	I-P
-	I-P
functioning	I-P
young	I-P
adults	I-P
with	I-P
ASD	I-P
(	I-P
ages	I-P
18	I-P
-	I-P
23	I-P
)	I-P
using	O
self	O
-	O
and	O
caregiver	O
-	O
report	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
The	O
equipotency	O
of	O
ropivacaine	B-I
,	O
bupivacaine	B-I
and	O
etidocaine	B-I
]	O
.	O

METHODS	O
.	O

METHODS	O
:	O
In	O
a	O
double	O
blind	O
randomized	O
study	O
,	O
epidural	B-I
anesthesia	I-I
was	O
carried	O
out	O
with	O
20	B-I
ml	I-I
bupivacaine	I-I
0	O
.	O
75	O
%	O
(	O
n	O
=	O
24	O
)	O
and	O
ropivacaine	B-I
1	O
%	O
(	O
n	O
=	O
21	O
)	O
.	O

Following	O
this	O
study	O
epidural	B-I
anesthesia	I-I
was	O
carried	O
out	O
with	O
20	B-I
ml	I-I
etidocaine	I-I
1	O
%	O
(	O
n	O
=	O
20	O
)	O
in	O
an	O
open	O
study	O
.	O

Patients	B-P
with	I-P
ASA	I-P
I	I-P
or	I-P
II	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

All	O
patients	O
were	O
scheduled	O
for	O
varicose	O
vein	O
stripping	O
.	O

Male	B-P
and	I-P
female	I-P
patients	I-P
aged	I-P
18	I-P
-	I-P
70	I-P
years	I-P
and	I-P
weighing	I-P
50	I-P
-	I-P
100	I-P
kg	I-P
were	O
included	O
in	O
the	O
study	O
.	O

Patients	O
were	O
all	O
placed	O
in	O
a	O
sitting	O
position	O
,	O
after	O
which	O
the	O
epidural	O
space	O
was	O
identified	O
by	O
the	O
"	O
loss	O
of	O
resistance	O
"	O
technique	O
and	O
a	O
midline	O
approach	O
,	O
at	O
the	O
L	O
-	O
3	O
/	O
4	O
interspace	O
.	O

Injections	O
of	O
3	O
ml	O
of	O
the	O
local	O
anesthetic	O
were	O
given	O
,	O
followed	O
by	O
the	O
remainder	O
of	O
the	O
local	O
anesthetic	O
at	O
10	O
ml	O
/	O
min	O
1	O
min	O
later	O
.	O

METHODS	O
:	O
The	O
two	O
-	O
segment	O
regression	O
time	O
was	O
199	O
+	O
/	O
-	O
80	O
min	O
for	O
bupivacaine	O
,	O
201	O
+	O
/	O
-	O
52	O
min	O
for	O
ropivacaine	O
,	O
and	O
174	O
+	O
/	O
-	O
81	O
min	O
for	O
etidocaine	O
.	O

The	O
total	O
duration	O
of	O
sensory	O
block	O
was	O
340	O
+	O
/	O
-	O
103	O
min	O
for	O
bupivacaine	O
,	O
428	O
+	O
/	O
-	O
65	O
min	O
for	O
ropivacaine	O
and	O
223	O
+	O
/	O
-	O
62	O
min	O
for	O
etidocaine	O
,	O
respectively	O
.	O

In	O
the	O
ropivacaine	O
and	O
bupivacaine	O
groups	O
sensory	O
anesthesia	O
was	O
considered	O
adequate	O
for	O
surgery	O
in	O
all	O
cases	O
but	O
one	O
in	O
each	O
group	O
;	O
in	O
the	O
etidocaine	O
group	O
,	O
however	O
60	O
%	O
of	O
the	O
patients	O
showed	O
inadequate	O
analgesia	O
and	O
all	O
these	O
patients	O
(	O
12	O
/	O
20	O
)	O
required	O
additional	O
analgesics	O
.	O

Bupivacaine	O
achieved	O
an	O
average	O
of	O
motor	O
block	O
2	O
.	O
1	O
,	O
ropivacaine	O
2	O
.	O
3	O
,	O
and	O
etidocaine	O
2	O
.	O
4	O
.	O

CONCLUSION	O
.	O

-DOCSTART-	O

Title	O
:	O
Polymorphisms	B-I
of	I-I
ADORA2A	I-I
modulate	O
psychomotor	O
vigilance	O
and	O
the	O
effects	O
of	O
caffeine	B-I
on	O
neurobehavioural	O
performance	O
and	O
sleep	O
EEG	O
after	O
sleep	O
deprivation	O
.	O

METHODS	O
:	O
A	O
haplotype	O
analysis	O
of	O
eight	B-I
single	I-I
-	I-I
nucleotide	I-I
polymorphisms	I-I
of	I-I
ADORA2A	I-I
was	O
performed	O
in	O
82	B-P
volunteers	I-P
.	O

In	O
45	O
young	O
men	O
carrying	O
five	O
different	O
allele	O
combinations	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
prolonged	B-I
waking	I-I
and	O
2	B-I
	I-I
200	I-I
mg	I-I
caffeine	I-I
or	O
2	B-I
	I-I
100	I-I
mg	I-I
modafinil	I-I
on	O
psychomotor	B-O
vigilance	I-O
,	O
sleepiness	B-O
,	O
and	O
the	B-O
waking	I-O
and	O
sleep	B-O
EEG	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Methodologic	O
comparison	O
of	O
the	O
polyfrequency	O
oscillation	O
method	O
,	O
transcutaneous	O
oxygen	O
pressure	O
measurement	O
and	O
body	O
plethysmography	O
in	O
bronchial	O
provocation	O
with	O
methacholine	B-I
]	O
.	O

METHODS	O
:	O
A	B-O
bronchial	I-O
provocation	I-O
challenge	I-O
test	I-O
was	O
conducted	O
with	O
30	B-P
subjects	I-P
using	O
metacholin	B-I
.	O

In	O
randomised	O
sequence	O
lung	B-O
function	I-O
analysis	I-O
tests	I-O
were	O
carried	O
out	O
with	O
the	B-O
bodyplethysmograph	I-O
(	O
Raw	O
,	O
FEV1	O
)	O
and	O
the	B-O
polyfrequent	I-O
oscillation	I-O
method	I-O
(	O
resistance	B-O
,	O
reactance	B-O
between	O
2	O
and	O
52	O
Hz	O
)	O
,	O
whereas	O
the	B-O
transcutaneous	I-O
oxygen	I-O
pressure	I-O
(	I-O
tc	I-O
-	I-O
PO2	I-O
)	I-O
was	O
measured	O
continuously	O
.	O

Correlations	O
between	O
the	O
various	O
parameters	O
,	O
the	O
change	O
of	O
the	B-O
values	I-O
at	I-O
PD60	I-O
sGaw	I-O
in	O
relation	O
to	O
the	O
initial	O
values	O
,	O
the	B-O
interindividual	I-O
variability	I-O
and	O
the	B-O
reactivity	I-O
were	O
determined	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Comparative	O
effects	O
of	O
nebivolol	B-I
and	O
valsartan	B-I
on	O
atrial	O
electromechanical	O
coupling	O
in	O
newly	B-P
diagnosed	I-P
stage	I-P
1	I-P
hypertensive	I-P
patients	I-P
]	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
60	B-P
newly	I-P
diagnosed	I-P
stage	I-P
1	I-P
hypertensive	I-P
patients	I-P
with	I-P
no	I-P
other	I-P
systemic	I-P
disease	I-P
.	O

The	O
patients	O
were	O
randomized	O
to	O
receive	O
nebivolol	B-I
5	O
mg	O
(	O
30	O
patients	O
;	O
21	O
women	O
,	O
9	O
men	O
;	O
mean	O
age	O
48	O
.	O
4	O
	O
11	O
.	O
4	O
years	O
)	O
and	O
valsartan	B-I
160	O
mg	O
(	O
30	O
patients	O
;	O
21	O
women	O
,	O
9	O
men	O
;	O
mean	O
age	O
49	O
.	O
8	O
	O
11	O
.	O
3	O
years	O
)	O
.	O

All	O
the	O
patients	O
underwent	O
tissue	B-O
Doppler	I-O
echocardiographic	I-O
examination	I-O
before	O
and	O
three	O
months	O
after	O
treatment	O
to	O
compare	O
the	O
effects	O
of	O
the	O
two	O
drugs	O
on	O
atrial	O
electromechanical	O
coupling	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
body	B-I
orientation	I-I
on	O
maximum	O
voluntary	O
arm	O
torques	O
.	O

METHODS	O
:	O
Maximum	B-O
isometric	I-O
single	I-O
-	I-O
joint	I-O
and	O
multi	B-O
-	I-O
joint	I-O
arm	I-O
strength	I-O
was	O
observed	O
in	O
two	B-I
body	I-I
orientations	I-I
(	O
sitting	B-I
and	O
supine	B-I
)	O
while	O
maintaining	O
identical	O
head	O
/	O
neck	O
/	O
trunk	O
/	O
extremity	O
joint	O
configurations	O
in	O
order	O
to	O
identify	O
bulbospinal	O
contributions	O
to	O
maximum	O
joint	O
torque	O
generation	O
in	O
11	O
individuals	O
with	O
stroke	O
and	O
10	O
individuals	O
without	O
stroke	O
.	O

-DOCSTART-	O

Title	O
:	O
Arthroscopic	B-I
rotator	I-I
cuff	I-I
repair	I-I
with	I-I
and	O
without	B-I
acromioplasty	I-I
in	O
the	O
treatment	O
of	O
full	O
-	O
thickness	O
rotator	O
cuff	O
tears	O
:	O
a	O
multicenter	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Eighty	B-P
-	I-P
six	I-P
patients	I-P
consented	O
and	O
were	O
randomly	O
assigned	O
intraoperatively	O
to	O
one	O
of	O
two	O
study	O
groups	O
,	O
and	O
sixty	O
-	O
eight	O
of	O
them	O
completed	O
the	O
study	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
Western	I-O
Ontario	I-O
Rotator	I-O
Cuff	I-O
(	I-O
WORC	I-O
)	I-O
index	I-O
.	O

Secondary	O
outcome	O
measures	O
included	O
the	B-O
American	I-O
Shoulder	I-O
and	I-O
Elbow	I-O
Surgeons	I-O
(	I-O
ASES	I-O
)	I-O
shoulder	I-O
assessment	I-O
form	I-O
and	O
a	O
count	O
of	O
revisions	O
required	O
in	O
each	O
group	O
.	O

Outcome	O
measures	O
were	O
completed	O
preoperatively	O
and	O
at	O
three	O
,	O
six	O
,	O
twelve	O
,	O
eighteen	O
,	O
and	O
twenty	O
-	O
four	O
months	O
after	O
surgery	O
.	O

-DOCSTART-	O

Title	O
:	O
Atrial	B-I
fibrillation	I-I
catheter	I-I
ablation	I-I
versus	O
surgical	B-I
ablation	I-I
treatment	I-I
(	I-I
FAST	I-I
)	I-I
:	O
a	O
2	O
-	O
center	O
randomized	O
clinical	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
Development	O
of	O
an	B-I
adaptive	I-I
low	I-I
-	I-I
pass	I-I
filtered	I-I
speech	I-I
test	I-I
for	O
the	O
identification	O
of	O
auditory	O
processing	O
disorders	O
.	O

METHODS	O
:	O
In	O
this	O
preliminary	O
study	O
,	O
33	B-P
adults	I-P
and	I-P
30	I-P
children	I-P
(	I-P
aged	I-P
8	I-P
-	I-P
11	I-P
years	I-P
)	I-P
with	I-P
no	I-P
known	I-P
history	I-P
of	I-P
listening	I-P
difficulties	I-P
were	O
tested	O
.	O

The	B-I
University	I-I
of	I-I
Canterbury	I-I
Adaptive	I-I
Speech	I-I
Test	I-I
(	I-I
UCAST	I-I
)	I-I
platform	I-I
was	O
used	O
to	O
administer	O
a	B-I
four	I-I
-	I-I
alternative	I-I
forced	I-I
-	I-I
choice	I-I
adaptive	I-I
test	I-I
that	O
altered	O
a	O
low	O
-	O
pass	O
filter	O
(	O
LPF	O
)	O
to	O
track	O
the	B-O
corner	I-O
frequency	I-O
at	O
which	O
participants	O
correctly	O
identified	O
a	B-O
certain	I-O
percentage	I-O
of	I-O
the	I-O
word	I-O
stimuli	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Tinzaparin	B-I
versus	O
dalteparin	B-I
for	O
periprocedure	O
prophylaxis	O
of	O
thromboembolic	O
events	O
in	O
hemodialysis	B-P
patients	I-P
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Open	O
-	O
label	O
randomized	O
controlled	O
trial	O
.	O

HD	B-P
patients	I-P
undergoing	I-P
periprocedure	I-P
bridging	I-P
anticoagulation	I-P
.	O

After	O
warfarin	O
therapy	O
was	O
discontinued	O
,	O
participants	O
were	O
randomly	O
assigned	O
to	O
either	O
3	B-I
daily	I-I
doses	I-I
of	I-I
tinzaparin	I-I
(	O
175	O
IU	O
/	O
kg	O
)	O
or	O
dalteparin	B-I
(	O
200	O
IU	O
/	O
kg	O
)	O
,	O
with	O
2	O
intervening	O
HD	O
treatments	O
between	O
the	O
first	O
dose	O
of	O
study	O
drug	O
and	O
their	O
procedure	O
.	O

-DOCSTART-	O

Title	O
:	O
Teacher	B-I
-	I-I
implemented	I-I
joint	I-I
attention	I-I
intervention	I-I
:	O
pilot	O
randomized	O
controlled	O
study	O
for	O
preschoolers	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
Sixteen	B-P
dyads	I-P
(	I-P
preschoolers	I-P
with	I-P
ASD	I-P
and	I-P
the	I-P
public	I-P
school	I-P
teachers	I-P
who	I-P
worked	I-P
in	I-P
the	I-P
child	I-P
'	I-P
s	I-P
classroom	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
the	B-I
6	I-I
-	I-I
week	I-I
JASP	I-I
/	I-I
ER	I-I
intervention	I-I
or	O
a	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
skin	B-I
-	I-I
to	I-I
-	I-I
skin	I-I
contact	I-I
on	O
autonomic	O
pain	O
responses	O
in	O
preterm	B-P
infants	I-P
.	O

The	O
purpose	O
of	O
this	O
randomized	O
crossover	O
trial	O
was	O
to	O
determine	O
the	O
effects	O
on	O
autonomic	O
responses	O
in	O
preterm	O
infants	O
of	O
longer	O
Kangaroo	O
Care	O
(	O
30	O
minutes	O
,	O
KC30	O
)	O
and	O
shorter	O
KC	O
(	O
15	O
minutes	O
,	O
KC15	O
)	O
before	O
and	O
throughout	O
heel	O
stick	O
compared	O
with	O
incubator	O
care	O
(	O
IC	O
)	O
.	O

Beat	O
-	O
to	O
-	O
beat	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
spectral	O
power	O
analysis	O
of	O
heart	O
rate	O
variability	O
,	O
low	O
frequency	O
power	O
(	O
LF	O
)	O
,	O
high	O
frequency	O
power	O
(	O
HF	O
)	O
,	O
and	O
LF	O
/	O
HF	O
ratio	O
were	O
measured	O
in	O
26	O
infants	O
.	O

HR	O
changes	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
were	O
significantly	O
less	O
in	O
KC30	O
and	O
KC15	O
than	O
in	O
IC	O
,	O
and	O
more	O
infants	O
had	O
HR	O
decrease	O
in	O
IC	O
than	O
in	O
2	O
KC	O
conditions	O
.	O

In	O
IC	O
,	O
LF	O
and	O
HF	O
significantly	O
increased	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
and	O
dropped	O
from	O
Heel	O
Stick	O
to	O
Recovery	O
;	O
in	O
2	O
KC	O
conditions	O
,	O
no	O
changes	O
across	O
study	O
phases	O
were	O
found	O
.	O

During	O
Heel	O
Stick	O
,	O
LF	O
and	O
HF	O
were	O
significantly	O
higher	O
in	O
IC	O
than	O
in	O
KC30	O
.	O

In	O
all	O
3	O
conditions	O
,	O
LF	O
/	O
HF	O
ratio	O
decreased	O
from	O
Baseline	O
to	O
Heel	O
Stick	O
and	O
increased	O
to	O
Recovery	O
;	O
no	O
differences	O
were	O
found	O
between	O
IC	O
and	O
two	O
KC	O
conditions	O
.	O

Both	O
longer	O
and	O
shorter	O
KC	O
before	O
and	O
throughout	O
heel	O
stick	O
can	O
stabilize	O
HR	O
response	O
in	O
preterm	O
infants	O
,	O
and	O
longer	O
KC	O
significantly	O
affected	O
infants	O
'	O
sympathetic	O
and	O
parasympathetic	O
responses	O
during	O
heel	O
stick	O
compared	O
with	O
incubator	O
care	O
.	O

-DOCSTART-	O

Title	O
:	O
Plerixafor	B-I
plus	I-I
granulocyte	I-I
colony	I-I
-	I-I
stimulating	I-I
factor	I-I
versus	O
placebo	B-C
plus	I-C
granulocyte	I-C
colony	I-C
-	I-C
stimulating	I-C
factor	I-C
for	O
mobilization	O
of	O
CD34	O
(	O
+	O
)	O
hematopoietic	O
stem	O
cells	O
in	O
patients	B-P
with	I-P
multiple	I-P
myeloma	I-P
and	I-P
low	I-P
peripheral	I-P
blood	I-P
CD34	I-P
(	I-P
+	I-P
)	I-P
cell	I-P
count	I-P
:	O
results	O
of	O
a	O
subset	O
analysis	O
of	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
post	O
hoc	O
analysis	O
,	O
we	O
evaluated	O
the	O
mobilization	O
efficacy	O
of	O
plerixafor	B-I
plus	I-I
granulocyte	I-I
colony	I-I
-	I-I
stimulating	I-I
factor	I-I
(	I-I
G	I-I
-	I-I
CSF	I-I
)	I-I
versus	O
placebo	B-C
plus	I-C
G	I-C
-	I-C
CSF	I-C
in	O
patients	B-P
with	I-P
multiple	I-P
myeloma	I-P
,	I-P
stratified	I-P
by	I-P
preapheresis	I-P
PB	I-P
CD34	I-P
(	I-P
+	I-P
)	I-P
cell	I-P
count	I-P
:	I-P
<	I-P
10	I-P
,	I-P
<	I-P
15	I-P
,	I-P
<	I-P
20	I-P
,	I-P
and	I-P
?20	I-P
cells	I-P
/	I-P
?L	I-P
.	O

Regardless	O
of	O
the	B-O
PB	I-O
CD34	I-O
(	I-O
+	I-O
)	I-O
cell	I-O
count	I-O
,	O
the	B-O
total	I-O
yield	I-O
of	I-O
CD34	I-O
(	I-O
+	I-O
)	I-O
cells	I-O
from	I-O
apheresis	I-O
was	O
significantly	O
higher	O
in	O
the	B-I
plerixafor	I-I
group	O
than	O
in	O
the	B-C
placebo	I-C
group	O
,	O
and	O
significantly	O
more	O
patients	O
in	O
the	B-I
plerixafor	I-I
group	O
collected	O
the	O
minimum	O
(	O
?2	O
	O
10	O
(	O
6	O
)	O
cells	O
/	O
kg	O
)	O
and	O
optimum	O
(	O
?6	O
	O
10	O
(	O
6	O
)	O
cells	O
/	O
kg	O
)	O
stem	O
cell	O
yields	O
on	O
each	O
day	O
of	O
apheresis	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
acute	O
effects	O
of	O
fluid	B-I
intake	I-I
on	O
urine	O
specific	O
gravity	O
and	O
fluid	O
retention	O
in	O
a	O
mildly	O
dehydrated	O
state	O
.	O

METHODS	O
:	O
Ten	B-P
recreational	I-P
athletes	I-P
(	I-P
6	I-P
women	I-P
,	I-P
4	I-P
men	I-P
;	I-P
71	I-P
.	I-P
9	I-P
	I-P
4	I-P
.	I-P
6	I-P
kg	I-P
,	I-P
25	I-P
.	I-P
2	I-P
	I-P
0	I-P
.	I-P
9	I-P
years	I-P
)	I-P
participated	O
in	O
the	O
studies	O
to	O
examine	O
(	O
a	O
)	O
the	B-O
day	I-O
-	I-O
to	I-O
-	I-O
day	I-O
variability	I-O
of	I-O
morning	I-O
urine	I-O
specific	I-O
gravity	I-O
(	I-O
USG	I-O
)	I-O
,	O
(	O
b	O
)	O
the	B-O
effects	I-O
of	I-O
consuming	I-O
600	I-O
ml	I-O
of	I-O
water	I-O
on	I-O
the	I-O
hydration	I-O
status	I-O
of	I-O
HYD	I-O
and	I-O
HYPO	I-O
(	I-O
USG	I-O
>	I-O
1	I-O
.	I-O
020	I-O
)	I-O
subjects	I-O
,	O
and	O
(	O
c	O
)	O
the	B-O
effects	I-O
of	I-O
consuming	I-O
water	I-O
(	I-O
W	I-O
)	I-O
,	O
salt	B-O
-	I-O
water	I-O
(	I-O
SW	I-O
,	I-O
40	I-O
mM	I-O
Na	I-O
)	I-O
,	O
a	B-O
carbohydrate	I-O
-	I-O
electrolyte	I-O
solution	I-O
with	I-O
3	I-O
%	I-O
or	I-O
light	I-O
carbohydrate	I-O
(	I-O
CES	I-O
-	I-O
L	I-O
,	I-O
20	I-O
mM	I-O
Na	I-O
)	I-O
or	O
a	B-O
CES	I-O
with	I-O
6	I-O
%	I-O
carbohydrate	I-O
(	I-O
CES	I-O
,	I-O
20	I-O
mM	I-O

Na	I-O
)	I-O
on	I-O
the	I-O
hydration	I-O
status	I-O
of	O
HYPO	O
subjects	O
.	O

The	B-O
hydration	I-O
status	I-O
was	O
assessed	O
with	O
USG	B-O
and	O
body	B-O
mass	I-O
measures	I-O
and	O
urine	B-O
volume	I-O
collections	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Pentraxin	B-I
-	I-I
3	I-I
in	O
chronic	O
heart	O
failure	O
:	O
the	O
CORONA	O
and	O
GISSI	O
-	O
HF	O
trials	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
impact	O
of	O
patient	B-I
and	O
physician	B-I
computer	I-I
mediated	I-I
communication	I-I
skill	I-I
training	I-I
on	O
reported	O
communication	O
and	O
patient	O
satisfaction	O
.	O

METHODS	O
:	O
Separate	B-I
patient	I-I
and	I-I
clinician	I-I
web	I-I
-	I-I
tools	I-I
comprised	I-I
of	I-I
over	I-I
500	I-I
,	I-I
10	I-I
-	I-I
s	I-I
video	I-I
clips	I-I
demonstrating	O
patient	B-I
-	I-I
centered	I-I
skills	I-I
in	O
various	O
ways	O
.	O

Four	B-P
clinician	I-P
members	I-P
of	I-P
the	I-P
American	I-P
Academy	I-P
of	I-P
Family	I-P
Physicians	I-P
National	I-P
Research	I-P
Network	I-P
participated	O
by	O
enrolling	O
194	B-P
patients	I-P
into	O
a	O
randomized	O
patient	O
trial	O
and	O
29	B-P
physicians	I-P
into	O
a	O
non	O
-	O
randomized	O
clinician	O
trial	O
of	O
respective	O
interventions	O
.	O

All	O
participants	O
completed	O
baseline	O
and	O
follow	B-O
-	I-O
up	I-O
self	I-O
-	I-O
report	I-O
measures	I-O
of	O
visit	B-O
communication	I-O
and	O
satisfaction	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Promoting	O
physical	O
activity	O
in	O
patients	B-P
with	I-P
colon	I-P
adenomas	I-P
:	O
a	O
randomized	O
pilot	O
intervention	O
trial	O
.	O

METHODS	O
:	O
Sixteen	B-P
adults	I-P
with	I-P
adenomas	I-P
detected	I-P
and	I-P
removed	I-P
at	I-P
screening	I-P
colonoscopy	I-P
were	O
recruited	O
to	O
a	B-I
12	I-I
-	I-I
week	I-I
physical	I-I
activity	I-I
intervention	O
.	O

Participants	O
were	O
randomized	O
to	O
receive	O
a	B-C
standard	I-C
(	I-C
30	I-C
minutes	I-C
/	I-C
day	I-C
)	I-C
or	O
high	B-I
(	I-I
60	I-I
minutes	I-I
/	I-I
day	I-I
)	I-I
walking	I-I
program	I-I
.	O

Physical	B-O
activity	I-O
was	O
measured	O
via	O
blinded	B-O
pedometer	I-O
and	O
accelerometer	B-O
at	O
baseline	O
and	O
follow	O
-	O
up	O
.	O

Intervention	O
messages	O
focused	O
on	O
self	B-O
-	I-O
monitoring	I-O
using	O
pedometers	B-O
and	O
overcoming	B-O
barriers	I-O
to	I-O
engaging	I-O
in	I-O
physical	I-O
activity	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Localised	O
prostate	O
cancer	O
:	O
the	O
PREFERE	O
trial	O
]	O
.	O

METHODS	O
:	O
Based	O
on	O
the	O
discussions	O
of	O
the	O
Joint	O
Federal	O
Committee	O
(	O
G	O
-	O
BA	O
)	O
and	O
the	O
conceptual	O
work	O
of	O
the	O
MDS	O
,	O
the	O
Competence	O
Centre	O
Oncology	O
of	O
the	O
MDK	O
,	O
the	O
IQWIG	O
and	O
the	O
National	O
Association	O
of	O
Statutory	O
Health	O
Insurance	O
Funds	O
(	O
GKV	O
-	O
Spitzenverband	O
)	O
,	O
a	O
prospective	O
randomised	O
multicentre	O
trial	O
was	O
developed	O
comparing	O
the	O
four	O
treatments	O
actually	O
recommended	O
by	O
the	O
German	O
and	O
European	O
guidelines	O
for	O
localised	O
prostate	O
cancer	O
(	O
radical	B-I
prostatectomy	I-I
,	O
percutaneous	B-I
radiotherapy	I-I
and	O
permanent	B-I
seed	I-I
implantation	I-I

and	O
active	B-I
surveillance	I-I
)	O
allowing	O
a	O
rejection	O
of	O
one	O
or	O
two	O
treatment	O
options	O
.	O

-DOCSTART-	O

Title	O
:	O
Adjunctive	B-I
perampanel	I-I
for	O
refractory	O
partial	O
-	O
onset	O
seizures	O
:	O
randomized	O
phase	O
III	O
study	O
304	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
ClinicalTrials	O
.	O
gov	O
identifier	O
:	O
NCT00699972	O
)	O
.	O

Patients	B-P
(	I-P
?12	I-P
years	I-P
,	I-P
with	I-P
ongoing	I-P
seizures	I-P
despite	I-P
1	I-P
-	I-P
3	I-P
AEDs	I-P
)	I-P
were	O
randomized	O
(	O
1:1:1	O
)	O
to	O
once	B-I
-	I-I
daily	I-I
perampanel	I-I
8	O
mg	O
,	O
12	O
mg	O
,	O
or	O
placebo	B-C
.	O

Following	O
baseline	O
(	O
6	O
weeks	O
)	O
,	O
patients	O
entered	O
a	O
19	O
-	O
week	O
double	O
-	O
blind	O
phase	O
:	O
6	O
-	O
week	O
titration	O
(	O
2	O
mg	O
/	O
week	O
increments	O
to	O
target	O
dose	O
)	O
followed	O
by	O
a	O
13	O
-	O
week	O
maintenance	O
period	O
.	O

Percent	O
change	O
in	O
seizure	B-O
frequency	I-O
was	O
the	O
primary	O
endpoint	O
;	O
50	O
%	O
responder	O
rate	O
was	O
the	O
primary	O
endpoint	O
for	O
EU	O
registration	O
.	O

METHODS	O
:	O
This	O
study	O
provides	O
Class	O
I	O
evidence	O
that	O
once	O
-	O
daily	O
8	O
and	O
12	O
mg	O
doses	O
of	O
adjunctive	O
perampanel	O
are	O
effective	O
in	O
patients	O
with	O
uncontrolled	O
partial	O
-	O
onset	O
seizures	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
effects	O
of	O
ezetimibe	B-I
-	O
plus	O
-	O
statin	B-I
therapy	I-I
on	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
levels	O
as	O
compared	O
with	O
double	O
-	O
dose	O
statin	O
therapy	O
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
.	O

METHODS	O
:	O
Coronary	B-P
artery	I-P
disease	I-P
patients	I-P
whose	I-P
LDL	I-P
-	I-P
C	I-P
?	I-P
70	I-P
mg	I-P
/	I-P
dL	I-P
after	I-P
treatment	I-P
with	I-P
atorvastatin	I-P
10	I-P
mg	I-P
/	I-P
day	I-P
or	I-P
rosuvastatin	I-P
2	I-P
.	I-P
5	I-P
mg	I-P
/	I-P
day	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
ezetimibe	B-I
10	O
mg	O
/	O
day	O
+	O
statin	B-I
(	O
n	O
=	O
78	O
)	O
or	O
double	B-I
-	I-I
dose	I-I
statin	I-I
(	O
n	O
=	O
72	O
)	O
for	O
52	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
bexarotene	B-I
combined	I-I
with	I-I
psoralen	I-I
-	I-I
ultraviolet	I-I
A	I-I
(	I-I
PUVA	I-I
)	I-I
compared	O
with	O
PUVA	B-C
treatment	I-C
alone	I-C
in	O
stage	O
IB	O
-	O
IIA	O
mycosis	O
fungoides	O
:	O
final	O
results	O
from	O
the	O
EORTC	O
Cutaneous	O
Lymphoma	O
Task	O
Force	O
phase	O
III	O
randomized	O
clinical	O
trial	O
(	O
NCT00056056	O
)	O
.	O

METHODS	O
:	O
EORTC	O
21011	O
(	O
NCT	O
00056056	O
)	O
was	O
a	O
randomized	O
phase	O
III	O
study	O
comparing	O
combined	O
bexarotene	B-I
(	I-I
Targretin	I-I
(	I-I
	I-I
)	I-I
)	I-I
and	O
PUVA	B-I
vs	O
.	O

PUVA	B-C
alone	I-C
in	O
patients	B-P
with	I-P
stage	I-P
IB	I-P
and	I-P
IIA	I-P
mycosis	I-P
fungoides	I-P
(	I-P
MF	I-P
)	I-P
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
overall	I-O
response	I-O
rate	I-O
[	O
complete	B-O
clinical	I-O
response	I-O
(	I-O
CCR	I-O
)	I-O
plus	O
partial	B-O
response	I-O
(	I-O
PR	I-O
)	I-O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Airway	O
responses	O
and	O
inflammation	O
in	O
subjects	B-P
with	I-P
asthma	I-P
after	O
four	B-I
days	I-I
of	I-I
repeated	I-I
high	I-I
-	I-I
single	I-I
-	I-I
dose	I-I
allergen	I-I
challenge	I-I
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
27	I-P
patients	I-P
aged	I-P
18	I-P
to	I-P
40	I-P
years	I-P
with	I-P
positive	I-P
skin	I-P
-	I-P
prick	I-P
tests	I-P
and	I-P
mild	I-P
asthma	I-P
underwent	O
repetitive	B-I
high	I-I
-	I-I
dose	I-I
allergen	I-I
challenges	I-I
with	O
household	O
dust	O
mites	O
for	O
four	O
consecutive	O
days	O
.	O

Pulmonary	B-O
function	I-O
and	O
exhaled	B-O
NO	I-O
were	O
measured	O
at	O
every	O
visit	O
.	O

Induced	B-O
sputum	I-O
was	O
analysed	O
before	O
and	O
after	O
the	O
allergen	O
challenges	O
for	O
cell	B-O
counts	I-O
,	O
ECP	B-O
,	O
IL	B-O
-	I-O
5	I-O
,	O
INF	B-O
-	I-O
?	I-O
,	O
IL	B-O
-	I-O
8	I-O
,	O
and	O
the	B-O
transcription	I-O
factor	I-O
Foxp3	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Improving	O
RBC	O
K	O
transport	O
and	O
hemoglobin	O
-	O
O2	O
binding	O
by	O
amiloride	B-I
:	O
A	O
novel	O
therapeutic	O
approach	O
for	O
reversion	O
of	O
angina	O
and	O
myocardial	O
ischemia	O
in	O
coronary	O
heart	O
diseases	O
.	O

Coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
is	O
the	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
across	O
the	O
entire	O
world	O
,	O
in	O
which	O
reversion	O
of	O
angina	O
or	O
improvement	O
of	O
ECG	O
remains	O
an	O
unrealistic	O
therapeutic	O
option	O
for	O
most	O
patients	O
,	O
suggesting	O
that	O
microvascular	O
dysfunction	O
or	O
impaired	O
oxygen	O
delivery	O
might	O
be	O
critical	O
factors	O
in	O
CHD	O
.	O

This	O
research	O
article	O
,	O
thus	O
presents	O
the	O
rationale	O
basis	O
,	O
clinical	O
and	O
experimental	O
,	O
for	O
the	O
first	O
therapeutic	O
innovation	O
addressing	O
the	O
role	O
of	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
H	O
/	O
K	O
and	O
O2	O
/	O
CO2	O
exchanges	O
in	O
CHD	O
.	O

It	O
is	O
followed	O
by	O
a	O
randomized	O
single	O
-	O
blind	O
trial	O
of	O
Amiloride	O
and	O
Optimal	O
Medical	O
Therapy	O
(	O
OMT	O
,	O
n=35	O
cases	O
)	O
vs	O
OMT	O
alone	O
(	O
n=35	O
cases	O
)	O
in	O
patients	O
having	O
angina	O
,	O
ST	O
-	O
T	O
alteration	O
and	O
a	O
defective	O
RBC	O
-	O
K	O
transport	O
.	O

All	O
patients	O
had	O
serial	O
clinical	O
evaluation	O
,	O
Ion	O
Transport	O
Studies	O
,	O
ECGs	O
and	O
non	O
-	O
invasive	O
aortic	O
waveform	O
and	O
cardiovascular	O
hemodynamic	O
recordings	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
SAS	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
brief	I-I
Early	I-I
Start	I-I
Denver	I-I
model	I-I
(	I-I
ESDM	I-I
)	I-I
-	I-I
based	I-I
parent	I-I
intervention	I-I
on	O
toddlers	B-P
at	I-P
risk	I-P
for	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
controlled	O
trial	O
involving	O
98	B-P
children	I-P
and	I-P
families	I-P
was	I-P
carried	I-P
out	I-P
in	I-P
three	I-P
different	I-P
sites	I-P
investigating	O
the	B-O
efficacy	I-O
of	O
a	B-I
parent	I-I
delivery	I-I
of	I-I
the	I-I
Early	I-I
Start	I-I
Denver	I-I
model	I-I
(	I-I
P	I-I
-	I-I
ESDM	I-I
)	I-I
,	O
which	O
fosters	O
parental	O
use	O
of	O
a	O
child	O
-	O
centered	O
responsive	O
interaction	O
style	O
that	O
embeds	O
many	O
teaching	O
opportunities	O
into	O
play	O
,	O
compared	O
to	O
community	B-C
treatment	I-C
as	I-C
usual	I-C
.	O

Assessments	O
were	O
completed	O
at	O
baseline	O
and	O
12	O
weeks	O
later	O
,	O
immediately	O
after	O
the	O
end	O
of	O
parent	O
coaching	O
sessions	O
.	O

-DOCSTART-	O

Title	O
:	O
Potential	O
effect	O
of	O
the	O
risk	O
of	O
ovarian	B-I
cancer	I-I
algorithm	I-I
(	I-I
ROCA	I-I
)	I-I
on	O
the	O
mortality	O
outcome	O
of	O
the	O
Prostate	O
,	O
Lung	O
,	O
Colorectal	O
and	O
Ovarian	O
(	O
PLCO	O
)	O
trial	O
.	O

METHODS	O
:	O
We	O
investigated	O
whether	O
having	O
had	O
used	O
ROCA	B-I
in	O
PLCO	O
could	O
have	O
,	O
under	O
optimal	O
assumptions	O
,	O
resulted	O
in	O
a	B-O
significant	I-O
mortality	I-O
benefit	I-O
by	O
applying	O
ROCA	B-I
to	O
PLCO	O
CA125	O
screening	O
values	O
.	O

A	O
best	O
-	O
case	O
scenario	O
assumed	O
that	O
all	O
cancers	O
showing	O
a	O
positive	O
screen	O
result	O
earlier	O
with	O
ROCA	B-I
than	O
under	O
the	O
PLCO	O
protocol	O
would	O
have	O
avoided	O
mortality	B-O
;	O
under	O
a	O
stage	O
-	O
shift	O
scenario	O
,	O
such	O
women	O
were	O
assigned	O
survival	O
equivalent	O
to	O
Stage	O
I	O
/	O
II	O
screen	O
-	O
detected	O
cases	O
.	O

-DOCSTART-	O

Title	O
:	O
End	O
-	O
expiratory	O
lung	O
volume	O
recovers	O
more	O
slowly	O
after	O
closed	B-I
endotracheal	I-I
suctioning	I-I
than	O
after	O
open	B-I
suctioning	I-I
:	O
a	O
randomized	O
crossover	O
study	O
.	O

METHODS	O
:	O
Randomized	O
crossover	O
study	O
examining	O
20	B-P
patients	I-P
postcardiac	I-P
surgery	I-P
.	O

CS	B-I
and	O
OS	B-I
were	O
performed	O
in	O
random	O
order	O
,	O
30	O
minutes	O
apart	O
.	O

Lung	B-O
impedance	I-O
was	O
measured	O
during	O
suction	O
,	O
and	O
end	B-O
-	I-O
expiratory	I-O
lung	I-O
impedance	I-O
was	O
measured	O
at	O
baseline	O
and	O
postsuctioning	O
using	O
electrical	O
impedance	O
tomography	O
.	O

Oximetry	B-O
,	O
partial	B-O
pressure	I-O
of	I-O
oxygen	I-O
in	I-O
the	I-O
alveoli	I-O
/	I-O
fraction	I-O
of	I-O
inspired	I-O
oxygen	I-O
ratio	I-O
and	O
compliance	B-O
were	O
collected	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
the	O
use	O
of	O
oxytocin	B-I
on	O
blood	O
loss	O
during	O
different	O
postpartum	O
periods	O
.	O

METHODS	O
:	O
In	O
the	O
study	O
,	O
89	O
pregnant	O
women	O
to	O
whom	O
oxytocin	B-I
was	O
administered	O
after	O
placenta	O
separation	O
were	O
studied	O
in	O
Group	O
1	O
,	O
89	O
pregnant	O
women	O
were	O
included	O
in	O
Group	O
2	O
,	O
and	O
oxytocin	B-I
was	O
administered	O
after	O
delivery	O
of	O
the	O
shoulder	O
.	O

The	B-O
levels	I-O
of	I-O
hemoglobin	I-O
and	O
hematocrit	B-O
before	O
and	O
after	O
delivery	O
were	O
quantified	O
.	O

-DOCSTART-	O

Title	O
:	O
Chocolate	B-I
frogs	I-I
do	O
not	O
increase	O
completion	O
of	O
parent	O
survey	O
:	O
randomised	O
study	O
.	O

METHODS	O
:	O
Families	B-P
enrolled	I-P
between	I-P
15	I-P
March	I-P
and	I-P
25	I-P
May	I-P
2012	I-P
were	O
randomised	O
to	O
receive	O
a	B-I
chocolate	I-I
frog	I-I
versus	O
no	B-C
chocolate	I-C
frog	I-C
.	O

Both	O
groups	O
received	O
a	O
written	O
reminder	O
and	O
replacement	O
survey	O
2	O
weeks	O
after	O
the	O
survey	O
was	O
posted	O
and	O
up	O
to	O
two	O
telephone	O
reminders	O
thereafter	O
.	O

We	O
analysed	O
the	O
effect	O
of	O
the	O
incentive	O
using	O
?	O
(	O
2	O
)	O
tests	O
for	O
the	B-O
categorical	I-O
response	I-O
variable	O
and	O
t	O
-	O
tests	O
for	O
the	B-O
continuous	I-O
reminder	I-O
and	O
length	B-O
of	I-O
response	I-O
variables	I-O
at	O
the	O
end	O
of	O
(	O
i	O
)	O
randomisation	O
and	O
(	O
ii	O
)	O
the	O
study	O
(	O
1	O
November	O
2012	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
phase	O
II	O
study	O
of	O
afatinib	B-I
versus	O
cetuximab	B-I
in	O
metastatic	O
or	O
recurrent	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
.	O

METHODS	O
:	O
An	O
open	O
-	O
label	O
,	O
randomized	O
,	O
phase	O
II	O
trial	O
was	O
conducted	O
in	O
43	O
centers	O
;	O
124	B-P
patients	I-P
were	O
randomized	O
(	O
1	O
:	O
1	O
)	O
to	O
either	O
afatinib	B-I
(	O
50	O
mg	O
/	O
day	O
)	O
or	O
cetuximab	B-I
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
week	O
)	O
until	O
disease	O
progression	O
or	O
intolerable	O
adverse	O
events	O
(	O
AEs	O
)	O
(	O
stage	O
I	O
)	O
,	O
with	O
optional	O
crossover	O
(	O
stage	O
II	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
tumor	B-O
shrinkage	I-O
before	O
crossover	O
assessed	O
by	O
investigator	O
(	O
IR	O
)	O
and	O
independent	O
central	O
review	O
(	O
ICR	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Electrothermal	B-I
arthroscopic	I-I
capsulorrhaphy	I-I
:	O
old	O
technology	O
,	O
new	O
evidence	O
.	O

A	O
multicenter	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Patients	B-P
(	I-P
>	I-P
14	I-P
years	I-P
)	I-P
diagnosed	I-P
with	I-P
multidirectional	I-P
instability	I-P
or	I-P
multidirectional	I-P
laxity	I-P
with	I-P
anteroinferior	I-P
instability	I-P
and	I-P
failed	I-P
nonoperative	I-P
treatment	I-P
were	O
enrolled	O
.	O

Patients	O
with	O
bone	O
lesions	O
or	O
labral	O
,	O
biceps	O
anchor	O
,	O
or	O
full	O
-	O
thickness	O
rotator	O
cuff	O
tears	O
were	O
excluded	O
intraoperatively	O
.	O

Outcomes	O
included	O
Western	B-O
Ontario	I-O
Shoulder	I-O
Instability	I-O
Index	I-O
,	O
function	B-O
and	O
recurrent	B-O
instability	I-O
at	O
2	O
years	O
postoperatively	O
,	O
and	O
surgical	B-O
times	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Compared	O
with	O
the	O
intake	O
of	O
commercial	B-C
vegetable	I-C
juice	I-C
,	O
the	O
intake	O
of	O
fresh	B-I
fruit	I-I
and	O
komatsuna	B-I
(	I-I
Brassica	I-I
rapa	I-I
L	I-I
.	I-I
var	I-I
.	I-I
perviridis	I-I
)	I-I
juice	I-I
mixture	I-I
reduces	O
serum	O
cholesterol	O
in	O
middle	B-P
-	I-P
aged	I-P
men	I-P
:	O
a	O
randomized	O
controlled	O
pilot	O
study	O
.	O

METHODS	O
:	O
This	O
study	O
was	O
performed	O
as	O
a	O
single	O
blind	O
and	O
randomized	O
controlled	O
trial	O
.	O

Subjects	B-P
were	I-P
16	I-P
men	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
46	I-P
.	I-P
4	I-P
	I-P
7	I-P
.	I-P
1	I-P
years	I-P
)	I-P
,	O
and	O
they	O
were	O
divided	O
into	O
two	O
groups	O
(	O
control	O
group	O
and	O
intervention	O
group	O
)	O
.	O

The	O
intervention	O
group	O
consumed	O
the	B-I
juice	I-I
mixture	I-I
of	I-I
fresh	I-I
fruit	I-I
and	O
B	B-I
.	I-I
rapa	I-I
.	O

The	O
control	O
group	O
consumed	O
commercial	B-C
vegetable	I-C
juice	I-C
.	O

Subjects	O
consumed	O
juice	O
twice	O
a	O
day	O
throughout	O
the	O
weekday	O
,	O
for	O
4	O
weeks	O
.	O

We	O
prepared	O
both	O
juices	O
with	O
an	O
equivalent	O
energy	O
balance	O
.	O

-DOCSTART-	O

Title	O
:	O
Vitamin	B-I
D	I-I
supplementation	I-I
ameliorates	O
hypoinsulinemia	O
and	O
hyperglycemia	O
in	O
static	B-P
magnetic	I-P
field	I-P
-	I-P
exposed	I-P
rat	I-P
.	O

-DOCSTART-	O

Title	O
:	O
A	O
further	O
investigation	O
of	O
goal	O
-	O
directed	O
intention	O
understanding	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Transcervical	B-I
Foley	I-I
'	I-I
s	I-I
catheter	I-I
versus	O
Cook	B-I
balloon	I-I
for	O
cervical	O
ripening	O
in	O
stillbirth	O
with	O
a	O
scarred	O
uterus	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
study	O
.	O

El	O
Minia	O
University	O
Hospital	O
,	O
El	O
Minia	O
,	O
Egypt	O
.	O

Two	B-P
-	I-P
hundred	I-P
pregnant	I-P
women	I-P
with	I-P
stillbirth	I-P
,	I-P
unfavorable	I-P
cervix	I-P
and	I-P
scarred	I-P
uterus	I-P
were	O
recruited	O
into	O
this	O
study	O
.	O

They	O
were	O
randomized	O
into	O
two	O
groups	O
.	O

In	O
group	O
I	O
(	O
n	O
=	O
100	O
)	O
,	O
cervical	B-I
ripening	I-I
was	O
done	O
using	O
Foley	B-I
'	I-I
s	I-I
catheter	I-I
.	O

In	O
group	O
II	O
(	O
n	O
=	O
100	O
)	O
,	O
cervical	B-I
ripening	I-I
was	O
done	O
using	O
Cook	B-I
cervical	I-I
ripening	I-I
balloon	I-I
.	O

Balloon	B-O
insertion	I-O
to	I-O
delivery	I-O
interval	I-O
,	O
successful	B-O
ripening	I-O
rate	I-O
,	O
cesarean	B-O
delivery	I-O
rate	I-O
,	O
maternal	B-O
adverse	I-O
events	I-O
and	O
maternal	B-O
satisfaction	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Coping	O
strategies	O
as	O
mediators	O
of	O
the	O
effect	O
of	O
the	B-I
START	I-I
(	I-I
strategies	I-I
for	I-I
RelaTives	I-I
)	I-I
intervention	I-I
on	O
psychological	O
morbidity	O
for	O
family	B-P
carers	I-P
of	I-P
people	I-P
with	I-P
dementia	I-P
in	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
260	B-P
family	I-P
carers	I-P
from	I-P
NHS	I-P
dementia	I-P
services	I-P
were	O
randomised	O
to	O
START	B-I
(	I-I
manualised	I-I
coping	I-I
skills	I-I
intervention	I-I
)	I-I
,	O
or	O
treatment	B-C
-	I-C
as	I-C
-	I-C
usual	I-C
(	I-C
TAU	I-C
)	I-C
.	O

Blinded	O
raters	O
administered	O
the	B-O
Hospital	I-O
Anxiety	I-O
and	I-O
Depression	I-O
Scale	I-O
(	I-O
HADS	I-O
-	I-O
T	I-O
)	I-O
and	O
Brief	B-O
COPE	I-O
inventory	O
at	O
baseline	O
,	O
4	O
and	O
8	O
months	O
.	O

HADS	B-O
-	I-O
T	I-O
improved	O
in	O
the	O
intervention	O
group	O
when	O
compared	O
to	O
TAU	B-C
at	O
all	O
levels	O
of	O
psychological	O
distress	O
.	O

We	O
tested	O
whether	O
coping	O
was	O
a	O
mediator	O
and	O
for	O
moderated	O
mediation	O
,	O
and	O
(	O
post	O
-	O
hoc	O
)	O
subgroup	O
treatment	O
effects	O
on	O
coping	O
.	O

-DOCSTART-	O

Title	O
:	O
Assessing	O
the	O
benefit	O
of	O
a	B-I
personalized	I-I
EHR	I-I
-	I-I
generated	I-I
informed	I-I
consent	I-I
in	O
a	O
dental	O
school	O
setting	O
.	O

METHODS	O
:	O
In	O
the	O
study	O
,	O
a	B-I
set	I-I
of	I-I
informed	I-I
consents	I-I
,	O
or	O
SmartConsents	B-I
,	O
were	O
developed	O
for	O
specific	O
diagnoses	O
and	O
procedures	O
,	O
enhanced	O
with	O
graphics	O
,	O
and	O
delivered	O
through	O
the	O
school	O
'	O
s	O
EHR	O
.	O

Fifty	B-P
patients	I-P
were	I-P
recruited	I-P
in	I-P
the	I-P
school	I-P
'	I-P
s	I-P
Urgent	I-P
Care	I-P
Clinic	I-P
and	O
divided	O
evenly	O
into	O
two	O
groups	O
:	O
one	O
(	O
control	O
)	O
receiving	O
the	B-C
standard	I-C
consent	I-C
,	O
with	O
the	O
second	O
receiving	O
a	B-I
SmartConsent	I-I
.	O

Following	O
treatment	O
,	O
patients	O
were	O
assessed	O
based	O
on	O
demographics	B-O
,	O
decisional	B-O
conflict	I-O
,	O
satisfaction	B-O
,	O
health	B-O
literacy	I-O
,	O
and	O
knowledge	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
effectiveness	O
of	O
bevacizumab	B-I
-	O
containing	O
treatment	O
for	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
:	O
final	O
results	O
of	O
the	O
ARIES	O
observational	O
cohort	O
study	O
.	O

METHODS	O
:	O
From	B-P
2006	I-P
to	I-P
2009	I-P
,	I-P
ARIES	I-P
enrolled	I-P
patients	I-P
with	I-P
locally	I-P
advanced	I-P
or	I-P
metastatic	I-P
NSCLC	I-P
who	O
were	O
eligible	O
for	O
bevacizumab	B-I
,	O
excluding	O
those	O
with	O
predominantly	O
squamous	O
histology	O
.	O

Patients	O
were	O
required	O
to	O
provide	O
informed	O
consent	O
and	O
to	O
have	O
initiated	O
bevacizumab	B-I
with	O
chemotherapy	B-I
within	O
4	O
months	O
before	O
enrollment	O
.	O

There	O
were	O
no	O
protocol	O
-	O
defined	O
treatments	O
or	O
assessments	O
.	O

The	O
dosing	O
of	O
bevacizumab	B-I
and	O
chemotherapy	B-I
,	O
and	O
the	O
choice	O
of	O
chemotherapy	O
regimen	O
,	O
was	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physician	O
.	O

-DOCSTART-	O

Title	O
:	O
GPs	B-I
'	I-I
experiences	I-I
with	I-I
brief	I-I
intervention	I-I
for	O
medication	O
-	O
overuse	O
headache	O
:	O
a	O
qualitative	O
study	O
in	O
general	O
practice	O
.	O

METHODS	O
:	O
Qualitative	O
study	O
in	O
Norwegian	O
general	O
practice	O
.	O

Data	O
were	O
collected	O
through	O
four	O
focus	O
group	O
interviews	O
with	O
22	B-P
GPs	I-P
who	O
participated	O
in	O
an	O
intervention	O
study	O
on	O
BI	O
for	O
MOH	O
.	O

Systematic	B-O
text	I-O
condensation	I-O
was	O
used	O
to	O
analyse	O
transcripts	O
from	O
the	O
focus	O
group	O
interviews	O
.	O

-DOCSTART-	O

Title	O
:	O
Gene	B-I
variants	I-I
in	I-I
CYP2C19	I-I
are	O
associated	O
with	O
altered	O
in	O
vivo	O
bupropion	O
pharmacokinetics	O
but	O
not	O
bupropion	O
-	O
assisted	O
smoking	O
cessation	O
outcomes	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
rhubarb	B-I
combined	O
with	O
early	B-I
enteral	I-I
nutrition	I-I
for	O
the	O
treatment	O
of	O
severe	O
acute	O
pancreatitis	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
126	I-P
patients	I-P
with	I-P
SAP	I-P
were	O
randomly	O
assigned	O
into	O
three	O
groups	O
:	O
parenteral	B-I
nutrition	I-I
group	O
,	O
treated	O
with	O
standard	O
solution	O
first	O
and	O
EN	B-I
14	O
days	O
later	O
;	O
EEN	B-I
group	O
,	O
treated	O
with	O
EN	B-I
suspension	I-I
;	O
or	O
EEN	B-I
combined	O
with	O
rhubarb	B-I
group	I-I
,	O
treated	O
with	O
rhubarb	B-I
and	O
then	O
EN	B-I
2	O
h	O
later	O
.	O

The	B-O
gastrointestinal	I-O
function	I-O
,	O
APACHE	B-O
II	I-O
scores	I-O
,	O
the	B-O
levels	I-O
of	I-O
plasma	I-O
IL	I-O
-	I-O
6	I-O
,	O
IL	B-O
-	I-O
11	I-O
,	O
C	B-O
-	I-O
reactive	I-O
proteins	I-O
(	I-O
CRP	I-O
)	I-O
and	O
the	B-O
liver	I-O
and	O
kidney	B-O
functional	I-O
measures	I-O
were	O
longitudinally	O
analyzed	O
.	O

-DOCSTART-	O

Title	O
:	O
Everolimus	B-I
for	O
subependymal	O
giant	O
cell	O
astrocytoma	O
in	O
patients	B-P
with	I-P
tuberous	I-P
sclerosis	I-P
complex	I-P
:	O
2	O
-	O
year	O
open	O
-	O
label	O
extension	O
of	O
the	O
randomised	O
EXIST	O
-	O
1	O
study	O
.	O

METHODS	O
:	O
We	O
assessed	O
data	O
from	O
a	O
prospective	O
,	O
open	O
-	O
label	O
extension	O
of	O
a	O
multicentre	O
,	O
phase	O
3	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
in	O
patients	B-P
with	I-P
tuberous	I-P
sclerosis	I-P
complex	I-P
who	I-P
had	I-P
SEGA	I-P
that	O
was	O
growing	O
and	O
needed	O
treatment	O
.	O

In	O
this	O
extension	O
study	O
,	O
we	O
included	O
all	O
patients	O
who	O
had	O
been	O
assigned	O
everolimus	B-I
during	O
the	O
double	O
-	O
blind	O
,	O
randomised	O
phase	O
of	O
the	O
trial	O
and	O
those	O
patients	O
who	O
crossed	O
over	O
from	O
the	B-C
placebo	I-C
group	O
to	O
receive	O
everolimus	B-I
during	O
the	O
randomised	O
phase	O
or	O
at	O
the	O
start	O
of	O
the	O
extension	O
phase	O
.	O

All	O
patients	O
received	O
oral	B-I
everolimus	I-I
at	O
a	O
starting	O
dose	O
of	O
45	O
mg	O
/	O
m	O
(	O
2	O
)	O
per	O
day	O
.	O

Everolimus	B-I
dose	O
was	O
subsequently	O
adjusted	O
subject	O
to	O
tolerability	O
to	O
attain	O
blood	O
trough	O
concentrations	O
of	O
5	O
-	O
15	O
ng	O
/	O
mL	O
.	O

An	O
independent	O
central	O
radiology	O
review	O
team	O
assessed	O
SEGA	B-O
response	I-O
(	O
at	O
least	O
a	O
50	O
%	O
reduction	O
from	O
baseline	O
in	O
total	O
volume	O
of	O
all	O
target	O
SEGAs	O
;	O
the	O
primary	O
endpoint	O
)	O
by	O
MRI	B-O
at	O
12	O
,	O
24	O
,	O
and	O
48	O
weeks	O
,	O
then	O
every	O
year	O
thereafter	O
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	B-I
dose	I-I
of	I-I
everolimus	I-I
.	O

This	O
study	O
was	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
number	O
NCT00789828	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
low	B-I
versus	O
high	B-I
dialysate	I-I
sodium	I-I
concentration	I-I
on	O
blood	O
pressure	O
and	O
endothelial	O
-	O
derived	O
vasoregulators	O
during	O
hemodialysis	O
:	O
a	O
randomized	O
crossover	O
study	O
.	O

METHODS	O
:	O
3	O
-	O
week	O
,	O
2	O
-	O
arm	O
,	O
randomized	O
,	O
crossover	O
study	O
.	O

16	B-P
patients	I-P
with	I-P
intradialytic	I-P
hypertension	I-P
.	O

Low	B-I
(	I-I
5	I-I
mEq	I-I
/	I-I
L	I-I
below	I-I
serum	I-I
sodium	I-I
)	I-I
versus	O
high	B-I
(	I-I
5	I-I
mEq	I-I
/	I-I
L	I-I
above	I-I
serum	I-I
sodium	I-I
)	I-I
dialysate	I-I
sodium	I-I
concentration	I-I
.	O

METHODS	O
:	O
Mixed	O
linear	O
regression	O
was	O
used	O
to	O
compare	O
the	O
effect	O
of	O
dialysate	O
sodium	O
(	O
low	O
vs	O
high	O
)	O
and	O
randomization	O
arm	O
(	O
low	O
-	O
then	O
-	O
high	O
vs	O
high	O
-	O
then	O
-	O
low	O
)	O
on	O
intradialytic	O
changes	O
in	O
endothelin	B-O
1	I-O
,	O
NO2	B-O
(	I-O
-	I-O
)	I-O
,	O
and	O
BP	B-O
values	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Crohn	B-I
'	I-I
s	I-I
disease	I-I
management	I-I
after	O
intestinal	O
resection	O
:	O
a	O
randomised	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomised	O
trial	O
,	O
consecutive	B-P
patients	I-P
from	I-P
17	I-P
centres	I-P
in	I-P
Australia	I-P
and	I-P
New	I-P
Zealand	I-P
undergoing	I-P
intestinal	I-P
resection	I-P
of	I-P
all	I-P
macroscopic	I-P
Crohn	I-P
'	I-P
s	I-P
disease	I-P
,	I-P
with	I-P
an	I-P
endoscopically	I-P
accessible	I-P
anastomosis	I-P
,	I-P
received	I-P
3	I-P
months	I-P
of	I-P
metronidazole	I-P
therapy	I-P
.	O

Patients	O
at	O
high	O
risk	O
of	O
recurrence	O
also	O
received	O
a	B-I
thiopurine	I-I
,	O
or	O
adalimumab	B-I
if	O
they	O
were	O
intolerant	O
to	O
thiopurines	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
parallel	O
groups	O
:	O
colonoscopy	B-I
at	I-I
6	I-I
months	I-I
(	O
active	O
care	O
)	O
or	O
no	B-C
colonoscopy	I-C
(	O
standard	O
care	O
)	O
.	O

We	O
used	O
computer	O
-	O
generated	O
block	O
randomisation	O
to	O
allocate	O
patients	O
in	O
each	O
centre	O
to	O
active	O
or	O
standard	O
care	O
in	O
a	O
2	O
:	O
1	O
ratio	O
.	O

For	O
endoscopic	O
recurrence	O
(	O
Rutgeerts	O
score	O
?i2	O
)	O
at	O
6	O
months	O
,	O
patients	O
stepped	O
-	O
up	O
to	O
thiopurine	B-I
,	O
fortnightly	B-I
adalimumab	I-I
with	O
thiopurine	B-I
,	O
or	O
weekly	B-I
adalimumab	I-I
.	O

The	O
primary	O
endpoint	O
was	O
endoscopic	B-O
recurrence	I-O
at	O
18	O
months	O
.	O

Patients	O
and	O
treating	O
physicians	O
were	O
aware	O
of	O
the	O
patient	O
'	O
s	O
study	O
group	O
and	O
treatment	O
,	O
but	O
central	B-O
reading	I-O
of	I-O
the	I-O
endoscopic	I-O
findings	I-O
was	O
undertaken	O
blind	O
to	O
the	O
study	O
group	O
and	O
treatment	O
.	O

Analysis	O
included	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
number	O
NCT00989560	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
functional	O
outcomes	O
and	O
predictors	O
of	O
shunt	B-I
-	I-I
dependent	I-I
hydrocephalus	O
after	O
treatment	O
of	O
ruptured	O
intracranial	O
aneurysms	O
in	O
the	O
BRAT	O
trial	O
:	O
revisiting	B-I
the	I-I
clip	I-I
vs	O
coil	B-I
debate	I-I
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
471	I-P
patients	I-P
who	O
were	O
part	O
of	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
from	O
2003	O
to	O
2007	O
were	O
retrospectively	O
reviewed	O
.	O

All	O
variables	O
including	O
demographic	B-O
data	I-O
,	O
medical	B-O
history	I-O
,	O
treatment	B-O
,	O
imaging	B-O
,	O
and	O
functional	B-O
outcomes	O
were	O
included	O
as	O
part	O
of	O
the	O
trial	O
.	O

No	O
additional	O
variables	O
were	O
retrospectively	O
collected	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Effects	O
of	O
Naltrexone	B-I
on	O
Subjective	O
Response	O
to	O
Methamphetamine	O
in	O
a	O
Clinical	O
Sample	O
:	O
a	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
Controlled	O
Laboratory	O
Study	O
.	O

METHODS	O
:	O
Non	B-P
-	I-P
treatment	I-P
-	I-P
seeking	I-P
individuals	I-P
meeting	I-P
DSM	I-P
-	I-P
IV	I-P
criteria	I-P
for	I-P
MA	I-P
abuse	I-P
or	I-P
dependence	I-P
(	I-P
n=30	I-P
)	I-P
completed	O
two	O
separate	O
5	O
-	O
day	O
inpatient	O
stays	O
.	O

During	O
each	O
admission	O
,	O
participants	O
completed	O
testing	O
sessions	O
comprised	O
of	O
MA	B-O
cue	I-O
-	I-O
reactivity	I-O
and	O
intravenous	B-O
MA	I-O
administration	I-O
(	I-O
30	I-O
mg	I-O
)	I-O
after	O
receiving	O
oral	B-I
NTX	I-I
(	O
50	O
mg	O
)	O
or	O
placebo	B-C
for	O
4	O
days	O
.	O

This	O
study	O
tested	O
the	O
hypotheses	O
that	O
NTX	B-I
would	O
(	O
a	O
)	O
attenuate	O
cue	B-O
-	I-O
induced	I-O
MA	I-O
craving	I-O
,	O
and	O
(	O
b	O
)	O
reduce	O
subjective	B-O
responses	I-O
to	I-O
MA	I-O
administration	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Visual	O
Assessment	O
of	O
Relative	O
Apical	O
Sparing	O
Pattern	O
Is	O
More	O
Useful	O
Than	O
Quantitative	O
Assessment	O
for	O
Diagnosing	O
Cardiac	O
Amyloidosis	O
in	O
Borderline	O
or	O
Mildly	O
Increased	O
Left	O
Ventricular	O
Wall	O
Thickness	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
Quest	I-I
to	I-I
Lava	I-I
Mountain	I-I
Computer	I-I
Game	I-I
on	O
Dietary	O
and	O
Physical	O
Activity	O
Behaviors	O
of	O
Elementary	B-P
School	I-P
Children	I-P
:	O
A	O
Pilot	O
Group	O
-	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
Quasi	O
-	O
experimental	O
group	O
-	O
randomized	O
controlled	O
trial	O
conducted	O
during	O
the	O
2012	O
-	O
2013	O
school	O
year	O
.	O

A	O
total	O
of	O
107	O
children	O
in	O
fourth	O
and	O
fifth	O
grade	O
consented	O
.	O

There	O
was	O
an	O
attrition	O
rate	O
of	O
8	O
.	O
8	O
%	O
with	O
a	O
final	O
sample	O
size	O
of	O
44	O
children	O
in	O
three	O
intervention	O
schools	O
,	O
and	O
a	O
sample	O
of	O
50	O
children	O
in	O
three	O
comparison	O
schools	O
.	O

Dietary	O
intake	O
was	O
measured	O
using	O
two	O
random	O
24	O
-	O
hour	O
recalls	O
,	O
whereas	O
child	B-O
self	I-O
-	I-O
report	I-O
surveys	I-O
measured	O
diet	B-O
,	O
physical	B-O
activity	I-O
,	O
and	O
psychosocial	B-O
factors	I-O
before	O
and	O
after	O
the	O
intervention	O
.	O

Process	O
data	O
on	O
QTLM	B-O
usability	I-O
and	O
back	B-O
-	I-O
end	I-O
server	I-O
data	I-O
on	I-O
QTLM	I-O
exposure	O
and	O
progress	O
achieved	O
were	O
collected	O
.	O

QTLM	B-I
was	O
implemented	O
as	O
part	O
of	O
the	O
in	O
-	O
school	O
or	O
afterschool	O
program	O
.	O

Recommended	O
game	O
exposure	O
duration	O
was	O
90	O
min	O
/	O
wk	O
for	O
6	O
weeks	O
.	O

Analysis	O
of	O
covariance	O
or	O
logistic	O
regression	O
models	O
evaluated	O
effects	O
of	O
QTLM	B-I
on	O
diet	B-O
,	O
physical	B-O
activity	I-O
,	O
and	O
psychosocial	B-O
factors	I-O
.	O

Post	O
hoc	O
exploratory	O
analysis	O
examined	O
the	O
changes	O
before	O
and	O
after	O
the	O
intervention	O
in	O
outcome	O
variables	O
among	O
children	O
in	O
the	O
intervention	O
group	O
.	O

Significance	O
was	O
set	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Comparison	O
of	O
Teaching	O
Modalities	O
and	O
Fidelity	O
of	O
Simulation	O
Levels	O
in	O
Teaching	O
Resuscitation	O
Scenarios	O
.	O

METHODS	O
:	O
Totally	B-P
39	I-P
medical	I-P
students	I-P
and	I-P
physician	I-P
assistant	I-P
students	I-P
were	O
randomly	O
assigned	O
to	O
4	O
training	O
conditions	O
:	O
control	O
(	O
lecture	B-C
only	O
)	O
,	O
video	B-I
-	I-I
based	I-I
didactic	I-I
instruction	I-I
,	O
low	B-I
-	I-I
,	O
and	O
high	B-I
-	I-I
fidelity	I-I
simulation	I-I
activities	I-I
.	O

Participants	O
were	O
assessed	O
using	O
a	O
baseline	O
written	B-O
pretest	I-O
of	I-O
ACLS	I-O
knowledge	I-O
.	O

Following	O
this	O
,	O
all	O
participants	O
received	O
a	B-I
lecture	I-I
outlining	O
ACLS	O
science	O
and	O
algorithm	O
interpretation	O
.	O

Participants	O
were	O
then	O
trained	O
in	O
specific	O
aspects	O
of	O
ACLS	O
according	O
to	O
their	O
assigned	O
instructional	O
condition	O
.	O

After	O
training	O
,	O
each	O
participant	O
was	O
assessed	O
via	O
a	B-O
Megacode	I-O
performance	I-O
examination	I-O
and	O
a	B-O
written	I-O
posttest	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Supplementation	O
with	O
a	B-I
blend	I-I
of	I-I
krill	I-I
and	I-I
salmon	I-I
oil	I-I
is	O
associated	O
with	O
increased	O
metabolic	O
risk	O
in	O
overweight	B-P
men	I-P
.	O

METHODS	O
:	O
The	O
design	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
crossover	O
trial	O
.	O

A	B-P
total	I-P
of	I-P
47	I-P
men	I-P
with	I-P
a	I-P
mean	I-P
	I-P
SD	I-P
age	I-P
of	I-P
46	I-P
.	I-P
5	I-P
	I-P
5	I-P
.	I-P
1	I-P
y	I-P
,	I-P
who	I-P
were	I-P
overweight	I-P
[	I-P
body	I-P
mass	I-P
index	I-P
(	I-P
in	I-P
kg	I-P
/	I-P
m	I-P
(	I-P
2	I-P
)	I-P
)	I-P
from	I-P
25	I-P
to	I-P
30	I-P
]	I-P
but	I-P
otherwise	I-P
healthy	I-P
,	O
received	O
5	B-I
1	I-I
-	I-I
g	I-I
capsules	I-I
of	I-I
KS	I-I
oil	I-I
or	O
a	O
control	O
(	O
canola	B-C
oil	I-C
)	O
for	O
8	O
wk	O
and	O
crossed	O
over	O
to	O
another	O
treatment	O
after	O
an	O
8	O
-	O
wk	O
washout	O
period	O
.	O

The	O
primary	O
outcome	O
was	O
insulin	B-O
sensitivity	I-O
assessed	O
by	O
using	O
the	B-O
Matsuda	I-O
method	I-O
from	I-O
an	I-O
oral	I-O
-	I-O
glucose	I-O
-	I-O
tolerance	I-O
test	I-O
.	O

Secondary	O
outcomes	O
included	O
lipid	B-O
profiles	I-O
,	O
inflammatory	B-O
markers	I-O
,	O
24	B-O
-	I-O
h	I-O
ambulatory	I-O
blood	I-O
pressure	I-O
,	O
and	O
carotid	B-O
artery	I-O
intimamedia	I-O
thickness	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
2	B-I
doses	I-I
of	I-I
vortioxetine	I-I
in	O
adults	B-P
with	I-P
major	I-P
depressive	I-P
disorder	I-P
.	O

METHODS	O
:	O
Adults	B-P
aged	I-P
18	I-P
-	I-P
75	I-P
years	I-P
with	I-P
MDD	I-P
(	I-P
DSM	I-P
-	I-P
IV	I-P
-	I-P
TR	I-P
)	I-P
and	I-P
Montgomery	I-P
-	I-P
Asberg	I-P
Depression	I-P
Rating	I-P
Scale	I-P
(	I-P
MADRS	I-P
)	I-P
total	I-P
score	I-P
?	I-P
26	I-P
were	I-P
randomized	O
(	O
1:1:1	O
)	O
to	O
receive	O
vortioxetine	B-I
10	O
mg	O
or	O
15	O
mg	O
or	O
placebo	B-C
once	O
daily	O
,	O
with	O
the	O
primary	O
efficacy	O
end	O
point	O
being	O
change	O
from	O
baseline	O
at	O
week	O
8	O
in	O
MADRS	O
analyzed	O
by	O
mixed	O
model	O
for	O
repeated	O
measures	O
.	O

Adverse	B-O
events	I-O
were	O
recorded	O
during	O
the	O
study	O
,	O
suicidal	B-O
ideation	I-O
and	O
behavior	B-O
were	O
assessed	O
using	O
the	B-O
Columbia	I-O
-	I-O
Suicide	I-O
Severity	I-O
Rating	I-O
Scale	I-O
(	I-O
C	I-O
-	I-O
SSRS	I-O
)	I-O
,	O
and	O
sexual	B-O
dysfunction	I-O
was	O
assessed	O
using	O
the	B-O
Arizona	I-O
Sexual	I-O
Experience	I-O
(	I-O
ASEX	I-O
)	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Placebo	O
-	O
controlled	O
clinical	O
trial	O
evaluating	O
9	B-I
.	I-I
5	I-I
%	I-I
hydrogen	I-I
peroxide	I-I
high	I-I
-	I-I
adhesion	I-I
whitening	I-I
strips	I-I
.	O

METHODS	O
:	O
In	O
this	O
parallel	O
-	O
design	O
,	O
double	O
-	O
blind	O
clinical	O
trial	O
,	O
54	B-P
adult	I-P
volunteers	I-P
were	O
randomized	O
to	O
an	B-I
experimental	I-I
9	I-I
.	I-I
5	I-I
%	I-I
hydrogen	I-I
peroxide	I-I
whitening	I-I
strip	I-I
or	O
placebo	B-C
strip	I-C
balancing	O
for	O
age	O
and	O
baseline	O
tooth	O
color	O
,	O
and	O
received	O
treatment	O
.	O

Strips	B-I
were	O
worn	O
on	O
the	O
maxillary	O
arch	O
30	O
minutes	O
daily	O
for	O
20	O
days	O
.	O

Efficacy	B-O
was	O
measured	O
objectively	O
as	O
L	B-O
*	I-O
a	I-O
*	I-O
b	I-O
*	I-O
color	I-O
change	O
from	O
digital	B-O
images	I-O
at	O
Days	O
4	O
,	O
7	O
,	O
15	O
,	O
and	O
21	O
.	O

-DOCSTART-	O

Title	O
:	O
Gluten	B-I
and	O
casein	B-I
supplementation	I-I
does	O
not	O
increase	O
symptoms	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	O

METHODS	O
:	O
A	O
randomised	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
trial	O
was	O
performed	O
on	O
74	B-P
children	I-P
with	I-P
ASD	I-P
with	I-P
severe	I-P
maladaptive	I-P
behaviour	I-P
and	I-P
increased	I-P
urinary	I-P
I	I-P
-	I-P
FABP	I-P
.	O

Subjects	O
were	O
randomised	O
to	O
receive	O
gluten	B-I
-	I-I
casein	I-I
or	O
a	B-C
placebo	I-C
for	O
seven	O
days	O
.	O

We	O
evaluated	O
maladaptive	B-O
behaviour	I-O
before	O
and	O
after	O
supplementation	O
,	O
using	O
I	B-O
-	I-O
FABP	I-O
excretion	I-O
,	O
the	B-O
approach	I-O
withdrawal	I-O
problem	I-O
composite	O
subtest	O
of	O
the	B-O
Pervasive	I-O
Developmental	I-O
Disorder	I-O
Behavior	I-O
Inventory	I-O
and	O
the	B-O
Gastrointestinal	I-O
Symptom	I-O
Severity	I-O
Index	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
controlled	O
trial	O
of	O
the	B-I
SibworkS	I-I
group	I-I
program	I-I
for	O
siblings	B-P
of	I-P
children	I-P
with	I-P
special	I-P
needs	I-P
.	O

METHODS	O
:	O
SibworkS	B-I
is	O
a	O
six	O
-	O
week	O
manual	O
-	O
based	O
,	O
cognitive	B-I
-	I-I
behavioral	I-I
group	I-I
support	I-I
program	I-I
focussed	O
on	O
strengthening	B-O
siblings	I-O
'	I-O
perceived	I-O
social	I-O
support	I-O
,	O
self	B-O
-	I-O
esteem	I-O
,	O
problem	B-O
-	I-O
solving	I-O
skills	I-O
,	O
adaptive	B-O
coping	I-O
behaviors	I-O
and	O
positive	B-O
sibling	I-O
relationships	I-O
.	O

Fifty	B-P
-	I-P
six	I-P
children	I-P
aged	I-P
7	I-P
-	I-P
12	I-P
were	O
allocated	O
to	O
either	O
the	B-I
SibworkS	I-I
program	I-I
(	O
n=30	O
)	O
or	O
waitlist	B-C
control	O
(	O
n=26	O
)	O
in	O
alternating	O
sequence	O
.	O

The	O
primary	O
outcome	O
was	O
siblings	B-O
'	I-O
emotional	I-O
and	O
behavioral	B-O
functioning	I-O
.	O

Additional	O
outcomes	O
were	O
self	B-O
-	I-O
esteem	I-O
,	O
perceived	B-O
social	I-O
support	I-O
,	O
the	B-O
sibling	I-O
relationship	I-O
and	O
coping	B-O
behaviors	I-O
.	O

Siblings	B-P
were	O
followed	O
-	O
up	O
immediately	O
after	O
the	O
intervention	O
and	O
at	O
3	O
-	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Extended	B-I
-	I-I
Release	I-I
Guanfacine	I-I
for	O
Hyperactivity	O
in	O
Children	B-P
With	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
.	O

METHODS	O
:	O
In	O
a	O
multisite	O
,	O
randomized	O
clinical	O
trial	O
,	O
extended	B-I
-	I-I
release	I-I
guanfacine	I-I
was	O
compared	O
with	O
placebo	B-C
in	O
children	B-P
with	I-P
ASD	I-P
accompanied	O
by	O
hyperactivity	B-O
,	O
impulsiveness	B-O
,	O
and	O
distractibility	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Use	O
of	O
the	O
learning	O
conversation	O
improves	O
instructor	O
confidence	O
in	O
life	O
support	O
training	O
:	O
An	O
open	O
randomised	O
controlled	O
cross	O
-	O
over	O
trial	O
comparing	O
teaching	O
feedback	O
mechanisms	O
.	O

METHODS	O
:	O
Open	O
randomised	O
crossover	O
study	O
undertaken	O
between	O
October	O
2014	O
and	O
March	O
2015	O
at	O
the	O
University	O
of	O
Birmingham	O
,	O
United	O
Kingdom	O
.	O

Six	B-P
-	I-P
hundred	I-P
and	I-P
forty	I-P
healthcare	I-P
students	I-P
undertaking	I-P
a	I-P
European	I-P
Resuscitation	I-P
Council	I-P
(	I-P
ERC	I-P
)	I-P
BLS	I-P
course	I-P
were	O
enrolled	O
,	O
each	O
of	O
whom	O
was	O
randomised	O
to	O
receive	O
teaching	O
using	O
either	O
the	B-I
sandwich	I-I
technique	I-I
or	O
the	B-I
learning	I-I
conversation	I-I
.	O

Fifty	O
-	O
eight	O
instructors	O
were	O
randomised	O
to	O
initially	O
teach	O
using	O
either	O
the	B-I
learning	I-I
conversation	I-I
or	O
sandwich	B-I
technique	I-I
,	O
prior	O
to	O
crossing	O
-	O
over	O
and	O
teaching	O
with	O
the	O
alternative	O
technique	O
after	O
a	O
pre	O
-	O
defined	O
time	O
period	O
.	O

Outcome	O
measures	O
included	O
skill	O
acquisition	O
as	O
measured	O
by	O
an	B-O
end	I-O
-	I-O
of	I-O
-	I-O
course	I-O
competency	I-O
assessment	I-O
,	O
instructors	B-O
'	I-O
perception	I-O
of	I-O
teaching	I-O
with	I-O
each	I-O
feedback	I-O
technique	I-O
and	O
candidates	B-O
'	I-O
perception	I-O
of	I-O
the	I-O
feedback	I-O
they	O
were	O
provided	O
with	O
.	O

-DOCSTART-	O

Title	O
:	O
An	B-I
endovascular	I-I
simulation	I-I
exercise	I-I
among	O
radiology	B-P
residents	I-P
:	O
comparison	O
of	O
simulation	O
performance	O
with	O
and	O
without	O
practice	O
.	O

METHODS	O
:	O
Radiology	B-P
residents	I-P
were	O
guided	O
through	O
a	B-I
practice	I-I
simulation	I-I
and	O
lectured	B-I
on	I-I
endovascular	I-I
therapy	I-I
,	O
then	O
randomized	O
to	O
simulate	B-I
femoral	I-I
arterial	I-I
intervention	O
with	B-I
or	O
without	B-I
prior	I-I
iliac	I-I
simulation	I-I
.	O

Simulator	B-O
measurements	I-O
,	O
performance	B-O
grading	I-O
and	O
resident	B-O
surveys	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effectiveness	O
of	O
single	B-I
-	I-I
dose	I-I
metronidazole	I-I
therapy	I-I
for	O
patients	B-P
and	I-P
their	I-P
partners	I-P
with	I-P
bacterial	I-P
vaginosis	I-P
.	O

METHODS	O
:	O
In	O
addition	O
,	O
the	O
effectiveness	O
of	O
a	B-I
2	I-I
-	I-I
g	I-I
single	I-I
dose	I-I
of	I-I
metronidazole	I-I
was	O
compared	O
with	O
a	B-I
seven	I-I
-	I-I
day	I-I
course	I-I
of	I-I
500	I-I
mg	I-I
of	I-I
metronidazole	I-I
twice	O
a	O
day	O
in	O
patients	B-P
with	I-P
bacterial	I-P
vaginosis	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
trial	O
of	O
recombinant	B-I
alpha	I-I
2b	I-I
-	I-I
interferon	I-I
with	I-I
or	O
without	B-I
indomethacin	I-I
in	O
patients	B-P
with	I-P
metastatic	I-P
malignant	I-P
melanoma	I-P
.	O

METHODS	O
:	O
53	B-P
patients	I-P
were	O
stratified	O
according	O
to	O
performance	O
status	O
and	O
randomized	O
to	O
receive	O
alpha	B-I
2b	I-I
-	I-I
interferon	I-I
,	O
20	O
million	O
units	O
per	O
m2	O
i	O
.	O
v	O
.	O
,	O
5	O
days	O
per	O
week	O
for	O
4	O
weeks	O
followed	O
by	O
10	O
million	O
units	O
per	O
m2	O
s	O
.	O
c	O
.	O
three	O
times	O
per	O
week	O
,	O
either	O
with	B-I
or	O
without	B-I
indomethacin	I-I
,	O
25	O
mg	O
orally	O
three	O
times	O
a	O
day	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
propofol	B-I
and	O
isoflurane	B-I
on	O
haemodynamics	O
and	O
the	O
inflammatory	O
response	O
in	O
cardiopulmonary	O
bypass	O
surgery	O
.	O

METHODS	O
:	O
CRP	B-O
,	O
IL	B-O
-	I-O
6	I-O
,	O
IL	B-O
-	I-O
8	I-O
,	O
HIF	B-O
-	I-O
1?	I-O
(	O
ELISA	B-O
)	O
,	O
CD11	B-O
and	O
CD18	B-O
expression	I-O
(	O
flow	B-O
cytometry	I-O
)	O
,	O
and	O
haemoxygenase	B-O
(	O
HO	B-O
-	I-O
1	I-O
)	O
promoter	B-O
polymorphisms	I-O
(	O
PCR	B-O
/	O
electrophoresis	B-O
)	O
were	O
measured	O
before	O
anaesthetic	O
induction	O
,	O
4	O
hours	O
post	O
-	O
CPB	O
,	O
and	O
24	O
hours	O
later	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
therapeutic	B-I
horse	I-I
riding	I-I
on	O
gait	O
cycle	O
parameters	O
and	O
some	O
aspects	O
of	O
behavior	O
of	O
children	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
six	I-P
pupils	I-P
(	I-P
12	I-P
boys	I-P
and	I-P
14	I-P
girls	I-P
)	I-P
of	I-P
a	I-P
special	I-P
needs	I-P
school	I-P
participated	O
in	O
therapeutic	B-I
riding	I-I
.	O

We	O
analyzed	O
walking	B-O
twice	O
during	O
a	O
school	O
-	O
term	O
:	O
full	O
body	O
analyses	O
each	O
time	O
before	O
and	O
after	O
one	O
-	O
month	O
therapy	O
.	O

The	O
research	O
included	O
a	B-C
non	I-C
-	I-C
riding	I-C
control	O
group	O
.	O

All	O
together	O
104	O
analyses	O
were	O
performed	O
.	O

We	O
measured	O
mental	B-O
skills	I-O
using	O
Pedagogical	B-O
Analysis	I-O
and	I-O
Curriculum	I-O
(	I-O
PAC	I-O
)	I-O
test	I-O
consisting	O
of	O
four	O
parts	O
being	O
communication	B-O
,	O
self	B-O
care	I-O
,	O
motor	B-O
skills	I-O
and	O
socialization	B-O
.	O

The	B-O
Gait	I-O
Cycle	I-O
Analysis	O
consists	O
of	O
the	O
time	O
-	O
series	O
analysis	O
,	O
the	O
analysis	O
of	O
part	O
of	O
the	B-O
gait	I-O
cycle	I-O
and	O
the	B-O
measurement	I-O
of	I-O
joint	I-O
angles	I-O
in	O
each	O
plane	O
.	O

-DOCSTART-	O

Title	O
:	O
Amiprilose	B-I
hydrochloride	I-I
for	O
rheumatoid	O
arthritis	O
.	O

METHODS	O
:	O
Prospective	O
,	O
multicenter	O
,	O
randomized	O
,	O
parallel	O
group	O
,	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
12	O
-	O
week	O
trial	O
.	O

Two	B-P
hundred	I-P
and	I-P
one	I-P
functional	I-P
class	I-P
I	I-P
and	I-P
II	I-P
patients	I-P
with	I-P
definite	I-P
or	I-P
classic	I-P
rheumatoid	I-P
arthritis	I-P
,	I-P
previously	I-P
untreated	I-P
with	I-P
disease	I-P
modifying	I-P
antirheumatic	I-P
drugs	I-P
.	O

Patients	O
were	O
withdrawn	O
from	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
therapy	O
.	O

Those	O
who	O
flared	O
were	O
randomly	O
assigned	O
to	O
amiprilose	B-I
HCl	I-I
,	O
6	O
g	O
/	O
d	O
,	O
or	O
placebo	B-C
for	O
12	O
weeks	O
.	O

No	O
concomitant	O
anti	O
-	O
inflammatory	O
or	O
antirheumatic	O
drug	O
therapy	O
was	O
permitted	O
during	O
the	O
study	O
.	O

Combination	O
acetaminophen	O
and	O
propoxyphene	O
napsylate	O
was	O
the	O
only	O
supplemental	O
analgesic	O
medication	O
allowed	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Low	B-I
-	I-I
Dose	I-I
Buspirone	I-I
for	O
Restricted	O
and	O
Repetitive	O
Behavior	O
in	O
Young	B-P
Children	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
:	O
A	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
Children	B-P
2	I-P
-	I-P
6	I-P
years	I-P
of	I-P
age	I-P
with	I-P
ASD	I-P
(	I-P
N	I-P
=	I-P
166	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
placebo	B-C
or	O
2	B-I
.	I-I
5	I-I
or	O
5	O
.	B-I
0	I-I
mg	I-I
of	I-I
buspirone	I-I
twice	O
daily	O
.	O

The	O
primary	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
24	O
weeks	O
of	O
buspirone	B-I
on	O
the	B-O
Autism	I-O
Diagnostic	I-O
Observation	I-O
Schedule	I-O
(	I-O
ADOS	I-O
)	I-O
Composite	I-O
Total	I-O
Score	I-O
.	O

Secondary	O
objectives	O
included	O
evaluating	O
the	B-O
effects	I-O
of	I-O
buspirone	I-O
on	I-O
social	I-O
competence	I-O
,	O
repetitive	B-O
behaviors	I-O
,	O
language	B-O
,	O
sensory	B-O
dysfunction	I-O
,	O
and	O
anxiety	B-O
and	O
to	O
assess	O
side	B-O
effects	I-O
.	O

Positron	B-O
emission	I-O
tomography	I-O
measures	O
of	O
tryptophan	B-O
metabolism	I-O
and	O
blood	B-O
serotonin	I-O
concentrations	I-O
were	O
assessed	O
as	O
predictors	B-O
of	I-O
buspirone	I-O
efficacy	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Dacarbazine	B-I
versus	O
dacarbazine	B-I
-	O
vindesine	B-I
in	O
disseminated	O
malignant	O
melanoma	O
:	O
a	O
randomized	O
phase	O
II	O
study	O
.	O

METHODS	O
:	O
Dacarbazine	B-I
was	O
given	O
i	O
.	O
v	O
.	O
at	O
250	O
mg	O
m	O
-	O
2	O
per	O
day	O
X	O
V	O
every	O
4	O
weeks	O
.	O

In	O
the	O
combination	O
regimen	O
vindesine	B-I
given	O
at	O
3	O
mg	O
m	O
-	O
2	O
per	O
week	O
was	O
included	O
.	O

-DOCSTART-	O

Title	O
:	O
Methods	O
for	O
assessing	O
treatment	O
efficacy	O
in	O
trials	O
for	O
adjuvant	O
therapy	O
for	O
breast	O
cancer	O
.	O

-DOCSTART-	O

Title	O
:	O
Protective	O
effect	O
of	O
high	B-I
-	I-I
dose	I-I
medroxyprogesterone	I-I
acetate	I-I
(	I-I
HD	I-I
-	I-I
MPA	I-I
)	I-I
on	O
hematological	O
toxicity	O
induced	O
by	O
chemotherapy	O
for	O
advanced	O
solid	O
tumors	O
:	O
a	O
multicentric	O
controlled	O
clinical	O
trial	O
.	O

MPA	O
-	O
Hematology	O
Italian	O
Cooperative	O
Group	O
.	O

METHODS	O
:	O
A	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
was	O
conducted	O
comparing	O
active	O
treatment	O
with	O
placebo	B-C
in	O
227	B-P
patients	I-P
with	I-P
breast	I-P
,	I-P
colorectal	I-P
,	I-P
lung	I-P
and	I-P
other	I-P
solid	I-P
forms	I-P
of	I-P
cancer	I-P
.	O

Combination	B-I
therapy	I-I
,	I-I
(	I-I
CT	I-I
)	I-I
conventionally	O
employed	O
for	O
the	O
various	O
types	O
of	O
tumor	O
involved	O
,	O
was	O
associated	O
with	O
MPA	B-I
(	O
117	O
patients	O
)	O
or	O
placebo	B-C
(	O
110	O
patients	O
)	O
.	O

MPA	B-I
was	O
given	O
orally	O
as	O
tablets	O
,	O
as	O
a	O
dose	O
of	O
500	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Antibiotic	B-I
elimination	I-I
of	O
group	O
-	O
B	O
streptococci	O
in	O
urine	O
in	O
prevention	O
of	O
preterm	O
labour	O
.	O

METHODS	O
:	O
Urine	B-O
samples	I-O
from	O
4122	B-P
women	I-P
at	I-P
27	I-P
-	I-P
31	I-P
weeks	I-P
'	I-P
gestation	I-P
were	O
examined	O
for	O
bacteria	O
.	O

METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
,	O
controlled	O
study	O
these	O
patients	O
were	O
given	O
either	O
penicillin	B-I
(	O
10	O
(	O
6	O
)	O
IU	O
three	O
times	O
daily	O
for	O
6	O
days	O
;	O
37	O
patients	O
)	O
or	O
placebo	B-C
(	O
32	O
patients	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Bronchial	O
carcinoma	O
.	O

II	O
.	O

Quantitative	O
measurements	O
of	O
the	O
quality	O
of	O
survival	O
.	O

A	O
prospective	O
randomized	O
study	O
of	O
the	O
result	O
of	O
therapy	O
in	O
inoperable	B-P
patients	I-P
with	I-P
advanced	I-P
disease	I-P
.	O

METHODS	O
:	O
Forty	B-P
-	I-P
eight	I-P
bronchial	I-P
carcinoma	I-P
patients	I-P
in	I-P
clinicoanatomical	I-P
stage	I-P
4	I-P
of	I-P
the	I-P
disease	I-P
(	I-P
advanced	I-P
disease	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
groups	O
for	O
radiotherapy	B-I
,	O
chemotherapy	B-I
(	I-I
cyclophosphamide	I-I
)	I-I
and	O
placebo	B-C
treatment	I-C
,	O
respectively	O
.	O

The	O
results	O
were	O
assessed	O
by	O
the	B-O
survival	I-O
time	I-O
and	O
quality	B-O
of	I-O
survival	I-O
.	O

-DOCSTART-	O

Title	O
:	O
5	B-I
-	I-I
Fluorouracil	I-I
,	I-I
adriamycin	I-I
,	I-I
cyclophosphamide	I-I
(	I-I
FAC	I-I
)	I-I
vs	O
.	O
5	B-I
-	I-I
fluorouracil	I-I
,	I-I
epirubicin	I-I
,	I-I
cyclophosphamide	I-I
(	I-I
FEC	I-I
)	I-I
in	O
metastatic	O
breast	O
cancer	O
.	O

-DOCSTART-	O

Title	O
:	O
Flow	O
-	O
cytometric	O
studies	O
with	O
eleutherococcus	B-I
senticosus	I-I
extract	I-I
as	O
an	B-I
immunomodulatory	I-I
agent	I-I
.	O

METHODS	O
:	O
Volunteers	O
in	O
the	O
verum	O
group	O
received	O
10	B-I
ml	I-I
of	I-I
an	I-I
ethanolic	I-I
(	I-I
vincamine	I-I
free	I-I
)	I-I
eleutherococcus	I-I
senticosus	I-I
preparation	I-I
,	O
3	O
times	O
daily	O
for	O
4	O
weeks	O
.	O

In	O
the	B-C
placebo	I-C
,	O
the	B-I
eleutherococcus	I-I
extract	I-I
was	O
substituted	O
by	O
additional	B-C
wine	I-C
,	O
resulting	O
in	O
identical	O
final	O
concentrations	O
of	O
ethanol	O
in	O
both	O
preparations	O
.	O

The	O
purpose	O
of	O
the	O
double	O
-	O
blind	O
study	O
was	O
the	O
demonstration	O
of	O
possible	O
effects	O
on	O
the	B-O
cellular	I-O
immune	I-O
status	I-O
,	O
as	O
determined	O
by	O
quantitative	B-O
flow	I-O
cytometry	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Antihypertensive	O
effect	O
of	O
single	B-I
doses	I-I
of	I-I
enalapril	I-I
in	O
hypertensive	B-P
patients	I-P
treated	I-P
with	I-P
bendrofluazide	I-P
.	O

METHODS	O
:	O
Enalapril	B-I
in	O
single	O
doses	O
of	O
10	O
and	O
20	O
mg	O
was	O
given	O
to	O
13	B-P
hypertensive	I-P
patients	I-P
on	I-P
treatment	I-P
with	I-P
bendrofluazide	I-P
5	I-P
mg	I-P
daily	I-P
in	I-P
a	I-P
randomised	I-P
,	I-P
crossover	I-P
,	I-P
placebo	I-P
controlled	I-P
study	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Comparative	O
effects	O
of	O
pinacidil	B-I
and	O
nifedipine	B-I
in	O
the	O
treatment	O
of	O
arterial	O
hypertension	O
.	O

-DOCSTART-	O

Title	O
:	O
Dose	O
dependent	O
response	O
of	O
symptoms	O
,	O
pituitary	O
,	O
and	O
bone	O
to	O
transdermal	B-I
oestrogen	I-I
in	O
postmenopausal	B-P
women	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Antibiotic	B-I
prophylaxis	I-I
in	O
high	O
-	O
risk	O
head	O
and	O
neck	O
surgery	O
:	O
one	O
-	O
day	O
vs	O
.	O
five	O
-	O
day	O
therapy	O
.	O

METHODS	O
:	O
A	O
multi	O
-	O
institutional	O
prospective	O
randomized	O
double	O
-	O
blind	O
study	O
was	O
designed	O
.	O

Patients	O
who	O
were	O
identified	O
as	O
requiring	O
pedicled	O
flap	O
reconstruction	O
were	O
potential	O
candidates	O
for	O
the	O
study	O
.	O

Later	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
cefoperazone	B-I
sodium	I-I
for	O
either	O
24	O
hours	O
or	O
120	O
hours	O
.	O

In	O
each	O
case	O
,	O
the	O
drug	O
was	O
administered	O
intravenously	O
,	O
beginning	O
1	O
to	O
2	O
hours	O
preoperatively	O
and	O
continued	O
for	O
the	O
prescribed	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Total	O
parenteral	O
nutrition	O
in	O
colon	O
surgery	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Psoriasis	O
of	O
the	O
scalp	O
treated	O
with	O
Grenz	B-I
rays	I-I
or	O
topical	B-I
corticosteroid	I-I
combined	O
with	O
Grenz	B-I
rays	I-I
.	O

A	O
comparative	O
randomized	O
trial	O
.	O

METHODS	O
:	O
One	O
group	O
received	O
4	B-I
Gy	I-I
of	I-I
Grenz	I-I
rays	I-I
administered	O
on	O
six	O
occasions	O
at	O
intervals	O
of	O
1	O
week	O
and	O
the	O
other	O
group	O
was	O
given	O
the	B-I
same	I-I
Grenz	I-I
ray	I-I
treatment	I-I
plus	O
topical	B-I
corticosteroid	I-I
.	O

The	O
patients	O
were	O
assessed	O
before	O
and	O
after	O
Grenz	O
ray	O
therapy	O
and	O
were	O
followed	O
-	O
up	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Educational	B-I
intervention	I-I
for	O
altering	O
water	O
-	O
sanitation	O
behavior	O
to	O
reduce	O
childhood	O
diarrhea	O
in	O
urban	O
Bangladesh	O
:	O
impact	O
on	O
nutritional	O
status	O
.	O

METHODS	O
:	O
Fifty	B-P
-	I-P
one	I-P
communities	I-P
of	I-P
38	I-P
families	I-P
each	I-P
were	O
randomized	O
to	O
receive	O
the	O
intervention	O
or	O
no	O
intervention	O
.	O

-DOCSTART-	O

Title	O
:	O
Physiological	B-I
pacing	I-I
improves	O
symptoms	O
and	O
increases	O
exercise	O
capacity	O
in	O
the	B-P
elderly	I-P
patient	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Interferon	B-I
treatment	I-I
for	O
hairy	O
cell	O
leukemia	O
.	O

An	O
update	O
on	O
a	B-P
cohort	I-P
of	I-P
69	I-P
patients	I-P
treated	I-P
from	I-P
1983	I-P
to	I-P
1986	I-P
.	O

METHODS	O
:	O
Follow	O
-	O
up	O
through	O
April	O
,	O
1993	O
shows	O
that	O
only	O
14	O
patients	O
have	O
expired	O
.	O

-DOCSTART-	O

Title	O
:	O
Naltrexone	B-I
in	O
young	B-P
autistic	I-P
children	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
study	O
.	O

METHODS	O
:	O
Thirteen	B-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
,	I-P
aged	I-P
3	I-P
.	I-P
4	I-P
to	I-P
8	I-P
.	I-P
3	I-P
years	I-P
(	I-P
mean	I-P
5	I-P
.	I-P
4	I-P
)	I-P
,	I-P
were	I-P
studied	I-P
in	I-P
home	I-P
,	I-P
school	I-P
,	I-P
and	I-P
outpatient	I-P
laboratory	I-P
.	O

Naltrexone	B-I
,	O
1	O
.	O
0	O
mg	O
/	O
kg	O
,	O
was	O
given	O
daily	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
crossover	O
design	O
.	O

Dependent	O
measures	O
included	O
parent	B-O
and	I-O
teacher	I-O
Clinical	I-O
Global	I-O
Impressions	I-O
(	I-O
CGI	I-O
)	I-O
,	O
Conners	B-O
Rating	I-O
Scales	I-O
,	O
and	O
Naltrexone	B-O
Side	I-O
-	I-O
Effects	I-O
(	I-O
SE	I-O
)	I-O
Rating	I-O
Scale	I-O
;	O
laboratory	B-O
CGI	I-O
,	O
movement	B-O
actometer	I-O
readings	I-O
,	O
and	O
a	B-O
10	I-O
-	I-O
second	I-O
interval	I-O
recording	I-O
system	I-O
analysis	O
of	O
on	O
-	O
task	O
,	O
communication	B-O
initiations	I-O
,	O
disruptive	B-O
behavior	I-O
,	O
and	O
self	B-O
-	I-O
stimulation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
an	O
intervention	O
to	O
change	O
benzodiazepine	O
-	O
prescribing	O
behavior	O
in	O
a	O
prepaid	O
group	O
practice	O
setting	O
.	O

METHODS	O
:	O
Our	O
setting	O
was	O
a	O
270	O
,	O
000	O
member	O
group	O
-	O
model	O
PPGP	O
in	O
Colorado	O
,	O
from	O
1990	O
to	O
1991	O
.	O

Participants	B-P
included	I-P
91	I-P
physicians	I-P
,	I-P
62	I-P
men	I-P
and	I-P
29	I-P
women	I-P
;	I-P
median	I-P
age	I-P
was	I-P
38	I-P
.	I-P
7	I-P
years	I-P
.	O

Group	O
1	O
received	O
a	B-I
one	I-I
-	I-I
on	I-I
-	I-I
one	I-I
educational	I-I
presentation	I-I
by	I-I
a	I-I
clinical	I-I
pharmacist	I-I
,	O
written	B-I
educational	I-I
materials	I-I
,	O
a	B-I
brief	I-I
follow	I-I
-	I-I
up	I-I
visit	I-I
,	O
and	O
feedback	B-I
with	I-I
recommendations	I-I
.	O

Group	O
2	O
received	O
only	B-I
a	I-I
face	I-I
-	I-I
to	I-I
-	I-I
face	I-I
presentation	I-I
,	O
given	B-I
to	I-I
departmental	I-I
groups	I-I
,	O
as	O
well	O
as	O
the	B-I
same	I-I
written	I-I
educational	I-I
materials	I-I
used	I-I
in	I-I
group	I-I
1	I-I
.	O

Controls	O
received	O
no	B-C
intervention	I-C
.	O

Our	O
primary	O
outcome	O
measure	O
was	O
the	B-O
benzodiazepine	I-O
"	I-O
on	I-O
/	I-O
off	I-O
"	I-O
status	I-O
of	I-O
the	I-O
elderly	I-O
PPGP	I-O
members	I-O
.	O

The	O
secondary	O
outcome	O
measure	O
was	O
the	O
median	O
change	O
(	O
preintervention	O
minus	O
postintervention	O
)	O
in	O
a	B-O
standardized	I-O
amount	I-O
of	I-O
benzodiazepines	I-O
prescribed	I-O
per	I-O
physician	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Report	O
of	O
a	O
controlled	O
clinical	O
trial	O
of	O
a	O
new	O
synthetic	O
drug	O
,	O
parsalmide	B-I
,	O
in	O
rheumatic	O
arthropathies	O
(	O
inflammatory	O
and	O
degenerative	O
)	O
]	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
carried	O
out	O
in	O
30	B-P
subjects	I-P
using	O
the	O
controlled	O
experiment	O
technique	O
according	O
to	O
the	O
"	O
between	O
patient	O
"	O
pattern	O
,	O
attributing	O
parsalmide	B-I
and	O
indomethacin	B-I
at	O
random	O
to	O
two	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
fish	I-I
-	I-I
oil	I-I
and	O
vegetable	B-I
-	I-I
oil	I-I
formula	I-I
on	O
aggregation	O
and	O
ethanolamine	O
-	O
containing	O
lysophospholipid	O
generation	O
in	O
activated	O
human	O
platelets	O
and	O
on	O
leukotriene	O
production	O
in	O
stimulated	O
neutrophils	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
consuming	O
a	B-I
liquid	I-I
formula	I-I
containing	I-I
either	I-I
fish	I-I
oil	I-I
enriched	I-I
in	I-I
omega	I-I
-	I-I
3	I-I
fatty	I-I
acids	I-I
or	O
vegetable	B-I
oil	I-I
enriched	I-I
in	I-I
oleic	I-I
acid	I-I
was	O
evaluated	O
in	O
20	B-P
male	I-P
subjects	I-P
randomly	O
allocated	O
into	O
two	O
groups	O
over	O
a	O
42	O
-	O
d	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Brief	O
report	O
:	O
a	O
controlled	O
evaluation	O
of	O
facilitated	O
communication	O
using	O
open	B-I
-	I-I
ended	I-I
and	O
fill	B-I
-	I-I
in	I-I
questions	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Peripheral	B-I
intravenous	I-I
line	I-I
survival	O
and	O
phlebitis	O
prevention	O
in	O
patients	B-P
receiving	I-P
intravenous	I-P
antibiotics	I-P
:	O
heparin	B-I
/	O
hydrocortisone	B-I
versus	O
in	B-I
-	I-I
line	I-I
filters	I-I
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
cystic	I-P
fibrosis	I-P
receiving	I-P
intermittent	I-P
i	I-P
.	I-P
v	I-P
.	I-P
antibiotics	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
their	O
drugs	O
either	O
through	O
an	B-I
in	I-I
-	I-I
line	I-I
filter	I-I
using	O
a	B-I
drug	I-I
-	I-I
free	I-I
infusate	I-I
or	O
with	B-I
no	I-I
filter	I-I
and	O
an	B-I
infusate	I-I
containing	I-I
heparin	I-I
500	O
units	O
and	O
hydrocortisone	B-I
10	O
mg	O
/	O
L	O
.	O

Infusion	B-O
sites	I-O
were	O
assessed	O
daily	O
.	O

-DOCSTART-	O

Title	O
:	O
Videofluoroscopic	O
evidence	O
of	O
aspiration	O
predicts	O
pneumonia	O
and	O
death	O
but	O
not	O
dehydration	O
following	O
stroke	O
.	O

METHODS	O
:	O
The	B-I
videofluoroscopic	I-I
modified	I-I
barium	I-I
swallow	I-I
technique	I-I
included	O
5	B-I
ml	I-I
-	I-I
thin	I-I
and	O
thick	B-I
liquid	I-I
barium	I-I
,	O
5	B-I
ml	I-I
barium	I-I
pudding	I-I
,	O
and	O
1	B-I
/	I-I
4	I-I
cookie	I-I
coated	I-I
with	I-I
barium	I-I
,	O
plus	O
additional	B-I
20	I-I
and	O
30	B-I
ml	I-I
of	I-I
thin	I-I
liquid	I-I
barium	I-I
.	O

Patients	O
were	O
assessed	O
a	O
mean	O
of	O
2	O
+	O
/	O
-	O
1	O
SD	O
months	O
poststroke	O
and	O
were	O
followed	O
for	O
a	O
mean	O
of	O
16	O
+	O
/	O
-	O
8	O
SD	O
months	O
poststroke	O
.	O

-DOCSTART-	O

Title	O
:	O
Cyclosporin	B-I
versus	O
cyclophosphamide	B-I
for	O
patients	B-P
with	I-P
steroid	I-P
-	I-P
dependent	I-P
and	I-P
frequently	I-P
relapsing	I-P
idiopathic	I-P
nephrotic	I-P
syndrome	I-P
:	O
a	O
multicentre	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Open	O
,	O
prospective	O
,	O
randomized	O
,	O
multicentre	O
,	O
controlled	O
study	O
for	O
parallel	O
groups	O
,	O
stratified	O
for	O
adults	O
and	O
children	O
.	O

The	O
setting	O
was	O
in	O
nephrological	O
departments	O
in	O
Italy	O
.	O

Seventy	B-P
-	I-P
three	I-P
patients	I-P
with	I-P
steroid	I-P
-	I-P
sensitive	I-P
idiopathic	I-P
NS	I-P
admitted	I-P
to	I-P
the	I-P
study	I-P
were	O
randomly	O
assigned	O
to	O
cyclophosphamide	B-I
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
8	O
weeks	O
or	O
CsA	B-I
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
in	O
adults	O
,	O
6	O
mg	O
/	O
kg	O
/	O
day	O
in	O
children	O
)	O
for	O
9	O
months	O
,	O
tapered	O
off	O
by	O
25	O
%	O
every	O
month	O
until	O
complete	O
discontinuation	O
at	O
month	O
12	O
.	O

Seven	O
patients	O
lost	O
to	O
follow	O
up	O
were	O
not	O
considered	O
in	O
the	O
analysis	O
.	O

The	O
remaining	O
66	O
patients	O
were	O
followed	O
up	O
for	O
3	O
-	O
24	O
months	O
after	O
randomization	O
.	O

Relapse	B-O
-	I-O
free	I-O
survival	I-O
;	O
number	B-O
of	I-O
N	I-O
.	I-O
S	I-O
.	I-O
relapses	I-O
/	I-O
patient	I-O
/	I-O
year	I-O
;	O
cumulative	B-O
dose	I-O
of	I-O
prednisone	I-O
/	I-O
patient	I-O
;	O
laboratory	B-O
investigations	I-O
(	O
kidney	B-O
and	O
liver	B-O
functions	I-O
,	O
haematological	B-O
parameters	I-O
)	O
;	O
incidence	B-O
of	I-O
adverse	I-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
High	O
purity	O
factor	O
VIII	O
and	O
immune	O
state	O
in	O
HIV	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
double	O
-	O
blind	O
comparison	O
of	O
oral	B-I
ketoprofen	I-I
'	O
controlled	O
release	O
'	O
and	O
indomethacin	B-I
suppository	I-I
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
with	O
special	O
regard	O
to	O
morning	O
stiffness	O
and	O
pain	O
on	O
awakening	O
.	O

METHODS	O
:	O
Patients	O
were	O
allocated	O
at	O
random	O
to	O
receive	O
a	O
daily	O
bedtime	O
dose	O
of	O
either	O
1	B-I
ketoprofen	I-I
tablet	I-I
or	O
1	B-I
indomethacin	I-I
suppository	I-I
plus	O
the	B-I
dummy	I-I
of	I-I
the	I-I
other	I-I
formulation	I-I
for	O
a	O
period	O
of	O
3	O
weeks	O
.	O

They	O
were	O
then	O
crossed	O
over	O
to	O
the	O
alternative	O
treatment	O
for	O
a	O
further	O
3	O
weeks	O
.	O

Daily	B-O
diary	I-O
records	I-O
were	O
kept	O
by	O
patients	O
of	O
the	B-O
number	I-O
of	I-O
night	I-O
-	I-O
time	I-O
awakenings	I-O
due	I-O
to	I-O
pain	I-O
,	O
pain	B-O
severity	I-O
at	I-O
awakening	I-O
in	I-O
the	I-O
morning	I-O
and	O
the	B-O
duration	I-O
of	I-O
early	I-O
morning	I-O
stiffness	I-O
.	O

Treatment	B-O
efficacy	I-O
was	O
also	O
assessed	O
at	O
the	O
end	O
of	O
each	O
trial	O
period	O
by	O
means	O
of	O
an	B-O
articular	I-O
index	I-O
and	O
by	O
physician	B-O
'	I-O
s	I-O
and	O
patient	B-O
'	I-O
s	I-O
overall	I-O
evaluation	I-O
of	I-O
response	I-O
.	O

Adverse	B-O
effects	I-O
spontaneously	O
mentioned	O
by	O
the	O
patients	O
or	O
elicited	O
by	O
direct	O
questioning	O
using	O
a	B-O
symptom	I-O
check	I-O
-	I-O
list	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
tidal	O
volumes	O
obtained	O
by	O
one	B-I
-	I-I
handed	I-I
and	O
two	B-I
-	I-I
handed	I-I
ventilation	I-I
techniques	I-I
.	O

METHODS	O
:	O
Subjects	B-P
(	I-P
108	I-P
healthcare	I-P
providers	I-P
from	I-P
a	I-P
500	I-P
-	I-P
bed	I-P
teaching	I-P
hospital	I-P
)	I-P
were	O
assigned	O
randomly	O
to	O
one	O
of	O
two	O
procedures	O
:	O
one	O
-	O
followed	O
by	O
two	B-I
-	I-I
handed	I-I
compression	I-I
or	O
two	O
-	O
followed	O
by	O
one	B-I
-	I-I
handed	I-I
compression	I-I
.	O

A	B-O
1	I-O
-	I-O
liter	I-O
resuscitation	I-O
bag	I-O
,	O
lung	B-O
performance	I-O
analyzer	I-O
and	O
Wright	B-O
spirometer	I-O
were	O
used	O
to	O
measure	O
tidal	B-O
volume	I-O
.	O

Data	O
collection	O
occurred	O
in	O
a	O
simulated	O
situation	O
.	O

-DOCSTART-	O

Title	O
:	O
Omeprazole	B-I
ameliorates	O
aspirin	O
-	O
induced	O
gastroduodenal	O
injury	O
.	O

METHODS	O
:	O
Twenty	B-P
healthy	I-P
volunteers	I-P
were	O
randomized	O
to	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
to	O
determine	O
if	O
omeprazole	B-I
,	O
40	O
mg	O
/	O
day	O
prevents	O
gastroduodenal	B-O
injury	I-O
due	O
to	O
two	O
weeks	O
of	O
aspirin	O
administration	O
(	O
650	O
mg	O
four	O
times	O
a	O
day	O
)	O
.	O

The	B-O
severity	I-O
of	I-O
mucosal	I-O
injury	I-O
was	O
quantitated	O
by	O
endoscopy	B-O
and	O
stratified	O
by	O
a	B-O
scale	I-O
from	I-O
0	I-O
(	I-O
normal	I-O
)	I-O
to	I-O
4	I-O
(	I-O
ulcer	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
multicenter	O
study	O
on	O
the	O
use	O
of	O
pulsed	B-I
low	I-I
-	I-I
intensity	I-I
direct	I-I
current	I-I
for	O
healing	O
chronic	O
stage	O
II	O
and	O
stage	O
III	O
decubitus	O
ulcers	O
.	O

METHODS	O
:	O
Pulsed	B-I
low	I-I
-	I-I
intensity	I-I
direct	I-I
current	I-I
(	O
300	O
to	O
600	O
microA	O
)	O
has	O
been	O
used	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
multicenter	O
study	O
in	O
the	O
treatment	O
of	O
stage	O
II	O
and	O
stage	O
III	O
chronic	O
decubitus	O
ulcers	O
.	O

-DOCSTART-	O

Title	O
:	O
Cimetidine	B-I
is	O
not	O
more	O
effective	O
than	O
placebo	B-C
in	O
acute	O
infectious	O
mononucleosis	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
reduced	B-I
alcohol	I-I
consumption	I-I
on	O
blood	O
pressure	O
in	O
untreated	B-P
hypertensive	I-P
men	I-P
.	O

METHODS	O
:	O
The	O
purpose	O
of	O
the	O
trial	O
was	O
to	O
test	O
the	O
effects	O
of	O
alcohol	B-I
reduction	I-I
on	O
blood	B-O
pressure	I-O
.	O

After	O
a	O
2	O
-	O
week	O
familiarization	O
period	O
,	O
the	O
participants	O
were	O
assigned	O
to	O
either	O
a	B-I
reduced	I-I
alcohol	I-I
drinking	I-I
group	O
or	O
a	B-C
usual	I-C
drinking	I-C
group	O
for	O
3	O
weeks	O
(	O
experimental	O
period	O
1	O
)	O
.	O

The	O
situation	O
was	O
then	O
reversed	O
for	O
the	O
next	O
3	O
weeks	O
(	O
experimental	O
period	O
2	O
)	O
.	O

The	O
participants	O
were	O
requested	O
to	O
limit	O
their	O
daily	O
alcohol	O
consumption	O
to	O
zero	O
or	O
reduce	O
it	O
as	O
much	O
as	O
possible	O
for	O
the	O
reduced	O
alcohol	O
consumption	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Prevention	O
of	O
pneumonia	O
by	O
endotracheal	B-I
micronebulization	I-I
of	I-I
tobramycin	I-I
]	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
clinical	O
evaluation	O
of	O
a	B-I
blood	I-I
conservation	I-I
device	I-I
in	O
medical	B-P
intensive	I-P
care	I-P
unit	I-P
patients	I-P
.	O

METHODS	O
:	O
Prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

A	O
clinical	O
trial	O
using	O
prospective	O
,	O
random	O
allocation	O
of	O
consecutive	O
eligible	O
patients	O
.	O

The	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
a	O
university	O
hospital	O
located	O
in	O
a	O
large	O
metropolitan	O
area	O
.	O

A	B-P
total	I-P
of	I-P
100	I-P
patients	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
the	I-P
medical	I-P
ICU	I-P
,	I-P
required	I-P
arterial	I-P
line	I-P
monitoring	I-P
for	I-P
clinical	I-P
purposes	I-P
,	I-P
and	I-P
were	I-P
managed	I-P
by	I-P
the	I-P
ICU	I-P
medical	I-P
service	I-P
.	O

Exclusion	O
criteria	O
included	O
active	O
bleeding	O
or	O
chronic	O
renal	O
failure	O
at	O
the	O
time	O
of	O
ICU	O
admission	O
.	O

Patients	O
in	O
the	O
experimental	O
group	O
had	O
a	B-I
blood	I-I
conservation	I-I
device	I-I
incorporated	O
into	O
the	O
arterial	O
pressure	O
monitoring	O
system	O
,	O
while	O
patients	O
in	O
the	O
control	O
group	O
received	O
a	B-C
conventional	I-C
arterial	I-C
pressure	I-C
monitoring	I-C
system	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Recurrence	O
of	O
condylomata	O
acuminata	O
following	O
cryotherapy	O
is	O
not	O
prevented	O
by	O
systemically	B-I
administered	I-I
interferon	I-I
.	O

METHODS	O
:	O
Randomised	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

Statistical	O
analysis	O
was	O
by	O
2	O
-	O
tailed	O
Fisher	O
'	O
s	O
Exact	O
Test	O
.	O

97	B-P
patients	I-P
with	I-P
recurrent	I-P
condylomata	I-P
acuminata	I-P
.	O

49	O
patients	O
were	O
treated	O
with	O
cryotherapy	O
plus	O
subcutaneously	O
administered	O
interferon	B-I
alpha	I-I
-	I-I
2a	I-I
,	O
and	O
48	O
received	O
cryotherapy	B-I
plus	O
placebo	B-C
.	O

Of	O
these	O
,	O
36	O
and	O
37	O
patients	O
,	O
respectively	O
,	O
completed	O
the	O
study	O
and	O
were	O
evaluable	O
.	O

Clinical	B-O
eradication	I-O
of	I-O
condylomata	I-O
for	O
six	O
months	O
following	O
adjuvant	O
chemotherapy	O
.	O

-DOCSTART-	O

Title	O
:	O
0	B-I
.	I-I
1	I-I
%	I-I
bupivacaine	I-I
does	O
not	O
reduce	O
the	O
requirement	O
for	O
epidural	O
fentanyl	O
infusion	O
after	O
major	O
abdominal	O
surgery	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
fentanyl	B-I
(	O
10	O
micrograms	O
/	O
mL	O
)	O
or	O
a	B-I
fentanyl	I-I
/	O
bupivacaine	B-I
(	O
0	O
.	O
1	O
%	O
)	O
mixture	O
epidurally	O
corresponding	O
to	O
the	O
dermatome	O
of	O
the	O
surgical	O
incision	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
for	O
the	O
first	O
18	O
hours	O
after	O
major	O
abdominal	O
surgery	O
.	O

The	O
infusion	O
was	O
titrated	O
for	O
each	O
patient	O
to	O
the	O
rate	O
required	O
for	O
pain	O
relief	O
during	O
forced	O
inspiration	O
(	O
pain	O
score	O
<	O
or	O
=	O
2	O
,	O
maximum	O
10	O
)	O
.	O

Pain	B-O
scores	I-O
,	O
the	B-O
fentanyl	I-O
doses	I-O
required	I-O
,	O
plasma	B-O
concentrations	I-O
of	I-O
fentanyl	I-O
at	O
18	O
hours	O
,	O
and	O
the	B-O
incidence	I-O
and	O
severity	B-O
of	I-O
adverse	I-O
effects	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Measurement	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
in	O
multiple	O
myeloma	O
.	O

Nordic	O
Myeloma	O
Study	O
Group	O
.	O

METHODS	O
:	O
We	O
used	O
the	B-I
questionnaire	I-I
(	I-I
QLQ	I-I
-	I-I
C30	I-I
)	I-I
developed	O
by	O
the	O
European	O
Organization	O
of	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
Study	O
Group	O
on	O
Quality	O
of	O
Life	O
.	O

The	B-I
QLQ	I-I
-	I-I
C30	I-I
incorporates	O
five	B-O
functional	I-O
scales	I-O
,	O
three	B-O
symptom	I-O
scales	I-O
,	O
a	B-O
global	I-O
health	I-O
and	O
quality	B-O
-	I-O
of	I-O
life	I-O
scale	I-O
and	O
some	B-O
single	I-O
symptom	I-O
measures	I-O
.	O

The	B-I
questionnaire	I-I
was	O
completed	O
prior	O
to	O
treatment	O
and	O
after	O
1	O
,	O
6	O
,	O
12	O
,	O
24	O
,	O
36	O
and	O
48	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Processing	O
familiar	B-I
and	O
unfamiliar	B-I
auditory	I-I
stimuli	I-I
during	O
general	O
anesthesia	O
.	O

METHODS	O
:	O
Stimuli	B-I
were	O
presented	O
via	O
headphones	O
and	O
consisted	O
of	O
common	B-C
facts	I-C
(	O
Group	O
A	O
,	O
29	O
patients	O
)	O
,	O
or	O
familiar	B-I
or	O
unfamiliar	B-I
full	I-I
names	I-I
of	I-I
fictitious	I-I
people	I-I
(	O
GRoup	O
B	O
,	O
29	O
patients	O
)	O
.	O

Group	O
A	O
was	O
expected	O
to	O
give	O
more	O
correct	B-O
answers	I-O
to	I-O
questions	I-O
about	I-O
the	I-O
common	I-O
facts	I-O
than	O
Group	O
B	O
,	O
when	O
tested	O
postoperatively	O
,	O
and	O
Group	O
B	O
to	O
attribute	O
more	O
fame	O
to	O
presented	O
names	O
than	O
Group	O
A	O
(	O
famous	B-O
names	I-O
test	I-O
)	O
.	O

Because	O
the	O
process	O
for	O
learning	O
new	O
or	O
unfamiliar	B-I
stimuli	I-I
(	O
elaboration	O
)	O
in	O
particular	O
may	O
be	O
impaired	O
under	O
general	O
anesthesia	O
,	O
more	O
memory	O
priming	O
was	O
expected	O
for	O
familiar	O
than	O
for	O
unfamiliar	O
material	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
early	O
phase	O
II	O
study	O
of	O
bicalutamide	B-I
(	I-I
Casodex	I-I
)	I-I
in	O
patients	B-P
with	I-P
prostatic	I-P
cancer	I-P
]	O
.	O

METHODS	O
:	O
The	O
patients	O
were	O
given	O
50	B-I
,	O
80	B-I
or	O
100	B-I
mg	I-I
of	I-I
bicalutamide	I-I
orally	O
once	O
a	O
day	O
in	O
fixed	O
doses	O
for	O
12	O
weeks	O
;	O
122	B-P
patients	I-P
were	O
eligible	O
for	O
evaluation	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
diclofenac	B-I
sodium	I-I
and	O
morphine	B-I
sulphate	I-I
for	O
postoperative	O
analgesia	O
after	O
day	O
case	O
inguinal	O
hernia	O
surgery	O
.	O

METHODS	O
:	O
This	O
study	O
compared	O
two	O
postoperative	O
oral	O
analgesic	O
protocols	O
after	O
day	O
case	O
inguinal	O
hernia	O
repair	O
;	O
30	B-I
mg	I-I
morphine	I-I
sulphate	I-I
(	I-I
MST	I-I
)	I-I
and	O
10	B-I
mg	I-I
metoclopramide	I-I
every	O
8	O
h	O
for	O
48	O
h	O
or	O
75	B-I
mg	I-I
diclofenac	I-I
twice	O
daily	O
for	O
48	O
h	O
.	O

The	B-O
pain	I-O
reported	O
in	O
the	B-I
MST	I-I
group	O
was	O
significantly	O
greater	O
on	O
both	O
the	O
day	O
of	O
operation	O
and	O
the	O
first	O
postoperative	O
day	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Mann	O
-	O
Whitney	O
U	O
test	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
analgesic	O
effect	O
of	O
locally	B-I
and	O
systemically	B-I
administered	I-I
ketorolac	I-I
in	O
mastectomy	B-P
patients	I-P
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
60	B-P
group	I-P
I	I-P
-	I-P
II	I-P
(	I-P
American	I-P
Society	I-P
of	I-P
Anesthesiology	I-P
criteria	I-P
)	I-P
mastectomy	I-P
patients	I-P
,	O
20	O
in	O
each	O
group	O
.	O

Near	O
the	O
end	O
of	O
surgery	O
and	O
every	O
6	O
h	O
postoperatively	O
,	O
20	B-I
ml	I-I
of	I-I
the	I-I
study	I-I
solution	I-I
containing	O
normal	B-I
saline	I-I
with	I-I
or	O
without	B-C
30	I-C
mg	I-C
of	I-C
ketorolac	I-C
were	O
administered	O
simultaneously	O
either	O
via	O
a	O
Jackson	O
-	O
Pratt	O
drain	O
or	O
intravenously	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
.	O

The	B-O
quality	I-O
of	I-O
pain	I-O
control	I-O
,	O
the	B-O
amount	I-O
and	O
character	B-O
of	I-O
the	I-O
drain	I-O
fluid	I-O
,	O
incidence	B-O
of	I-O
nausea	I-O
and	O
vomiting	B-O
,	O
length	B-O
of	I-O
stay	I-O
in	I-O
the	I-O
postoperative	I-O
care	I-O
unit	I-O
,	O
and	O
amount	B-O
of	I-O
morphine	I-O
used	I-O
for	I-O
treatment	I-O
of	I-O
break	I-O
-	I-O
through	I-O
pain	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
of	O
chronic	B-I
naltrexone	I-I
treatment	I-I
in	O
young	B-P
autistic	I-P
children	I-P
:	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
crossover	O
study	O
.	O

METHODS	O
:	O
Drug	B-O
effects	I-O
were	O
monitored	O
with	O
behavior	B-O
checklists	I-O
rated	O
by	O
parents	O
and	O
teachers	O
,	O
and	O
ethological	B-O
playroom	I-O
observations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
practice	B-I
on	O
laterality	O
in	O
a	O
mental	O
rotation	O
task	O
.	O

METHODS	O
:	O
Forty	B-P
-	I-P
six	I-P
females	I-P
and	I-P
46	I-P
males	I-P
completed	O
four	B-I
blocks	I-I
of	I-I
64	I-I
trials	I-I
in	O
a	O
lateralized	O
mental	O
rotation	O
task	O
.	O

-DOCSTART-	O

Title	O
:	O
Levels	O
of	O
recombinant	B-I
human	I-I
granulocyte	I-I
colony	I-I
-	I-I
stimulating	I-I
factor	I-I
in	O
serum	O
are	O
inversely	O
correlated	O
with	O
circulating	O
neutrophil	O
counts	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
relationship	O
between	O
serum	B-O
G	I-O
-	I-O
CSF	I-O
levels	I-O
and	O
circulating	B-O
neutrophil	I-O
counts	I-O
and	O
the	B-O
pharmacokinetics	I-O
of	O
rhG	B-I
-	I-I
CSF	I-I
for	O
patients	B-P
with	I-P
lung	I-P
cancer	I-P
who	I-P
had	I-P
been	I-P
treated	I-P
with	I-P
myelosuppressive	I-P
chemotherapy	I-P
and	I-P
then	I-P
with	I-P
subcutaneous	I-P
rhG	I-P
-	I-P
CSF	I-P
(	I-P
lenograstim	I-P
,	I-P
2	I-P
micrograms	I-P
per	I-P
kg	I-P
of	I-P
body	I-P
weight	I-P
per	I-P
day	I-P
)	I-P
.	O

Twelve	B-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
four	O
groups	O
with	O
different	B-I
rhG	I-I
-	I-I
CSF	I-I
therapy	I-I
schedules	O
.	O

Serum	B-O
G	I-O
-	I-O
CSF	I-O
levels	I-O
were	O
measured	O
by	O
an	B-O
enzyme	I-O
immunoassay	I-O
method	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
evolving	O
clinical	O
status	O
of	O
patients	B-P
after	I-P
a	I-P
myocardial	I-P
infarction	I-P
:	O
the	O
importance	O
of	O
post	O
-	O
hospital	O
data	O
for	O
mortality	O
prediction	O
.	O

METHODS	O
:	O
An	B-P
inception	I-P
cohort	I-P
of	I-P
patients	I-P
enrolled	I-P
in	I-P
the	I-P
Beta	I-P
-	I-P
Blocker	I-P
in	I-P
Heart	I-P
Attack	I-P
Trial	I-P
(	I-P
n	I-P
=	I-P
2830	I-P
)	I-P
was	O
included	O
.	O

Forty	O
-	O
three	O
variables	O
(	O
including	O
in	O
-	O
hospital	O
and	O
post	O
-	O
hospital	O
data	O
)	O
were	O
evaluated	O
using	O
stepwise	O
logistic	O
regression	O
.	O

-DOCSTART-	O

Title	O
:	O
Age	B-I
and	O
autonomic	B-I
effects	I-I
on	O
interrelationships	O
between	O
lung	O
volume	O
and	O
heart	O
rate	O
.	O

METHODS	O
:	O
Estimates	O
of	O
respiratory	B-O
and	O
heart	B-O
rate	I-O
power	I-O
spectra	I-O
and	O
linear	B-O
transfer	I-O
functions	I-O
between	O
the	O
two	O
groups	O
were	O
generated	O
by	O
Fourier	O
analysis	O
.	O

Age	B-O
,	O
double	B-O
blockade	I-O
effects	I-O
,	O
the	B-O
age	I-O
-	I-O
drug	I-O
interactions	I-O
were	O
determined	O
by	O
analysis	O
of	O
variance	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
age	O
at	O
introduction	O
of	O
complementary	B-I
foods	I-I
to	O
breast	B-P
-	I-P
fed	I-P
infants	I-P
on	I-P
duration	I-P
of	I-P
lactational	I-P
amenorrhea	I-P
in	I-P
Honduran	I-P
women	I-P
.	O

METHODS	O
:	O
Data	O
on	O
LA	O
were	O
collected	O
during	O
and	O
after	O
a	O
2	O
-	O
mo	O
intervention	O
trial	O
in	O
which	O
low	B-P
-	I-P
income	I-P
Honduran	I-P
women	I-P
who	I-P
had	I-P
breast	I-P
-	I-P
fed	I-P
fully	I-P
for	I-P
4	I-P
mo	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
continued	B-I
full	I-I
breast	I-I
-	I-I
feeding	I-I
until	O
6	O
mo	O
(	O
FBF	B-I
,	O
n	O
=	O
50	O
)	O
,	O
introduction	B-I
of	I-I
complementary	I-I
foods	I-I
at	O
4	O
mo	O
with	O
ad	O
libitum	O
breast	O
-	O
feeding	O
from	O
4	O
to	O
6	O
mo	O
(	O
SF	B-I
,	O
n	O
=	O
47	O
)	O
,	O
or	O
introduction	B-I
of	I-I
complementary	I-I
foods	I-I
at	O
4	O
mo	O
with	O
maintenance	O
of	O
baseline	O
breast	O
-	O
feeding	O
frequency	O
from	O
4	O
to	O
6	O
mo	O
(	O
SF	B-I
-	I-I
M	I-I
,	O
n	O
=	O
44	O
)	O
.	O

Women	O
were	O
followed	O
up	O
until	O
the	O
infant	O
was	O
12	O
mo	O
of	O
age	O
,	O
or	O
later	O
if	O
menses	O
had	O
not	O
occurred	O
by	O
then	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
pretreatment	I-I
of	I-I
hypertonic	I-I
saline	I-I
can	O
prevent	O
systemic	O
hypotension	O
induced	O
by	O
spinal	O
anesthesia	O
.	O

METHODS	O
:	O
Sixty	B-P
ASA	I-P
class	I-P
I	I-P
patients	I-P
scheduled	I-P
for	I-P
herniorrhapy	I-P
under	I-P
spinal	I-P
anesthesia	I-P
were	O
assigned	O
randomly	O
into	O
two	O
groups	O
.	O

Group	O
1	O
=	O
patients	O
were	O
prehydrated	O
with	O
isotonic	B-I
lactated	I-I
Ringer	I-I
'	I-I
s	I-I
solution	I-I
at	O
7	O
mg	O
/	O
kg	O
(	O
n	O
=	O
30	O
)	O
;	O
Group	O
2	O
=	O
patients	O
were	O
given	O
prehydration	O
with	O
3	B-I
%	I-I
hypertonic	I-I
saline	I-I
at	O
7	O
ml	O
/	O
kg	O
(	O
n	O
=	O
30	O
)	O
.	O

Following	O
prehydration	O
,	O
arterial	B-O
blood	I-O
pressure	I-O
and	O
heart	B-O
rate	I-O
were	O
recorded	O
and	O
serum	B-O
electrolyte	I-O
concentrations	I-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Acute	O
rejection	O
and	O
heart	O
infection	O
rates	O
in	O
FK	B-I
506	I-I
-	I-I
versus	O
cyclosporine	B-I
A	I-I
-	O
treated	O
heart	B-P
transplant	I-P
recipients	I-P
:	O
an	O
endomyocardial	O
biopsy	O
pathologic	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
open	O
,	O
parallel	O
group	O
comparison	O
of	O
quinapril	B-I
and	O
captopril	B-I
,	O
when	O
added	O
to	O
diuretic	B-I
therapy	I-I
,	O
in	O
the	O
treatment	O
of	O
elderly	B-P
patients	I-P
with	I-P
heart	I-P
failure	I-P
.	O

METHODS	O
:	O
The	O
study	O
was	O
performed	O
at	O
a	O
single	O
centre	O
as	O
an	O
open	O
randomised	O
parallel	O
-	O
group	O
study	O
,	O
patients	O
being	O
selected	O
for	O
inclusion	O
from	O
the	O
outpatient	O
population	O
.	O

Following	O
a	O
starting	O
dose	O
of	O
either	O
2	B-I
.	I-I
5	I-I
mg	I-I
once	I-I
-	I-I
daily	I-I
quinapril	I-I
,	O
or	O
6	B-I
.	I-I
25	I-I
mg	I-I
twice	I-I
-	I-I
daily	I-I
captopril	I-I
,	O
patients	O
were	O
reviewed	O
at	O
two	O
-	O
weekly	O
intervals	O
,	O
and	O
following	O
clinical	O
assessment	O
a	O
decision	O
was	O
made	O
either	O
to	O
titrate	O
up	O
to	O
the	O
next	O
medication	O
stage	O
or	O
to	O
enter	O
the	O
patient	O
into	O
the	O
16	O
-	O
week	O
maintenance	O
phase	O
.	O

Efficacy	B-O
was	O
assessed	O
using	O
a	B-O
six	I-O
-	I-O
minute	I-O
walking	I-O
test	I-O
,	O
the	B-O
New	I-O
York	I-O
Heart	I-O
Association	I-O
(	I-O
NYHA	I-O
)	I-O
class	I-O
,	O
a	B-O
functional	I-O
lifescale	I-O
(	I-O
FLS	I-O
)	I-O
questionnaire	I-O
and	O
the	B-O
cardiothoracic	I-O
ratio	I-O
(	I-O
CTR	I-O
)	I-O
-	O
at	O
study	O
entry	O
and	O
at	O
the	O
end	O
of	O
the	O
maintenance	O
phase	O
.	O

Blood	B-O
pressure	I-O
was	O
measured	O
for	O
5	O
h	O
post	O
-	O
first	O
-	O
dose	O
of	O
medication	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
drug	O
interaction	O
study	O
between	O
ticlopidine	B-I
and	O
cyclosporin	B-I
in	O
heart	B-P
transplant	I-P
recipients	I-P
.	O

METHODS	O
:	O
Twenty	B-P
heart	I-P
-	I-P
transplant	I-P
recipients	I-P
were	O
randomised	O
into	O
either	O
a	B-I
treated	I-I
or	O
a	B-C
placebo	I-C
group	O
.	O

Blood	B-O
samples	I-O
were	O
drawn	O
for	O
time	O
-	O
course	O
evaluation	O
of	O
cyclosporin	B-O
blood	I-O
levels	I-O
over	O
a	O
period	O
of	O
12	O
h	O
,	O
following	O
the	B-I
morning	I-I
intake	I-I
of	I-I
cyclosporin	I-I
and	O
,	O
for	O
platelet	O
aggregation	O
studies	O
,	O
before	O
and	O
after	O
14	B-I
days	I-I
of	I-I
ticlopidine	I-I
administration	O
.	O

Twenty	B-O
four	I-O
-	I-O
hour	I-O
urine	I-O
samples	I-O
were	O
collected	O
for	O
6	B-O
-	I-O
beta	I-O
-	I-O
hydroxycortisol	I-O
measurements	I-O
,	O
before	O
and	O
after	O
14	O
days	O
of	O
ticlopidine	B-I
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
preoperative	B-I
antibiotics	I-I
on	O
success	O
of	O
endosseous	O
implants	O
up	O
to	O
and	O
including	O
stage	O
II	O
surgery	O
:	O
a	O
study	O
of	O
2	B-P
,	I-P
641	I-P
implants	I-P
.	O

METHODS	O
:	O
As	O
part	O
of	O
the	O
comprehensive	O
Dental	O
Implant	O
Clinical	O
Research	O
Group	O
clinical	O
implant	O
study	O
,	O
the	B-O
preoperative	I-O
or	O
postoperative	B-O
use	I-O
of	I-O
antibiotics	I-O
,	O
the	B-O
type	I-O
used	I-O
,	O
and	O
the	B-O
duration	I-O
of	I-O
coverage	I-O
was	I-O
left	I-O
to	I-O
the	I-O
discretion	I-O
of	I-O
the	I-O
surgeon	I-O
.	O

These	O
data	O
were	O
recorded	O
and	O
correlated	O
with	O
failure	B-O
of	I-O
osseointegration	I-O
during	O
healing	O
(	O
stage	O
I	O
)	O
and	O
at	O
stage	O
II	O
surgery	O
(	O
uncovering	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
reliability	O
of	O
catheter	B-I
-	I-I
tip	I-I
transducers	I-I
for	O
the	O
measurement	O
of	O
intrauterine	O
pressure	O
in	O
the	O
third	O
stage	O
of	O
labour	O
.	O

METHODS	O
:	O
In	O
each	O
case	O
in	O
the	O
first	O
group	O
two	O
catheters	O
were	O
tied	O
together	O
and	O
introduced	O
transcervically	O
into	O
the	O
uterine	O
cavity	O
after	O
delivery	O
of	O
the	O
placenta	O
.	O

In	O
each	O
case	O
in	O
the	O
second	O
group	O
two	O
catheters	O
were	O
inserted	O
independently	O
into	O
the	O
same	O
uterine	O
cavity	O
.	O

The	B-O
active	I-O
and	O
cumulative	B-O
active	I-O
pressures	I-O
recorded	O
from	O
the	O
pairs	O
of	O
catheters	O
within	O
each	O
uterine	O
cavity	O
were	O
compared	O
.	O

-DOCSTART-	O

Title	O
:	O
Zolmitriptan	B-I
(	I-I
311C90	I-I
)	I-I
does	O
not	O
interact	O
with	O
fluoxetine	B-I
in	O
healthy	B-P
volunteers	I-P
.	O

METHODS	O
:	O
Twenty	B-P
volunteers	I-P
were	O
given	O
single	B-I
doses	I-I
of	I-I
fluoxetine	I-I
20	O
mg	O
or	O
an	B-C
identical	I-C
placebo	I-C
daily	O
for	O
28	O
days	O
prior	O
to	O
receiving	O
a	B-I
single	I-I
10	I-I
mg	I-I
oral	I-I
dose	I-I
of	I-I
zolmitriptan	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Improved	O
survival	O
with	O
early	B-I
intensification	I-I
:	O
combined	O
results	O
from	O
the	O
Medical	O
Research	O
Council	O
childhood	O
ALL	O
randomised	O
trials	O
,	O
UKALL	O
X	O
and	O
UKALL	O
XI	O
.	O

Medical	O
Research	O
Council	O
Working	O
Party	O
on	O
Childhood	O
Leukaemia	O
.	O

METHODS	O
:	O
This	O
paper	O
examines	O
the	O
effect	O
of	O
the	B-I
addition	I-I
of	I-I
the	I-I
early	I-I
intensification	I-I
block	I-I
to	O
treatment	O
which	O
included	O
late	O
intensification	O
,	O
combining	O
the	O
data	O
from	O
UKALL	O
X	O
and	O
the	O
first	O
part	O
of	O
UKALL	O
XI	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Treatment	O
of	O
Lead	B-P
-	I-P
exposed	I-P
Children	I-P
(	O
TLC	O
)	O
trial	O
:	O
design	O
and	O
recruitment	O
for	O
a	O
study	O
of	O
the	O
effect	O
of	O
oral	O
chelation	O
on	O
growth	O
and	O
development	O
in	O
toddlers	O
.	O

METHODS	O
:	O
TLC	O
clinical	O
sites	O
were	O
in	O
Baltimore	O
,	O
Cincinnati	O
and	O
Columbus	O
,	O
Newark	O
and	O
Philadelphia	O
.	O

Children	O
were	O
eligible	O
for	O
TLC	O
if	O
they	O
were	O
between	O
12	O
and	O
33	O
months	O
of	O
age	O
,	O
had	O
a	O
confirmed	O
blood	O
lead	O
concentration	O
between	O
20	O
and	O
44	O
micrograms	O
/	O
dL	O
and	O
lived	O
in	O
a	O
residence	O
suitable	O
for	O
lead	O
dust	O
reduction	O
.	O

Randomised	O
children	O
received	O
up	O
to	O
three	B-I
26	I-I
-	I-I
day	I-I
courses	I-I
of	I-I
succimer	I-I
or	O
placebo	B-C
,	O
and	O
were	O
then	O
followed	O
for	O
3	O
years	O
.	O

The	O
study	O
can	O
detect	O
a	B-O
three	I-O
-	I-O
point	I-O
difference	I-O
in	I-O
full	I-O
-	I-O
scale	I-O
IQ	I-O
at	O
3	O
-	O
year	O
follow	O
-	O
up	O
.	O

Statistical	O
power	O
for	O
the	O
other	O
end	O
points	O
is	O
more	O
difficult	O
to	O
estimate	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
sequential	O
annual	B-I
vaccination	I-I
and	O
of	O
DHEA	B-I
administration	I-I
on	O
the	O
efficacy	O
of	O
the	O
immune	O
response	O
to	O
influenza	O
vaccine	O
in	O
the	B-P
elderly	I-P
.	O

METHODS	O
:	O
Seventy	B-P
-	I-P
one	I-P
elderly	I-P
volunteers	I-P
,	I-P
aged	I-P
61	I-P
-	I-P
89	I-P
years	I-P
,	O
enrolled	O
in	O
a	O
prospective	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
to	O
receive	O
either	O
DHEA	B-I
(	O
50	O
mg	O
qd	O
p	O
.	O
o	O
.	O
for	O
4	O
consecutive	O
days	O
starting	O
2	O
days	O
before	O
immunization	O
)	O
or	O
placebo	B-C
.	O

Antibody	B-O
response	I-O
against	O
the	O
three	O
strains	O
of	O
vaccine	O
was	O
measured	O
before	O
and	O
28	O
days	O
after	O
vaccination	O
,	O
and	O
compared	O
between	O
previously	O
vaccinated	O
and	O
non	O
-	O
vaccinated	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Treatment	O
of	O
children	B-P
with	I-P
autism	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
a	B-I
caregiver	I-I
-	I-I
based	I-I
intervention	I-I
program	I-I
in	O
community	O
day	O
-	O
care	O
centers	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
five	I-P
preschool	I-P
children	I-P
with	I-P
a	I-P
DSM	I-P
III	I-P
-	I-P
R	I-P
diagnosis	I-P
of	I-P
autism	I-P
or	I-P
pervasive	I-P
developmental	I-P
disorder	I-P
were	O
randomized	O
to	O
an	O
experimental	O
or	O
control	O
group	O
.	O

Children	O
in	O
the	O
experimental	O
group	O
were	O
enrolled	O
in	O
day	O
care	O
and	O
their	O
parents	O
and	O
child	O
care	O
workers	O
received	O
a	B-I
12	I-I
-	I-I
week	I-I
intervention	I-I
consisting	O
of	O
lectures	B-I
and	O
on	B-I
-	I-I
site	I-I
consultations	I-I
to	I-I
day	I-I
-	I-I
care	I-I
centers	I-I
.	O

In	O
addition	O
,	O
supportive	O
work	O
was	O
undertaken	O
with	O
families	O
.	O

Control	O
subjects	O
received	O
day	B-C
care	I-C
alone	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Accuracy	O
and	O
feasibility	O
of	O
contrast	B-I
echocardiography	I-I
for	O
detection	O
of	O
perfusion	O
defects	O
in	O
routine	O
practice	O
:	O
comparison	O
with	O
wall	B-I
motion	I-I
and	O
technetium	B-I
-	I-I
99m	I-I
sestamibi	I-I
single	I-I
-	I-I
photon	I-I
emission	I-I
computed	I-I
tomography	I-I
.	O

The	O
Nycomed	O
NC100100	O
Investigators	O
.	O

METHODS	O
:	O
Fundamental	B-C
or	O
harmonic	B-I
MCE	I-I
was	O
performed	O
with	O
continuous	O
or	O
triggered	O
imaging	O
in	O
203	B-P
patients	I-P
with	I-P
a	I-P
previous	I-P
MI	I-P
using	I-P
bolus	I-P
doses	I-P
of	I-P
a	I-P
perfluorocarbon	I-P
-	I-P
filled	I-P
contrast	I-P
agent	I-P
(	I-P
NC100100	I-P
)	I-P
.	O

All	O
patients	O
underwent	O
single	B-I
-	I-I
photon	I-I
emission	I-I
computed	I-I
tomography	I-I
(	I-I
SPECT	I-I
)	I-I
after	O
the	B-I
injection	I-I
of	I-I
technetium	I-I
-	I-I
99m	I-I
(	I-I
Tc	I-I
-	I-I
99m	I-I
)	I-I
sestamibi	I-I
at	O
rest	O
.	O

Quantitative	B-O
and	O
semiquantitative	B-O
SPECT	I-O
,	O
wall	B-O
motion	I-O
and	O
digitized	B-O
echocardiographic	I-O
data	I-O
were	O
interpreted	O
independently	O
.	O

The	B-O
accuracy	I-O
of	I-O
MCE	I-O
was	O
assessed	O
for	O
detection	B-O
of	I-O
segments	I-O
and	O
patients	B-O
with	I-O
moderate	I-O
and	I-O
severe	I-O
sestamibi	I-O
-	I-O
SPECT	I-O
defects	I-O
,	O
as	O
well	O
as	O
for	O
detection	B-O
of	I-O
patients	I-O
with	I-O
extensive	I-O
perfusion	I-O
defects	I-O
(	I-O
>	I-O
12	I-O
%	I-O
of	I-O
left	I-O
ventricle	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Ten	O
-	O
year	O
results	O
of	O
a	O
randomised	O
trial	O
comparing	O
cisplatin	B-I
with	O
cisplatin	B-I
and	O
cyclophosphamide	B-I
in	O
advanced	O
,	O
suboptimally	O
debulked	O
ovarian	O
cancer	O
.	O

METHODS	O
:	O
176	B-P
eligible	I-P
patients	I-P
with	I-P
advanced	I-P
suboptimally	I-P
operated	I-P
ovarian	I-P
carcinoma	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
cisplatin	B-I
75	O
mg	O
/	O
m2	O
or	O
cisplatin	B-I
50	O
mg	O
/	O
m2	O
and	O
cyclophosphamide	B-I
500	O
mg	O
/	O
m2	O
(	O
CP	O
)	O
every	O
28	O
days	O
for	O
six	O
courses	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
seven	I-P
platinum	I-P
-	I-P
resistant	I-P
and	I-P
27	I-P
platinum	I-P
-	I-P
sensitive	I-P
tumours	I-P
were	O
treated	O
with	O
carboplatin	B-I
or	O
cisplatin	B-I
as	O
second	O
-	O
line	O
therapy	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparative	O
efficacy	O
and	O
safety	O
of	O
calcium	B-I
carbasalate	I-I
plus	O
metoclopramide	B-I
versus	O
ergotamine	B-I
tartrate	I-I
plus	O
caffeine	B-I
in	O
the	O
treatment	O
of	O
acute	O
migraine	O
attacks	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
296	I-P
patients	I-P
fulfilling	I-P
the	I-P
International	I-P
Headache	I-P
Society	I-P
diagnostic	I-P
criteria	I-P
for	I-P
migraine	I-P
were	O
enrolled	O
.	O

In	O
total	O
,	O
one	O
or	O
two	O
migraine	O
attacks	O
were	O
treated	O
in	O
268	O
and	O
235	O
patients	O
,	O
respectively	O
.	O

The	O
primary	O
endpoint	O
for	O
the	O
first	O
treated	O
attack	O
was	O
headache	B-O
relief	I-O
,	O
with	O
intensity	O
decreasing	O
from	O
moderate	O
or	O
severe	O
to	O
mild	O
or	O
absent	O
2	O
h	O
after	O
drug	O
intake	O
.	O

Usual	O
secondary	O
efficacy	O
endpoints	O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
preparation	O
of	O
patients	B-P
for	I-P
cardiac	I-P
surgery	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Network	O
support	O
for	O
drinking	O
,	O
Alcoholics	O
Anonymous	O
and	O
long	O
-	O
term	O
matching	O
effects	O
.	O

METHODS	O
:	O
Outpatients	O
were	O
re	O
-	O
interviewed	O
3	O
years	O
following	O
treatment	O
.	O

ANCOVAs	O
tested	O
the	O
matching	O
hypothesis	O
.	O

Outpatients	B-P
from	I-P
five	I-P
clinical	I-P
research	I-P
units	I-P
distributed	I-P
across	I-P
the	I-P
United	I-P
States	I-P
.	O

Eight	B-P
hundred	I-P
and	I-P
six	I-P
alcohol	I-P
-	I-P
dependent	I-P
clients	I-P
.	O

Clients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	B-I
12	I-I
-	I-I
week	I-I
,	I-I
manually	I-I
-	I-I
guided	I-I
,	I-I
individual	I-I
treatments	I-I
:	O
TSF	B-I
,	O
MET	B-I
or	O
Cognitive	B-I
Behavioral	I-I
Coping	I-I
Skills	I-I
Therapy	I-I
(	I-I
CBT	I-I
)	I-I
.	O

Network	B-O
support	I-O
for	I-O
drinking	I-O
prior	I-O
to	I-O
treatment	I-O
,	O
Alcoholics	B-O
Anonymous	I-O
(	I-O
AA	I-O
)	I-O
involvement	I-O
during	I-O
and	O
following	B-O
treatment	I-O
,	O
percentage	B-O
of	I-O
days	I-O
abstinent	I-O
and	O
drinks	B-O
per	I-O
drinking	I-O
day	I-O
during	O
months	O
37	O
-	O
39	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
alanyl	B-I
-	I-I
glutamine	I-I
in	O
postoperative	O
total	O
parenteral	O
nutrition	O
on	O
postoperative	O
immunosuppression	O
and	O
morbidity	O
.	O

Preliminary	O
results	O
of	O
a	O
prospective	O
randomized	O
study	O
]	O
.	O

METHODS	O
:	O
To	O
analyze	O
immune	B-O
competence	I-O
,	O
the	B-O
expression	I-O
of	I-O
CD3	I-O
,	O
CD4	B-O
,	O
and	O
CD8	B-O
on	I-O
lymphocytes	I-O
and	O
of	O
HLA	B-O
-	I-O
DR	I-O
and	O
CD14	B-O
on	I-O
monocytes	I-O
as	O
well	O
as	O
the	B-O
plasma	I-O
levels	I-O
of	I-O
IL	I-O
-	I-O
6	I-O
and	O
IL	B-O
-	I-O
10	I-O
was	O
evaluated	O
before	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
and	O
7	O
days	O
after	O
surgery	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
ventricular	O
fibrillation	O
duration	O
on	O
defibrillation	O
efficacy	O
using	O
biphasic	B-I
waveforms	I-I
in	O
humans	O
.	O

METHODS	O
:	O
Thirty	B-P
patients	I-P
undergoing	I-P
primary	I-P
ICD	I-P
implantation	I-P
or	I-P
pulse	I-P
generator	I-P
replacement	I-P
were	O
randomly	O
assigned	O
to	O
have	O
the	B-O
DFT	I-O
determined	O
using	O
biphasic	B-I
shocks	I-I
at	O
two	O
durations	O
of	O
VF	O
each	O
(	O
5	O
and	O
10	O
s	O
,	O
10	O
and	O
20	O
s	O
or	O
5	O
and	O
20	O
s	O
)	O
.	O

